OA17140A - Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof - Google Patents
Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof Download PDFInfo
- Publication number
- OA17140A OA17140A OA1201400458 OA17140A OA 17140 A OA17140 A OA 17140A OA 1201400458 OA1201400458 OA 1201400458 OA 17140 A OA17140 A OA 17140A
- Authority
- OA
- OAPI
- Prior art keywords
- propan
- phenyl
- group
- amino
- thieno
- Prior art date
Links
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 title claims description 7
- 238000000034 method Methods 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 230000001225 therapeutic Effects 0.000 title abstract description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 467
- 150000001875 compounds Chemical class 0.000 claims abstract description 263
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 36
- -1 amino, hydroxyl Chemical group 0.000 claims description 329
- 239000000203 mixture Substances 0.000 claims description 290
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 286
- 125000000217 alkyl group Chemical group 0.000 claims description 282
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 282
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 170
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 167
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 107
- 125000005843 halogen group Chemical group 0.000 claims description 97
- 125000001424 substituent group Chemical group 0.000 claims description 87
- 125000003545 alkoxy group Chemical group 0.000 claims description 78
- 125000003118 aryl group Chemical group 0.000 claims description 76
- VFWVWPWWZVTJDG-UHFFFAOYSA-N thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C1=NC=C2SC(C(=O)N)=CC2=N1 VFWVWPWWZVTJDG-UHFFFAOYSA-N 0.000 claims description 63
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 43
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 41
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 40
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 37
- 150000002367 halogens Chemical class 0.000 claims description 37
- 125000004076 pyridyl group Chemical group 0.000 claims description 37
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 36
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 35
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 30
- 229910052757 nitrogen Inorganic materials 0.000 claims description 30
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 29
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 29
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 28
- 125000003386 piperidinyl group Chemical group 0.000 claims description 27
- 229910052731 fluorine Chemical group 0.000 claims description 26
- 125000004193 piperazinyl group Chemical group 0.000 claims description 25
- 125000004943 pyrimidin-6-yl group Chemical compound N1=CN=CC=C1* 0.000 claims description 24
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 24
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 23
- 125000003566 oxetanyl group Chemical group 0.000 claims description 22
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 19
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 15
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000002541 furyl group Chemical group 0.000 claims description 14
- 229910003827 NRaRb Inorganic materials 0.000 claims description 13
- 229910052701 rubidium Inorganic materials 0.000 claims description 13
- 125000001544 thienyl group Chemical group 0.000 claims description 13
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 12
- 125000002785 azepinyl group Chemical group 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 125000002883 imidazolyl group Chemical group 0.000 claims description 11
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 11
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 11
- 125000001425 triazolyl group Chemical group 0.000 claims description 11
- 125000004104 aryloxy group Chemical group 0.000 claims description 10
- 150000003857 carboxamides Chemical class 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- YIKSCQDJHCMVMK-UHFFFAOYSA-N oxalic acid diamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 claims description 10
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 8
- 239000003880 polar aprotic solvent Substances 0.000 claims description 8
- ZXAZWXJOKVUXST-UHFFFAOYSA-N 3'-methyl-N-(3'-methylspiro[1,3-dithiolane-2,4'-6,7-dihydro-5H-1-benzofuran]-2'-carbonyl)-N-(2-morpholin-4-ylethyl)spiro[1,3-dithiolane-2,4'-6,7-dihydro-5H-1-benzofuran]-2'-carboxamide Chemical compound C1=2C(C)=C(C(=O)N(CCN3CCOCC3)C(=O)C3=C(C=4C5(SCCS5)CCCC=4O3)C)OC=2CCCC21SCCS2 ZXAZWXJOKVUXST-UHFFFAOYSA-N 0.000 claims description 7
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 6
- 125000005418 aryl aryl group Chemical group 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 6
- YZCKVEUIGOORGS-UHFFFAOYSA-N hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 claims description 6
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 150000007529 inorganic bases Chemical class 0.000 claims description 5
- 125000002524 organometallic group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003638 reducing agent Substances 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 150000007942 carboxylates Chemical class 0.000 claims description 3
- 239000000546 pharmaceutic aid Substances 0.000 claims description 3
- YYEOVZLKTIOHCA-UHFFFAOYSA-N 2-[2-methoxy-4-(4-propan-2-ylpiperazin-1-yl)anilino]-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(N2CCN(CC2)C(C)C)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=CC=C1 YYEOVZLKTIOHCA-UHFFFAOYSA-N 0.000 claims description 2
- NSLGSZHZYSGWIW-UHFFFAOYSA-N 2-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]-7-(1-oxidopyridin-1-ium-2-yl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound CC(C)OC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=CC=[N+]1[O-] NSLGSZHZYSGWIW-UHFFFAOYSA-N 0.000 claims description 2
- JOSMUINAEBUKID-UHFFFAOYSA-N 2-[5-fluoro-4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=NC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC(F)=C(C2CCN(C)CC2)C=C1OC(C)C JOSMUINAEBUKID-UHFFFAOYSA-N 0.000 claims description 2
- UBTPOTYFTACHLX-UHFFFAOYSA-N 2-[5-methyl-4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]-7-pyridin-2-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound CC=1C=C(NC=2N=C3C(C=4N=CC=CC=4)=C(C(N)=O)SC3=CN=2)C(OC(C)C)=CC=1C1CCN(C)CC1 UBTPOTYFTACHLX-UHFFFAOYSA-N 0.000 claims description 2
- FDMXXYUERBEQCH-UHFFFAOYSA-N 2-[[5-(oxan-4-yl)-2-propan-2-ylpyrazol-3-yl]amino]-7-[2-(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound CC(C)N1N=C(C2CCOCC2)C=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=CC=C1OC(F)(F)F FDMXXYUERBEQCH-UHFFFAOYSA-N 0.000 claims description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- ZTSBQXRJHOAALS-UHFFFAOYSA-N 7-(2-methoxyphenyl)-2-[4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(C2CCN(C)CC2)C=C1OC(C)C ZTSBQXRJHOAALS-UHFFFAOYSA-N 0.000 claims description 2
- YUAGJCVZVLZRDP-UHFFFAOYSA-N 7-(2-methoxyphenyl)-2-[4-[(4-methylpiperazin-1-yl)methyl]-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC(C(=C1)OC(C)C)=CC=C1CN1CCN(C)CC1 YUAGJCVZVLZRDP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001204 N-oxides Chemical class 0.000 claims description 2
- CFCOJRHWJUQESP-UHFFFAOYSA-N [2-[5-methyl-4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]-7-(6-methylpyridin-3-yl)thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound CC=1C=C(NC=2N=C3C(C=4C=NC(C)=CC=4)=C(CO)SC3=CN=2)C(OC(C)C)=CC=1N1CCN(C)CC1 CFCOJRHWJUQESP-UHFFFAOYSA-N 0.000 claims description 2
- MJUMMQYFDSWGBQ-UHFFFAOYSA-N [7-(2-methoxyphenyl)-2-[4-(1-methylpyrrolidin-3-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound COC1=CC=CC=C1C(C1=N2)=C(CO)SC1=CN=C2NC1=CC=C(C2CN(C)CC2)C=C1OC(C)C MJUMMQYFDSWGBQ-UHFFFAOYSA-N 0.000 claims description 2
- LWIYFHVELZHIRR-UHFFFAOYSA-N [7-(2-methoxypyridin-3-yl)-2-[4-(1-methylpyrazol-4-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound COC1=NC=CC=C1C(C1=N2)=C(CO)SC1=CN=C2NC1=CC=C(C2=CN(C)N=C2)C=C1OC(C)C LWIYFHVELZHIRR-UHFFFAOYSA-N 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical compound 0.000 claims description 2
- 125000003277 amino group Chemical compound 0.000 claims 65
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical compound FC(F)(F)O* 0.000 claims 2
- BKZLYBPDLICTAO-UHFFFAOYSA-N 2-(4-methoxy-2-propan-2-yloxyanilino)-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound CC(C)OC1=CC(OC)=CC=C1NC1=NC=C(SC(C(N)=O)=C2C=3C(=NC=CC=3)OC)C2=N1 BKZLYBPDLICTAO-UHFFFAOYSA-N 0.000 claims 1
- GNARSXVXTXCNHQ-UHFFFAOYSA-N 2-[(5-cyclopropyl-2-phenylpyrazol-3-yl)amino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC(C2CC2)=NN1C1=CC=CC=C1 GNARSXVXTXCNHQ-UHFFFAOYSA-N 0.000 claims 1
- LDEBNXDPZBATHN-UHFFFAOYSA-N 2-[2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(C)(C)O)SC1=CN=C2NC1=CC=C(N2CCN(C)CC2)C=C1OC LDEBNXDPZBATHN-UHFFFAOYSA-N 0.000 claims 1
- JYXGXBOVSJGYLI-UHFFFAOYSA-N 2-[2-methoxy-4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(N2CCC(CC2)N2CCCC2)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=CC=C1 JYXGXBOVSJGYLI-UHFFFAOYSA-N 0.000 claims 1
- AXQDXMPQTFTAQE-UHFFFAOYSA-N 2-[2-methoxy-4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]-7-thiophen-2-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(N2CCC(CC2)N2CCCC2)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=CS1 AXQDXMPQTFTAQE-UHFFFAOYSA-N 0.000 claims 1
- NBLCSNFRQGSPQB-UHFFFAOYSA-N 2-[2-methyl-4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound CC1=CC(N2CCC(CC2)N2CCCC2)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=CC=C1 NBLCSNFRQGSPQB-UHFFFAOYSA-N 0.000 claims 1
- JZOTWUBBXRRBAL-UHFFFAOYSA-N 2-[4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]-7-thiophen-3-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound CC(C)OC1=CC(C2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C=1C=CSC=1 JZOTWUBBXRRBAL-UHFFFAOYSA-N 0.000 claims 1
- VBOITYZXDPZZND-RTWAWAEBSA-N 2-[4-[(2S,4R)-2-ethyl-1-methylpiperidin-4-yl]-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C1CN(C)[C@@H](CC)C[C@@H]1C(C=C1OC(C)C)=CC=C1NC1=NC=C(SC(C(N)=O)=C2C=3C(=CC=CC=3)OC)C2=N1 VBOITYZXDPZZND-RTWAWAEBSA-N 0.000 claims 1
- NBSDWAXXNJAKOL-RXVVDRJESA-N 2-[4-[(3R,4S)-3-hydroxy-1-methylpiperidin-4-yl]-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C([C@H]2[C@H](CN(C)CC2)O)C=C1OC(C)C NBSDWAXXNJAKOL-RXVVDRJESA-N 0.000 claims 1
- HDTUFWXMILTSCR-UHFFFAOYSA-N 2-[4-[3-(2-hydroxyethyl)-4-methylpiperazin-1-yl]-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(N2CC(CCO)N(C)CC2)C=C1OC(C)C HDTUFWXMILTSCR-UHFFFAOYSA-N 0.000 claims 1
- PWGFKFHKQPCJMZ-UHFFFAOYSA-N 2-[4-[3-(dimethylamino)pyrrolidin-1-yl]-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(N2CC(CC2)N(C)C)C=C1OC(C)C PWGFKFHKQPCJMZ-UHFFFAOYSA-N 0.000 claims 1
- BEPBNCMMSSDBAH-UHFFFAOYSA-N 2-[7-(4-fluoro-2-methoxyphenyl)-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1SC(C(C)(C)O)=C2C1=CC=C(F)C=C1OC BEPBNCMMSSDBAH-UHFFFAOYSA-N 0.000 claims 1
- AZMOIBWRFTZEOQ-UHFFFAOYSA-N 2-phenylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound N=1C=C2SC(C(=O)N)=CC2=NC=1C1=CC=CC=C1 AZMOIBWRFTZEOQ-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- SATNXWPOHUSZHO-UHFFFAOYSA-N 7-(2-ethoxypyridin-3-yl)-2-[5-methyl-4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound CCOC1=NC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC(C)=C(N2CCN(C)CC2)C=C1OC(C)C SATNXWPOHUSZHO-UHFFFAOYSA-N 0.000 claims 1
- IVBWTHZUOBOIPM-UHFFFAOYSA-N 7-(2-fluoro-5-methoxyphenyl)-2-[4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=C(F)C(C=2C3=NC(NC=4C(=CC(=CC=4)C4CCN(C)CC4)OC(C)C)=NC=C3SC=2C(N)=O)=C1 IVBWTHZUOBOIPM-UHFFFAOYSA-N 0.000 claims 1
- OIKSVYWWWQXBNI-UHFFFAOYSA-N 7-(2-methoxyphenyl)-2-[4-(1-methylpyrazol-3-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(C2=NN(C)C=C2)C=C1OC(C)C OIKSVYWWWQXBNI-UHFFFAOYSA-N 0.000 claims 1
- VQNUCLNZPUAVDC-UHFFFAOYSA-N 7-(2-methoxyphenyl)-2-[5-methyl-4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC(C)=C(C2CCN(C)CC2)C=C1OC(C)C VQNUCLNZPUAVDC-UHFFFAOYSA-N 0.000 claims 1
- PNNKWVRRZASDHG-UHFFFAOYSA-N 7-(2-methoxyphenyl)-2-[[6-(4-methylpiperazin-1-yl)-4-propan-2-yloxypyridin-3-yl]amino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CN=C(N2CCN(C)CC2)C=C1OC(C)C PNNKWVRRZASDHG-UHFFFAOYSA-N 0.000 claims 1
- BVJNPNRRJNNZST-UHFFFAOYSA-N 7-(2-methoxypyridin-3-yl)-2-[5-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=NC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC(N2CCN(C)CC2)=CC=C1OC(C)C BVJNPNRRJNNZST-UHFFFAOYSA-N 0.000 claims 1
- YJBHYBLEDWKUSI-UHFFFAOYSA-N 7-(2-methoxypyridin-3-yl)-2-[5-methyl-4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=NC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC(C)=C(C2CCN(C)CC2)C=C1OC(C)C YJBHYBLEDWKUSI-UHFFFAOYSA-N 0.000 claims 1
- GIPIAGYZUQYSGK-UHFFFAOYSA-N 7-(2-methoxypyridin-3-yl)-2-[5-methyl-4-(2-methylimidazol-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=NC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC(C)=C(N2C(=NC=C2)C)C=C1OC(C)C GIPIAGYZUQYSGK-UHFFFAOYSA-N 0.000 claims 1
- XNDSFIPVKJXKGJ-UHFFFAOYSA-N 7-(3-cyanophenyl)-2-[4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound CC(C)OC1=CC(C2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=CC(C#N)=C1 XNDSFIPVKJXKGJ-UHFFFAOYSA-N 0.000 claims 1
- FUNBHARHCOHFJL-UHFFFAOYSA-N 7-(4-fluoro-2-methoxyphenyl)-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=C(F)C=C1OC FUNBHARHCOHFJL-UHFFFAOYSA-N 0.000 claims 1
- LIRZIHOTVNPJIS-UHFFFAOYSA-N 7-(5-fluoro-2-methoxypyridin-3-yl)-2-[5-methyl-4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=NC=C(F)C=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC(C)=C(C2CCN(C)CC2)C=C1OC(C)C LIRZIHOTVNPJIS-UHFFFAOYSA-N 0.000 claims 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 381
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 214
- 239000000243 solution Substances 0.000 description 170
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 137
- 229910001868 water Inorganic materials 0.000 description 114
- 239000012074 organic phase Substances 0.000 description 113
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 113
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 96
- 239000007787 solid Substances 0.000 description 95
- 230000002829 reduced Effects 0.000 description 89
- 238000010828 elution Methods 0.000 description 84
- 239000012429 reaction media Substances 0.000 description 60
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 58
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 56
- 239000000377 silicon dioxide Substances 0.000 description 52
- 239000003921 oil Substances 0.000 description 48
- 235000019198 oils Nutrition 0.000 description 48
- 239000008346 aqueous phase Substances 0.000 description 47
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 46
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 44
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 41
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 40
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 40
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 35
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 32
- 238000003756 stirring Methods 0.000 description 32
- 239000000706 filtrate Substances 0.000 description 31
- 239000000741 silica gel Substances 0.000 description 30
- 229910002027 silica gel Inorganic materials 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 29
- 238000003818 flash chromatography Methods 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 229910052786 argon Inorganic materials 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 22
- 229910000024 caesium carbonate Inorganic materials 0.000 description 22
- 238000000746 purification Methods 0.000 description 20
- 239000001184 potassium carbonate Substances 0.000 description 19
- 229910000027 potassium carbonate Inorganic materials 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 18
- 102100011141 ALK Human genes 0.000 description 18
- 239000012043 crude product Substances 0.000 description 18
- 239000011737 fluorine Substances 0.000 description 17
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 17
- 238000004587 chromatography analysis Methods 0.000 description 16
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 16
- VZTDIZULWFCMLS-UHFFFAOYSA-N Ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 239000012071 phase Substances 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 235000019253 formic acid Nutrition 0.000 description 13
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 238000007792 addition Methods 0.000 description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cells Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 11
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- FMKOJHQHASLBPH-OUBTZVSYSA-N 2-iodopropane Chemical compound CC([13CH3])I FMKOJHQHASLBPH-OUBTZVSYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 8
- 229920000591 gum Polymers 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- PRDMZNDYNNMIGZ-UHFFFAOYSA-N 4-bromo-1-nitro-2-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC(Br)=CC=C1[N+]([O-])=O PRDMZNDYNNMIGZ-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- PVNUIRUAPVSSOK-UHFFFAOYSA-N tert-butylimino(tripyrrolidin-1-yl)-$l^{5}-phosphane Chemical compound C1CCCN1P(N1CCCC1)(=NC(C)(C)C)N1CCCC1 PVNUIRUAPVSSOK-UHFFFAOYSA-N 0.000 description 7
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 6
- SLRNETDLLJMLMR-UHFFFAOYSA-N 4-fluoro-1-nitro-2-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC(F)=CC=C1[N+]([O-])=O SLRNETDLLJMLMR-UHFFFAOYSA-N 0.000 description 6
- 108010005474 Anaplastic Lymphoma Kinase Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- HVTICUPFWKNHNG-UHFFFAOYSA-N Ethyl iodide Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 6
- 102000001253 Protein Kinases Human genes 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- MVFGXYPEQHIKIX-UHFFFAOYSA-M heptane;acetate Chemical compound CC([O-])=O.CCCCCCC MVFGXYPEQHIKIX-UHFFFAOYSA-M 0.000 description 6
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 6
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 6
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 6
- SEPCYCDQJZTPHO-UHFFFAOYSA-N 5-chloro-2-methylsulfanylpyrimidine-4-carboxylic acid Chemical compound CSC1=NC=C(Cl)C(C(O)=O)=N1 SEPCYCDQJZTPHO-UHFFFAOYSA-N 0.000 description 5
- 102000005906 Anaplastic Lymphoma Kinase Human genes 0.000 description 5
- 108060006633 Protein Kinases Proteins 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 125000004429 atoms Chemical group 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 125000005842 heteroatoms Chemical group 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002198 insoluble material Substances 0.000 description 5
- 150000003385 sodium Chemical class 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 5
- 239000001187 sodium carbonate Substances 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000012418 sodium perborate tetrahydrate Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-Oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 4
- YYLLIJHXUHJATK-UHFFFAOYSA-N Cyclohexyl acetate Chemical compound CC(=O)OC1CCCCC1 YYLLIJHXUHJATK-UHFFFAOYSA-N 0.000 description 4
- 241000400611 Eucalyptus deanei Species 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N Potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- XUXNAKZDHHEHPC-UHFFFAOYSA-M Sodium bromate Chemical compound [Na+].[O-]Br(=O)=O XUXNAKZDHHEHPC-UHFFFAOYSA-M 0.000 description 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- OQWRXSBRGMUSMJ-UHFFFAOYSA-N [7-(2-methoxyphenyl)-2-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound COC1=CC=CC=C1C(C1=N2)=C(CO)SC1=CN=C2NC1=CC=C(N2CCN(C)CC2)C=C1OC(C)C OQWRXSBRGMUSMJ-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- 238000003760 magnetic stirring Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 102220197961 rs1057519784 Human genes 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- HGTBAIVLETUVCG-UHFFFAOYSA-M (methylthio)acetate Chemical compound CSCC([O-])=O HGTBAIVLETUVCG-UHFFFAOYSA-M 0.000 description 3
- KRDGKHZNAHNYKH-UHFFFAOYSA-N 2-chloro-5-nitro-4-propan-2-yloxypyridine Chemical compound CC(C)OC1=CC(Cl)=NC=C1[N+]([O-])=O KRDGKHZNAHNYKH-UHFFFAOYSA-N 0.000 description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 3
- RTVZAJWALICLJH-UHFFFAOYSA-N 3-methoxy-4-(4-nitro-3-propan-2-yloxyphenyl)pyridine Chemical compound COC1=CN=CC=C1C1=CC=C([N+]([O-])=O)C(OC(C)C)=C1 RTVZAJWALICLJH-UHFFFAOYSA-N 0.000 description 3
- PBADMFCCNPCCEI-UHFFFAOYSA-N 4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyaniline Chemical compound C1=C(N)C(OC(C)C)=CC(C2CCN(C)CC2)=C1 PBADMFCCNPCCEI-UHFFFAOYSA-N 0.000 description 3
- DKFKAZUTHFILIQ-UHFFFAOYSA-N 6-chloro-3-nitro-2-propan-2-yloxypyridine Chemical compound CC(C)OC1=NC(Cl)=CC=C1[N+]([O-])=O DKFKAZUTHFILIQ-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- 240000007087 Apium graveolens Species 0.000 description 3
- HSDAJNMJOMSNEV-UHFFFAOYSA-N Benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 229920001429 Chelating resin Polymers 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- SWPZIPBTYRTCNF-UHFFFAOYSA-N N-[4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyphenyl]formamide Chemical compound C1=C(NC=O)C(OC(C)C)=CC(C2CCN(C)CC2)=C1 SWPZIPBTYRTCNF-UHFFFAOYSA-N 0.000 description 3
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- PTKPZXDSBWIDIW-UHFFFAOYSA-N benzyl N-[4-(3-hydroxy-1-methylpiperidin-4-yl)-2-propan-2-yloxyphenyl]carbamate Chemical compound CC(C)OC1=CC(C2C(CN(C)CC2)O)=CC=C1NC(=O)OCC1=CC=CC=C1 PTKPZXDSBWIDIW-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ZPAQOEQIFZUYRH-UHFFFAOYSA-N cyanoboron(1-) Chemical compound [B-]C#N ZPAQOEQIFZUYRH-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- JIQLKWCGSXFXTN-UHFFFAOYSA-N methyl 2-methylsulfanyl-7-(trifluoromethylsulfonyloxy)thieno[3,2-d]pyrimidine-6-carboxylate Chemical compound N1=C(SC)N=C2C(OS(=O)(=O)C(F)(F)F)=C(C(=O)OC)SC2=C1 JIQLKWCGSXFXTN-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- VLYFRFHWUBBLRR-UHFFFAOYSA-L potassium;sodium;carbonate Chemical compound [Na+].[K+].[O-]C([O-])=O VLYFRFHWUBBLRR-UHFFFAOYSA-L 0.000 description 3
- BJDYCCHRZIFCGN-UHFFFAOYSA-N pyridin-1-ium;iodide Chemical compound I.C1=CC=NC=C1 BJDYCCHRZIFCGN-UHFFFAOYSA-N 0.000 description 3
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- CWTQWDKKXPDLGF-UHFFFAOYSA-N tert-butyl 7-(4-nitro-3-propan-2-yloxyphenyl)-1,7-diazaspiro[4.4]nonane-1-carboxylate Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(N2CC3(N(CCC3)C(=O)OC(C)(C)C)CC2)=C1 CWTQWDKKXPDLGF-UHFFFAOYSA-N 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- FYSZEUPKLMCUAW-CYBMUJFWSA-N (3R)-1-(4-nitro-3-propan-2-yloxyphenyl)-N-(oxetan-3-yl)piperidin-3-amine Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(N2C[C@@H](CCC2)NC2COC2)=C1 FYSZEUPKLMCUAW-CYBMUJFWSA-N 0.000 description 2
- IZGBNUQKVBFOKZ-LLVKDONJSA-N (3R)-1-(4-nitro-3-propan-2-yloxyphenyl)piperidin-3-amine Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(N2C[C@H](N)CCC2)=C1 IZGBNUQKVBFOKZ-LLVKDONJSA-N 0.000 description 2
- DQUUYAQHYNFZNY-RFVHGSKJSA-N (3R)-1-(4-nitro-3-propan-2-yloxyphenyl)piperidin-3-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C([N+]([O-])=O)C(OC(C)C)=CC(N2C[C@H](N)CCC2)=C1 DQUUYAQHYNFZNY-RFVHGSKJSA-N 0.000 description 2
- YZKIFCWIRQWINA-UHFFFAOYSA-N (5-chloro-2-methylsulfanylpyrimidin-4-yl)-[2-(difluoromethoxy)phenyl]methanone Chemical compound CSC1=NC=C(Cl)C(C(=O)C=2C(=CC=CC=2)OC(F)F)=N1 YZKIFCWIRQWINA-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 2
- HRVRAYIYXRVAPR-UHFFFAOYSA-N 1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound N1C(=O)CCCC2=CC=CC=C21 HRVRAYIYXRVAPR-UHFFFAOYSA-N 0.000 description 2
- QOPKYHXJEDTKJQ-UHFFFAOYSA-N 1-bromo-3-nitro-2-propan-2-yloxybenzene Chemical compound CC(C)OC1=C(Br)C=CC=C1[N+]([O-])=O QOPKYHXJEDTKJQ-UHFFFAOYSA-N 0.000 description 2
- FDPIXBUGVYTJDN-UHFFFAOYSA-N 1-ethyl-7-(4-nitro-3-propan-2-yloxyphenyl)-1,7-diazaspiro[4.4]nonane Chemical compound CCN1CCCC11CN(C=2C=C(OC(C)C)C(=CC=2)[N+]([O-])=O)CC1 FDPIXBUGVYTJDN-UHFFFAOYSA-N 0.000 description 2
- OKOBPIVWQLPDOO-UHFFFAOYSA-N 1-methyl-3-(4-nitro-3-propan-2-yloxyphenyl)pyrazole Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(C2=NN(C)C=C2)=C1 OKOBPIVWQLPDOO-UHFFFAOYSA-N 0.000 description 2
- BVYIOZQTCGTPMG-UHFFFAOYSA-N 1-methyl-4-(4-nitro-3-propan-2-yloxyphenyl)-1,4-diazepane Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(N2CCN(C)CCC2)=C1 BVYIOZQTCGTPMG-UHFFFAOYSA-N 0.000 description 2
- BLOMWFFHHBZJLV-UHFFFAOYSA-N 1-methyl-4-[(4-nitro-3-propan-2-yloxyphenyl)methyl]piperazine Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(CN2CCN(C)CC2)=C1 BLOMWFFHHBZJLV-UHFFFAOYSA-N 0.000 description 2
- MABGBHJLVITCDB-UHFFFAOYSA-N 1-methyl-7-nitro-6-propan-2-yloxy-4,5-dihydro-3H-1-benzazepin-2-one Chemical compound C1CCC(=O)N(C)C2=CC=C([N+]([O-])=O)C(OC(C)C)=C21 MABGBHJLVITCDB-UHFFFAOYSA-N 0.000 description 2
- BFQRVSKZMJTGTH-UHFFFAOYSA-N 1-methyl-7-nitro-8-propan-2-yloxy-4,5-dihydro-3H-1-benzazepin-2-one Chemical compound CN1C(=O)CCCC2=C1C=C(OC(C)C)C([N+]([O-])=O)=C2 BFQRVSKZMJTGTH-UHFFFAOYSA-N 0.000 description 2
- QEALKZSLBRSEGJ-UHFFFAOYSA-N 1-methyl-8-nitro-4,5-dihydro-3H-1-benzazepin-2-one Chemical compound C1CCC(=O)N(C)C2=CC([N+]([O-])=O)=CC=C21 QEALKZSLBRSEGJ-UHFFFAOYSA-N 0.000 description 2
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 2
- CRLUFNDSTIPVSD-UHFFFAOYSA-N 2-[4-(1-formyl-1,7-diazaspiro[4.4]nonan-7-yl)-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(N2CC3(N(CCC3)C=O)CC2)C=C1OC(C)C CRLUFNDSTIPVSD-UHFFFAOYSA-N 0.000 description 2
- BWRKMYYNLMGXAT-UHFFFAOYSA-M 2-[4-(4-nitro-3-propan-2-yloxyphenyl)pyridin-1-ium-1-yl]ethanol;iodide Chemical compound [I-].C1=C([N+]([O-])=O)C(OC(C)C)=CC(C=2C=C[N+](CCO)=CC=2)=C1 BWRKMYYNLMGXAT-UHFFFAOYSA-M 0.000 description 2
- KIFOTUFZYSSPJX-UHFFFAOYSA-N 4-(1-ethyl-1,7-diazaspiro[4.4]nonan-7-yl)-2-propan-2-yloxyaniline Chemical compound CCN1CCCC11CN(C=2C=C(OC(C)C)C(N)=CC=2)CC1 KIFOTUFZYSSPJX-UHFFFAOYSA-N 0.000 description 2
- OBCJKVYAJSWYKI-UHFFFAOYSA-N 4-(1-methyl-1,7-diazaspiro[4.4]nonan-7-yl)-2-propan-2-yloxyaniline Chemical compound C1=C(N)C(OC(C)C)=CC(N2CC3(N(CCC3)C)CC2)=C1 OBCJKVYAJSWYKI-UHFFFAOYSA-N 0.000 description 2
- LQZQKVREJYSRQS-UHFFFAOYSA-N 4-(3-methoxypyridin-4-yl)-2-propan-2-yloxyaniline Chemical compound COC1=CN=CC=C1C1=CC=C(N)C(OC(C)C)=C1 LQZQKVREJYSRQS-UHFFFAOYSA-N 0.000 description 2
- BROIANGGWMJNFO-UHFFFAOYSA-N 4-(4-amino-3-propan-2-yloxyphenyl)-1-methylpiperidin-3-ol Chemical compound C1=C(N)C(OC(C)C)=CC(C2C(CN(C)CC2)O)=C1 BROIANGGWMJNFO-UHFFFAOYSA-N 0.000 description 2
- SDJWFJVGUUUSRW-UHFFFAOYSA-N 4-(4-nitro-3-propan-2-yloxyphenyl)pyridine Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(C=2C=CN=CC=2)=C1 SDJWFJVGUUUSRW-UHFFFAOYSA-N 0.000 description 2
- ZNLBXYXZBIZSPL-UHFFFAOYSA-N 4-(5-methoxy-1-methyl-3,6-dihydro-2H-pyridin-4-yl)-2-propan-2-yloxyaniline Chemical compound C1CN(C)CC(OC)=C1C1=CC=C(N)C(OC(C)C)=C1 ZNLBXYXZBIZSPL-UHFFFAOYSA-N 0.000 description 2
- BAIZWELNDHXHRW-UHFFFAOYSA-N 4-bromo-2-nitro-1-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC=C(Br)C=C1[N+]([O-])=O BAIZWELNDHXHRW-UHFFFAOYSA-N 0.000 description 2
- HCIBCEGQISKOTI-UHFFFAOYSA-N 4-chloro-1-nitro-2-propan-2-yloxybenzene Chemical compound CC(C)OC1=CC(Cl)=CC=C1[N+]([O-])=O HCIBCEGQISKOTI-UHFFFAOYSA-N 0.000 description 2
- IIBDGXBTHGJVKQ-UHFFFAOYSA-N 4-chloro-2-propan-2-yloxyaniline Chemical compound CC(C)OC1=CC(Cl)=CC=C1N IIBDGXBTHGJVKQ-UHFFFAOYSA-N 0.000 description 2
- TWXGWRJVGWNOMS-UHFFFAOYSA-N 4-methoxy-1-nitro-2-propan-2-yloxybenzene Chemical compound COC1=CC=C([N+]([O-])=O)C(OC(C)C)=C1 TWXGWRJVGWNOMS-UHFFFAOYSA-N 0.000 description 2
- NXGNQLUYHXOIII-UHFFFAOYSA-N 4-methoxy-2-propan-2-yloxyaniline Chemical compound COC1=CC=C(N)C(OC(C)C)=C1 NXGNQLUYHXOIII-UHFFFAOYSA-N 0.000 description 2
- AJGLCXBDYCEVIE-UHFFFAOYSA-N 5-chloro-3-hydroxy-1H-pyridin-2-one Chemical compound OC1=CC(Cl)=CN=C1O AJGLCXBDYCEVIE-UHFFFAOYSA-N 0.000 description 2
- OCSWHADWFJTNAZ-UHFFFAOYSA-N 5-methyl-2-propan-2-ylpyrazol-3-amine Chemical compound CC(C)N1N=C(C)C=C1N OCSWHADWFJTNAZ-UHFFFAOYSA-N 0.000 description 2
- RYQXCAXRQNXCHG-UHFFFAOYSA-N 5-propan-2-yloxy-3,4-dihydro-2H-naphthalen-1-one Chemical compound O=C1CCCC2=C1C=CC=C2OC(C)C RYQXCAXRQNXCHG-UHFFFAOYSA-N 0.000 description 2
- UEFXWQOKHBMXDH-UHFFFAOYSA-N 6-(1-methylpiperidin-4-yl)-2-propan-2-yloxypyridin-3-amine Chemical compound C1=C(N)C(OC(C)C)=NC(C2CCN(C)CC2)=C1 UEFXWQOKHBMXDH-UHFFFAOYSA-N 0.000 description 2
- LYPUUHYKJZXNGS-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)-2-propan-2-yloxypyridin-3-amine Chemical compound C1=C(N)C(OC(C)C)=NC(N2CCN(C)CC2)=C1 LYPUUHYKJZXNGS-UHFFFAOYSA-N 0.000 description 2
- CHOIQMMWKLGPFO-UHFFFAOYSA-N 6-propan-2-yloxy-1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound N1C(=O)CCCC2=C1C=CC=C2OC(C)C CHOIQMMWKLGPFO-UHFFFAOYSA-N 0.000 description 2
- XWGIRZDSWAJTFR-UHFFFAOYSA-N 7-(4-fluorophenyl)-2-methylsulfanylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C12=NC(SC)=NC=C2SC(C(N)=O)=C1C1=CC=C(F)C=C1 XWGIRZDSWAJTFR-UHFFFAOYSA-N 0.000 description 2
- FANYWUKLETZPRV-UHFFFAOYSA-N 7-(4-fluorophenyl)-2-methylsulfonylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C12=NC(S(=O)(=O)C)=NC=C2SC(C(N)=O)=C1C1=CC=C(F)C=C1 FANYWUKLETZPRV-UHFFFAOYSA-N 0.000 description 2
- NHPOHLKFJVPDHW-UHFFFAOYSA-N 7-(4-nitro-3-propan-2-yloxyphenyl)-1,7-diazaspiro[4.4]nonane Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(N2CC3(NCCC3)CC2)=C1 NHPOHLKFJVPDHW-UHFFFAOYSA-N 0.000 description 2
- ASVGSXZZZWXPRE-UHFFFAOYSA-N 7-nitro-1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound N1C(=O)CCCC2=CC([N+](=O)[O-])=CC=C21 ASVGSXZZZWXPRE-UHFFFAOYSA-N 0.000 description 2
- VZIMPCBSCHXDQB-UHFFFAOYSA-N 7-nitro-6-propan-2-yloxy-1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound C1CCC(=O)NC2=CC=C([N+]([O-])=O)C(OC(C)C)=C21 VZIMPCBSCHXDQB-UHFFFAOYSA-N 0.000 description 2
- PSMYYXFHNPSLMV-UHFFFAOYSA-N 7-nitro-8-propan-2-yloxy-1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound N1C(=O)CCCC2=C1C=C(OC(C)C)C([N+]([O-])=O)=C2 PSMYYXFHNPSLMV-UHFFFAOYSA-N 0.000 description 2
- AUGWLCKXIKKWDN-UHFFFAOYSA-N 7-propan-2-yloxy-3,4-dihydro-2H-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC(OC(C)C)=CC=C21 AUGWLCKXIKKWDN-UHFFFAOYSA-N 0.000 description 2
- SSTQWTAKTYMLTB-UHFFFAOYSA-N 8-nitro-1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound C1CCC(=O)NC2=CC([N+](=O)[O-])=CC=C21 SSTQWTAKTYMLTB-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108060004749 CAD Proteins 0.000 description 2
- GADHRUYGQJCGMD-UHFFFAOYSA-M CSC=1N=CC2=C(N=1)C(=C(S2)C(=O)[O-])C1=CC=CC=C1 Chemical compound CSC=1N=CC2=C(N=1)C(=C(S2)C(=O)[O-])C1=CC=CC=C1 GADHRUYGQJCGMD-UHFFFAOYSA-M 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N Cesium Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 240000000437 Eucalyptus leucoxylon Species 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000835890 Hoa Species 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- WUMBECQTVQQGEH-UHFFFAOYSA-N N-(4-nitro-3-propan-2-yloxyphenyl)oxan-4-amine Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(NC2CCOCC2)=C1 WUMBECQTVQQGEH-UHFFFAOYSA-N 0.000 description 2
- ZYAWHKRNEDKXNT-UHFFFAOYSA-N N-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]formamide Chemical compound C1=C(NC=O)C(OC)=CC(N2CCN(C)CC2)=C1 ZYAWHKRNEDKXNT-UHFFFAOYSA-N 0.000 description 2
- SFTPOZBNUGVPLB-UHFFFAOYSA-N N-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyphenyl]formamide Chemical compound C1=C(NC=O)C(OC(C)C)=CC(N2CCN(C)CC2)=C1 SFTPOZBNUGVPLB-UHFFFAOYSA-N 0.000 description 2
- FGANBKFFJPLZOP-UHFFFAOYSA-N N-[5-methyl-4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyphenyl]formamide Chemical compound C1=C(NC=O)C(OC(C)C)=CC(N2CCN(C)CC2)=C1C FGANBKFFJPLZOP-UHFFFAOYSA-N 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N Nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N Phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- IIMIOEBMYPRQGU-UHFFFAOYSA-L Picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000004116 Sepiolitic clay Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M Sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- LCYPMPXXLYPMML-UHFFFAOYSA-N [1-(4-nitro-3-propan-2-yloxyphenyl)piperidin-4-yl] acetate Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(N2CCC(CC2)OC(C)=O)=C1 LCYPMPXXLYPMML-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- BKWPYEYWXVVTLU-UHFFFAOYSA-N benzyl N-[4-(3-methoxypyridin-4-yl)-2-propan-2-yloxyphenyl]carbamate Chemical compound COC1=CN=CC=C1C(C=C1OC(C)C)=CC=C1NC(=O)OCC1=CC=CC=C1 BKWPYEYWXVVTLU-UHFFFAOYSA-N 0.000 description 2
- GNPXHAKNRXCDAP-UHFFFAOYSA-N benzyl N-[4-(5-methoxy-1-methyl-3,6-dihydro-2H-pyridin-4-yl)-2-propan-2-yloxyphenyl]carbamate Chemical compound C1CN(C)CC(OC)=C1C(C=C1OC(C)C)=CC=C1NC(=O)OCC1=CC=CC=C1 GNPXHAKNRXCDAP-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- ILULYDJFTJKQAP-UHFFFAOYSA-N hydron;propan-2-ylhydrazine;chloride Chemical compound [Cl-].CC(C)N[NH3+] ILULYDJFTJKQAP-UHFFFAOYSA-N 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- WWOYCMCZTZTIGU-UHFFFAOYSA-L magnesium;2-carboxybenzenecarboperoxoate;hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].OOC(=O)C1=CC=CC=C1C([O-])=O.OOC(=O)C1=CC=CC=C1C([O-])=O WWOYCMCZTZTIGU-UHFFFAOYSA-L 0.000 description 2
- STFLQKHMFBPNGL-UHFFFAOYSA-N methyl 2-[N-formyl-4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(N(C=O)C=3C(=CC(=CC=3)N3CCN(C)CC3)OC(C)C)N=C2C=1C1=CC=CC=C1OC STFLQKHMFBPNGL-UHFFFAOYSA-N 0.000 description 2
- YECIUCRDDWHRGD-UHFFFAOYSA-N methyl 2-methylsulfonyl-7-(trifluoromethylsulfonyloxy)thieno[3,2-d]pyrimidine-6-carboxylate Chemical compound N1=C(S(C)(=O)=O)N=C2C(OS(=O)(=O)C(F)(F)F)=C(C(=O)OC)SC2=C1 YECIUCRDDWHRGD-UHFFFAOYSA-N 0.000 description 2
- UBABNNIWURMFLJ-UHFFFAOYSA-N methyl 7-(5-fluoro-2-methoxyphenyl)-2-[N-formyl-4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(N(C=O)C=3C(=CC(=CC=3)N3CCN(C)CC3)OC(C)C)N=C2C=1C1=CC(F)=CC=C1OC UBABNNIWURMFLJ-UHFFFAOYSA-N 0.000 description 2
- UIOSLEWHIXLGND-UHFFFAOYSA-N methyl 7-(6-methoxypyridin-2-yl)-2-methylsulfinylthieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(S(C)=O)N=C2C=1C1=CC=CC(OC)=N1 UIOSLEWHIXLGND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural Effects 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 230000002246 oncogenic Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 2
- XCOWFHRNGJAHDO-UHFFFAOYSA-N piperidin-4-yl acetate Chemical compound CC(=O)OC1CCNCC1 XCOWFHRNGJAHDO-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920002745 polystyrene-block- poly(ethylene /butylene) Polymers 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000000264 sodium ferrocyanide Substances 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 2
- WBQTXTBONIWRGK-UHFFFAOYSA-N sodium;propan-2-olate Chemical compound [Na+].CC(C)[O-] WBQTXTBONIWRGK-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- CWUKJEYJDUIJPD-UHFFFAOYSA-N tert-butyl 4-(4-amino-3-propan-2-yloxyphenyl)-2-ethylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)C(CC)CC1C1=CC=C(N)C(OC(C)C)=C1 CWUKJEYJDUIJPD-UHFFFAOYSA-N 0.000 description 2
- CCUBHVDCMYDDNV-UHFFFAOYSA-N tert-butyl 4-(4-nitro-3-propan-2-yloxyphenyl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(C=2CCN(CC=2)C(=O)OC(C)(C)C)=C1 CCUBHVDCMYDDNV-UHFFFAOYSA-N 0.000 description 2
- MRZRKBZIOPWYKI-UHFFFAOYSA-N tert-butyl 4-acetyloxypiperidine-1-carboxylate Chemical compound CC(=O)OC1CCN(C(=O)OC(C)(C)C)CC1 MRZRKBZIOPWYKI-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- DRHFKWMLGSUFMF-OAHLLOKOSA-N (3R)-1-(4-amino-3-propan-2-yloxyphenyl)-N-methyl-N-(oxetan-3-yl)piperidin-3-amine Chemical compound C1=C(N)C(OC(C)C)=CC(N2C[C@@H](CCC2)N(C)C2COC2)=C1 DRHFKWMLGSUFMF-OAHLLOKOSA-N 0.000 description 1
- PKECCLZTTSYOAU-UHFFFAOYSA-N (5-chloro-2-methylsulfanylpyrimidin-4-yl)-[2-(difluoromethoxy)phenyl]methanol Chemical compound CSC1=NC=C(Cl)C(C(O)C=2C(=CC=CC=2)OC(F)F)=N1 PKECCLZTTSYOAU-UHFFFAOYSA-N 0.000 description 1
- VPBBNFCFLAHMSJ-ZHACJKMWSA-N (NE)-N-(7-nitro-3,4-dihydro-2H-naphthalen-1-ylidene)hydroxylamine Chemical compound C1=C([N+]([O-])=O)C=C2C(=N/O)/CCCC2=C1 VPBBNFCFLAHMSJ-ZHACJKMWSA-N 0.000 description 1
- VPBBNFCFLAHMSJ-KHPPLWFESA-N (NZ)-N-(7-nitro-3,4-dihydro-2H-naphthalen-1-ylidene)hydroxylamine Chemical compound C1=C([N+]([O-])=O)C=C2C(=N/O)\CCCC2=C1 VPBBNFCFLAHMSJ-KHPPLWFESA-N 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-Dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-Tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
- AYQMNFRCBKOMIA-UHFFFAOYSA-N 1-benzazepin-2-one Chemical compound O=C1C=CC=C2C=CC=CC2=N1 AYQMNFRCBKOMIA-UHFFFAOYSA-N 0.000 description 1
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N 1-methyl-1,4-diazepane Chemical compound CN1CCCNCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 1
- ADMXMXNXEITSAX-UHFFFAOYSA-N 1-methyl-1,7-diazaspiro[4.4]nonane Chemical compound CN1CCCC11CNCC1 ADMXMXNXEITSAX-UHFFFAOYSA-N 0.000 description 1
- KPNCLBAGXXNZEU-UHFFFAOYSA-N 1-methyl-4-(2-methyl-4-nitro-5-propan-2-yloxyphenyl)piperazine Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(N2CCN(C)CC2)=C1C KPNCLBAGXXNZEU-UHFFFAOYSA-N 0.000 description 1
- TYJWTAURLHADBY-UHFFFAOYSA-N 1-methyl-4-(3-nitro-2-propan-2-yloxyphenyl)piperazine Chemical compound C1=CC=C([N+]([O-])=O)C(OC(C)C)=C1N1CCN(C)CC1 TYJWTAURLHADBY-UHFFFAOYSA-N 0.000 description 1
- CYCYZIXCLWLDPV-UHFFFAOYSA-N 1-methyl-4-(3-nitro-4-propan-2-yloxyphenyl)piperazine Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC=C1N1CCN(C)CC1 CYCYZIXCLWLDPV-UHFFFAOYSA-N 0.000 description 1
- DRKMIOWSACEGOH-UHFFFAOYSA-M 1-methyl-4-(4-nitro-3-propan-2-yloxyphenyl)pyridin-1-ium;iodide Chemical compound [I-].C1=C([N+]([O-])=O)C(OC(C)C)=CC(C=2C=C[N+](C)=CC=2)=C1 DRKMIOWSACEGOH-UHFFFAOYSA-M 0.000 description 1
- QVWJNPIUXQAZGV-UHFFFAOYSA-N 1-methyl-7-(4-nitro-3-propan-2-yloxyphenyl)-1,7-diazaspiro[4.4]nonane Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(N2CC3(N(CCC3)C)CC2)=C1 QVWJNPIUXQAZGV-UHFFFAOYSA-N 0.000 description 1
- MYNJXMCNLIFYEC-UHFFFAOYSA-N 1-methyl-7-nitro-4,5-dihydro-3H-1-benzazepin-2-one Chemical compound C1CCC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C21 MYNJXMCNLIFYEC-UHFFFAOYSA-N 0.000 description 1
- QHLFGJZHMIWQHL-UHFFFAOYSA-N 1-methyl-N-(4-nitro-3-propan-2-yloxyphenyl)piperidin-4-amine Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(NC2CCN(C)CC2)=C1 QHLFGJZHMIWQHL-UHFFFAOYSA-N 0.000 description 1
- PTRJHYDRYXRGEL-UHFFFAOYSA-N 2,3,5,6-tetrahydropyran Chemical group [CH]1CCOCC1 PTRJHYDRYXRGEL-UHFFFAOYSA-N 0.000 description 1
- SXOLLCJKZOPRQT-UHFFFAOYSA-N 2-(4-methoxy-2-propan-2-yloxyanilino)-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound CC(C)OC1=CC(OC)=CC=C1NC1=NC=C(SC(C(N)=O)=C2C=3C=CC=CC=3)C2=N1 SXOLLCJKZOPRQT-UHFFFAOYSA-N 0.000 description 1
- QPBNHDFPMRENBC-UHFFFAOYSA-N 2-(difluoromethoxy)benzaldehyde Chemical compound FC(F)OC1=CC=CC=C1C=O QPBNHDFPMRENBC-UHFFFAOYSA-N 0.000 description 1
- VEJSIOPQKQXJAT-UHFFFAOYSA-N 2-Bromo-6-nitrophenol Chemical compound OC1=C(Br)C=CC=C1[N+]([O-])=O VEJSIOPQKQXJAT-UHFFFAOYSA-N 0.000 description 1
- CMWKITSNTDAEDT-UHFFFAOYSA-N 2-Nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC=C1C=O CMWKITSNTDAEDT-UHFFFAOYSA-N 0.000 description 1
- SCNBGYYMSASYLL-UHFFFAOYSA-N 2-[(5-piperidin-4-yl-2-propan-2-ylpyrazol-3-yl)amino]-7-[2-(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide;hydrochloride Chemical compound Cl.CC(C)N1N=C(C2CCNCC2)C=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=CC=C1OC(F)(F)F SCNBGYYMSASYLL-UHFFFAOYSA-N 0.000 description 1
- GIOGZZHQUUMNHU-UHFFFAOYSA-N 2-[2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidin-6-yl]propan-2-ol;hydrochloride Chemical compound Cl.COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1SC(C(C)(C)O)=C2C1=CC=CC=C1OC GIOGZZHQUUMNHU-UHFFFAOYSA-N 0.000 description 1
- URRQIGRSWNTNIF-UHFFFAOYSA-N 2-[2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-7-phenylthieno[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1SC(C(C)(C)O)=C2C1=CC=CC=C1 URRQIGRSWNTNIF-UHFFFAOYSA-N 0.000 description 1
- MPINEZGEWKGVPO-UHFFFAOYSA-N 2-[2-methoxy-4-(1-propan-2-ylpiperidin-4-yl)anilino]-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(C2CCN(CC2)C(C)C)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=CC=C1 MPINEZGEWKGVPO-UHFFFAOYSA-N 0.000 description 1
- DELFGDRPABLCIX-UHFFFAOYSA-N 2-[2-methoxy-4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]-7-thiophen-3-ylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(N2CCC(CC2)N2CCCC2)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C=1C=CSC=1 DELFGDRPABLCIX-UHFFFAOYSA-N 0.000 description 1
- DLXXPQNMESCUPU-UHFFFAOYSA-N 2-[4-(1,7-diazaspiro[4.4]nonan-7-yl)-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(N2CC3(NCCC3)CC2)C=C1OC(C)C DLXXPQNMESCUPU-UHFFFAOYSA-N 0.000 description 1
- ZDHSKBIKYMJPSE-UHFFFAOYSA-N 2-[4-(1-cyclopropylpiperidin-4-yl)-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(C2CCN(CC2)C2CC2)C=C1OC(C)C ZDHSKBIKYMJPSE-UHFFFAOYSA-N 0.000 description 1
- DNMDZYZOWVOBFJ-UHFFFAOYSA-N 2-[4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]-7-[2-(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound CC(C)OC1=CC(C2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=CC=C1OC(F)(F)F DNMDZYZOWVOBFJ-UHFFFAOYSA-N 0.000 description 1
- JXVMTVZZUPFDKE-UHFFFAOYSA-N 2-[4-(3,5-dimethyl-1,2,4-triazol-1-yl)-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(N2C(=NC(C)=N2)C)C=C1OC(C)C JXVMTVZZUPFDKE-UHFFFAOYSA-N 0.000 description 1
- YETSHALPDJJODG-UHFFFAOYSA-N 2-[4-(4-nitro-3-propan-2-yloxyphenyl)-3,6-dihydro-2H-pyridin-1-yl]ethanol Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(C=2CCN(CCO)CC=2)=C1 YETSHALPDJJODG-UHFFFAOYSA-N 0.000 description 1
- BRJFEAYXKXWHBP-PMACEKPBSA-N 2-[4-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-2-propan-2-yloxyanilino]-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2C(C=C1OC(C)C)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=CC=C1 BRJFEAYXKXWHBP-PMACEKPBSA-N 0.000 description 1
- XIKJQBREHXXMHY-UHFFFAOYSA-N 2-[4-[1-(2-hydroxyethyl)piperidin-4-yl]-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(C2CCN(CCO)CC2)C=C1OC(C)C XIKJQBREHXXMHY-UHFFFAOYSA-N 0.000 description 1
- OEAVKGZVQSTIIS-UHFFFAOYSA-N 2-[4-[formyl(oxan-4-yl)amino]-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(N(C=O)C2CCOCC2)C=C1OC(C)C OEAVKGZVQSTIIS-UHFFFAOYSA-N 0.000 description 1
- RPZVTDSTGCVPIT-UHFFFAOYSA-N 2-[4-[formyl-(1-methylpiperidin-4-yl)amino]-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(N(C=O)C2CCN(C)CC2)C=C1OC(C)C RPZVTDSTGCVPIT-UHFFFAOYSA-N 0.000 description 1
- VLBZZCQOAKZGPV-UHFFFAOYSA-N 2-[5-fluoro-4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC(F)=C(C2CCN(C)CC2)C=C1OC(C)C VLBZZCQOAKZGPV-UHFFFAOYSA-N 0.000 description 1
- CFNJLEOIINEZQE-UHFFFAOYSA-N 2-[5-methyl-4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide Chemical compound CC=1C=C(NC=2N=C3C(C=4C=CC=CC=4)=C(C(N)=O)SC3=CN=2)C(OC(C)C)=CC=1C1CCN(C)CC1 CFNJLEOIINEZQE-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- VDNPSDNPBLWMBH-UHFFFAOYSA-N 2-[7-(2-methoxyphenyl)-2-methylsulfanylthieno[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound COC1=CC=CC=C1C1=C(C(C)(C)O)SC2=CN=C(SC)N=C12 VDNPSDNPBLWMBH-UHFFFAOYSA-N 0.000 description 1
- PYXPGUPMCVICSC-UHFFFAOYSA-N 2-[7-(2-methoxyphenyl)-2-methylsulfonylthieno[3,2-d]pyrimidin-6-yl]propan-2-ol Chemical compound COC1=CC=CC=C1C1=C(C(C)(C)O)SC2=CN=C(S(C)(=O)=O)N=C12 PYXPGUPMCVICSC-UHFFFAOYSA-N 0.000 description 1
- YLJDSGUXTKCYEN-UHFFFAOYSA-N 2-[[5-(1-ethylpiperidin-4-yl)-2-propan-2-ylpyrazol-3-yl]amino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound C1CN(CC)CCC1C1=NN(C(C)C)C(NC=2N=C3C(C=4C(=CC=CC=4)OC)=C(C(N)=O)SC3=CN=2)=C1 YLJDSGUXTKCYEN-UHFFFAOYSA-N 0.000 description 1
- QSECPQCFCWVBKM-UHFFFAOYSA-N 2-iodoethanol Chemical compound OCCI QSECPQCFCWVBKM-UHFFFAOYSA-N 0.000 description 1
- VTLLVKUTGUHQNT-UHFFFAOYSA-N 2-methyl-1-(4-nitro-3-propan-2-yloxyphenyl)-N-(oxetan-3-yl)piperidin-3-amine Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(N2C(C(NC3COC3)CCC2)C)=C1 VTLLVKUTGUHQNT-UHFFFAOYSA-N 0.000 description 1
- HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 1
- RMHQDKYZXJVCME-UHFFFAOYSA-N 2-pyridin-4-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=NC=C1 RMHQDKYZXJVCME-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004011 3 membered carbocyclic group Chemical group 0.000 description 1
- UOQNKEMEJXYTRG-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)-2-propan-2-yloxyaniline Chemical compound CC(C)OC1=C(N)C=CC=C1N1CCN(C)CC1 UOQNKEMEJXYTRG-UHFFFAOYSA-N 0.000 description 1
- BEMLWTKUQPQXNH-UHFFFAOYSA-N 3-(oxan-4-yl)-3-oxopropanenitrile Chemical compound N#CCC(=O)C1CCOCC1 BEMLWTKUQPQXNH-UHFFFAOYSA-N 0.000 description 1
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-Aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 1
- FQAWBGAIOYWONH-UHFFFAOYSA-N 3-chloroperoxybenzoic acid Chemical compound OC(=O)C1=CC=CC(OOCl)=C1 FQAWBGAIOYWONH-UHFFFAOYSA-N 0.000 description 1
- AUBBVPIQUDFRQI-UHFFFAOYSA-N 3-hydroxy-4-nitrobenzaldehyde Chemical compound OC1=CC(C=O)=CC=C1[N+]([O-])=O AUBBVPIQUDFRQI-UHFFFAOYSA-N 0.000 description 1
- SITJXRWLFQGWCB-UHFFFAOYSA-N 3-iodo-1-methylpyrazole Chemical compound CN1C=CC(I)=N1 SITJXRWLFQGWCB-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- AABRVDFHSGUMRY-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-(4-nitro-3-propan-2-yloxyphenyl)-1,3,2-dioxaborolane Chemical compound C1=C([N+]([O-])=O)C(OC(C)C)=CC(B2OC(C)(C)C(C)(C)O2)=C1 AABRVDFHSGUMRY-UHFFFAOYSA-N 0.000 description 1
- NOVURLSGKXZYRU-UHFFFAOYSA-N 4-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2-propan-2-yloxyaniline Chemical compound C1=C(N)C(OC(C)C)=CC(C2CC(C)(C)N(C)C(C)(C)C2)=C1 NOVURLSGKXZYRU-UHFFFAOYSA-N 0.000 description 1
- IEEVWPCOBKZSQP-UHFFFAOYSA-N 4-(1-methylpyrazol-3-yl)-2-propan-2-yloxyaniline Chemical compound C1=C(N)C(OC(C)C)=CC(C2=NN(C)C=C2)=C1 IEEVWPCOBKZSQP-UHFFFAOYSA-N 0.000 description 1
- KZIHGYWKGLOCDE-UHFFFAOYSA-N 4-(4-methyl-1,4-diazepan-1-yl)-2-propan-2-yloxyaniline Chemical compound C1=C(N)C(OC(C)C)=CC(N2CCN(C)CCC2)=C1 KZIHGYWKGLOCDE-UHFFFAOYSA-N 0.000 description 1
- SYJUCHNLGDYPKM-UHFFFAOYSA-N 4-N-(1-methylpiperidin-4-yl)-2-propan-2-yloxybenzene-1,4-diamine Chemical compound C1=C(N)C(OC(C)C)=CC(NC2CCN(C)CC2)=C1 SYJUCHNLGDYPKM-UHFFFAOYSA-N 0.000 description 1
- YZIWFJRXUIJATR-UHFFFAOYSA-N 4-[(4-methylpiperazin-1-yl)methyl]-2-propan-2-yloxyaniline Chemical compound C1=C(N)C(OC(C)C)=CC(CN2CCN(C)CC2)=C1 YZIWFJRXUIJATR-UHFFFAOYSA-N 0.000 description 1
- FVPSZXVMKKRZNQ-CQSZACIVSA-N 4-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-2-propan-2-yloxyaniline Chemical compound C1=C(N)C(OC(C)C)=CC(N2C[C@H]3CCCN3CC2)=C1 FVPSZXVMKKRZNQ-CQSZACIVSA-N 0.000 description 1
- UQEANKGXXSENNF-UHFFFAOYSA-N 4-bromo-1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1F UQEANKGXXSENNF-UHFFFAOYSA-N 0.000 description 1
- VQCWSOYHHXXWSP-UHFFFAOYSA-N 4-bromo-2-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C=C1F VQCWSOYHHXXWSP-UHFFFAOYSA-N 0.000 description 1
- PTCPUGKKWNMITF-UHFFFAOYSA-N 4-chloro-2-fluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1F PTCPUGKKWNMITF-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- DZPGYRKQXMJARK-UHFFFAOYSA-N 4-nitro-3-propan-2-yloxybenzaldehyde Chemical compound CC(C)OC1=CC(C=O)=CC=C1[N+]([O-])=O DZPGYRKQXMJARK-UHFFFAOYSA-N 0.000 description 1
- HXDAATULUKRKKG-UHFFFAOYSA-N 5-(4-methylpiperazin-1-yl)-2-propan-2-yloxyaniline Chemical compound C1=C(N)C(OC(C)C)=CC=C1N1CCN(C)CC1 HXDAATULUKRKKG-UHFFFAOYSA-N 0.000 description 1
- OXDWAOVKXGSEAY-UHFFFAOYSA-N 5-(oxan-4-yl)-2-propan-2-ylpyrazol-3-amine Chemical compound C1=C(N)N(C(C)C)N=C1C1CCOCC1 OXDWAOVKXGSEAY-UHFFFAOYSA-N 0.000 description 1
- QQURWFRNETXFTN-UHFFFAOYSA-N 5-fluoro-2-nitrophenol Chemical compound OC1=CC(F)=CC=C1[N+]([O-])=O QQURWFRNETXFTN-UHFFFAOYSA-N 0.000 description 1
- YPPZCRZRQHFRBH-UHFFFAOYSA-N 5-hydroxy-3,4-dihydro-2H-naphthalen-1-one Chemical compound O=C1CCCC2=C1C=CC=C2O YPPZCRZRQHFRBH-UHFFFAOYSA-N 0.000 description 1
- IMIFVLVXAQDYQA-UHFFFAOYSA-N 5-methyl-4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyaniline Chemical compound C1=C(N)C(OC(C)C)=CC(C2CCN(C)CC2)=C1C IMIFVLVXAQDYQA-UHFFFAOYSA-N 0.000 description 1
- PLVVFXPZTQAKMT-UHFFFAOYSA-N 5-methyl-4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyaniline Chemical compound C1=C(N)C(OC(C)C)=CC(N2CCN(C)CC2)=C1C PLVVFXPZTQAKMT-UHFFFAOYSA-N 0.000 description 1
- DFONSRBKCLQCSF-UHFFFAOYSA-N 6-(1-methylpiperidin-4-yl)-4-propan-2-yloxypyridin-3-amine Chemical compound C1=C(N)C(OC(C)C)=CC(C2CCN(C)CC2)=N1 DFONSRBKCLQCSF-UHFFFAOYSA-N 0.000 description 1
- CRMKMMOMVSKZRT-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)-4-propan-2-yloxypyridin-3-amine Chemical compound C1=C(N)C(OC(C)C)=CC(N2CCN(C)CC2)=N1 CRMKMMOMVSKZRT-UHFFFAOYSA-N 0.000 description 1
- SCGNWULOSYKTQP-UHFFFAOYSA-N 6-chloro-3-nitro-1H-pyridin-2-one Chemical compound [O-][N+](=O)C1=CC=C(Cl)NC1=O SCGNWULOSYKTQP-UHFFFAOYSA-N 0.000 description 1
- FVPGXHNJFFHIOR-UHFFFAOYSA-N 7-(2-methoxy-5-methylpyridin-3-yl)-2-[5-methyl-4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=NC=C(C)C=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC(C)=C(C2CCN(C)CC2)C=C1OC(C)C FVPGXHNJFFHIOR-UHFFFAOYSA-N 0.000 description 1
- GLBZYGQWGLXWKB-UHFFFAOYSA-N 7-(2-methoxy-6-methylpyridin-3-yl)-2-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=NC(C)=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(N2CCN(C)CC2)C=C1OC(C)C GLBZYGQWGLXWKB-UHFFFAOYSA-N 0.000 description 1
- REEYRMLDJMEREQ-UHFFFAOYSA-N 7-(2-methoxy-6-methylpyridin-3-yl)-2-[5-methyl-4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=NC(C)=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC(C)=C(N2CCN(C)CC2)C=C1OC(C)C REEYRMLDJMEREQ-UHFFFAOYSA-N 0.000 description 1
- BFISEBNYZAPJHI-UHFFFAOYSA-N 7-(2-methoxyphenyl)-2-(4-piperidin-4-yl-2-propan-2-yloxyanilino)thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(C2CCNCC2)C=C1OC(C)C BFISEBNYZAPJHI-UHFFFAOYSA-N 0.000 description 1
- VIDDZHPJJULPRQ-OAQYLSRUSA-N 7-(2-methoxyphenyl)-2-[4-[(3R)-3-[methyl(oxetan-3-yl)amino]piperidin-1-yl]-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(N2C[C@@H](CCC2)N(C)C2COC2)C=C1OC(C)C VIDDZHPJJULPRQ-OAQYLSRUSA-N 0.000 description 1
- RLJPPYPARTXRJS-UHFFFAOYSA-N 7-(2-methoxyphenyl)-2-[4-[methyl(2-pyrrolidin-1-ylethyl)amino]-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(N(C)CCN2CCCC2)C=C1OC(C)C RLJPPYPARTXRJS-UHFFFAOYSA-N 0.000 description 1
- ISLMPOLNYSOVQB-UHFFFAOYSA-N 7-(2-methoxyphenyl)-2-[[6-(1-methylpiperidin-4-yl)-4-propan-2-yloxypyridin-3-yl]amino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CN=C(C2CCN(C)CC2)C=C1OC(C)C ISLMPOLNYSOVQB-UHFFFAOYSA-N 0.000 description 1
- PWDWOOLNJBKKCC-UHFFFAOYSA-N 7-(2-methoxypyridin-3-yl)-2-[(1-methyl-2-oxo-6-propan-2-yloxy-4,5-dihydro-3H-1-benzazepin-7-yl)amino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=NC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=C(N(C)C(=O)CCC2)C2=C1OC(C)C PWDWOOLNJBKKCC-UHFFFAOYSA-N 0.000 description 1
- DRVZVFNOIVQRIO-UHFFFAOYSA-N 7-(2-methoxypyridin-3-yl)-2-[3-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=NC=CC=C1C(C1=N2)=C(C(N)=O)SC1=CN=C2NC1=CC=CC(N2CCN(C)CC2)=C1OC(C)C DRVZVFNOIVQRIO-UHFFFAOYSA-N 0.000 description 1
- MSQIMQPWGGKJKW-UHFFFAOYSA-N 7-(3-chlorophenyl)-2-[2-methoxy-4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(N2CCC(CC2)N2CCCC2)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=CC(Cl)=C1 MSQIMQPWGGKJKW-UHFFFAOYSA-N 0.000 description 1
- VNQQHFFAESDYGP-UHFFFAOYSA-N 7-(3-methoxyphenyl)-2-[4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC(C=2C3=NC(NC=4C(=CC(=CC=4)C4CCN(C)CC4)OC(C)C)=NC=C3SC=2C(N)=O)=C1 VNQQHFFAESDYGP-UHFFFAOYSA-N 0.000 description 1
- RXMCAIAVVGVTCX-UHFFFAOYSA-N 7-(4-chlorophenyl)-2-[2-methoxy-4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]thieno[3,2-d]pyrimidine-6-carboxamide Chemical compound COC1=CC(N2CCC(CC2)N2CCCC2)=CC=C1NC(N=C12)=NC=C1SC(C(N)=O)=C2C1=CC=C(Cl)C=C1 RXMCAIAVVGVTCX-UHFFFAOYSA-N 0.000 description 1
- ZFEPNHZKFHMDPN-UHFFFAOYSA-N 7-amino-1-methyl-4,5-dihydro-3H-1-benzazepin-2-one Chemical compound C1CCC(=O)N(C)C2=CC=C(N)C=C21 ZFEPNHZKFHMDPN-UHFFFAOYSA-N 0.000 description 1
- JLTVWDFRZOWIBE-UHFFFAOYSA-N 7-amino-1-methyl-6-propan-2-yloxy-4,5-dihydro-3H-1-benzazepin-2-one Chemical compound CN1C(=O)CCCC2=C1C=CC(N)=C2OC(C)C JLTVWDFRZOWIBE-UHFFFAOYSA-N 0.000 description 1
- POIHUFDPEJPROY-UHFFFAOYSA-N 7-amino-1-methyl-8-propan-2-yloxy-4,5-dihydro-3H-1-benzazepin-2-one Chemical compound CN1C(=O)CCCC2=C1C=C(OC(C)C)C(N)=C2 POIHUFDPEJPROY-UHFFFAOYSA-N 0.000 description 1
- CMOLPZZVECHXKN-UHFFFAOYSA-N 7-aminonaphthalene-1,3-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=CC(N)=CC=C21 CMOLPZZVECHXKN-UHFFFAOYSA-N 0.000 description 1
- LGFSAJZSDNYVCW-UHFFFAOYSA-N 7-hydroxy-3,4-dihydro-2H-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC(O)=CC=C21 LGFSAJZSDNYVCW-UHFFFAOYSA-N 0.000 description 1
- GWAQYWSNCVEJMW-UHFFFAOYSA-N 7-nitro-3,4-dihydro-2H-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC([N+](=O)[O-])=CC=C21 GWAQYWSNCVEJMW-UHFFFAOYSA-N 0.000 description 1
- CZZLXRRTQNBYEE-UHFFFAOYSA-N 8-amino-1-methyl-4,5-dihydro-3H-1-benzazepin-2-one Chemical compound C1CCC(=O)N(C)C2=CC(N)=CC=C21 CZZLXRRTQNBYEE-UHFFFAOYSA-N 0.000 description 1
- CECGWIHAUTYIAB-UHFFFAOYSA-N 8-propan-2-yloxy-1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound C1CCC(=O)NC2=CC(OC(C)C)=CC=C21 CECGWIHAUTYIAB-UHFFFAOYSA-N 0.000 description 1
- 101710026151 ALKBH5 Proteins 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N Anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 241000132092 Aster Species 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N Bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- OMUIAYYHDOLFHT-UHFFFAOYSA-N COC=1C=NC=CC=1C1=CC(=C(C=C1)NC=O)OC(C)C Chemical compound COC=1C=NC=CC=1C1=CC(=C(C=C1)NC=O)OC(C)C OMUIAYYHDOLFHT-UHFFFAOYSA-N 0.000 description 1
- HYRBJRAIZAXCOZ-UHFFFAOYSA-M CSC=1N=CC2=C(N=1)C(=C(S2)C(=O)[O-])OS(=O)(=O)C(F)(F)F Chemical compound CSC=1N=CC2=C(N=1)C(=C(S2)C(=O)[O-])OS(=O)(=O)C(F)(F)F HYRBJRAIZAXCOZ-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 108020001318 IL5 Proteins 0.000 description 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 240000008702 Modiola caroliniana Species 0.000 description 1
- 235000010703 Modiola caroliniana Nutrition 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102100020079 NPM1 Human genes 0.000 description 1
- 102100016102 NTRK1 Human genes 0.000 description 1
- 101700043017 NTRK1 Proteins 0.000 description 1
- 101710040036 NUTF2 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N P-Phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N Sodium orthovanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- JBUKJLNBQDQXLI-UHFFFAOYSA-N Sodium perborate Chemical compound [Na+].[Na+].O[B-]1(O)OO[B-](O)(O)OO1 JBUKJLNBQDQXLI-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- JUXHKUAUJXMSJS-UHFFFAOYSA-N [2-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]-7-[2-(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound CC(C)OC1=CC(N2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1SC(CO)=C2C1=CC=CC=C1OC(F)(F)F JUXHKUAUJXMSJS-UHFFFAOYSA-N 0.000 description 1
- HVVHTEGXFQXTGT-UHFFFAOYSA-N [2-[N-(hydroxymethyl)-4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound COC1=CC=CC=C1C1=C(CO)SC2=CN=C(N(CO)C=3C(=CC(=CC=3)N3CCN(C)CC3)OC(C)C)N=C12 HVVHTEGXFQXTGT-UHFFFAOYSA-N 0.000 description 1
- PAMHUNRZHXTXMV-UHFFFAOYSA-N [7-(2-ethoxypyridin-3-yl)-2-[5-methyl-4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound CCOC1=NC=CC=C1C(C1=N2)=C(CO)SC1=CN=C2NC1=CC(C)=C(N2CCN(C)CC2)C=C1OC(C)C PAMHUNRZHXTXMV-UHFFFAOYSA-N 0.000 description 1
- MRZXYVMZIHOPFG-UHFFFAOYSA-N [7-(2-methoxy-6-methylpyridin-3-yl)-2-[5-methyl-4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound COC1=NC(C)=CC=C1C(C1=N2)=C(CO)SC1=CN=C2NC1=CC(C)=C(N2CCN(C)CC2)C=C1OC(C)C MRZXYVMZIHOPFG-UHFFFAOYSA-N 0.000 description 1
- ZRTNIOGXYDQCFI-UHFFFAOYSA-N [7-(2-methoxyphenyl)-2-[4-(1-methylpyrazol-4-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound COC1=CC=CC=C1C(C1=N2)=C(CO)SC1=CN=C2NC1=CC=C(C2=CN(C)N=C2)C=C1OC(C)C ZRTNIOGXYDQCFI-UHFFFAOYSA-N 0.000 description 1
- ARWLJKOPLNORAI-UHFFFAOYSA-N [7-(2-methoxypyridin-3-yl)-2-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound COC1=NC=CC=C1C(C1=N2)=C(CO)SC1=CN=C2NC1=CC=C(N2CCN(C)CC2)C=C1OC(C)C ARWLJKOPLNORAI-UHFFFAOYSA-N 0.000 description 1
- SWRGFJBGNAEJOY-UHFFFAOYSA-N [7-(5-fluoro-2-methoxyphenyl)-2-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound COC1=CC=C(F)C=C1C(C1=N2)=C(CO)SC1=CN=C2NC1=CC=C(N2CCN(C)CC2)C=C1OC(C)C SWRGFJBGNAEJOY-UHFFFAOYSA-N 0.000 description 1
- JRXAMIJSXFPIRG-UHFFFAOYSA-N [7-(5-fluoro-2-methoxypyridin-3-yl)-2-[(5-methyl-2-propan-2-ylpyrazol-3-yl)amino]thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound COC1=NC=C(F)C=C1C(C1=N2)=C(CO)SC1=CN=C2NC1=CC(C)=NN1C(C)C JRXAMIJSXFPIRG-UHFFFAOYSA-N 0.000 description 1
- LLALZKLTINZPJU-UHFFFAOYSA-N [7-(5-fluoro-2-methoxypyridin-3-yl)-2-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound COC1=NC=C(F)C=C1C(C1=N2)=C(CO)SC1=CN=C2NC1=CC=C(N2CCN(C)CC2)C=C1OC(C)C LLALZKLTINZPJU-UHFFFAOYSA-N 0.000 description 1
- MOJYEZSWKAOYIO-YSSOQSIOSA-N [N+](=O)([O-])C1=C(C=C(C=C1)N1C[C@@H](CCC1)NC(OC(CC)C)=O)OC(C)C Chemical compound [N+](=O)([O-])C1=C(C=C(C=C1)N1C[C@@H](CCC1)NC(OC(CC)C)=O)OC(C)C MOJYEZSWKAOYIO-YSSOQSIOSA-N 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 239000001164 aluminium sulphate Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- FCLMISQJLYDDFI-UHFFFAOYSA-N benzyl N-[4-(1-methyl-3-oxopiperidin-4-yl)-2-propan-2-yloxyphenyl]carbamate Chemical compound CC(C)OC1=CC(C2C(CN(C)CC2)=O)=CC=C1NC(=O)OCC1=CC=CC=C1 FCLMISQJLYDDFI-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- NFYSPCDOUJCKBJ-UHFFFAOYSA-N butan-2-yl 7-(4-amino-3-propan-2-yloxyphenyl)-1,7-diazaspiro[4.4]nonane-1-carboxylate Chemical compound CCC(C)OC(=O)N1CCCC11CN(C=2C=C(OC(C)C)C(N)=CC=2)CC1 NFYSPCDOUJCKBJ-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000000279 calcium ferrocyanide Substances 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-N carbonic acid;silver Chemical compound [Ag].OC(O)=O LKZMBDSASOBTPN-UHFFFAOYSA-N 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 230000001143 conditioned Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000542 fatty acid esters of ascorbic acid Substances 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- AKPUJVVHYUHGKY-UHFFFAOYSA-N hydron;propan-2-ol;chloride Chemical compound Cl.CC(C)O AKPUJVVHYUHGKY-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- CBUDZRZIGMEWPU-YSMPRRRNSA-N methyl (2Z)-2-[[3-[[3-cyano-4-methyl-6-(trifluoromethyl)pyridin-2-yl]sulfanylmethyl]-4-methoxyphenyl]methylidene]-5-[4-(dimethylamino)phenyl]-7-methyl-3-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate Chemical compound O=C1N2C(C=3C=CC(=CC=3)N(C)C)C(C(=O)OC)=C(C)N=C2S\C1=C/C(C=1)=CC=C(OC)C=1CSC1=NC(C(F)(F)F)=CC(C)=C1C#N CBUDZRZIGMEWPU-YSMPRRRNSA-N 0.000 description 1
- YCDZDWBOHMOKLL-UHFFFAOYSA-N methyl 2-[N-formyl-5-methyl-4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]-7-(2-methoxy-6-methylpyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(N(C=O)C=3C(=CC(=C(C)C=3)N3CCN(C)CC3)OC(C)C)N=C2C=1C1=CC=C(C)N=C1OC YCDZDWBOHMOKLL-UHFFFAOYSA-N 0.000 description 1
- SHUVSCKIPWHSCP-UHFFFAOYSA-N methyl 2-methylsulfanyl-7-phenylthieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(SC)N=C2C=1C1=CC=CC=C1 SHUVSCKIPWHSCP-UHFFFAOYSA-N 0.000 description 1
- ZOTWORXJAWLEBJ-UHFFFAOYSA-N methyl 2-methylsulfonyl-7-phenylthieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(S(C)(=O)=O)N=C2C=1C1=CC=CC=C1 ZOTWORXJAWLEBJ-UHFFFAOYSA-N 0.000 description 1
- PSBLUGJWGGDSKM-UHFFFAOYSA-N methyl 5-chloro-2-methylsulfanylpyrimidine-4-carboxylate Chemical compound COC(=O)C1=NC(SC)=NC=C1Cl PSBLUGJWGGDSKM-UHFFFAOYSA-N 0.000 description 1
- LBKMESFWLKJBJJ-UHFFFAOYSA-N methyl 7-(1-methylpyrazol-4-yl)-2-methylsulfinylthieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(S(C)=O)N=C2C=1C=1C=NN(C)C=1 LBKMESFWLKJBJJ-UHFFFAOYSA-N 0.000 description 1
- IZJJBLNPTACUTP-UHFFFAOYSA-N methyl 7-(2-ethoxyphenyl)-2-methylsulfonylthieno[3,2-d]pyrimidine-6-carboxylate Chemical compound CCOC1=CC=CC=C1C1=C(C(=O)OC)SC2=CN=C(S(C)(=O)=O)N=C12 IZJJBLNPTACUTP-UHFFFAOYSA-N 0.000 description 1
- IURVXNSSIPITBL-UHFFFAOYSA-N methyl 7-(2-methoxy-6-methylpyridin-3-yl)-2-methylsulfonylthieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(S(C)(=O)=O)N=C2C=1C1=CC=C(C)N=C1OC IURVXNSSIPITBL-UHFFFAOYSA-N 0.000 description 1
- VALGZNNMAYMJCX-UHFFFAOYSA-N methyl 7-(2-methoxyphenyl)-2-[4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxylate Chemical compound N1=C2C(C=3C(=CC=CC=3)OC)=C(C(=O)OC)SC2=CN=C1NC(C(=C1)OC(C)C)=CC=C1C1CCN(C)CC1 VALGZNNMAYMJCX-UHFFFAOYSA-N 0.000 description 1
- LPJLSJBTTFGLJR-UHFFFAOYSA-N methyl 7-(2-methoxyphenyl)-2-methylsulfonylthieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(S(C)(=O)=O)N=C2C=1C1=CC=CC=C1OC LPJLSJBTTFGLJR-UHFFFAOYSA-N 0.000 description 1
- XTRWETCXNUNVOI-UHFFFAOYSA-N methyl 7-(4-fluoro-2-methoxyphenyl)-2-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]thieno[3,2-d]pyrimidine-6-carboxylate Chemical compound N1=C2C(C=3C(=CC(F)=CC=3)OC)=C(C(=O)OC)SC2=CN=C1NC(C(=C1)OC(C)C)=CC=C1N1CCN(C)CC1 XTRWETCXNUNVOI-UHFFFAOYSA-N 0.000 description 1
- KVOKLCDSLBQDRG-UHFFFAOYSA-N methyl 7-(4-fluoro-2-methoxyphenyl)-2-methylsulfonylthieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(S(C)(=O)=O)N=C2C=1C1=CC=C(F)C=C1OC KVOKLCDSLBQDRG-UHFFFAOYSA-N 0.000 description 1
- FGRGDEFUWGAGNZ-UHFFFAOYSA-N methyl 7-(4-fluorophenyl)-2-methylsulfanylthieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(SC)N=C2C=1C1=CC=C(F)C=C1 FGRGDEFUWGAGNZ-UHFFFAOYSA-N 0.000 description 1
- QPNGNXMMUXZFPC-UHFFFAOYSA-N methyl 7-(5-fluoro-2-methoxyphenyl)-2-methylsulfonylthieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(S(C)(=O)=O)N=C2C=1C1=CC(F)=CC=C1OC QPNGNXMMUXZFPC-UHFFFAOYSA-N 0.000 description 1
- BOZDEEDJNHIQNN-UHFFFAOYSA-N methyl 7-(6-methoxypyridin-2-yl)-2-methylsulfanylthieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(SC)N=C2C=1C1=CC=CC(OC)=N1 BOZDEEDJNHIQNN-UHFFFAOYSA-N 0.000 description 1
- UTWUHBKLGPJLTI-UHFFFAOYSA-N methyl 7-[2-(difluoromethoxy)phenyl]-2-methylsulfanylthieno[3,2-d]pyrimidine-6-carboxylate Chemical compound COC(=O)C=1SC2=CN=C(SC)N=C2C=1C1=CC=CC=C1OC(F)F UTWUHBKLGPJLTI-UHFFFAOYSA-N 0.000 description 1
- CNCMVGXVKBJYNU-UHFFFAOYSA-N methyl oxane-4-carboxylate Chemical compound COC(=O)C1CCOCC1 CNCMVGXVKBJYNU-UHFFFAOYSA-N 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108010025568 nucleophosmin Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- GUWZGMWHDAJAOC-UHFFFAOYSA-N oxoplatinum;hydrate Chemical compound O.[Pt]=O GUWZGMWHDAJAOC-UHFFFAOYSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
- PEUGKEHLRUVPAN-UHFFFAOYSA-N piperidin-3-amine Chemical compound NC1CCCNC1 PEUGKEHLRUVPAN-UHFFFAOYSA-N 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- VQGISNOMGHCEPX-UHFFFAOYSA-N propanenitrile Chemical compound C[CH]C#N VQGISNOMGHCEPX-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- YPOXGDJGKBXRFP-UHFFFAOYSA-M pyrimidine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-M 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940075581 sodium bromide Drugs 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- LZBANXJWOBNBLH-UHFFFAOYSA-N tert-butyl 1,7-diazaspiro[4.4]nonane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC11CNCC1 LZBANXJWOBNBLH-UHFFFAOYSA-N 0.000 description 1
- GJZHXLNQQNAXNW-UHFFFAOYSA-N tert-butyl 2-ethyl-4-oxopiperidine-1-carboxylate Chemical compound CCC1CC(=O)CCN1C(=O)OC(C)(C)C GJZHXLNQQNAXNW-UHFFFAOYSA-N 0.000 description 1
- VSLLBQBSHAGKLC-UHFFFAOYSA-N tert-butyl 4-(2-cyanoacetyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C(=O)CC#N)CC1 VSLLBQBSHAGKLC-UHFFFAOYSA-N 0.000 description 1
- DRAARPHSFOTACG-UHFFFAOYSA-N tert-butyl 4-(4-amino-3-propan-2-yloxyphenyl)piperidine-1-carboxylate Chemical compound C1=C(N)C(OC(C)C)=CC(C2CCN(CC2)C(=O)OC(C)(C)C)=C1 DRAARPHSFOTACG-UHFFFAOYSA-N 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Abstract
The present invention relates to compounds of formula (I):
Description
NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION
THEREOF AND THERAPEUTIC USES THEREOF
The présent invention relates to novel thienopyrimidine dérivatives, to processes for the préparation thereof, and also to the therapeutic uses thereof, in particular as anticancer agents via ALK kinase inhibition.
The présent invention also relates to pharmaceutical compositions containing these dérivatives, which hâve anticancer activity via ALK kinase modulation.
îo At the current time, most commercial compounds used in chemotherapy are cytotoxic compounds which pose considérable problems in terms of side effects and tolérance by patients. These effects could be limited insofar as the medicines used act selectively on cancer cells, with exclusion of healthy celis. One of the solutions for limiting the adverse effects of chemotherapy can therefore consist of the use of medicines which act on is metabolic pathways or constituent éléments of these pathways, expressed predominantly in cancer cells, and which would be expressed little or not at ail In healthy cells. Protein kinases are a family of enzymes which catalyze the phosphorylation of hydroxyl groups of spécifie residues of proteins, such as tyrosine, serine or threonine residues. Such phosphorylations can widely modify the function of proteins: thus, protein kinases play an 20 important rôle in the régulation of a large variety of cell processes, including in particular metabolism, cell prolifération, cell adhesion and motility, cell différentiation or cell survival, some protein kinases playing a central rôle in the initiation, development and completion of cell cycle events.
Among the various cell fonctions in which the activity of a protein kinase is involved, 25 certain processes represent attractive targets for treating certain diseases. As an example, mention may particularly be made of angiogenesis and control of the cell cycle and also the control of cell prolifération, in which processes protein kinases can play an essential rôle. These processes are in particular essential for the growth of solid tumours and also other diseases. In particular, molécules which inhibit such kinases are capable of 30 limiting undesired cell proliférations such as those observed in cancers, and can intervene In the prévention, régulation or treatment of neurodegenerative diseases such as Alzheimeris disease or else neuronal apoptosis.
The ALK kinase (or anaplastic lymphoma kinase) is a tyrosine kinase receptor, which belongs to the insulin receptor subfamily. ALK is expressed predominantly in the brain of 35 newbom babies, which suggests a possible rôle for ALK in brain development.
t
ALK was initially identified in the form of a constitutively activated, oncogenic fusion protein in large cell anaplastic lymphomas. It has in particular been demonstrated that the mutant protein nucleophosmin (NMP)/ALK has an active tyrosine kinase domain responsible for its oncogenic activity (Falini, B. et al., Blood, 1999, 94, 3509-3515; Morris, S.W. et al., Brit. J. Haematol, 2001, 113, 275-295; Duyster et al.; Kutok & Aster). Recently, fusion proteins of similar forms hâve been identified in other types of human cancers: DLBCL diffuse large B-cell lymphoma, IMT inflammatory myofibroblastic tumour, ovarian cancer, breast cancer, colorectal cancer, glioblastoma, and also in non-small cell lung carcinomas (NSCLC). NSCLC cancers are common and léthal in human beîngs. Moreover, ALK gene amplifications and also active mutations hâve been found In neuroblastomas. In healthy adults, ALK expression is low and remains confined to neuronal tissues. ALK is therefore a therapeutic target in many types of cancers (Cheng and Ott, Anti-Cancer Agents in Médicinal Chemistry, 2010,10, 236-249).
The objective of the présent invention is to provide novel ALK kinase-inhibiting compounds intended for cancer treatment.
Thus, the présent invention relates to compounds of formula (I):
R7 wherein:
R6 is -CONH2 or a -C(Ra)(Rp)(OH) group in which R, and Rp are, independently of one another, a hydrogen atom or a (CrCe) alkyl group or together form, with the carbon atom which bears them, a 3- to 5-menrtbered carbocycle;
R is a phenyl or heteroaryl group substituted with R1, R’1, R2 and R3;
R1 is a hydrogen atom or Is selected from the following groups: (Ci-Cs)alkyl, (CiCe)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted with one or several substituents selected, Independently in each instance, from: amino, hydroxyl, thiol, halogen, (Cf-CeJalkyl, (Ci-Ce)alkoxy, (Ci-Ce)alkylthîo, (C,Ce)alkylamino, aryloxy, aryl(Ci-Ce)alkoxy, cyano, halo(CrCe)alkyl, carboxyl and carboxy(Ci-Ce)alkyl;
R'1 is a hydrogen atom or a (Ci-Ce)alkoxy group;
R2 is selected from:
- a hydrogen atom, a halogen atom, or a (CrCe)alkyl, (C3-C7)cycloalkyl or (Cr
Ce) alkoxy group;
- a heterocycloalkyl, heterocycloalkyl-CHr or heteroaryl group;
wherein each said heterocycloalkyl, heterocycloalkyl-CH2- and heteroaryl group is optionally substituted with one or several substituents selected, to independently in each instance, from: (CrCe)alkyl, (Ca-C^cycioalkyl, (CrCe)alkoxy, heterocycloalkyl, carboxy(CrCe)alkyl, NR4R5 and 0R4;
said (Ct-Ce)alkyi group being optionally substituted with a halogen atom or a (CrCe)alkoxy, heterocycloalkyl, NHZ or OH group; and
R4 and R5 being each, independently of one another, a hydrogen atom, a 15 (CpCeJalkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;
- an NRaRb group, where Ra and Rb are, independently of one another:
. a hydrogen atom;
.a heterocycloalkyl group, said heterocycloalkyl group being optionally substituted with a (CrCe)alkyl group; or . a (Ct-Ce)alkyl group, said alkyl group being optionally substituted with an NR4R5 group;
R4 and R5 being each, independently of one another, a hydrogen atom, a 25 (CrCe)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;
R3 is a hydrogen atom, a halogen atom or a (CrCejalkyl group;
wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyl ring fused with the phenyl bearing them, this heterocycloalkyl being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (CrCe)alkyl group;
t t
R7 is an aryl group or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (CrCeJalkyl, OR’4, CH2OH, CH2NH2, S(O)nR'4, R8 and 0R8;
wherein:
R’4 is a hydrogen atom or a (CrCe)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
n is 1 or 2; and
R8 is a halo(CrCe)alkyl group.
In the compounds of general formula (I), the nitrogen atom(s) can optionally be in oxidized form (N-oxide).
The présent invention also relates to compounds of formula (Γ):
CD in which:
R ls a phenyl or heteroaryl group substituted with R1, R‘1, R2 and R3;
R1 is a hydrogen atom or is selected from the following groups: (Ci-Ce)alkyl, (Ci· Ce)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted with one or several substituents selected, independently in each instance, from: amino, hydroxyl, thiol, halogen, (Ci-Ce)alkyl, (CrCe)alkoxy, (Ci-Ce)alkylthio1 (Ci-Ce)alkylamino, aryloxy, aryl(Cr Ce)alkoxy, cyano, halo(C1-Ce)alkyl, carboxyl and carboxy(Ci-Ce)alkyl;
R'1 is a hydrogen atom or a (CrCeïalkoxy group;
R2 is selected from:
- a hydrogen atom, a halogen atom, or a (Ci-Ce)alkyl, (Cs-Crïcycloalkyl or (Ci-Ce)alkoxy group;
- a heterocycloalkyl, heterocycloalky1-CH2- or heteroaryl group;
wherein each said heterocycloalkyl, heterocycloalkyl-CH2- and heteroaryl group ls optionally substituted with one or several substituents selected, independently in each · instance, from: (Ci-Ce)alkyl, (Ca-Czjcycloalkyl, (Ci-Ce)alkoxy, heterocycloalkyl, carboxy(CrCe)alkyl, NR4R5 and 0R4;
said (CrCe)alkyl group being optionally substituted with a halogen atom or a (C,Ce)alkoxy, heterocycloalkyl, NH2 or OH group; and · an NRaRb group, where Ra and Rb are, Independently of one another:
. a hydrogen atom;
. a heterocycloalkyl group, said heterocycloalkyl group being optionally substituted with a (CrCe)alkyl group; or . a (CrCfl)alkyl group, said alkyl group being optionally substituted with an NR4R5 group; îo R4 and R5 being, independently of one another, a hydrogen atom, a (Ct-Ce)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7membered ring;
R3 Is a hydrogen atom, a halogen atom or a (Ct-Ce)alkyl group;
wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyl ring fused with the phenyl bearing them, this heterocycloalkyl being optionally substituted with one or several substituents selected, 20 independently ln each Instance, from: an oxo group and a (Ci-Ce)alkyl group;
R7 is an aryl or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (CiCe)alkyl, OR‘4, CH2OH, CH2NH2, S(O)nR’4, R8 and OR8;
wherein:
R'4 is a hydrogen atom or a (Ct-Ce)alkyl or aryl group; said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
n is 1 or 2;
R8 is a halo(Ci-Ce)alkyl group.
The présent invention also relates to compounds of formula (I):
d) in which:
»
Ra and Rp are, independently of one another, a hydrogen atom or a (CrC9)aîkyl group; or Ra and Rp can together form, with the carbon atom bearing them, a 3- to 5-membered carbocycle;
R is a phenyl or heteroaryl group substituted with R1, R'1, R2 and R3;
R1 is a hydrogen atom or is selected from the following groups: (CrCe)alkyl, (CrCe)alkoxy, (Ca-Cyjcycloalkyl and aryl, these groups being optionally substituted with one or several substituents selected, independently in each instance, from: amino, hydroxy!, thiol, halogen, (CrCeJalkyl, (Cf-Cejalkoxy, (Ci-Ce)alkylthio, (Ci-Ce)alkylamino, aryloxy, arylÎCrCeJalkoxy, cyano, halo(CrCe)alkyl, carboxyl and carboxy(CrCe)alkyl;
R'1 represents a hydrogen atom or a (CrCeJalkoxy group;
R2 is selected from:
- a hydrogen atom, a halogen atom, or a (Cf-CeJalkyl, (C3-C7)cycloalkyl or (CrCeJalkoxy group;
- a heterocycloalkyl, heterocycloalkyl-CHr or heteroaryl group;
wherein each said heterocycloalkyl, heterocycloalkyl-CHr and heteroaryl group is optionally substituted with one or several substituents selected, independently in each instance, from: (CrCeJalkyl, (Ca-Crjcycloalkyl, (Ci-Ce)alkoxy, heterocycloalkyl, carboxy(CrCe)alkyl, NR4R5 and 0R4;
said alkyl group being optionally substituted with a halogen atom or a (CrCe)alkoxy, heterocycloalkyl, NH2 or OH group; and
- an NRaRb group, where Ra and Rb are, independently of one another:
. a hydrogen atom;
. a heterocycloalkyl group, said heterocycloalkyl group being optionally substituted with a (CrCe)alkyl group; or . a (CrCe)alkyl group, said alkyl group being optionally substituted with an NR4R5 group; wherein:
R4 and R5 each is, independently of one another, a hydrogen atom, a (Ci-Ce)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;
R3 is a hydrogen atom, a halogen atom or a (CrCe)alkyl group;
* f wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyl ring fused with the phenyl bearing them, this heterocycloalkyl being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (CrCe)alkyl group:
R7 is an aryl group or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (Cr Ce)alkyl, OR'4, CH2OH, CH2NH2, S(O)nR’4, R8 and 0R8;
wherein:
R'4 Is a hydrogen atom or a (CrC0)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
n is 1 or 2;
R8 is a halo(C1-C0)alkyl group.
Also within the présent invention are the precursors (prodrugs) of the compounds of formula (I).
The compounds of formula (I), (Γ) or (Γ) can comprise one or more asymmetric carbon atoms. They can therefore exîst in the form of enantiomers or of diastereoisomers. These enantiomers and diastereoisomers, and also mixtures thereof, including racemic mixtures, form part of the invention.
The compounds of formula (I), (Γ) or (I) can exist ln the form of bases or of addition salts with acids. Such addition salts form part of the invention.
The compounds of formula (I), (Γ) or (I) can exist in the form of pharmaceutically acceptable salts.
These salts can be prepared with pharmaceutically acceptable acids, but the salts of other acids that are of use, for example, for purifying or isolating the compounds of formula (I), (Γ) or (I”) also form part of the invention.
ln the context of the présent invention:
- the expression C,-^ where t and z can take the values from 1 to 7 means a carbonbased chain which can hâve from t to z carbon atoms, for example CrC3 means a carbon-based chain which can hâve from 1 to 3 carbon atoms;
- the term a halogen atom means: a fluorine, a chlorine, a bromine or an iodine;
- the term an aîkyl group means: a linear or branched, saturated, hydrocarbon-based aliphatic group comprising, unless otherwise mentîoned, from 1 to 12 carbon atoms. By way of examples, mention may be made of methyl, ethyi, n-propyl, isopropyl, butyl, isobutyl, tert-butyl or pentyl groups;
s - the term a cycloalkyl group means: a cyclic carbon-based group comprising, unless otherwise mentîoned, from 3 to 6 carbon atoms. By way of examples, mention may be made of cydopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. groups;
- the term a haloalkyl group means: an alkyl group as defined above, in which one or more of the hydrogen atoms is (are) replaced with a halogen atom. By way of example, to mention may be made of fluoroalkyls, in particular CF3 or CHF2;
- the term an alkoxy group means: an -O-alkyl radical where the alkyl group is as previously defined. By way of examples, mention may be made of -O-(Ci-C4)alkyl groups, and in particular the -O-methyl group, the -O-ethyl group as -O-C3alkyl group, the -Opropyl group, the -O-lsopropyl group, and as -O-C^alkyl group, the -O-butyl, -O-isobutyl or is -O-tert-butyl group;
- the term aryl group means: a cyclic aromatic group comprising between 6 and 10 carbon atoms. By way of examples of aryl groups, mention may be made of phenyl or naphthyl groups;
- the term a heteroaryl means: a 5- to 10-membered aromatic monocydic or bicydic 20 group containing from 1 to 4 heteroatoms selected from O, S or N. By way of examples, mention may be made of imidazolyl, thiazolyl, oxazolyl, furanyl, thiophenyl, pyrazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzimidazolyl, indazolyl, benzothiazolyl, isobenzothiazolyl, benzotriazolyl, quinolinyl and isoquinolinyl groups;
by way of a heteroaryl comprising 5 to 6 atoms, including 1 to 4 nitrogen atoms, mention may in particular be made of the following représentative groups: pyrrolyl, pyrazolyl, 1,2,3triazoly1,1,2,4-triazolyl, tetrazolyl and 1,2,3-triazinyl;
Mention may also be made, by way of heteroaryl, of thiophenyl, oxazolyl, furazanyl, 1,2,4thiadiazolyl, naphthyridinyl, quinoxalinyl, phthalazinyl, imidazo[1,2-a]pyridine, imidazo[2,130 b]thiazolyl, cinnolinyl, benzofurazanyl, azaindolyl, benzimidazolyl, benzothiophenyl, thienopyridyl, thienopyrimidinyl, pyrrolopyridyl, imidazopyridyl, benzoazaindole, 1,2,4-triazinyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, purinyl, quinazolinyl, quinolinyl, isoquinolyl, 1,3,4-thiadiazolyl, thiazolyl, isothiazolyl, carbazolyl, and also the corresponding groups resulting from their fusion or from fusion with the phenyl nucléus;
- the term a heterocycloalkyl means: a 4- to 10-membered, saturated or partially unsaturated, monocydic or bicydic group comprising from one to three heteroatoms selected from O, S or N; the heterocycloalkyl group may be attached to th© rest of the molécule via a carbon atom or via a heteroatom; the term bicyclic heterocycloalkyl includes fused bicycles and spiro-type rings.
By way of saturated heterocycloalkyl comprising from 5 to 6 atoms, mention may be made 5 of oxetanyl, tetrahydrofuranyl, dioxolanyl, pyrrolidinyl, azepinyl, oxazepinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl, dithiolanyl, thiazolidinyl, tetrahydropyranyl, tetrahydropyridinyl, dioxanyl, morpholinyl, piperidinyl, piperazinyl, tetrahydrothiopyranyl, dithianyl, thiomorpholinyl or isoxazolidinyl.
Among the heterocycloalkyls, mention may also be made, by way of examples, of bicyclic ίο groups such as (8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, octahydroindozilinyl, diazepanyl, dihydrolmidazopyrazinyl and diazablcycloheptanyl groups, or else diazaspiro rings such as 1,7-diazaspiro[4.4]non-7-yl or 1 -ethyi-1,7-diazaspiro[4.4]non-7-yl.
When the heterocycloalkyl is substituted, the substitution(s) may be on one (or more) carbon atom(s) and/or on the heteroatom(s). When the heterocycloalkyl comprises 15 several substituents, they may be borne by one and the same atom or different atoms.
The abovementioned alkyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl radicals can be substituted with one or more substituents. Among these substituents, mention may be made of the following groups: amino, hydroxyl, thiol, oxo, halogen, alkyl, alkoxy, alkytthio, alkylamino, aryloxy, arylalkoxy, cyano, trifluoromethyl, carboxy or 20 carboxyalkyl;
- the term an alkytthio means: an -S-alkyl group, the alkyl group being as defîned above;
- the term an alkylamino means: an -NH-alkyl group, the alkyl group being as defîned above;
- the term an aryloxy means: an -O-aryl group, the aryl group being as defîned above;
- the term an arylalkoxy means: an aryl-alkoxy- group, the aryl and alkoxy groups being as defîned above;
- the term a carboxyalkyl means: an HOOC-alkyl- group, the alkyl group being as defîned above. As examples of carboxyalkyl groups, mention may in particular be made of carboxymethyl or carboxyethyl;
- the term a carboxyl means: a COOH group;
- the term an oxo means: B=O.
When an alkyl radical is substituted with an aryl group, the term arylalkyl or aralkyl radical is used. The arylalkyl or aralkyl radicals are aryl-alkyl- radicals, the aryl and alkyl groups being as defîned above. Among the arylalkyl radicals, mention may in particular be made of the benzyl or phenethyl radicals.
ιο
Subgroup 1 is defined by the compounds of formula (I) for which:
R6 is -CONH2 or a -C(Ro)(Rp)(OH) group in which Ra and Rp are, independently of one another, a hydrogen atom or a (Ci-Ce)alkyl group.
Subgroup 2 is defined by the compounds of formula (I) for which:
R6 is -CONH2, -CH2OH or C(CH3)2OH.
Subgroup 3 is defined by the compounds of formula (I) for which:
R is a phenyl, pyridinyl or pyrazolyl group substituted with R1, R’1, R2 and R3; R1, R’1, 10 R2 and R3 being as defined in formula (I).
Subgroup 4 is defined by the compounds of formula (I) for which:
R1, R'1, R2 and R3 being as defined in formula (I).
Subgroup 5 is defined by the compounds of formula (I) for which:
R1, R’1, R2 and R3 being as defined in formula (I).
Subgroup 6 is defined by the compounds of formula (I) for which: R is an (A) group
(A)
R2
R1, R'1, R2 and R3 being as defined in formula (I).
îo Subgroup 7 is defined by the compounds of formula (I) for which:
R1 is a hydrogen atom or is selected from the following groups: (CrCeJalkyl, such as methyl or isopropyl, (CrCe)alkoxy, such as methoxy or isopropyloxy, (C3-C7)cycloalkyl, such as cyclobutyl, and aryl, such as phenyl.
is Subgroup 8 is defined by the compounds of formula (I) for which:
R1 is an isopropyloxy group.
Subgroup 9 is defined by the compounds of formula (I) for which:
R'1 is an hydrogen atom or an isopropyloxy group.
Subgroup 10 is defined by the compounds of formula (I) for which:
R’1 is a hydrogen atom.
Subgroup 11 is defined by the compounds of formula (I) for which:
R2 is selected from:
- a hydrogen or chlorine atom, or a methyl, cyclopropyl or methoxy group;
-a pyrrolldinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1,4diazepan-1-yl, diazabicydoheptanyl, (8aR)-hexahydropyrrolo[1,2-a]pyrazîn-2(1H)-yl, 1,7diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CHj, 30 pyrazolyl, imidazolyl, triazolyl or pyridiny! group;
these groups being optionally substituted with one or more substituents selected, independently in each instance, from: (CrCe)alkyl, (C3-C7)cycloalkyl, (Cj-CeJalkoxy, heterocycloalkyl, carboxy(CrCe)alkyl, NR4R5 and 0R4;
said (Cf-Cejalkyl group being optionally substituted with a halogen atom or a (Cr
Ce)alkoxy, heterocycloalkyl, NH2 or OH group; and
R4 and R5 each is, independently of one another, a hydrogen atom, a (CrCe)alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring, such as pyrrolidinyl;
- an NRaRb group, where Ra and Rb are, independently of one another:
. a hydrogen atom;
. a piperidinyl group or tetrahydropyranyl group, wherein each of said piperidinyl and tetrahydropyranyl groups is independently optionally substituted with a (Ci*Ce)alkyl group, such as methyl; or to . a methyl or ethyl group, said group being optionally substituted with an NR4R5 group; wherein:
R4 and R5 each is, independently of one another, a hydrogen atom, a (CrCe)alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4· to 15 7-membered ring, such as pyrrolidinyl;
R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrCB)alkyl group, such as a methyl;
and when R corresponds to formula (A), R2 and R3 can together form an azepinyl or oxazepinyl ring fused with the phenyl bearing them, this azepinyl or oxazepinyl being 20 optionally substituted with one or more substituents selected, independently in each instance, from: an oxo group and a (Ci-Ce)alkyl group, such as methyl.
Subgroup 12 is defined by the compounds of formula (I) for which:
R2 is a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1,425 dia2epan-1-yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, 1,7dia2aspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, pipera2inyl-CH2l pyrazolyl, imidazolyl, triazolyl or pyridinyl group;
these groups being optionally substituted with at least one substituent selected from: (Cr Ce)alkyl, such as methyl, ethyl or isopropyl, (C3-C7)cycloalkyl, such as cyclopropyl, (Cr 30 Ce)alkoxy, such as methoxy, heterocycloalkyl, such as oxetanyl or pyrrolidinyl, carboxytCrCeJalkyl, such as C(O)O(CH3)31 NR4R5 and OH;
said alkyl group being optionally substituted with a (Ci-Ce)alkoxy group, such as methoxy, or OH;
R4 and R5 being, independently of one another, a hydrogen atom, a (CrCe)alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7membered ring, such as pyrrolidinyl;
R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (C1-Ce)alkyl group, such as a methyl.
Subgroup 13 is defined by the compounds of formula (I) for which:
R2 Is a piperidinyi or piperazinyl group, these groups being optionally substituted with at least one substituent selected from: (CrCeJalkyl, (C3-C7)cycloalkyl, (CrCeJalkoxy, heterocycloalkyi, carboxyiCf-Ceïalkyl, NR4R5 and 0R4;
said alkyl group being optionally substituted with a halogen atom or a (CrC^alkoxy, heterocycloalkyi, NH2 or OH group;
R4 and R5 being as defined in formula (I);
R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrCe)alkyl group, such as a methyl.
Subgroup 14 is defined by the compounds of formula (I) for which:
R2 is a piperidinyi or piperazinyl group, these groups being optionally substituted with at least one substituent selected from: a methyl, ethyl, Isopropyl, cyclopropyl, OH, oxetanyl, pyrrolidinyl, C(O)O(CH3)3, NR4R5 and 0R4 group;
said methyl, ethyl and Isopropyl groups being optionally substituted with a (Ci-Ce)alkoxy group, such as methoxy, or with an OH;
R4 and R5 being, independently of one another, a hydrogen atom, a (CrCe)alkyl group, such as methyl, or a heterocycloalkyi group, such as oxetanyl;
R3 is a hydrogen or fluorine atom or a methyl.
Subgroup 15 is defined by the compounds of formula (I) for which:
R2 is a piperidinyi or piperazinyl group, these groups being optionally substituted with at least one substituent selected from: a methyl, ethyl or isopropyl group:
R3 is a hydrogen or fluorine atom or a methyl.
Subgroup 16 is defined by the compounds of formula (I) for which: R2 is a group selected from the foliowing groups:
'Ό- KX k^· fcT i<ç «4 fgÇ
FO*“\ ^O1- i-CH
R3 is a hydrogen or fluorine atom or a methyl.
Subgroup 17 is defined by the compounds of formula (I) for which:
R7 Is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each 25 Instance, from: cyano, halogen, (Ct-Ce)alkyl, OR’4, CH2OH, CH2NH2, S(O)nR’4, R8 and 0R8;
wherein:
R'4 is a hydrogen atom or a (Ci-Ce)alky! or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
n îs 1 or 2;
R8 îs a halo(CrCe)alkyl group.
Subgroup 18 is defined by the compounds of formula (I) for which:
R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents independently selected from: cyano, halogen, such as chlorine or fluorine, (Ct-Ce)alkyi, such as methyi, OR'4, CH2OH, 5 CH2NH2, S(0)nR’4 and 0R8;
wherein:
R'4 is a (Ct-CB)alkyl group, such as methyi or ethyl;
n is 1;
R8 is a halo(CrC6)alkyi group, such as CF3 or CHF2.
Subgroup 19 is defined by the compounds of formula (I) for which R, R6 and R7 are defined in one of subgroups 1 to 18 above.
Subgroup 20 is defined by the compounds of formula (I) for which:
R6 Is -CONH2 or a -C(Ra)(Rp)(OH) group in which Ro and Rp are, independently of one another, a hydrogen atom or a (CrCe)alkyi group;
R is a phenyl, pyridinyl or pyrazolyl group substituted with R1, R’1, R2 and R3;
R1 is a hydrogen atom or is selected from the following groups: (Ci-Ce)alkyl, such as methyl or isopropyl, (Ct-CB)alkoxy, such as methoxy or isopropyloxy, (C3-C7)cycloalkyl, 20 such as cyclobutyl, and aryl, such as phenyl;
R’1 is a hydrogen atom or an Isopropyloxy group;
R2 is selected from:
- a hydrogen or chlorine atom or a methyl, cyclopropyl or methoxy group;
- a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1,425 diazepan-1-yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, 1,7- diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydrotmtdazopyrazinyl, piperazinyl-Chk, pyrazolyl, imidazoiyl, triazolyl or pyridinyl group;
these groups being optionally substituted with one or more substituents Independently selected from: (CrCeJalkyl, (C3-C7)cycloalkyl, (Ct-Ce)alkoxy, heterocycloalkyl, carboxytC,30 Ce)alkyl, NR4R5 and OR4;
said alkyl group being optionally substituted with a halogen atom or a (C,Ce)alkoxy, heterocycloalkyl, NH2 or OH group; and
- an NRaRb group, where Ra and Rb are, independently of one another:
. a hydrogen atom;
. a piperidinyl or tetrahydropyranyl group, said group being optionally substituted with a (Ct-Ce)alkyl group, such as methyl; or . a methyl or ethyl group, said group being optionally substituted with an NR4R5 group; R4 and R5 being, independently of one another, a hydrogen atom, a (Ci-Ce)alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7membered ring, such as a pyrrolidinyl;
R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrCeJalkyl group, such as a methyl;
wherein when R corresponds to formula (A), R2 and R3 may together form an azepinyl or oxazepinyl ring fused with the phenyl bearing them, this azepinyl or oxazepinyl ring being optionally substituted with at least one substituent selected from: an oxo group and a (CiC9)alkyl group;
R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (CrCe)alkyl, OR’4, CH2OH, CH2NH2, S(O)nR'4, R8 and 0R8;
wherein:
R'4 is a hydrogen atom or a (CrCB)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
n is 1 or 2; and
R8 is a halo(Ci-Cs)alky! group.
Subgroup 21 is defined by the compounds of formula (I) for which:
R6 is -CONH2 or a -C(Ra)(Rp)(OH) group in which Ra and Rp are, independently of one another, a hydrogen atom or a (CrCe)alkyl group;
R is selected from the following groups:
R1 is a hydrogen atom or is selected from the following groups: (CrCe)alkyl, such as methyi or isopropyl, (CrCe)alkoxy, such as methoxy or isopropyloxy, (C3-C7)cycloalkyl, such as cyclobutyl, and aryl, such as phenyl;
R’1 is a hydrogen atom or an isopropyloxy group;
R2 is a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1,4diazepan-1-yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, 1,7diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyi, piperazinyl-C^, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;
these groups being optionally substituted with one or more substituents selected, îo independently in each instance, from: (CrCeJalkyl, such as methyl, ethyl or isopropyl, (C3C7)cycloalkyi, such as cyclopropyl, (Ci-Ce)alkoxy, such as methoxy, heterocycloalkyl, such as oxetanyl or pyrrolidinyl, carboxy(Ct-Ce)alkyl, such as C(O)O(CH3)3, NR4R5 and OH;
said (Ci-Ce)alkyl group being optionally substituted with a (CrCejalkoxy group, such as methoxy, or OH;
wherein:
R4 and R5 each is, independently of one another, a hydrogen atom, a (Cr Ce)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4to 7-membered ring;
R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrCe)alkyl group, such as a methyl;
R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (Ci-Ce)alkyl, OR'4, CH2OH, CH2NH2, S(O)nR’4, R8 and 25 0R8;
wherein:
R'4 is a hydrogen atom or a (Ct-CB)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
n 1 or 2; and
R8 is a halo(Ci-C6)alkyl group.
Subgroup 22 Is defined by the compounds of formula (I) for which:
R6 is -CONH2 or a -C(Ra)(Rp)(OH) group in which Ra and Rp are, independently of one another, a hydrogen atom or a (CrCe)alkyl group;
R1 is an isopropyloxy group; R’1 is a hydrogen atom;
ΙΟ
R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with one or more substituents selected, independently in each instance, from: a methyl, ethyl, isopropyl, cyclopropyl, OH, oxetanyl, pyrrolidinyl, C(O)O(CH3)3, NR4R5 and 0R4 group;
said methyl, ethyl and isopropyl groups being optionally substituted with a (CrCe)alkoxy group, such as methoxy, or with an OH;
wherein R4 and R5 each is, independently of one another, a hydrogen atom, a (C,C9) alkyl group, such as methyl, or a heterocycloalkyi group, such as oxetanyl;
R3 is a hydrogen or fluorine atom or a methyl;
R7 is a phenyl, pyridinyl, thienyl, furanyi, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each Instance, from: cyano, halogen, such as chlorine or fluorine, (Ci-Ce)alkyl, such as methyl, OR'4, CHsOH, CHaNHa, S(0)nR’4 and 0R8;
wherein:
R'4 is a (CrCe)alkyl group, such as methyl or ethyl; n is 1; and
R8 is a halo(Ci-Ce)alkyl group, such as CF3 or CHF2
Subgroup 23 is defined by the compounds of formula (I') for which:
R is a phenyl, pyridinyl or pyrazolyl group substituted with R1, R'1, R2 and R3; R1, R'1, R2 and R3 being as defined in formula (I').
Subgroup 24 is defined by the compounds of formula (l‘) for which: R is selected from the following groups:
R1, R'1, R2 and R3 being as defined in formula (Γ).
Subgroup 25 is defined by the compounds of formula (I’) for which: R Is an (A), (E) or (F) group
R1, R'1, R2 and R3 being as defined in formula (!').
Subgroup 26 is defined by the compounds of formula (!’) for which:
R is an (A) group
(A)
R1, R’1, R2 and R3 being as defined in formula (Γ).
Subgroup 27 is defined by the compounds of formula (Γ) for which:
R1 is a hydrogen atom or is selected from the following groups: (CrCe)alkyl, such as methyl or isopropyl, (CrCeJalkoxy, such as methoxy or isopropyloxy, (C3-C7)cycloalkyl, such as cyclobutyl, and aryl, such as phenyl.
Subgroup 28 is defined by the compounds of formula (Γ) for which: R1 is an isopropyloxy group.
Subgroup 29 is defined by the compounds of formula (Γ) for which:
R'1 is a hydrogen atom or an isopropyioxy group.
Subgroup 30 is defined by the compounds of formula (Γ) for which: R'1 is a hydrogen atom.
Subgroup 31 is defined by the compounds of formula (Γ) for which:
R2 is selected from:
- a hydrogen atom or a methyl, cyclopropyl or methoxy group;
- a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1,4diazepan-1-yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, 1,7diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;
these groups being optionally substituted with one or several substituents independently selected from: (Cj-CfOalkyl, (C3-C7)cycloalkyl, (CrCeialkoxy, heterocycloalkyl, carboxy(CiCe)alkyl, NR4R5 and 0R4;
said alkyl group being optionally substituted with a halogen atom or a (Ci-Cfl)alkoxy, heterocycloalkyl, NH2 or OH group; and
- an NRaRb group, where Ra and Rb are, independently of one another:
. a hydrogen atom;
. a piperidinyl or tetrahydropyranyl group, said group being optionally substituted with a (CrCe) alkyl group, such as methyl; or . a methyl or ethyl group, said alkyl group being optionally substituted with an NR4R5 group;
R4 and R5 being, independently of one another, a hydrogen atom, a (Ci-Ce)alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7membered ring, such as a pyrrolidinyl;
R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrCe)alkyl group, such as a methyl;
and when R corresponds to formula (A), R2 and R3 can together form an azepinyl or oxazepinyl ring, fused with the phenyl bearing them, this azepinyl or oxazepinyl ring being optionally substituted with at least one substituent selected from: an oxo group and a (C,Ce)alkyl group, such as methyl.
Subgroup 32 is defined by the compounds of formula (Γ) for which:
R2 is a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1,4diazepan-1-yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, 1,717140 diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;
these groups being optionally substituted with one or several substituents Independently selected from: (CrCe)a!kyl, such as methyl, ethyl or isopropyl, (Ca-Crjcycloalkyl, such as cyclopropyl, (CrCe)alkoxy, such as methoxy, heterocycloalkyl, such as oxetanyl or pyrrolidinyl, carboxytCi-CeJaikyl, such as C(O)O(CH3)31 NR4R5 and OH;
said alkyl group being optionally substituted with a (CrCe)aIkoxy group, such as methoxy, or OH;
R4 and R5 being, independently of one another, a hydrogen atom, a (CrCe)alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7membered ring, such as a pyrrolidinyl;
R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrCeJalkyl group, such as a methyl.
Subgroup 33 is defined by the compounds of formula (Γ) for which:
R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with one or several substituents independently selected from: (CrCe)alkyl, (C3-C7)cycloalkyl, (Cr Cejalkoxy, heterocycloalkyl, carboxy(CrCe)alkyl, NR4R5 and OR4;
said alkyl group being optionally substituted with a halogen atom or a (CpCeJalkoxy, heterocycloalkyl, NH2 or OH group;
R4 and R5 being as defined in formula (I);
R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrCe)aIkyl group, such as a methyl.
Subgroup 34 is defined by the compounds of formula (Γ) for which:
R2 represents a piperidinyl or piperazinyl group, these groups being optionally substituted with one or several substituents independently selected from: a methyl, ethyl, isopropyl, cyclopropyl, OH, oxetanyl, pyrrolidinyl, C(O)O(CH3)3, NR4R5 and OR4 group;
said alkyl group being optionally substituted with a (Ci-Ce)alkoxy group, such as methoxy, or with an OH;
R4 and R5 being, independently of one another, a hydrogen atom, a (CrCeJalkyl group, such as methyl, or a heterocycloalkyl group, such as oxetanyl;
R3 is a hydrogen or fluorine atom or a methyl.
Subgroup 35 is defined by the compounds of formula (Γ) for which:
R2 is a pipendinyl group or piperarinyl group, these plperidinyl or piperazinyl groups being optionally substituted with one or more substituents selected, Independently in each instance, from: a methyl, ethyl or isopropyl group;
R3 is a hydrogen or fluorine atom or a methyl.
Subgroup 36 is defined by the compounds of formula (Γ) for which: R2 is a group selected from the following groups:
Ά- KH KDkT kK
HOa
R3 is a hydrogen or fluorine atom or a methyl.
Subgroup 37 is defined by the compounds of formula (l‘) for which:
R7 is a phenyl, pyridinyl, thienyi, furanyl, pyrazolyl or pyrolyl group, this group being 30 optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (CrC9)alkyl, OR’4, CH2OH, CH2NH2, S(0)nR'4, R8 and 0R8;
wherein:
R'4 is a hydrogen atom or a (CrC9)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
n is 1 or 2; and
R8 is a halo(Ct-Ce)alkyl group.
Subgroup 38 is defined by the compounds of formula (Γ) for which:
R7 is a phenyl, pyridînyJ, thlenyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, such as chlorine or fluorine, (Ci-Ce)alkyl, such as methyl,
OR’4, CH2OH, CH2NH2, S(O)nR’4 and 0R8;
wherein:
R’4 is a (Ct-Ce)alkyl group, such as methyl or ethyl;
n is 1;
R8 is a halo(CrCB)alkyl group, such as CF3 or CHF2.
Subgroup 39 is defined by the compounds of formula (!’) for which R and R7 are defined in one of subgroups 23 to 38 above.
Subgroup 40 is defined by the compounds of formula (I’) for which:
R is a phenyl, pyridinyl or pyrazolyl group substituted with R1, R'1, R2 and R3;
R1 is a hydrogen atom or is selected from the following groups: (CrC6)alkyl, such as methyl or isopropyl, (Ct-C9)alkoxy, such as methoxy or Isopropyloxy, (GrCzJcycloalkyl, such as cyclobutyl, and aryl, such as phenyl;
R*1 is a hydrogen atom or an isopropyloxy group;
R2 is selected from:
- a hydrogen atom or a methyl, cyclopropyl or methoxy group;
- a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1,4diazepan-1-yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, 1,7diazaspiro[4.4]non-7-yi, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;
these groups being optionally substituted with one or more substituents selected, independently in each instance, from: (Ci-Ce)alkyl, (Ca-Cyjcycloalkyl, (Ci-C9)alkoxy, heterocycloalkyl, carboxy(CrC9)alkyl, NR4R5 and OR4;
said alkyl group being optionally substituted with a halogen atom or a (CrC9)alkoxy, heterocycloalkyl, NH2 or OH group; and
- an NRaRb group, where Ra and Rb are, independently of one another:
. a hydrogen atom;
. a piperidinyl or tetrahydropyranyl group, said group being optionally substituted with a (CrC9)alkyl group, such as methyl; or . a methyi or ethyl group, said alkyl group being optionally substituted with an NR4R5 group;
R4 and R5 are, independently of one another, a hydrogen atom, a (CrCe)alkyl group, such as methyi or ethyl, or a heterocycloalkyl group, such as oxetanyl;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7membered ring, such as a pyrrolidinyl;
R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrCe)alky! group, such as a methyi;
and when R corresponds to formula (A), R2 and R3 can together form an azepinyl or oxazepinyl ring, fused with the phenyl bearing them, this heterocycloalkyl being optionally substituted with at least one substituent selected from: an oxo group and a (CrCe)alkyl group, such as methyi;
R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (CrCuJalkyl, OR’4, CH2OH, CH2NH2, S(O)nR’4, R8 and 0R8;
wherein:
R'4 is a hydrogen atom or a (Ci-Ce)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
n is 1 or 2; and
R8 îs a halo(CrCe)alkyl group.
Subgroup 41 is defined by the compounds of formula (Γ) for which:
R is selected from the following groups:
R1 is a hydrogen atom or is selected from the following groups: (Ci-Ce)alkyl, such as methyl or isopropyl, (CrCe)alkoxy, such as methoxy or isopropyloxy, (Cs-Cyjcycloalkyl, such as cyclobutyl, and aryl, such as phenyl;
R’1 is a hydrogen atom or an isopropyloxy group;
R2 is a pyrrolidinyl, piperidinyl, tetrahydropyrîdinyl, piperazînyl, tetrahydropyranyl, 1,4diazepan-1-yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1,2-a]pyrazîn-2(1 H)-yl, 1,7diazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimîdazopyrazinyl, pîperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group;
these groups being optionally substituted with one or more substituents selected, to independently in each instance, from: (Ci-Ce)alkyl, such as methyl, ethyl or isopropyl, (C3Crjcycloalkyl, such as cyclopropyl, (CrCe)alkoxy, such as methoxy, heterocycloalkyl, such as oxetanyl or pyrrolidinyl, carboxyfCrCeJalkyl, such as C(O)O(CH3)3, NR4R5 and OH; said alkyl group being optionally substituted with a (CrCe)alkoxy group, such as methoxy, or OH;
R4 and R5 being, independently of one another, a hydrogen atom, a (CrCe)alkyl group, such as methyl or ethyl, or a heterocycloalkyl group, such as oxetanyl;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7membered ring, such as a pyrrolidinyl;
R3 is a hydrogen atom, a halogen atom, such as a fluorine, or a (CrCe)alkyl group, such 20 as a methyl;
R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (Ci-Ce)aîkyl, OR'4, CH2OH, CH2NH2, S(O)nR’4, R8 and 0R8;
wherein:
R'4 is a hydrogen atom or a (CrCe)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
n is 1 or 2;
R8 is a halo(CrCe)alkyl group.
Subgroup 42 is defined by the compounds of formula (Γ) for which:
R is an (A), (E) or (F) group
R1 is an isopropyloxy group;
R'1 is a hydrogen atom;
R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with one or more substituents selected, independently in each instance, from: a methyl, ethyl, isopropyl, cyclopropyl, OH, oxetanyl, pyrrolidinyl, C(O)O(CH3)3, NR4R5 and 0R4 group; said alkyl group being optionally substituted with a (Ci-Ce)alkoxy group, such as methoxy, or with an OH;
R4 and R5 being, independently of one another, a hydrogen atom, a (Ci-Ce)alkyl group, ίο such as methyl, or a heterocycloalkyl group, such as oxetanyl;
R3 is a hydrogen or fluorine atom or a methyl;
R7 Is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, such as chlorine or fluorine, (Ci-Ce)alkyl, such as methyl, 15 OR’4, CH2OH, CH2NH2, S(O)nR’4 and 0R8;
wherein:
R’4 Is a (Ci-Ce)alkyl group, such as methyl or ethyl; n is 1;
R8 Is a halo(Ci-Ce)alkyl group, such as CF3 or CHF2
Subgroup 43 is defined by the compounds of formula (I”) for which:
R is a phenyl, pyridinyl or pyrazolyl group substituted with R1, R’1, R2'and R3; R1, R'1, R2 and R3 being as defined in formula (I).
Subgroup 44 is defined by the compounds of formula (I) for which:
R is selected from the following groups:
R1, R’1, R2 and R3 being as defined In formula (Γ).
Subgroup 45 is defined by the compounds of formula (I) for which: R is a an (A) group
R1, R’1, R2 and R3 being as defined in formula (Γ).
Subgroup 46 is defined by the compounds of formula (I) for which:
R1 Is selected from the following groups: (Ci-Ce)alkyl, such as isopropyl, and (CrCe)alkoxy, such as methoxy or isopropyloxy.
Subgroup 47 is defined by the compounds of formula (I) for which:
R1 Is an isopropyloxy group.
Subgroup 48 is defined by the compounds of formula (I”) for which:
R’1 is a hydrogen atom.
Subgroup 49 is defined by the compounds of formula (I) for which:
R2 is selected from:
- a hydrogen or chlorine atom or a methyl group;
- a pyrrolidinyl, piperidinyi, piperazinyl, tetrahydropyranyl, 1,7-diazaspiro[4.4Jnon-7-y! or pyrazolyl group;
these groups being optionally substituted with at least one (Ci-Ce)alkyl group;
R3 is a hydrogen atom or a (CrCeJalkyl group, such as a methyl.
Subgroup 50 is defined by the compounds of formula (I”) for which:
R2 is selected from a pyrrolidinyl, piperidinyi, piperazinyl, tetrahydropyranyl, 1,7diazaspiro[4.4Jnon-7-yl or pyrazolyl group;
these groups being optionally substituted with at least one (CrCe)alkyl group, such as methyl;
R3 is a hydrogen atom or a (CrCe)alkyl group, such as a methyl.
Subgroup 51 is defined by the compounds of formula (I) for which:
R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with at least one (CrCe)alkyl group, such as methyl;
R3 is a hydrogen atom or a (CrCe)alkyl group, such as a methyl.
Subgroup 52 is defined by the compounds of formula (I) for which:
R2 is a group selected from the following groups:
R3 is a hydrogen atom or a methyl.
Subgroup 53 is defined by the compounds of formula (I”) for which:
R7 is a phenyl or pyridinyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (CrCe)alkyl, OR'4, CH2OH, CH2NH2, S(O)nR'4, R8 and 0R8;
wherein:
R'4 is a hydrogen atom or a (Ci-Ce)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a hydrogen atom or an NH2 or OH group;
n is 1 or 2;
R8 is a halo(Ci-Ce)alkyl group.
Subgroup 54 Is defined by the compounds of formula (Γ) for which:
R7 is a phenyl or pyridinyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: halogen, such as fluorine, (Ci-CeJalkyl, such as methyl, OR’4 and 0R8;
wherein:
R’4 is a (Ci-C6)alkyl group, such as methyl or ethyl;
R8 îs a halo(CrCe)alkyl group, such as CFa.
Subgroup 55 is defined by the compounds of formula (Γ) for which R and R7 are defined in one of subgroups 43 to 54 above.
Subgroup 56 is defined by the compounds of formula (I”) for which:
R is a phenyl, pyridinyl or pyrazolyl group substituted with R1, R’1, R2 and R3;
R1 îs selected from the following groups: (CrC8)alkyl, such as isopropyl, (CrCe)alkoxy, such as methoxy or isopropyloxy;
R’1 is a hydrogen atom;
R2 is selected from:
- a hydrogen or chlorine atom or a methyl group;
- a pyrrolidinyî, piperidînyl, piperazinyl, tetrahydropyranyl, 1,7-diazaspiro[4.4]non-7-yl or pyrazolyl group;
these groups being optionally substituted with at least one (Ci-Ce)alkyi group;
R3 is a hydrogen atom or a (CrCs)alkyl group, such as a methyl;
R7 is a phenyl or pyridinyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (CpCJalkyl, OR’4, CH2OH, CH2NH2, S(O)nR’4, R8 and 0R8;
wherein:
R'4 Is a hydrogen atom or a (CrCe)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
n is 1 or 2;
R8 is a halo(C1-Ce)alkyi group.
Subgroup 57 is defined by the compounds of formula (I) for which: R is selected from the following groups:
R1 is selected from the following groups: (CrCe)alkyl, such as isopropyl, and (CrCeJalkoxy, such as methoxy or isopropyloxy;
R’1 ts a hydrogen atom;
R2 Is a substituent selected from a pyrrolidinyî, piperidînyl, piperazinyl, tetrahydropyranyl, 1,7-diazaspiro[4.4]non-7-yl or pyrazolyl group;
these groups being optionally substituted with at least one (CrCe)alkyl group, such as methyl;
R3 is a hydrogen atom or a (CpCoJalkyl group, such as a methyl;
R7 is a phenyl or pyridinyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (CrCe)alkyl,
OR’4, CH2OH, CH2NH2, S(O)nR'4, R8 and 0R8;
wherein:
R'4 is a hydrogen atom or a (Ci-Ce)a!kyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
n is 1 or 2;
R8 is a halo(Ci-Ce)alkyl group.
Subgroup 58 is defined by the compounds of formula (I) for which:
R is an (A) group
R1 (A)
R2
R1 is an isopropyloxy group;
R’1 is a hydrogen atom;
R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with at least one (Ci-Ce)alkyl group, such as methyl;
R3 is a hydrogen atom or a (CrCe)alkyl group, such as a methyl;
R7 is a phenyl or pyridinyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: halogen, such as fluorine, (Ci-Ce)alkyl, such as methyl, OR'4 and OR8;
wherein:
R’4 is a (CrCfl)alkyl group, such as methyl or ethyl;
R8 is a halofCrCeJalkyl group, such as CF3.
More particulariy, the présent invention relates to the following compounds: 2-({2-methoxy-4-[4-(pyrrolidin-1-yl)piperidin-1 -yl]phenyl}amino)-7-phenylthieno[3,2-d]pyrimidine-6-carboxarïiide;
2-({2-methyl-4-[4-(pyrrolidin-1-yl)piperidin'1-yl]phenyl)amino)-7-phenylthieno[S^-dJpyrimidÎne-e-carboxamide;
7-(3-chlorophenyl)-2-({2-methoxy-4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(4-chlorophenyl)-2-({2-methoxy-4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;
2-({2-methoxy-4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}amino)-7-(thiophen-3yl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-({2-methoxy-4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl)amino)-7-(thiophen-2yi)thîeno[3,2-d]pyrimidine-6-carboxamide;
2-({2-methoxy-4-[4-(propan-2-yl)piperazin-1-yl]phenyl}amino)-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide;
2-({2-methoxy-4-[1-(propan-2-yl)piperidin-4-yl]phenyl}amino)-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide;
7’(2-methoxyphenyl)-2-{[4-(4-methyipiperazin-1-yl)-2-(piOpan-2-yloxy)pheny!]amïno]thieno[3,2-d]pyrimîdine-6-carboxamide;
7-(4-fluoro-3-methoxyphenyl)-2-{[4-(4>methylpipera2În-1-yl)-2-(propan-2-yloxy)to phenyl]aniino}thieno[312-d]pyrimidÎne-6’Carboxamide;
7-(4-methoxyphenyl)-2-{[4-(4-methyipipera2in-1-yl)-2-(propan-2-yloxy)phenyl]amino} thieno [3,2-d]pyrimidine-6-carboxamide ;
7-(4-fluorophenyl)-2-{[4-(4-methylpipera2in-1-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimîdine-6-carboxamide;
2-j[2-methoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino}-7-phenylthieno[3,2d]pyrimidine-6-carboxamide;
7-(4-fluoro-2-methoxyphenyl)-2-{[2-methoxy-4-(4-methy1pipera2in-1-yl)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
24[2-methoxy-4-(4-methyipÎperazin-1-yl)phenyl]amino}-7-(3-methoxyphenyl)20 thieno[3,2-d]pyrimidine-6-carboxaniide ;
7-(2-methoxyphenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamÎde;
2-{[5-methyl-4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amÎno}-7phenylthieno[3,2-d]pyrimidine-6-carboxamide;
24[2-methoxy-5-methyl-4-(1-methylpîperidÎn-3-yl)phenyl]amîno}-7-phenylthÎeno[3,2dJpyrimidine-6-carboxamide;
2-({2-methoxy-4-[1-(propan-2-y1)piperidin-4-yl]phenyl}aniino)-7-phenylthieno[3,2-d]pyrimïdine-6-carboxamide;
2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy) phenyl]amino}-7-( 1-methyl-1H-pyra2ol-530 yJ)thieno[3,2-d]pyrimidine-6-carboxaniide; 7-(2-ethoxyphenyl)-2-{[4-(1-methylpÎperidin-4-yl)-2-(propan-2-y1oxy)phenyl]aminolthienopÆ-dJpynmidine-G-carboxamide;
7-(3-methoxyphenyl)-2-([4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[5-methyl-4-( 1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino)-7-(pyridin-2yl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(4-methyl-1,4-diazepan-1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-phenylthieno[3,2d]pyrimidine-6-carboxamide;
7-(2-fluoro-5-methoxyphenyl)-2-{[4-(1-methylpiperidin-4-y1)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(3-cyanophenyl)-2-([4-(1-methylplperidin-4-yl)-2-(propan-2-yloxy)phenyl]amîno}thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-[2(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide; 2-{(4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-phenylthîenoîo [3,2-d]pyrimîdine-6-carboxamîde; 2-({4-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-(propan-2-yloxy)phenyl}amino)-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide; 2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl] amino}-7-(1-methyl-1,2,3,6tetrahydropyridin-4-y1)thieno[3,2-d]pyiimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-{[5-methyl-4-(1-methylpÎperidin’4-yl)-2-(propan-2yloxy)phenyl]amino]thieno[3,2-d]pyrimidine-6-carboxamide; 2-{[4-methoxy-2-(propan-2-yloxy)phenyl]amino}-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1-methylpiperidÎn-4-yl)-2-(propan-2-yloxy)pheny1]amino}-7-[320 (methylsulfinyl)phenyl]thieno[3,2-d]pyrimîdine-6-carboxarnide; 7-(2-methoxypyridin-3-yl)-2-([4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl] amino]thieno[3,2-d]pyrimidine-6-carboxamÎde;
7-(2-cyanophenyl)-2-([4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino]thieno[3,2-d]pyrimidine-6-carboxamide;
2-((4-(1 H-imidazol-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-phenylthieno[3,2-d]pyrimidine-
6- carboxamide;
2-{[4-{methyl[2-(pyrrolidÎn-1-yl)ethyl]amino}-2-(propan-2-yloxy)phenyl]amino}-7phenylthieno[3,2-d]pyrimldine-6-carboxamide;
7- (2-methoxyphenyI)-2-((6-(4-methylpiperazin-1-yl)-4-(propan-2-yloxy)pyridin-3- yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-{[6-(1-methylpiperidin-4-yl}-4-(propan-2-yloxy)pyridin-3yl]amÎno}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(5-fluoro-2-methoxyphenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenylîamino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(3-fluoro-2-methoxyphenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino]thieno[3,2-d]pyrimIdÎne-6-carboxamîde;
2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenylJamino}-7-[2(methylsulfinyl)phenyqthieno[3(2-d]pyrimidine-6-carboxamide;
2-((4-[3-(dimethylamino)pyrrolidin-1-yl]’2’(propan-2-yloxy)phenyl}amino)'7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxaniide;
7-(2-methoxyphenyl)-2-{[4-{methyl[2-(pyrrolidin-1-yl)ethyl]amino}-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimîdine-6-carboxamide;
7-(2’fluoro-3-methoxyphenyt)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3(2-d]pyrimidine-6-carboxamide;
2-{[4-(1-ethylpiperidin-3-yl)-2-(propan-2-yloxy)phenyl]amino]-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-fluorophenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino]thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1H-pyrrol-2yi)thÎeno[3,2'd]pyrimidine-6-carboxamide;
7-[2-fluoro-5-(hydroxymethyl)phenyl]'2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(5-methoxy-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(propan-2-yîoxy)phenyl]amino}-7-(2-methoxyphenyl)thÎeno[3,2-d]pyrimidine-6-carboxamide;
7-(4-fluoro-2-methoxyphenyî)-2-{[4-(4-methylpiperazin’1-yl)’2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1H-lmidazol·1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypheπyl)thieno[3,2-d]pyrimidine-6-cart)Oxamide;
2-methylpropan-2-yl 4-[5-{[6-carbamoy1-7-(2-methoxyphenyl)thieno· [3,2-d]pyrimidin-2-yl]amino}-1 -(propan-2-yl)-1 H-pyrazol-3-ylJpiperidine-1 -carboxylate; 7-(2-methoxyphenyl)-2-{[2-(propan-2-yloxy)-4-(2,2,6,6-tetramethylpiperidin-4yl)phenyt]amino}thieno[3,2-d]pyrimidine-6-carboxamide: 2-{[4-(2,6-dimethylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]aniino}-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(2-ethylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino]-7-(2methoxyphenyl)thieno[3,2-d]pyrimÎdine-6-carboxamide;
7-(2-methoxyphenyl)-2-([4-(piperidin-4-yl)-2’(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(4-fluoro-2-methoxyphenyl)-2-[[4-(1-methylpiperidin-4-y1)-2-(propan-2-yloxy)phenyllamÎnoJthÏenoIS^-dJpyrimidine-e-carboxamide;
24[4-(3(5-dimethylpiperazin-1-yî)-2-(propan-2'yîoxy)pheny1]amino}-7-(2methoxyphenypthienoia^-dJpyrimidine-e-carboxamÎde;
7-(2-methoxyphenyl)-2-{[2-(propan-2-yloxy)-4-(3l4,5-trimethylpipera2in-1-yl)phenyl]amino}thieno[3,2-d]pyrÎmidine-6-cart)Oxamide;
2-({4-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(propan-2-yloxy)phenylJamino)-7’(2-methoxypheny!)thieno[3,2-d]pyrimîdine-6-cartx)xamide;
7-(2-methoxyphenyl)-2-{[3-(piperidin-4-yl)-1 -(propan-2-yl)-1 H-pyrazol-5yl]aniino]thieno[3>2-d]pyrimidine-6-carboxaniide;
2-({4-[(3R)*1-ethylpiperidin-3-yl]-2-(propan-2-yloxy)phenyl)amino)-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamÎde;
2-({4-[(3S)-1-ethy1piperidÎn-3-yl]-2-(propan-2-yloxy)phenyl}amino)-7-(2io methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1-methylpiperidin-4-yl)-2’(propan-2-yloxy)phenyl]aniino}’7-(thiophen-3-yl)thieno[312d]pyrimidine-6-carboxamide;
7-(5-fluoro-2-methoxypyridin-4-yl)-2-{[4-(1-methylpÎperidin-4-yl)-2-(propan-2yloxy)phenyl]aminoJthieno[3,2-d]pyrimidine-6-carboxaniide;
7-(2-methoxyphenyl)-2-((2-(propan-2-y!oxy)-4-[(2R14S)-2-(propan-2-yl)piperidin-4-yl]phenyl}amino)thieno[3,2-d]pyrÎmidine-6-carboxamide; 7-(2-methoxyphenyl)-2-({2-(propan-2-yloxy)-4-[(2R,4R)-2-(propan-2-yl)piperidin^-yilphenyljaminojthienois^-djpyrimidine-e-carboxamlde; 7-(2-chlorophenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]20 aminoJthienofS^-dlpyrimidine-e-carboxaniide;
2-({4-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2( 1 H)-yl]-2-(propan-2-yloxy)phenyl]amino)-7-(2-methoxypyridin-3-yl)thieno[312-d]pyrimidine-6-carboxamide; 7-(3-chlorophenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amÎno)thieno[3,2-d]pyrirTiÎdirie-6-carboxamide;
7-(2-methylphenyl)-2-{[4-(1-methyïpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amÎno)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1 -methylpiperidin’4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1 -methyl-1 H-pyrazol-4y!)thieno[3,2-d]pyrimÎdine-6-carboxaniide;
7-(2,5-dimethoxyphenyl)-2-{[4-(1-methylpipen'dÎn-4-yl)-2-(propan-2-yloxy)30 phenyl]amino)thieno[3,2-d]pyrirnÎdine-6-carboxamide;
7-[2-(difluoromethoxy)phenyl]-2'{[4-(1-methylpiperidÎn-4-yl)-2-(propan'2-yloxy)phenyl]aminoJthieno[3,2-d]pyrimidine-6-carboxamide;
2414-( 1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]aniino}-7-(1H-pyrazol-4yi)thieno[3,2-d]pyrimidine-6-carboxaniide;
2-({4-[3-(2-hydroxyethyl)-4-methylpiperazin-1-y1]-2-(propan-2-yloxy)phenyl}amïno)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxaniide;
7-(2-methoxypyridin-3-yl)-2-{[5-methy!-4-(1-methylpÎperidin-4-yl)-2-(propan-2yloxy)phenyl]amÎno)thieno[3,2’d]pyrimidine-6-cartx)xannÎde;
7-(2-methoxypyridÎn-3-yl)-2-{[4-(4-methylpipera2in-1-yl)-2-(propan-2-yloxy)phenylJaminoJthienoISÆ-dJpyrÎmidine-e-carboxaniïde;
5 2-({4-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(propan-2-yloxy)phenyl)amino)-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-{[4-(3-methoxypyridin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2’d]pyrimÎdine-6-carboxamÎde;
7-(2-methoxyphenyl)-2-{[6-(4-methylpïperazin-1-yl)-2-(prOpan-2-yloxy)pyridÎn-3lo ylJaminoJthienoIS^-dJpyrimidïne-G-carboxamide; 7-(2-methoxw3henyl)-2-{[4-(1,2,2,6,6-pentamethylpÎperidin-4-yl)-2-(propan-2yloxy)phenyl]amino)thieno[3,2-d]pyrimîdine-6-carboxaniide;
2-({4-[(2S,4S)-2-ethyl-1-methylpiperidin-4-yl]-2-(propan-2-yloxy)phenyl}amino)-7-(2-methoxypheny!)thieno[312-d]pyrimidine-6-carboxamide;
2-({4-[(2St4R)-2-ethyl-1-methylpiperidin-4-yl]-2-(propan-2-yloxy)pheny!)amino)-7-(2-methoxyphenyl)thÎeno[3I2-d]pyrimidine-6-carboxamide; 7-(2-methoxypyridin-3-yl)-2-({2-(propan-2-yloxy)-4-[1-(propan-2-yl)piperidîn-4yljphenyljaminojthienois^-djpyrimidine-e-carboxamîde;
7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-220 yloxyJphenylJaminoJthienoISÆ-dJpyrimidine-e-carboxamide;
7-(5-fluoro-2-methoxypyridin-3-yl)-2-({2-(propan-2-yloxy)-4-[1-(propan-2-yl)piperidin-4-yl]phenyl}amino)thieno[312’d]pyrimidine-6-cartx>xamide;
7-(5-fluoro-2-methoxypyridin-3-yl)-2-([5-methyl-4-(1-methy!piperidin-4-y!)-2-(propan-2yloxyjphenyllaminojthienop^-djpyrïmidine-e-carboxaniide;
7-(6-methoxypyridin-2-yl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2’d]pyrimidine-6’Carboxamide; 7-(2-chlorophenyl)-2-({4-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(propan-2-yloxy)phenyOaminoJthienofS^-dJpyrimidine-e-carboxamide; 7-(2-methoxyphenyl)-2-{[6-(1-methylpiperidÎn-4-yl)-2-(propan-2-yloxy)pyridin-330 yl]amino)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1,7-diazaspiro[4.4]non-7-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-({4-[3-(dÎethylamino)pyrrolidin-1-yl]-2-(propan-2-yloxy)phenyl)amino)-7-(2methoxypyridin-S-ytJthienop^-djpyrîmidine-e-carboxamide;
2-({4-[3-(dimethylamino)pyrrolidin-1-yl]-2-(propan-2-yloxy)phenyl)amino)-7-(1 -methyl-1 Hpyrro1-2-yl)thieno[3,2-d]pyrimidine-6-carboxamïde;
2-i[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-{1-methyl-1H-pyrrol-2yl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-f[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methylpyridin-3· yl)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(furan-2-yl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)pheny!]amino)thieno[3,2d]pyrimidine-6-carboxamide;
7-[5-(aminomethyl)furan-2-yl]’2-([4-(1-methylpiperidin-4’yl)-2-{propan-2yloxyJphenylJaminoJthienoIS^-tflpyrimïdine-G-carboxamide;
7-(2-methoxypyridin-3-yl)-2-{[5-methyl-4-(4-methylplperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
24[4-(1^βΙήγΙρίρβπόΐη-4-γΙ)-2-(ρΓορ3η-2’7ΐ(^)ρήβΓ^Ι]3Γηίηο)-7-(1Η-ρ7ΠΌΐ-3yl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-({4-[3-(dimethylamÎno)pyrrolÎdin-1-yl]-2-{propan-2-yloxy)phenyl}amino)-7’(2methoxypyridin-S-yOthienofSÆ-dlpyrimidine-G-carboxamÎde;
7-(2-ethoxypyridin-3-yl)-2-({2-(propan-2-yloxy)-4-[1-(propan-2-yl)piperidin-4-yl]phenyllaminolthienopÆ-dlpyrimidine-G-carboxamide;
7-(2-ethoxypyridin-3-yl)-2-{[5-methyl-4-(1-methy!piperidin-4-yl)-2-(propan-2yloxy)phenyl]amÎno}thieno[3,2-d]pyrimidine-6-cartx)xamide;
7-(2-methoxyphenyl)-2-{[5-methyl-4-(4-methylpipera2În-1’yl)’2-(propan-2yloxyÏphenylJaminoJthienoIS^-djpyrimidine-S-cartxjxamide;
7-(2-ethoxypyridin-3-yl)-2-{[4-{1-methylpiperidin-4-yl)-2-(propan-2yloxy)phenyl]amÎno}thieno[3,2-d]pyrÎmidine-6-carboxamida;
7-(2-ethoxypyridin-3-yl)-2-{[4-(4-methylpipera2in-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxy-5-methylpyridin’3-yl)-2-{[4-{4-methylpipera2in-1-yl)-2-(propan-2yloxy}phenyl]amino}thieno[3,2-d]pyrimidine-6-cartx)xamide;
7-(2-methoxy-5-methylpyridin-3-yl)’2-{[4-(1-methylpiperidin-4-yl)-2’(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7’{5-fluoro-2’methoxypyridin-3-yl)-2-{[4-(4-methylpipera2in'1’yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrlmidine-6-carboxamide;
7-(2-methoxy-5-methylpyridin-3-yl)-2-{[5-methyl-4-(1-methylpiperidin-4-yl)-2-(propan-2yloxy)phenyl]amino)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-( 1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1 -methyl-1 H-pyrazol-3yQthieno[3,2-d]pyrimidine-6-carboxamide;
2-{{4-[3-(2-methoxyethyl)-4-methylpiperazin-1-yl]-2-{propan-2-yloxy)phenyl}amino)-7-(2’methoxyphenyl)thieno[3,2-d]pyrîmidine-6-carboxamida;
7-(2-methoxyphenyl)-2-{[4-{(3R)-3-[methyl(oxetan-3-yl)amino]piperidin-1-yl}-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methylfuran-3-yl)-2-{[4-(1-methylpÎperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino]thieno[3,2-d]pyrimidine-6*carboxamide;
/-(e-methoxypyridin^-yli^-flS'methyl^-il-melhylpiperidirM-ylJ^-tpropan^yloxy)phenyl]amino}thieno[3,2*d]pyrimidine-6-carboxamide;
2-({4-[3-(dimethylamino)pynOlidin-1-yl]-5-methyl-2-(propan-2-yloxy)phenyl}amino)-7-(2-methoxypyridin-3-yl)thîeno[3,2-d]pyrimrdine-6-carboxamrde;
2-({4-[3-(dimethylamino)pyrtolidin-1-yl]-5-methyl-2-(propan-2-yloxy)phenyl}amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidÎne-6-carboxamide;
2-({3-[ 1 -(oxetan-3-yl)pîperidin-4-yl]-1 -(propan-2-yl)-1 H-pyrazol-5-yl]amino)-7-[2(trifluoromethoxy)phenyl]thieno[3,2-d]pyrîmidine-6-carboxamide;
7-(2-methoxy-6-methylpyridin'3-yl)-2-{[5-methyl-4-(1-methylpiperidin-4-yl)-2-(propan-2yfoxy)phenyl]amÎno}thieno[3,2-d]pyrirnidine-6-carboxarnide;
7-(2-methoxy-6-methylpyridïn-3-yl)-2-{[4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxy-6-methylpyridin-3-yl)-2-{[4-(1-methylpÎperidin-4-yl)-2-(propan-2yloxy)phenyl]amÎno}thieno[3,2*d]pyrimidine-6-carboxamide;
2-{[3-(1 -ethylpiperidin-4-yl)-1 -(propan-2-yl)-1 H-pyrazol-5-yi]amino]-7-[2(trifluoromethoxy)phenyl]thieno[3,2-cl]pyrïmidine-6-carboxamide; 2-({4-[(3R,4S)-3-hydroxy-1*methylpiperidin-4-yl]-2-(propan-2-yloxy)phenyl}amino)-7-(2-methoxyphenyl)thieno[312-d]pyrimidine-6-carboxamide; 7-(2-methoxypyrÎdin-3-yl)-2-({4-[(8S,8aS)-octahydroindolizin-8-yl]-2-(propan-2yloxy)phenyl}amino)thieno[3,2-d]pyrimÎdine-6'Carboxamide;
7-(2-methoxypyridin-3-yl)-2-({4-[(8R,8aS)-octahydroindolizïn-8'yl]-2-(propan-2yloxy)phenyl}amino)thieno[3,2-d]pyrimîdine-6-cafboxamide;
7-(2-methoxyphenyl)'2-{[4-(1-methyl-1H-pyr3zol-4-yl)-2-(prOp3n-2-yloxy)phenyl]amino]thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-[(1-methyl-2-oxo-2l3,4,5-tetrahydro-1H-1-benzazepin-8yOaminojthieno^^-dJpyrimidine-e-carboxamide;
7-(2-methoxypyrÎdin-3-yl)-2-{[4-(2'methyMH-imidazol-1-yl)-2-(propan-2-yloxy)phenyl]amîno}thieno[3,2-d]pyrimidine-6-carboxamïde;
2-{[5-fluoro-4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[5-fluoro-4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxypyrïdin-3-yl)thieno[3,2-d]pyrïmidine-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-{[5-methyl-4-(2-methyl-1H-imidazol-1-yl)-2-(piOpan-2yloxy)phenylJamino}thieno[3,2-d]pyrirnidine-6-carboxamide;
7-(2-methoxyphenyl)-2-([2-(propan-2-yloxy)-4-(1 H-1,2,4-triazo!-1 -yl)phenyl]amÎno}thieno[3,2-d]pyrimidine-6-carboxamÎde;
7-(2-methoxyphenyl)-2-[(1-phenyl-1H-pyrazol-5-yl)amino]thieno[3l2-d]pyrimidine-6carboxamide;
7-(2-methoxyphenyl)-2-{[4-(1-methyl-1H-pyrazol-3-yl)-2-(propan-2-yloxy)phenylJaminoHhienop^-dlpyrimidine-S-carboxamide;
7-(2-methoxypyridin-3-yl)-2-{[3-methyl-1-(propan-2-yl)-1H-pyrazol-5-y!]amino]thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-fluorophenyl)-2-{[5-methyl-4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-caiboxamide;
7-(2-methoxyphenyl)-2-[(1 -methyl-2-oxo-2,3l4I5-letrahydro-1 H-1 -benzazepin-8yl)amino]thieno[3,2-d]pyrimidine-6-cart)oxaniide;
7-(4-fluoro-2-methoxyphenyl)-2-{[3-(piperidin-3-yl)-1-(propan-2-yl)-1 H-pyrazol-5yl]amino}thieno[3,2-d]pyrimidine-6-cart)oxamide;
2-{[3-cyclopropyl-1-(propan-2-yl)-1H-pyrazol-5-yl]amino}-7-(2-methoxypyridin-3yJ)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(4-fluoro-2-methoxyphenyl)-2-{[1-(piOpan-2-y!)-3-(pyridÎn-3-yl)-1H-pyrazo!-5ylJaminoJthienoPÆ-dJpyrimidine-e-carboxamide;
7-(2-methoxypyridin-3-yl)-2-[(1 -methyl-2-oxo-2l3,4,5-tetrahydro-1 H-1 -benzazepin-7yl)amino]thieno[3,2-d]pyrimidine-6-carboxaniide;
7-(4-f!uoro-2-methoxyphenyl)-2-{[2-(propan-2-yloxy)-4-(1 H-1,2,4-triazol-1 -yl)phenyl]amino}thieno[3,2-d]pyrimidine-6-cartx)xaniide;
2-{[4-(2,4-dimethyl-1H-imidazol-1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxypyridin-3-yl)thieno[3,2-d]pyrimidine’6-carboxamide;
2-{[4-methoxy-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridÎn-3-yl)thieno[3,2-d]pyrimidÎne-6-cart)oxamide;
2-[(3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl)amino]-7-(2-methoxyphenyl)thienop^-dJpyrimidine-G-carboxamide;
2-{[4-(5l6-dihydroimidazo[1l2-a[pyrazin-7(8H)-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidîne-6-carboxamide;
2-{[4-(1-cyclopropylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxyphenyl)thÎeno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1-cyclopropylpiperidin-4-y!)-2-(propan-2-yloxy)phenyl]amÎno}-7-(5-fluoro-2methoxyphenyOthienop^-dlpyrimidine-e-carboxamide;
2-((4-(1-cyclopropylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridÎn-3yl)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-([4-(4-methyl· 1 H-imidazol-1 -yl)-2-(propan-2-y!oxy)· phenyl]amino)thieno(3,2-d]pyrimidine-6-carboxamide;
7-(4-ίΙυοΓθ-2-πΐ6ΐή(^ρΚβη^)-2·[(1-ηΐθΙή^-2-οχο-21314,5-ΙθΐΓ3ΐ^Γθ-1Η·1-5βηζ3ζβρΐη-7· y!)amino]thÎeno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]amino)-7-(1-oxidopyridin-2yl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1-ethyl-1,7-diazaspiro[4.4]non-7-y!)-2-(propan-2-yloxy)phenyl]amino]-7-(2methoxypheny!)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-ethoxypyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]aminoJthieno[3,2-d]pyrimidine-6-carboxamide;
2-([4-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-2-(propan-2-yloxy)phenyl]amino)-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(5-fluoro-2-methoxypyridin-3-yl)-2-([5-methyl-4-(4-methy!piperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxy-6-methylpyridin-3-yl)-2-{[4-(2-mettiyl-1 H-imidazol-1-yl)-2-(propan-2yloxy)phenyl]amino}thîeno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-((4-[(4-methylpiperazïn-1-yl)methyl]-2-(propan-2yloxy)phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxy-6-methylpyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypheny!)-2-{[1 -methyl-2-oxo-6-(propan-2-yloxy)-2,3,4,5-tetrahydro-1 H-1 benzazepin-7-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-{[1 -methyl-2-oxo-6-(propan-2-yloxy)-2,3,4,5-tetrahydro-1 H-1 benzazepin-7-yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypheny!)-2-{[5-(4-methylpiperazin-1-yl)-2-(propan-2-y!oxy)phenyl]amino)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-[[2-(propan-2-yloxy)-4-(tetrahydro-2H-pyran-4ylaminojphenyljaminojthienojs^-djpyrimidine-e-carboxamide;
7-(3-methoxypyridin-2-yl)-2-{[5-methyl-4-(4-methylpiperazin-1-y!)-2-(propan-2yloxy)phenyl]amino)thieno[3,2-d]pyrimîdine-6-carboxamide;
2-{[4-(4-hydroxypiperidin-1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridin-3y!)thieno[3,2-d]pyrimidine-6-carboxamide,*
7-(2-methoxypheny!)-2-({4-[(1-methylpiperidin-4-yl)amino]-2-(propan-2y!oxy)phenyl}amino)thieno[3>2-d]pyrimidine-6-carboxamide;
2-{[1-cyclobutyl-3-(1-ethyîpiperidÎn-4-yl)-1H-pyrazol-5-yl]amino}-7-(4-fluoro-2methoxyphenyl)thieno[3,2-d]pyrimÎdÎne-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-({4-[(4-methylpîperazin-1-yl)methy!]-2-(propan-2yloxy)phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-{[4-(1-rnethylpyrrolidin-3-yl)-2-(propan-2yloxy)phenyl]amino]thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-{[3-(4-methyîpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino]thÎeno[3,2-d]pyrimidine-6-carboxamide;
7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[1-(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1Hio pyrazol-5-yl]aniino]thieno[3,2-d]pyrimidine-6-carboxamtde;
7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[3-rnethyl-1-(propan-2-yl)-1H-pyrazoI-5· yl]amino}thîeno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-[(5-methyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-7· yl)amino]thieno[3,2-d]pyrimÎdine-6-carboxanriîde;
2-{ [1 -(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-5-yl]amÎno}-7-[2(trifluoromethoxy)phenyl]thieno[3,2-d]pyrÎmidine-6-carboxamide; 7-(2-methoxypyridin-3-yl)-2-{[3-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidÎne-6-carboxamîde;
7-(2-methoxypyrîdin-3-yl)-2-{[5-(4-methylpiperazin-1-yl)-2-(propan-220 yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxaniide;
7-(2-methoxypyridin-3-yl)-2-({4-[(1-methylpiperidin-4-yl)amino]-2-(propan-2yloxyjphenyljaminojthienois^-dlpyrimîdine-e-carboxamide;
24[4-(4-ethylpîperazln-1-yl)-2-(propan-2-yloxy)pheny!]amino}’7-(2-rnethoxypyridin-3yl)thieno[3,2-d]pyrimidine-6-carboxaniide;
7-(2-methoxyphenyl)-2-{[1 -methyl-2-oxo-8-(propan-2-yloxy)-2,3,4,5-tetrahydro-1 H-1 benzazepin-T-ylJaminoJthienoIS^-dlpyrimidine-G-carboxamide; 7-(2-methoxyphenyl)-2-{[1-(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5yî]amino}thieno[3,2-d]pyrimidine*6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-{[1-methyl-2-oxo-8-(propan-2-yloxy)-2,3,4,5-tetrahydrO-1 H-130 benzazepin-7-yl]amino}thîeno[3,2-d]pyrimidÎne-6-carboxaniide;
7-(2-methoxypyridin-3-yl)-2-{[4-(1-methyl-1H-pyrazol-4-yl)-2-(propan-2yloxyjphenyljamïnojthienots^-dlpyrimidine-e-carboxanriide;
[7-(2-methoxyphenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2y!oxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;
[7-(2-methoxyphenyl)-2-{[4-(4-methylpiperazin-1 -yl)-2-(propan-2yloxy)phenyl]amino)thieno[3,2-d]pyrimidin-6-yl]methanol;
[7-(2-methoxy'6-methylpyridin'3-yl)-2'{[4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrïniidin-6'yl]methanol;
[7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;
[7-(2-ethoxypyridin-3-yl)-2-{[4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yi]methanol; [7-(2-methoxypyridin-3-yl)-2-{[5-methyi-4-(4-methylpiperazïn-1-yl)-2-(propan-2yloxy)phenyl]amino}thïeno[3,2-d]pyrîmîdïn-6-yl]methanol;
[7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2io yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol; [7-(2-methoxy-6-methylpyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrîmidin-6-yl]methanol,· [7-(2-methoxy-6-methylpyridin-3-yl)-2-[[1-(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1Hpyrazol-5-yl]amino}thîeno[3,2-d]pyrïniïdin-6-y1]methanol;
[7-(2-ethoxypyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;
[7-(2-methoxyphenyl)-2-{[5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrÎmidin-6-yi]methanol;
[7-(2-methoxy-6-methylpyridin-3-yl)-2-{[4-(1-methyl-1,7-diazaspiro[4.4]non-7-yl)-220 (propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol; [2-{[4-chloro-2-(propan-2-yloxy)phenyl]aniino}-7-(2-melhoxypyridin-3-yl)thieno[3,2dJpyrimidin-6-yl]methanol;
(2-{[3-methyl-1 -(propan-2-yl)-1 H-pyrazol-5-yl]amino}-7-[2(trifluoromethoxyJphenylJthienop^-dJpyrimidin-e-yOmethanol;
[7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[3-methyl-1 -(propan-2-yl)-1 H-pyrazol-5yl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;
(2-{[1-(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-5-yl]amino}-7-[2(trifluoromethoxyJphenyllthienop^-dJpyrimidin-S-yOmethanol;
[7-(2-methoxyphenyl)-2-{[1-(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-530 yt]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;
[7-(5-fluoro-2-methoxypheny1)-2-{[3-rriethyl-1-(propari-2-yI)-1 H-pyrazol-5yl]amino}thieno[3,2-d]pyrimidin-6-yl]niethanol;
[7-(5-fluoro-2-methoxyphenyl)-2-{[4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyriniidin-6-yl]methanol;
(2-{[4-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-[2(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidin-6-yl)methanol;
[7-(2-methoxypyridin-3-yl)-2-([4-(1-methyl-1H-pyrazol-4-yl)-2-(propan-2yloxy)phenyl]amino)thieno[3,2-d]pyrimidin-6-yl]methanol; [7-(2-methoxyphenyl)-2-{[4-(1-methyl-1H-pyrazol-4-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol; [2-{[5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(6methylpyridin-3-yl)thieno[3,2-d]pyrimidin-6-yl]methanol; [7-(2-methoxypyridin-3-yl)-2-{[4-(4-methylpiperazin-1-yl}-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol; [7-(2-methoxyphenyl)-2-{[4-(1-methylpyrrolidin-3-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol; 2-(2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-7-phenylthieno[3,2-d]pyrimidin6-yl)propan-2-ol; 2-[2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2d]pyrimidin-6-yl]propan-2-ol; and 2-[7-(4-fluoro-2-methoxyphenyl)-2-{[2-methoxy-4-(4-methylpiperazin-1yl)phenyl]amino}thieno[312-d]pyrimidin-6-yl]propan-2-ol;
and pharmaceutically acceptable salts thereof.
The présent invention also relates to a process for preparing a compound of formula (I) as defined above, characterized in that a thienopyrimidine of formula (II):
in which
R7 is as defined in formula (I) above;
n is 1 or 2; and
R16 is a (CrCe)alkoxy group, is reacted
a) with a compound of formula (lllb) below:
.CHO (H|b)
Hï|l
R in which R is as defined in formula (I) above;
b) then step a) is followed:
- either by a step of treating the mixture obtained with an aqueous ammonia solution, for example in a solvent such as methanoi, which makes it possible to obtain the compounds of formula (I) in which R6 is -CONH2;
- or by a step of reducing the mixture obtained with a reducing agent, such as DIBALH, in a solvent such as toluene or THF, which makes it possible to obtain the compounds of formula (I) in which R6 is a -C(Rc)(Rp)(OH) group where Ro and Rp are hydrogen atoms;
- or by a step of treating the mixture obtained with an excess of an organometallic dérivative (R0MgX or RpLi for example) in a solvent such as THF, which makes it possible to obtain the compounds of formula (I) in which R6 is a -C(Ra)(Rp)(OH) group where Ro and Rp are identical and are a (CrC6)alkyl group.
According to one particular embodiment of step a), the reaction between the compounds (II) and (lllb) is carried out in the presence of an organic or inorganic base, in a polar aprotic solvent.
The products of formula (II) can be prepared according to schemes 1 and 2 hereinafter.
L1 = leaving group such as OSO2CF3 or OTs.
The commercial 5-chloro-2-(methylsulfanyl)pyrimidine-4-carboxylic acid (1) is converted into ester (2) by reaction with methanoi in the presence of acid as a catalyst. The treatment of the ester (2) with methyl sulfanylacetate in the presence of a base such as sodium hydride, potassium carbonate, sodium carbonate or caesium carbonate in a polar aprotic solvent such as DMF or THF gives a dérivative (V). The dérivative (V) can also be isolated in sait form. Finally, the hydroxyl group can be converted into a leaving group by reaction with a sulfonic anhydride or sulfonic acid chloride, in the presence of a base such as pyridine, potassium carbonate, sodium carbonate or caesium carbonate, in a polar aprotic solvent such as DMF or THF.
Scheme 2
A Suzuki-type metallo-catalyzed coupling reaction on the compound (VI) makes it possible to install the (hetero)aryl R7 group In position 7. This reaction can précédé or follow a reaction of oxidation of the sulfur with an oxidizing agent such as 3-chloroperbenzoic acid, aqueous hydrogen peroxide, sodium perborate tetrahydrate or sodium bromate in order to préparé the dérivatives II (n - 1,2).
Altematively, the products of formula (VII) can be prepared according to scheme 3, where R16 is a methoxy group.
Heating of the 5-chloro-2-(methy1sulfanyl)pyrimidine-4-carboxylic acid (1) in the presence of an aldéhyde, ln an apolar solvent such as toluene, gives a benzyl alcohol (IX) (J.
Heterocyclic Chem. 2003, 40, 219). Oxidation of the alcohol with manganèse dioxide or a Swem-type reaction gives a ketone (X). Treatment of the ketone (X) with methyl su If an y I acetate ln the presence of a base such as sodium hydride, potassium carbonate, sodium carbonate or caesium carbonate, in a polar aprotic solvent such as DMF or THF, at a température between ambient température and the reflux température, gives the 20 dérivative (VII).
Altematively, the products of formula (I’) can be prepared according to scheme 4.
Scheme 4
HljJ R
R7 (XII) n= 1,2
Treatment of the dérivatives (VII) for which R16 is a methoxy group, with an aqueous ammonia solution, in a solvent such as methanol, éthanol or water, gives carboxamide dérivatives (XI). The sulfur is then oxidized with an oxidizing agent such as 3-chloroperbenzoic acid, aqueous hydrogen peroxide, sodium perborate tetrahydrate, magnésium monoperoxyphthalate or sodium bromate, in order to préparé the dérivatives (XII) with n = 1 or 2. Fînally, the réaction of a compound of formula (lllb) with the thienopyrimidine (XII) in the presence of an organic base such as DBU or BTTP, or an inorganic base such as sodium hydride, caesium carbonate or potassium carbonate, in a polar aprotic solvent such as DMF, DMA, DMSO or THF, gives the compounds (Γ).
Altematively, the products of formula (!’·) can be prepared according to scheme 5.
Scheme 5 zR16
R7 (VI la) R16 = -OCH3 (VI Ib) R16 = -NMeOMe
Reaction of the dérivatives (Vlla) for which R16 is a methoxy group, with a reducing agent such as DIBALH, in a solvent such as THF or toluene, gives alcohol dérivatives (XIII), for which the Ra and Rp groups are hydrogen atoms.
Reaction of the dérivatives (Vlla) for which R16 is a methoxy group, with an excess of an organometallic dérivative (RaMgX or RaU, for example) in a solvent such as THF, gives alcohol dérivatives (XIII) for which the Ra and Rp groups are identical and are a (Ct-Ce)alkyl group.
Alcohol dérivatives (XIII) for which the Ra and Rp groups are alkyl groups that are different from one another can be obtained by means of a Weinreb amide (Vllb) for which R16 is N(OCH3)CH3 (obtained after hydrolysis of the ester (Vlla) with NaOH or LiOH and formation of the Weinreb amide according to the methods known to those skilled in the art), by addition of an organometallic dérivative RaMgX or RaLi, and then by treatment of the resulting ketone with another dérivative RpMgX or RpLi.
Alcohol dérivatives (XIII) for which one of the Ro or Rp groups is a hydrogen and the other 5 an alkyl group can be obtained by means of a Weinreb amide (Vllb) for which R16 is
N(OCH3)CH31 by addition of an organometallic dérivative RMgX or RU, and then by treatment of the resulting ketone with a reducing agent such as sodium borohydride in methanol or DIBALH, in a solvent such as THF or toluene.
Alcohol dérivatives (XIII) for which the Ra and Rp groups together form, with the carbon îo atom which bears them, a 3-membered carbocycle can be obtained by reaction with ethylmagnesium bromide in the presence of titanium IV isopropoxide, in a solvent such as THF or ether (see, for example, Tetrahedron 2011, 67(33), 5979).
Alcohol dérivatives (XIII) for which the Ra and Rp groups together form, with the carbon atom which bears them, a 4- to 5-membered carbocycle can be obtained by reaction with 15 the bismagnesium reagents derived from 1,3-dibromopropane or 1,4-dibromobutane in a solvent such as THF (see, for example, European Journal of Organic Chemistry 2004,24, 4995).
The sulfur of the compounds (XIII) is then oxidized with an oxidizing agent such as 3-chloroperbenzoic acid, aqueous hydrogen peroxide, magnésium monoperoxyphthalate, 2o sodium perborate tetrahydrate or sodium bromate, in order to préparé the dérivatives (XIV) with n = 1 or 2. Finally, the reaction of a compound of formuia (lllb) with the thienopyrimidine (XIV) in the presence of an organic base such as DBU or BTTP, or an inorganic base such as sodium hydride, caesium carbonate or potassium carbonate, in a polar aprotic solvent such as DMF, DMA, DMSO or THF, gives the compounds (I).
The préparation of the compounds of formula (lllb) can be carried out according to scheme 6.
Scheme 6 hco2h ï ------(Ilia)
The products of formula (lllb) can be prepared from the compounds (Ilia) by réaction with formic acid, optionally in the presence of acetic anhydride, at a température between ambîent température and the reflux température. Most of the compounds (Ilia) are prepared according to the methods known to those skilled in the art.
The présent invention also relates to the compounds of general formulae (II), (XII) and 5 (XIV), as well as pharmaceutically acceptable salts thereof. These compounds are of use as synthesis intermediates for the préparation of the compounds of general formula (I).
Tables A and B hereinafter describe compounds of the invention, without, however, being limiting.
Table A - Compounds of formula (!')
R7 | R | R1 | R2 | R3 | R’1 | |
1 | b | (A) | och3 | HDO | H | H |
2 | b | (A) | ch3 | H | H | |
3 | K- | (A) | och3 | ηΟΌ | H | H |
R7 | R | Rî | R2 | R3 | R’1 | |
4 | (A) | 0CH3 | H | H | ||
5 | Έ· | (A) | och3 | H | H | |
6 | (A) | och3 | H | H | ||
7 | 'b | (A) | och3 | XX | H | H |
β | ^b | (A) | och3 | XX | H | H |
9 | vb | (A) | isopropyloxy | 'T 0 1 | H | H |
R7 | R | R1 | R2 | R3 | R1 | |
10 | h --O F | (A) | isopropyloxy | i-O- | H | H |
11 | o— | (A) | isopropyloxy | fO*- | H | H |
12 | 'b F | (A) | isopropyloxy | fO- . | H | H |
13 | b | (A) | och3 | hO_ | Me | H |
14 | F | (A) | Isopropyloxy | fO- | H | H |
15 | --0 | (A) | och3 | f-O- | H | H |
R7 | R | R1 | R2 | R3 | R’1 | |
16 | K | (A) | isopropyloxy | Kl·- | H | H |
17 | K | (A) | isopropyloxy | Kl·- | Me | H |
18 | (A) | och3 | k>z | Me | H | |
19 | (A) | isopropyloxy | H | H | ||
20 | (A) | Isopropyloxy | KD*- | H | H | |
21 | —o | (A) | isopropyloxy | Kl·- | H | H |
R7 | R | R1 | R2 | R3 | R‘1 | |
22 | (A) | Isopropyloxy | KZ>- | Me | H | |
23 | b | (A) | Isopropyloxy | H | H | |
24 | (A) | Isopropyloxy | Kl·- | H | H | |
25 | (A) | isopropyloxy | KZ/_ | H | H | |
26 | κ8 | (A) | isopropyloxy | Kl·- | H | H |
R7 | R | R1 | R2 | R3 | R'1 | |
27 | b | (A) | Isopropyloxy | KZb | H | H |
28 | b | (A) | Isopropyloxy | H | H | |
29 | b- | (A) | Isopropyloxy | 1 hbb | H | H |
30 | 'b | (A) | isopropyloxy | Me | H | |
31 | b | (A) | isopropyloxy | OMe | H | H |
32 | b | (A) | isopropyloxy | H | H |
R7 | R | R1 | R2 | R3 | R'I | |
33 | (A) | isopropyloxy | H | H | ||
34 | -b | (A) | isopropyloxy | K>- | H | H |
35 | ^b | (A) | isopropyloxy | i-CN | H | H |
36 | ^b | (A) | isopropyloxy | ,_z-^ | H | H |
37 | x°b | (B) | isopropyloxy | fO- | - | H |
R7 | R | RI | R2. | R3 | R'1 | |
38 | K | (B) | isopropyloxy | K> | - | H |
39 | (A) | isopropyloxy | Kl·- | H | H | |
40 | (A) | isopropyloxy | KX | H | H | |
41 | (A) | isopropyloxy | Kl·- | H | H | |
42 | x°~o | (A) | isopropyloxy | H | H | |
43 | K | (A) | isopropyloxy | T K Ό | H | H |
Μ
R7 | R | R1 | R2 | R3 | R’1 | |
44 | —ο | (Α) | Isopropyloxy | KD- | H | H |
45 | (Α) | isopropyloxy | H | H | ||
46 | (Α) | isopropyloxy | «D- | H | H | |
47 | κ | (Α) | Isopropyloxy | K> | H | H |
48 | ^=7 CH | (Α) | Isopropyloxy | KD- | H | H |
49 | Χ°“^ | (Α) | Isopropyloxy | H | H |
R7 | R | R1 | R2 | R3 | R’1 | |
50 | ,¾ F | (A) | Isopropyloxy | H | H | |
51 | H | (A) | isopropyloxy | hG | H | H |
52 | x°b | (D) | Isopropyl | KH H- | - | H |
53 | x-b | (A) | isopropyloxy | H | H | |
54 | Xb | (A) | isopropyloxy | H | H | |
55 | (A) | isopropyloxy | kzÇ | H | H |
R7 | R | R1 | R2 | R3 | R'1 | |
56 | (A) | isopropyloxy | HD | H | H | |
57 | F | (A) | Isopropyloxy | HQ- | H | H |
58 | (A) | isopropyloxy | H | H | ||
59 | x°b | (A) | isopropyloxy | >/—(. | H | H |
60 | (A) | isopropyloxy | >/~A r ν/η H | H | H | |
61 | <b | (D) | isopropyî | KD” | - | H |
R7 | R | R1 | R2 | R3 | R'1 | |
62 | (A) | isopropyloxy | i rb | H | H | |
63 | xb | (A) | Isopropyloxy | H | H | |
64 | b | (A) | isopropyloxy | FO- | H | H |
65 | b | (A) | isopropyloxy | K> | H | H |
66 | x°b | (A) | isopropyloxy | μ 1.....όΗ | H | H |
67 | (A) | Isopropyloxy | K> | H | H |
R7 | R | RI | R2 | R3 | R’1 | |
68 | (A) | Isopropyloxy | K> | H | H | |
69 | (A) | Isopropyloxy | H | H | H | |
70 | (D) | Isopropyl | - | H | ||
71 | (A) | Isopropyloxy | FO- | H | H | |
72 | (A) | Isopropyloxy | K> | H | H | |
73 | 1 | (A) | Isopropyloxy | K> | H | H |
R7 | R | R1 | R2 | R3 | R’1 | |
74 | (Α) | isopropyloxy | H | H | ||
75 | F | (Α) | isopropyloxy | HO- | H | H |
76 | (Α) | isopropyloxy | HO- | H | H | |
77 | (Α) | isopropyloxy | t ^CH FO- | H | H | |
7Θ | (Α) | isopropyloxy | FO- | Me | H | |
79 | (Α) | isopropyloxy | hQ- | H | H |
R7 | R | R1 | R2 | R3 | R’1 | |
80 | K | (A) | isopropyloxy | KX | H | H |
81 | K | (A) | Isopropyloxy | H | H | |
82 | (C) | Isopropyloxy | FO- | H | H | |
83 | K | (A) | Isopropyloxy | K | H | H |
84 | K | (A) | Isopropyloxy | | yM— | H | H |
85 | K | (A) | Isopropyloxy | xk | H | H |
R7 | R | R1 | R2 | R3 | R'1 | |
86 | (A) | Isopropyloxy | ΚΉ | H | H | |
87 | (A) | isopropyloxy | HO- | H | H | |
88 | '°-b” | (A) | Isopropyloxy | HZH | H | H |
89 | (A) | isopropyloxy | K> | CH3 | H | |
90 | —o | (A) | Isopropyloxy | K>- | H | H |
91 | (A) | Isopropyloxy | KX | H | H |
R7 | R | R1 | R2 | R3 | R'1 | |
92 | H | (C) | Isopropyloxy | Kl·- | H | H |
93 | (A) | Isopropyloxy | kP | H | H | |
94 | Ή | (A) | Isopropyloxy | H | H | |
95 | Η | (A) | isopropyloxy | H | H | |
96 | (A) | isopropyloxy | Kl·- | H | H | |
97 | ^b | (A) | isopropyloxy | Kl·- | H | H |
R7 | R | R1 | R2 | R3 | R’1 | |
98 | Π | (A) | isopropyloxy | HZ/- | H | H |
99 | Nl^ | (A) | isopropyloxy | H | H | |
100 | Ή | (A) | Isopropyloxy | FO- | ch3 | H |
101 | b | (A) | isopropyloxy | HZ/- | H | H |
102 | x-b | (A) | isopropyloxy | H | H | |
103 | H | (A) | isopropyloxy | HZ/H | H | H |
R7 | R | RI | R2 | R3 | R’1 | |
104 | 03 N=/ | (A) | isopropyloxy | K>- | CH, | H |
105 | x°~o | (A) | isopropyloxy | FO- | ch3 | H |
106 | 03 N=/ | (A) | isopropyloxy | hO“ | H | H |
107 | 03 N=/ | (A) | isopropyloxy | hO- | H | H |
108 | (A) | Isopropyloxy | hO~ | H | H | |
109 | (A) | Isopropyloxy | FO1- | H | H |
R7 | R | R1 | R2 | R3 | R’1 | |
110 | (A) | isopropyloxy | FO^- | H | H | |
111 | (A) | isopropyloxy | K>- | ch3 | H | |
112 | (A) | Isopropyloxy | FO1- | H | H | |
113 | (A) | isopropyloxy | r\_K o— | H | H | |
114 | (A) | isopropyloxy | h*O | H | H | |
115 | (A) | isopropyloxy | K> | H | H |
R7 | R | R1 | R2 | R3 | R’1 | |
116 | 'F —ο | (A) | isopropyloxy | H3- | ch3 | H |
117 | B) | (A) | Isopropyloxy | X | ch3 | H |
116 | K | (A) | Isopropyloxy | I | ch3 | H |
119 | K | (D) | Isopropyl | KX> | - | H |
120 | K | (A) | isopropyloxy | «X | ch3 | H |
121 | K | (A) | Isopropyloxy | Η\Ζ/- | H | H |
w
R7 | R | R1 | R2 | R3 | R‘1 | |
122 | (A) | isopropyloxy | HO- | H | H | |
123 | (D) | isopropyl | - | H | ||
124 | ^b | (A) | isopropyloxy | hb- | H | H |
125 | WA \=/ | (A) | isopropyloxy | H | H | |
126 | ^b | (A) | Isopropyloxy | â5 | H | H |
127 | (A) | Isopropyloxy | hC< | H | H |
R7 | R | R1 | R2 | R3 | R’1 | |
128 | 4d | (A) | H | -P | fused with phenyl | H |
129 | N=/ | (A) | isopropyloxy | > | H | H |
130 | x°~o | (A) | isopropyloxy | K> | F | H |
131 | (A) | isopropyloxy | K>- | F | H | |
132 | N=/ | (A) | isopropyloxy | > | ch3 | H |
133 | x°~o | (A) | Isopropyloxy | >~V | H | H |
R7 | R | RI | R2 | R3 | R’1 | |
134 | x°~o | (D) | b | H | - | H |
135 | K) | (A) | Isopropyloxy | hOn | H | H |
136 | N=/ | (D) | isopropyl | methyl | - | H |
137 | (A) | isopropyloxy | HO- | ch3 | H | |
138 | (A) | H | -KH f \ fused —N ) with phenyi Γ | H | ||
139 | '-b F | (D) | Isopropyl | k3 | - | H |
R7 | R | R1 | R2 | R3 | R*1 | |
140 | (D) | isopropyl | cyclopropyl | - | H | |
141 | (D) | isopropyl | b N=/ | - | H | |
142 | N—7 | (A) | H | - Z \ with phenyl r | H | |
143 | (A) | Isopropyloxy | H | H | ||
144 | N=/ | (A) | isopropyloxy | I-H | H | H |
145 | N—' | (A) | isopropyloxy | methoxy | H | H |
R7 | R | Rt | R2 | R3 | R’t | |
146 | Ή | (D) | b | cyclopropyl | - | H |
147 | Ή | (A) | isopropyloxy | hcb | H | H |
148 | b | (A) | Isopropyloxy | hGN-<] | H | H |
149 | (A) | isopropyloxy | H | H | ||
150 | Ή N—' | (A) | isopropyloxy | H | H | |
151 | N—' | (A) | Isopropyloxy | H | H |
R7 | R | R1 | R2 | R3 | R’1 | |
152 | F | (A) | H | 1/ fused JX/X with phenyl V | H | |
153 | -F | (A) | Isopropyloxy | FO*- | H | H |
154 | (A) | Isopropyloxy | H | H | ||
155 | (A) | Isopropyloxy | FO- | ch3 | H | |
156 | '--O | (A) | Isopropyloxy | > •λα | H | H |
157 | x°K | (A) | Isopropyloxy | FO*- | ch3 | H |
R7 | R | RI | R2 | R3 | R’I | |
158 | (A) | isopropyloxy | > /^N | H | H | |
159 | <b | (A) | isopropyloxy | ,</~y | H | H |
160 | (A) | isopropyloxy | FNON_ | ch3 | H | |
161 | <b | (A) | H | r* I fused with phenyl r | isopropyloxy | |
162 | '•b | (A) | H | ΛΧ 1 \ fused __N ) with phenyl Γ | isopropyloxy | |
163 | X°“O | (A) | Isopropyloxy | FO- | H | H |
R7 | R | R1 | R2 | R3 | R’1 | |
164 | K | (A) | isopropyloxy | FO’ | H | H |
165 | '8 | (A) | Isopropyloxy | l_/~\ | ch3 | H |
166 | K | (A) | Isopropyloxy | ΗΟ-°η | H | H |
167 | K | (A) | isopropyloxy | hKl·- | H | H |
168 | F | (D) | cyclobutyl | HOa | - | H |
169 | K | (A) | Isopropyloxy | H | H |
R7 | R | R1 | R2 | R3 | R’1 | |
170 | '-b | (A) | isopropyloxy | H | H | |
171 | (E) | isopropyloxy | FO- | - | H | |
172 | (D) | isopropyl | FO | - | H | |
173 | x°-^=b | (D) | isopropyl | CH3 | - | H |
174 | (A) | H | fused [ \ with phenyl W | H | ||
175 | Ab | (D) | isopropyl | K> | - | H |
R7 | R | R1 | R2 | R3 | R’1 | |
176 | Ή Ν=/ | (Ε) | isopropyloxy | h’O'- | - | H |
177 | Ή | (F) | Isopropyloxy | HO- | - | H |
178 | Η | (Α) | Isopropyloxy | hrO1- | - | H |
179 | Ή | (Α) | Isopropyloxy | H | H | |
180 | Ή | (Α) | Isopropyloxy | fused / \ with phenyl 'K | H | |
181 | b | (D) | isopropyl | KD- | - | H |
R7 | R | RI | R2 | R3 | R'1 | |
182 | (A) | isopropyloxy | zX 1 \ fused N ) with phenyl y·”7 0 | H | ||
183 | <b N=/ | (A) | isopropyloxy | H | H |
Table B - Compounds of formula (I”)
R7 | R | R1 | R2 | R3 | Rct | RP | R’1 | |
184 | (A) | isopropyloxy | K> | H | H | H | H | |
185 | vb> | (A) | isopropyloxy | hQ- | H | H | H | H |
R7 | R | R1 | R2 | R3 | Ra | Rp | R’1 | |
166 | (A) | isopropyloxy | FO- | H | H | H | H | |
187 | \_X_F N=/ | (A) | isopropyloxy | FO- | H | H | H | H |
188 | vb | (A) | isopropyloxy | FO- | H | H | H | H |
189 | (A) | isopropyloxy | FO- | ch3 | H | H | H | |
190 | b>' | (A) | isopropyloxy | FO- | ch3 | H | H | H |
191 | H | (A) | isopropyloxy | FO~ | ch3 | H | H | H |
R7 | R | R1 | R2 | R3 | Ra | RP | R'1 | |
192 | 4τ N--Ç | (D) | isopropyl | FO | - | H | H | H |
193 | (A) | isopropyloxy | FO1- | ch3 | H | H | H | |
194 | (A) | isopropyloxy | ΗΌ4- | ch3 | H | H | H | |
195 | 4^ | (A) | isopropyloxy | , /Dp | H | H | H | H |
196 | 4d N^—' | (A) | isopropyloxy | Cl | H | H | H | H |
197 | '4d | (D) | isopropyl | ch3 | - | H | H | H |
R7 | R | R1 | R2 | R3 | Ra | Rp | R'1 | |
198 | K | (D) | isopropyl | ch3 | - | H | H | H |
199 | K | (D) | isopropyl | FO5 | - | H | H | H |
200 | x°~^3 | (D) | isopropyl | KD- | - | H | H | H |
201 | Zy | (D) | Isopropyl | ch3 | - | H | H | H |
202 | (A) | isopropyloxy | FO- | H | H | H | H | |
203 | K | (A) | isopropyloxy | FO- | H | H | H | H |
R7 | R | R1 | R2 | R3 | Ra | Rp | R’1 | |
204 | x:b | (A) | isopropyloxy | H | H | H | H | |
205 | ^b | (A) | isopropyloxy | hCF | H | H | H | H |
206 | b | (A) | isopropyloxy | |— | ch3 | H | H | H |
207 | x;b | (A) | isopropyloxy | FO- | H | H | H | H |
208 | Fd | (A) | isopropyloxy | H | H | H | H | |
209 | 'b | (A) | och3 | hO- | H | ch3 | ch3 | H |
»
R7 | R | R1 | R2 | R3 | Ra | R'1 | ||
210 | (A) | och3 | j—— | H | ch3 | ch3 | H | |
211 | F | (A) | och3 | H | ch3 | ch3 | H |
The following examples describe the préparation of certain compounds in accordance with the invention. These examples are not limiting and merely illustrate the présent Invention. The numbers of the compounds exemplified refer back to those given in the table hereinafter, which illustrâtes the chemical structures and the physical properties of some compounds according to the invention.
EXAMPLES / - MATERIALS AND METHODS
The 1H NMR spectra at 250,400 and 500 MHz were performed on a Broker Avance 250, Broker Avance DRX-400 or Broker Avance DPX-500 spectrometer with the chemical shifts (δ in ppm) in dimethyl sulfoxide-d6 (DMSO-d6) referenced at 2.5 ppm at the température of 303K.
The mass spectra (SM) were obtained by methods A to E.
Method A:
Waters UPLC-SQD apparatus; ionization: electrospray in positive and/or négative mode (ES+/·); chromatographie conditions: column: Acquity BEH C18 1.7 pm - 2.1 x 50 mm;
solvents: A: H20 (0.1% formic acid) B: CH3CN (0.1% formic acid); column température: 50*0; flow rate: 1 ml/min; gradient (2 min): from 5 to 50% of B in 0.8 min; 1.2 min: 100% of B; 1.85 min: 100% of B; 1.95:5% of B; rétention time = Tr (min).
Method B:
Waters UPLC-SQD apparatus; ionization: electrospray in positive and/or négative mode (ES+/-); chromatographie conditions: column: Acquity BEH C18 1.7 pm - 2.1 x 50 mm; solvents: A: H2O (0.1% formic acid) B: CH3CN (0.1% formic acid); column température: 50*C; flow rate: 0.8 ml/min; gradient (2.5 min): from 5 to 100% of B in 1.8 min; 2.4 min: îo 100% of B; 2.45 min: 100% to 5% of B in 0.05 min; rétention time = Tr (min).
Method C:
Waters UPLC-XEVO/QTof apparatus; ionization: electrospray in positive mode; chromatographie conditions: column: Acquity UPLC BEH C8 1.7 pm - 2.1 x 100 mm; 15 solvents: A: H2O (0.1% formic acid) B: CH3CN (0.1% formic acid); column température:
55Ό; flow rate: 0.55 ml/rnin; gradient (11 min): from 5 to 97% of B in 8.3 min; 8.6 min: 100% of B; 9 min: 5% of B; rétention time = Tr (min).
Method D
Waters ZQ apparatus; ionization: electrospray in positive and/or négative mode (ES+/-); chromatographie conditions: column: XBridge C18 2.5 pm - 3 x 50 mm; solvents: A: H2O (0.1% formic acid) B: CH3CN (0.1% formic acid); column température: 70*0; flow rate: 0.9 ml/min; gradient (7 min): from 5 to 100% of B ïn 5.3 min; 5.5 min: 100% of B; 6.3 min: 5% of B; rétention time = Tr (min).
Method E:
Waters UPLC-TOF apparatus; ionization: electrospray in positive mode; chromatographie conditions: column: Acquity UPLC BEH C8 1.7 pm - 2.1 x 50 mm; solvents: A: H2O (0.05% TFA) B: CH3CN (0.035% TFA); column température: 40*C; flow rate: 1.0 ml/min;
gradient (3 min): T0:98% of A; T1.6 min to T2.1mîn: 100%B; T2.5 min toT3 min: 98%A.
The microwave oven used is a Biotage, InitiatorTM Eight, 400W max, 2450 MHz device or a CEM discover, 300W max, device.
The H-cube used is a Thales-nanotechnology device.
Il - PREPARATION OF COMPOUNDS OF FORMULAE(II) and (XII)
Example 1 : Methyl 2-(methylsulfanyl)-7-{[(trifluoromethyl)sulfonyl]oxy}thieno[3,2d]pyrimidine-6-carboxylate
* bîÇ0Me | |||
w 1 | o x | ||
2 | O | ||
O | S OMe | rA /0Me | |
- | ψο | ||
OSOjCF3 | ONa | ||
4 | 3 |
16.0 g of ch1oro(trimethyl)silane are added dropwise to a solution of 6.2 g of 5-chloro-2(methylsulfanyl)pyrimidine-4-carboxy!ic acid 1 In 100 ml of methanol and 100 ml of dichloromethane. The mixture is stirred at ambient température for 20 h, and then concentrated under vacuum. The residue is taken up with water and extracted with dichloromethane. The organic phase Is dried over magnésium sulfate and concentrated under vacuum so as to obtain 6.3 g of methyl 5-chloro-2-(methylsulfanyl)pyrimidine-4carboxylate 2 In the form of a brown oil.
1.2 g of sodium hydride (60% In oil) are added slowly to a mixture of 6.0 g of methyl
5-chloro-2-(methy1sulfanyl)pyrimidine-4-carboxylate 2 and 3.0 g of methyl sulfanylacetate in 60 ml of DMF. After 15 min at ambient température, the mixture is heated at 60°C for 3 h, and then cooled to ambient température ovemight. The resulting suspension is filtered and the solid is washed with ethyl acetate and dried under vacuum so as to obtain 3.6 g of sodium 6-(methoxycarbony!)-2-(methylsulfany!)thieno[3,2-d]pyrimidin-7-olate 3 in the form of a beige solid.
g of N-phenylbistrifluoromethanesulfonimide are added to a solution of 10.0 g of sodium 6-(methoxycarbonyl)-2-(methylsulfany!)thÎeno[3,2-d]pyrimidin-7-o1ate 3 In 400 ml of anhydrous pyridine. The mixture is stirred at ambient température for 48 h, and then concentrated under reduced pressure. The reaction crude is solubilized in 400 ml of dichloromethane and then the organic phase is washed three times with 250 ml of water.
The organic phase Is dried over magnésium sulfate, filtered, and then concentrated under reduced pressure. The residue is purified on silica, elution being carried out with 15-30% of ethyl acetate in heptanes, so as to obtain 11.6g of methyl 2-(methylsulfanyl)-7{[(trifluoromethyl)sulfonyl]oxy}thieno[3,2-d]pyrimidine-6-carboxylate 4 ln the form of a whitish powder. Rf = 0.39 (heplane/ethyl acetate: 70/30).
Example 2: Methyl 2-(methylsulfonyl)-7-{[(trifluoromethyl)sulfonyl]oxy)thÎeno[3,2d]pyrimidine-6-carboxylate
tn | X | z 0Me . - J! | |
IU | \ υ | o | |
OSO2CF3 | (O)2 OSO2CF3 | ||
4 | 5 |
14.3 g of 3-chloroperbenzoic acid is added slowly, in fractions, to a solution of 10.0 g of methyl 2-(methylsulfanyl)-7-{[(trifluoromethyl)sulfonyl]oxy}thieno[3,2-d]pyrimidine-615 carboxylate 4 (example 1) in 140 ml of dichloromethane, cooled in an Ice bath. The mixture Is stirred for 6 h while cold, and then left at amblent température ovemight. The mixture is then diluted with 400 ml of dichloromethane and treated with 300 ml of saturated sodium thiosulfate solution. After stirring and settling out, the aqueous phase Is extracted with 2 x 100 ml of dichloromethane. The organic phases are washed with 20 400 ml of a saturated sodium bicarbonate solution, and then with 100 ml of a saturated sodium chioride solution. The organic phases are dried over magnésium sulfate, filtered, and then concentrated under vacuum so as to obtain 10.8 g of methyl 2-(methylsulfonyl)7-{[(trifluoromethyl)sulfonyl]oxy)thieno[3,2-d]pyrimidine-6-carboxylate 5 in the form of a white powder. ’H NMR (DMSO-d6) δ 3.48 (s, 3H); 4.02 (s, 3H); 10.01 (s, 1H).
Example 3: Methyl 2-(methyisulfonyl)-7-phenylthieno[3,2-d]pyrimidine-6-carboxylate
A mixture of 253 mg of methyl 2-(methylsulfonyl)-7{[(trifluoromethyl)sulfonyl]oxy)thieno[3,2-d]pyrimidine-6-carboxylate 5 (example 2), 30 110 mg of benzeneboronic acid, 392 mg of caesium carbonate and 49 mg of dichloropalladium(ll)bis(diphenyiphosphino)ferocene in 3.5 ml of toluene Is heated at 90’C for 30 min. The mixture Is cooled and poured Into water. The aqueous phase is extracted three times with dichloromethane. The organic phases are dried over magnésium sulfate, filtered, and then concentrated under vacuum. The residue Is purified on 25 g of silica, 35 elution being carried out with dichloromethane, so as to obtain 145 mg of methyl
2-(methylsulfonyl)-7-phenylthieno[3,2-d]pyrimidine-6-carboxy!ate in the form of a beige solid.
Example 4: Methy! 2-(methylsulfanyl)-7-phenylthÎeno[3,2-d]pyrimidine-6-carboxylate
Anhydrous dioxane is added, under argon, to a mixture of 2.5 g of methy! 2-(methylsulfanyl)-7-{[(trifluoromethyl)sulfonyl]oxy}thieno[3,2-d]pyrÎmidine-6-carboxylate 4 (example 1) and 0.785 g of phenylboronic acid. After the addition of 250 mg of dichloropalladium (dppf) and 4.09 g of BTPP, the mixture is refluxed for 20 h, and then ίο cooled to ambrent température. The mixture is filtered on silica gel, elution being carried out with ethyl acetate. The solvent is evaporated off under vacuum and the residue is triturated with an ethyl acetate/heptane mixture so as to obtain 1.6 g of methy! 2-(methylsulfanyl)-7-phenylthieno[3,2-d]pyrimidine-6-carboxylate in the form of a whitish precipitate.
Example 5: Methyl 7-[2-(difluoromethoxy)phenyl]-2-(methylsulfanyl)thieno[3,2d]pyrimidine-6-carboxylate
A mixture of 780 mg of 2-(difluoromethoxy)benzaldehyde and 300 mg of 5-chloro-2(methy!sulfany!)pyrimidine-4-carboxylic acid 1 in 15 m! of anisole is mîcrowave-heated at 130°C for 45 min and then again for 15 min and again at 140°C for 15 min. 160mg of 5-chloro-2-(methyisulfanyl)pyrimidine-4-carboxylic acid 1 is then added and the mixture is again heated at 130°C for 30 min. The mixture is concentrated under vacuum and purified on 40 g of silica, elution being carried out with 0-10% of ethyl acetate in heptane, so as to obtain 268 mg of [5-chloro-2-(methylsulfanyl)pyrimidin-4-yl][2(difluoromethoxy)phenyljmethanol 6 in the form of a colourless oil.
A solution of 78 mg of DMSO in 0.5 ml of dichioromethane is added slowly, under argon, to a solution of 75 mg of oxalyl chloride in 2 ml of dichioromethane, cooled to -78°C. After 20 min at -78°C, a solution of 308 mg of [5-chloro-2-(methylsulfanyl)pyrimidin-4-yl][2(difluoromethoxy)phenyl]methanol 6 in 2 ml of dichioromethane is added. After 1 h 30 at -78°C, 182mg of triethylamine are slowly added and the mixture is left to return to ambient température for 30 min. The mixture is then poured into water and extracted three times with dichioromethane. The organic phases are dried over magnésium sulfate, filtered, and then concentrated under vacuum so as to obtain 303 mg of [5-chloro-2(methylsulfanyl)pyrimidin-4-yl][2-(difluoromethoxy)phenyl]methanone 7 in the form of a pale yellow oil.
A mixture of 303 mg of [5-chloro-2-(methylsulfanyl)pyrimidin-4-yl][2(difluoromethoxy)phenyl]methanone 7, 107mg of methyl sulfanylacetate, 253 mg of potassium carbonate and 5 ml of acetonitrile is microwave-heated in a sealed tube at 60 °C for 4 h. The mixture is diluted with a 0.5 N aqueous hydrochloric acid solution and extracted twice with ethyl acetate and once with dichioromethane. The organic phases are dried over magnésium sulfate, filtered, and then concentrated under vacuum so as to obtain 343 mg of methyl 7-[2-(difiuoromethoxy)phenyl]-2-(methylsulfanyl)thieno[3,2d]pyrimidine-6-carboxylate 8 in the form of a pale yellow solid.
Example 6: Thiomethyl oxidation
Example 6.1 Methyl 2-(methylsulfonyl)-7-phenylthieno[3,2-d]pyrimidine-6-carboxylate
2.3 g of 3-chloroperoxybenzoic acid (75%) are added slowly, in fractions, to a solution of 1.6 g of methyl 2-(methylsulfanyl)-7-phenylthieno[3,2-d]pyrimidine-6-carboxylate (example 4) in 25 ml of dichioromethane, cooled in an ice bath. The mixture is stirred for 2.5 h while cold, and then left at ambient température ovemight. The mixture is then diluted with 80 ml of dichioromethane and treated with 60 ml of saturated sodium thiosulfate solution. After stirring and settling out, the aqueous phase is extracted with ml of dichloromethane. The organic phases are washed with 60 ml of a saturated sodium bicarbonate solution, and then with 60 ml of a saturated sodium chloride solution. The organic phases are dried over magnésium sulfate, filtered, and then concentrated under vacuum so as to obtain the crude product, which is purified on 200 g of silica, elution being carried out with dichloromethane, so as to obtain 1.4 g of methyl 2-(methy1sulfonyl)-7-pheny1thieno[3,2-d]pyrimidine-6-€arboxylate in the form of a white solid.
Example 6.2 Methyl 7-(1 -methyl-1 H-pyrazol-4-yl)-2-(methylsulfinyl)thieno[3,2d]pyrimidine-6-carboxylate
230 mg of methyl 7-(1-methyl-1 H-pyrazol-4-yl)-2-(methylsulfanyl)thienoI3,2-d]pyrimidine-
6-carboxylate, prepared by analogy with the method described in example 4, are added to a mixture of 25 équivalents of hydrogen peroxide (30% in water) and 1.49 g of phénol. The reaction medium is stirred for 30 minutes at ambient température and then heated at 50°C for 1 hour. The reaction medium is diluted in ethyl acetate and washed with a saturated aqueous NaHCO3 solution and then with a saturated sodium chloride solution. The organic phase is dried over magnésium sulfate, filtered, and then concentrated under vacuum so as to obtain the crude product, which is purified on silica, elution being carried out with a 0-10% gradient of methanol in dichloromethane so as to obtain 170 mg of methyl 7-( 1 -methyl-1 H-pyrazol-4-yl)-2-(methylsuIfinyl)thienoI3,2-d]pyrimÎdine-6- carboxylate in the form of a beige solid.
Example 6.3 Methyl 7-(2-ethoxyphenyl)-2-(methylsulfonyl)thlenoI3,2-d]pyrimidine-6carboxylate
A mixture of 330 mg of methyl 7-(2-ethoxyphenyl)-2-(methylsulfanyl)thieno[3,2d]pyrimidine-6-carboxylate, prepared by analogy to the method described in example 4, and 634 mg of sodium perborate tetrahydrate in 15 ml of acetic acid is microwave-heated at 70°C in a sealed tube for 1 h 30. The mixture is diluted with 5 volumes of water and the resulting precipitate is filtered off and washed with water. The solid is taken up with dichloromethane and 100 ml of a solution of sodium thiosulfate. The pH is adjusted to pH 8-9 by adding solid potassium carbonate and the aqueous phase is extracted with dichloromethane. The organic phases are dried over magnésium sulfate, filtered, and then concentrated under vacuum. This crude is purified on 40 g of silica, elution being carried out with dichloromethane, so as to obtain 296 mg of methyl 7-(2-ethoxyphenyl)-2(methylsulfonyl)thieno[3,2-d]pyrimÎdine-6-carboxylate in the form of a yellow solid.
Example 6.4 Methyl 7-(6-methoxypyridin-2-yl)-2-(methylsulfinyl)thieno[3,2-d]pyrimidine-6carboxylate mg of sodium bromide and 18 mg of sodium bromate are added, with stirring, to a suspension of 55 mg of methyl 7-(6-methoxypyridin-2-yl)-2-(methylsulfanyl)thieno[3,2d]pyrimidine-6-carboxylate, prepared by analogy to the method described in example 5, (at 50%) in 2 ml of water, and then 6.5 μΙ of concentrated sulfuric acid are slowly added. The yellow suspension rapidly turns orange. After 2 h 30 minutes of stirring at ambient température, the yellow suspension is filtered through a number 4 sintered glass filter. The yellow solid is dried under vacuum so as to obtain 28 mg of methyl 7-(6-methoxypyridin-2yl)-2-(methylsulfinyl)thieno[3,2-d]pyrimidine-6-carboxylate.
Example 7:7-(4-Fluorophenyl)-2-(methylsulfonyl)thieno[3,2-d]pyrimidine-6-carboxamide
A mixture of 200 mg of methyl 2-(methylsulfanyl)-7{[(trifluoromethyl)sulfonyl]oxy]thieno[3,2-d]pyrimidine-6-carboxylate 4 (example 1), 216 mg of 4-fluorophenylboronic acid, 19 mg of dichloropalladium (dppf) and 322 mg of BTP P in 2.5 ml of dioxane under argon is microwave-heated at 120C in a sealed tube for 1 h. The medium is taken up with dichloromethane and filtered. The organic phase is washed three times with water, then dried over magnésium sulfate, filtered, and then concentrated under vacuum so as to give a yellow solid. The crude is purified on 80 g of silica, elution being carried out with 0-20% of methanol in dichloromethane, so as to obtain 135 mg of methyl 7-(4-fluorophenyl)-2-(methylsulfanyl)thÎeno[3,2-d]pyrimidine-6carboxylate in the form of a yellow solid.
A solution of 200 mg of methyl 7-(4-fluorophenyl)-2-(methylsulfanyi)thîeno[3,2d]pyrimidine-6-carboxylate in 75 ml of 7N ammoniacal methanol is stirred at ambient température for 64 h. The mixture is concentrated under vacuum so as to give 135 mg of
7-(4-fluorophenyl)-2-(methylsulfanyl)thieno[3,2-d]pyrimidîne-6-carboxamide in the form of a yellow solid.
A mixture of 135mg of 7-(4-fluorophenyl)-2-(methylsulfanyl)thieno[3,2-d]pyrimidine-6carboxamide and 293 mg of sodium perborate tetrahydrate in 5 ml of acetic acid Is microwave-heated at 70’C in a sealed tube for 1 h 30. The mixture is taken up with dichloromethane and 100 ml of a sodium thiosulfate solution. The pH is adjusted to pH 8-9 by adding solid potassium carbonate and the aqueous phase is extracted with dichloromethane. The organic phases are dried over magnésium sulfate, filtered, and then concentrated under vacuum so as to obtain a beige solid. This crude is purified on 40 g of silica, elution being carried out with dichloromethane, so as to obtain 90 mg of 7-(4fluorophenyl)-2-(methylsulfonyl)thienoI3,2-d]pyrimÎdine-6-carboxamÎde in the form of a white solid.
The compounds (II) and (XII) obtained according to examples 3 to 7 are described ln table 1 hereinafter.
Table 1
Compounds Il/XII | Name | Prepared according to example No. | NMR | MS: conditions/ MH+/Tr |
11-1 | Methyl 2-(methylsulfonyl)-7phenylthieno[3,2-d]pyr1midine6-carboxylate | 4/6.1 | 3.45 (s, 3 H): 3.89 (s, 3 H); 7.54 to 7.67 (m, 5 H); 10.00 (s. 1 H) | A 349 0.82 |
II-2 | Methyl 7-(2-chlorophenyl)-2( methytsulfonyl)thieno[3,2dlpyrlmkjlne-6-carboxylate | 4/6.1 | 3.37 (s, 3 H): 3.81 (s, 3 H); 7.46 to 7.59 (m, 3 H); 7.64 (broad d. J - 8.0 Hz, 1 H): 9.98 (s. 1 H) | A 383 0.87 |
II-3 | Methyl 7-(3-chlorophenyl)-2(methytsulfonyl)thleno(3,2dlpyrimldine-6-carboxylate | 3 | 3.40 (s. 3 H); 3.85 (s. 3 H); 7.52 to 7.60 (m. 3 H); 7.70 (broad s, 1 H); 9.97 (s, 1 H) | A 383 0.93 |
II-4 | Methyl 7-(4-chtorophenyl)-2( methylsu1fonyl)thieno{3^dlpyrim ldine-6-carboxyfate | 4/6.3 | 3.40 (s. 3 H): 3.85 (s, 3 H); 7.57 (d, J - 8 Hz, 2 H): 7.63 (d, J - 8 Hz, 2 H); 9.97 (s, 1 H) | B 383 1.22 |
II-5 | Methyl 7-(2-methoxyphenyl)-2(methytsu1fonyl)thieno[3,2d]pyr1m Wine-6-carboxylate | 3 | 3.37 (s, 3 H); 3.68 (s, 3 H); 3.80 (s, 3 H); 7.10 (broad t, J - 7.6 Hz, 1 H): 7.17 (dd, J - 2.0 and 7.6 Hz, 1 H); 7.44 (dd. J - 2.0 and 7.6 Hz, 1 H); 7.48 (m, 1 H): 9.92 (s, 1 H) | A 379 0.81 |
II-6 | Methyl 7-(3-methoxyphenyl)-2(methytsu!fonyl)thleno{3^d]pyrim ldine-6-carboxylate | 4/6.1 | 3.40 (s, 3 H); 3.80 (s, 3 H); 3.84 (s, 3 H): 7.07 (ddd. J - 1.0 and 2.7 and 8.3 Hz, 1 H); 7.13 (dt, J - 1.3 and 7.6 Hz, 1 H); 7.18 (dd, J - 1.7 and 2.4 Hz, 1 H): 7.42 (t, J 7.9 Hz, 1 H); 9.94 (s. 1 H) | A 379 0.83 |
XII-7 | 7-(4-Methoxyphenyl)-2(methyfcu1fonyl)thfeno[3,2djpyrim ldine-6-carboxam Ide | 7 | 3.42 (s, 3 H); 3.84 (s, 3 H): 7.11 (broad d, J - S.8 Hz, 2 H): 7.60 (broad d. J - S.8 Hz, 2 H); 7.69 (broad s, 1 H); 8.05 (broad s, 1 H); 9 86 (s, 1 H) | A [M-HJ-362 0.57 |
IIS | Methyl 7-(2,5dimethoxyphenyl)-2(methylsu1fonyl)thleno(3.2dlpyrtm ldine-6-carboxylate | 3 | 3.39 (s, 3 H); 3.62 (s, 3 H); 3.75 (s, 3 H); 3.81 (s, 3 H): 7.00to 7.11 (m, 3 H); 9.91 (s, 1 H) | A 409 0.82 |
ΙΙ-9 | Methyl 7-(3-fluoro-2methoxyphenyl)-2(methytsulfony1)thieno(32dlpyrlm kjine-6-carboxylate | 3 | 3.39 (s, 3 H); 3.67 (d, J - 2,2 Hz, 3 H); 3.82 (S. 3 H): 7.17 to 727 (m, 2 H); 7.39 to 7.48 (m, 1 H): 9.96 (s, 1 H) | A 397 0.88 |
II-10 | Methyl 7-(4-fluoro-2methoxyphenyl)-2(methytsulfonyl)thleno[3.2d]pyrim ldine-6-carboxylate | 3 | 3.38 (s, 3 H); 3. 7 (s, 3 H); 3.8 (s, 3 H); 6.9 (m. 1 H), 7.1 (dd, J - 11.6 and 2.3 Hz, 1 H). 7.46 (dd, J - 8.2 and 6.6 Hz, 1 H). θ·θ (s. 1 H) | A 397 1.13 |
11-11 | Methyl 7-(5-fluoro-2methoxyphenyl)-2(methytsulfonyl)thieno[3,2 d]pyrlmldine-6-carboxylate | 3 | 3.3S (s, 3 H): 3.67 (s, 3 H); 3.62 (s, 3 H); 7.19 (m, 1 H);7.28to 7.37 (m, 2 H); 9.93 (s, 1 H) | A 397 0.84 |
xtr-i2 | 7-(4- Fluoro-3-methoxyphenyl)2-(methylsutfonyl)thlenof3,2· | 7 | 3.43 (s. 3 H); 3.87 (s. 3 H); 7.21 (ddd, J 2.1 and 4.4 and 8.4 Hz, | A ÎM-H1- 380 |
Compounds 11/ XII | Name | Prepared according to example No. | NMR | MS: conditions/ MH+/Tr |
d)pyrimidine-6-carboxamide | 1 H); 7.39 (dd, J - 8.4 and 11.5 Hz, 1 H); 7.52 (dd, J - 2,1 and 8.4 Hz, 1 H); 7.83 (broad s, 1 H); 8.10 (broad s, 1 H); 9.88 (s. 1 H) | 0.60 | ||
11-13 | Methyl 7-(2-fluoro-5methoxyphenyl)-2(methylsulfonyl)thleno[3,2dlpyrim ldine-6-carboxylate | 4/6.3 | 3.40 (S, 3 H): 3.78 (S. 3 H); 3.86 (s, 3 H); 7.11 (m, 1 H): 7.19 (dd, J - 3.2 and 5.9 Hz, 1 H); 7.30 (t, J 9.3 Hz, 1 H); 9.97 (s, 1 H) | A 397 0.85 |
IM 4 | Methyl 7-(2-fluoro-3methoxyphenyf)-2(methylsij|fony1)thieno{3,2dlpyrim )dlne-6-carboxylate | 3 | 3.38 (s, 3 H); 3.85 (s, 3 H); 3.91 (s, 3 H); 7.10 (m, 1 H);7.21to 7.40 (m. 2 H); 9.97 (s. 1 H) | A 397 0.82 |
11-15 | Methyl 7-(2-ethoxyphenyl)-2(methylsulfonyl)thieno(3J2d]pyrlm ldlne-6-carboxylate | 4/6.3 | 1.08 (t, J - 6.8 Hz, 3 H); 3.38 (s, 3 H); 3.80 (s. 3 H); 3.98 (q, J - 6.8 Hz, 2 H); 7.09 (t, J - 7.5 Hz, 1 H); 7.14 (d, J-8.0 Hz, 1 H);7.42to 7.50 (m, 2 H): 9.92 (s, 1 H) | A 393 0.90 |
11-16 | Methyl 7-(2-fluorophenyi)-2(methyfculfonyl)thleno[32dlpyrim id lne-6-carboxytate | 3 | 3.38 (s, 3 H); 3.85 (s, 3 H); 7.34 to 7.41 (m, 2 H); 7.53 to 7.64 (m, 2 H); 9.97 (s, 1 H) | A 367 0.83 |
XII-17 | 7-(4-Fluorophenyl)-2(methylsulfonyl)thieno[3,2djpyrim idlne-6-cart»xam ide | 7 | 3.42 (s, 3 H); 7.39 (broad t, J 8.3 Hz, 2 H); 7.70 (broad dd, J 5.5 and 8.3 Hz, 2 H); 7.87 (broad s, 1 H): 8.07 (broad s. 1 H); 9.88 (s, 1 H) | A 352 0.57 |
11-18 | Methyl 742(dlfiuoromethoxy)phenyl]-2(methylsulfinyl)thieno[32dlpyrim idine-6-carboxyiate | 5/6.4 | 3.17 (s, 3 H), 3.8 (m, 1 H), 3.81 (s, 3 H). 7.35 (m, 2 H), 7.8 (m, 2 H), 9.9 (s. 1 H) | A 399 0.78 |
IM 9 | Methyl 2-(methylsuifonyl)-7-{2(triftuoromethoxy)phenyl]thieno[3,2-d]pyTimld!ne6-carboxylate | 4/6.3 | 3.37 (s. 3 H); 3.82 (S. 3 H); 7.51 to 7.72 (m. 4 H); 9.99 (s, 1 H) | A 433 0.95 |
II-20 | Methyl 2-(methylsuifonyl)-7-(3(trlfluoromethoxy)phenyl]thleno(3,2-d]pyTim Idine6-carboxylate | 4/6.3 | 3.39 (s, 3 H); 3.84 (s, 3 H); 7.52 (m. 1 H); 7.62 to 7.69 (m. 3 H); 9.96 (s. 1 H) | A 433 0.99 |
11-21 | Methyl 7-(2-methylphenyl)-2(methylsLilfonyi)thleno{3,2dlpyrim idlne-6-carboxytate | 3 | 2.02 (s, 3 H); 3.34 (s, 3 H); 3.80 (s, 3 H); 7.20 to 7.42 (m. 4 H); 9.95 (s, 1 H) | A 363 0.87 |
II-22 | Methyl 7-(2-cyanophenyl)-2(methyteutfonyl)thieno[32d]pyrim idlne-6-carboxylate | 3 | 3.37 (s, 3 H); 3.85 (s, 3 H); 7.74 (m. 2 H); 7.89 (t, J - 7.8 Hz. 1 H); 8.04 (d, J - 7.8 Hz, 1 H); 10.01 (s, 1H) | A 374 0.73 |
II-23 | Methyl 7-(3-cyanophenyl)-2(methyteulfonyl)thieno[32d]pyrlm )dlne-6-carboxylate | 4/6.3 | 3.40 (s, 3 H); 3.86 (s, 3 H); 7.75 (t, J - 7.8 Hz, 1 H); 7.95 (td, J 1.5 and 7.8 Hz, 1 H); 7.99 (td, J 1.5 and 7.8 Hz, 1 H); 8.13 (t, J - 1.5 Hz, 1 H); 9.97 (s, 1 H) | A 374 0.77 |
II-24 | Methyl 742(methylsulfiny1)phenyl]-2(methylsulfo nyl)thieno(3,2dlpyrim idlne-6-carboxylate | 3 | A 411 0.57 and 0.59 | |
11-25 | Methyl 743(methylsu!finyl)phenyf}-2(methylsulfonyl)thieno(32cflpyrim id lne-6-carboxylate | 3 | A 411 0.88 | |
11-26 | Methyl 742-fluoro-5(hydroxymethyl)phenyl]-2(methylsultonyl)thleno[3,2dlpyrim idlne-6-carboxylate | 3 | 3.39 (s, 3 H); 3.85 (s, 3 H); 4.56 (d, J-5.7 Hz. 2 H); 5.30 (t, J 5.7 Hz, 1 H); 7.32 (m. 1 H); 7.47 to 7.57 (m, 2 H); 9.97 (s, 1 H) | A 397 0.68 |
11-27 | Methyl 2-(methylsulfonyl)-7(thiophen-3-yl)th feno[3,2djpyrim idlne-6-carboxytate | 3 | 3.45 (s, 3 H); 3.89 (s, 3 H); 7.52 (dd. J - 1.3 and 5.0 Hz. 1 H); 7.66 (dd. J - 3.1 and 5.0 Hz. 1 H); 8.08 (dd, J - 13 and 3.1 Hz. 1 H): 9.93 (s, 1 H) | C 355 4.35 |
11-28 | Methyl 2-(methylsulfonyl)-7(thlophen-2-y i)th ieno[3,2cflpvrim ldine-6-carboxylate | 4/6.3 | B 355 1.33 | |
11-29 | Methyl 7-(1 -methyl-1 H-pyrazoi5-yl)-2-(methylsulfonyl)thieno[3,2-d]pyrimidine-6carboxylate | 4/6.1 | A 353 0.55 | |
li-30 | Methyl 2-(methylsulfonyl)-7-(1 oxidopyridln-2-y l)th ieno[3,2dlpyrlmidine-6-carboxylate | 5/6.1 | D 365 2.45 | |
11-31 | Methyl 7-(2-methoxypyrldin-3yl)-2-(methylsulfonyl)* ΐΗβηο[3,2-ά]ρ^ΐΓΤ^Ιηβ-6carboxylate | 3 | 3.38 (s, 3 H); 3.79 (s, 3 H); 3.83 (s, 3 H); 7.19 (dd, J - 5.1 and 7.3 Hz, 1 H); 7.90 (dd, J - 2.0 and 73 Hz, 1 H); 8.32 (dd, J - 2.0 and 5.1 Hz, 1 H); 9.95 (s, 1 H) | A 380 0.71 |
II-32 | Methyl 7-(t-([(2-methylpropan2-yt)oxy]cartx>nyl}-1 H-pyrroI-2yO-2(methytsulfonyl)thieno[3,2d]pyrimldine-6-carboxy1ate | 3 | D 438 4.01 | |
11-33 | Methyl 7-(5-ftuoro-2methoxypyridln-4-yl)-2(methylsuifonyl)thieno[3,2dlPvrimldlne-6-carboxYlate | 3 | 2.90 (s, 3 H); 3.88 (s, 3 H); 3.92 (s, 3 H); 7.10 (d, J-4.8 Hz, 1 H); 8.31 (broad s, 1 H); 9.91 (s, 1 H) | A 382 0.69 |
11-34 | Methyl 7-(1-methyl-1 H-pyrazok 4-yl)-2(methylsulfonyl)thienc(3,2d]pyrlm ldlne-6-carboxylate | 4/6,2 | 3.51 (s, 3 H); 3.95 (s, 3 H); 3.99 (s, 3 H); 8.21 (s, 1 H); 8.49 (s, 1 H); 9.90 (s, 1 H) | A 353 0.60 |
11-35 | Methyl 2-(methylsulfonyl)-7(1 H-pyrazoM-ylJthlenopÆdjpyrimld lne-6-carboxylate | 4/6.2 | 3.50 (s, 3 H); 3.95 (s. 3 H); 6,75 (broad m, 1 H); 830 (broad m, 1 H); 9.90 (s, 1 H); 13.20 (broad m, 1 H) | A 339 0.54 |
11-36 | Methyl 7-(5-fluoro-2methoxypyridin-3-yl)-2(methylsulfonyl)thienc[3^dlpyrlm )dlne-6-carboxylate | 3 | 3.40 (s, 3 H); 3.79 (s, 3 H); 3.86 (s, 3 H); 7.97 (dd. J - 3.0 and 8.5 Hz, 1 H): 8.32 (d, J-3.0 Hz, 1 H); 9.97 (s, 1 H) | A 398 0.80 |
11-37 | Methyl 7-(6-methoxypyrldin-2yl)-2-(methyfeulfi nyl)thieno[3,2d]pyrimld lne-6-carboxytate | 5/6.4 | 2.95 (s, 3 H); 3.81 (s, 3 H); 3.88 (s, 3 H); 6.92 (d, J-8.0 Hz, 1 H); 7.69 (d, J - 8.0 Hz, 1 H); 7.91 (t, J - 8 0 Hz, 1 H); 9.89 (s, 1 H) | A 364 0.66 |
11-38 | Methyl 7-(1 -methyl-1 H-pyrrol2-yl)-2-(methyÎsutfonyl)thieno[3,2-d]pyrimWlne-6carboxytate | 3 | 3.41 (s. 3 H); 3.48 (s, 3 H); 3.88 (s, 3 H); 6.19 (dd, J - 2.8 and 3.8 Hz, 1 H); 6.32 (dd, J « 2.0 and 3.8 Hz, 1 H); 7.01 (dd, J - 2.0 and 2.8 Hz, 1 H); 9.92 (s, 1 H) | A 352 0.74 |
11-39 | Methyl 7-(2-methylpyridin-3yl)-2-(methylsutfonyl)thleno[3,2-d]pyrlmldine-6carboxytate | 3 | 2.21 (s, 3 H); 335 (s, 3 H); 3.81 (s. 3 H); 7.36 (dd, J - 5.1 and 7.3 Hz, 1 H); 7.70 (dd. J - 2.0 and 7.3 Hz, 1 H); 8.58 (dd, J - 2.0 and 5.1 Hz, 1 H); 9.98 (s. 1 H) | A 364 0.33 |
11-40 | Methyl 7-(furan-2-yl)-2(methyisulfonyl)thienc[3,2djpyrim ldine-6-carboxylate | 4/6.1 | 3.51 (s, 3 H); 3.97 (S. 3 H); 6.78 (dd, J - 1.5 and 3.0 Hz, 1 H); 7.41 (dd, J - 0.8 and 3.0 Hz, 1 H); 7.97 (dd, J - 0.8 and 1.5 Hz, 1 H); 9.93 (s, 1 H) | A 339 0.74 |
11-41 | Methyl 7-{5-{(([(2methylpropan-2yt)oxy)carbony1)am ino)methyl]f uran-2-yll-2- | 4/6.1 | 1.40 (s, 9 H); 3.51 (s, 3 H); 3.98 (S, 3 H); 4.22 (broad d, J - 5.5 Hz, 2 H); 6.48 (d, J-3.5 Hz, 1 H); 7.38 (d. J - 3.5 Hz, 1 H); 9.91 (s, | A 468 0.92 |
(methy1suifonyl)thieno(3,2dlpyrimldlne-6-carboxylate | 1 H): 13.30 (broad m, 1 H) | |||
11-42 | Methyl 7-(2-methylfuran-3-yl)2-(methyl$ulfinyl)thIeno[3,2dlpyrlmldlne-6-carboxylate | 4/6.2 | D 337 3.39 | |
11-43 | Methyl 7-(14[(2-methylpropan2-yl)oxyJcarbonyl}-1 H-pyrrol-3yl)-2-(methylsulfonyl)thieno[3,2-d]pyrimidine-6carboxyfate | 3 | 1.60 (s, 9 H); 3.50 (s, 3 H); 3.93 (s. 3 H); 6.89 (dd, J - 2.0 and 3.8 Hz, 1 H); 7.39 (dd, J - 2.8 and 3.8 Hz, 1 H); 8.15 (dd, J - 2.0 and 2.8 Hz. 1 H); 9.91 (s, 1 H) | A 438 1.03 |
li-44 | Methyl 7-(2-ethoxypyridln-3yl)-2-(methylsulfonyl)thieno[3,2-d]pyrimidine-6carboxylate | 3 | 1.15 (t, J - 7.1 Hz, 3 H); 3.40 (s, 3 H); 3.83 (s, 3 H); 4.29 (q. J . 7.0 Hz, 2 H); 7.19 (dd, J - 5.1 and 7.3 Hz, 1 H); 7.91 (dd, J - 2.0 and 7.3 Hz, 1 H); 8.30 (dd, J - 2.0 and 5.1 Hz, 1 H); 9.96 (S, 1 H) | A 394 0.79 |
11-45 | Methyl 7-(2-methoxy-5methylpyridin-3-yl)-2(methytsulfonyl)thieno[3,2dlpyrimldine-6-carboxYtate | 3 | 2.30 (s, 3 H); 3.40 (s, 3 H); 3.75 (s, 3 H); 3.83 (s, 3 H); 7.74 (d, J 3.0 Hz, 1 H); 8.11 (d, J-3.0 Hz. 1 H); 9.94 (s, 1 H) | A 394 0.78 |
11-46 | Methyl 7-(1 •methyl-1H-pyrazoi3-y1)-2-(methyisutfonyl)thleno[3,2-d]pyriniidlne-6carboxylate | 4/6.1 | 3.47 (s. 3 H); 3.88 (s, 3 H); 3.92 (S, 3 H); 6.89 (d, J-2.0 Hz, 1 H); 7.87 (d, J - 2.0 Hz, 1 H); 9.91 (s, IH) | A 353 0.56 |
11-47 | Methyl 7-(2-methoxy-6methy lpyridin-3-yl)-2 (methylsulfonyl)thleno[3,2d]pyrtrnldlne-6-carboxy1ate | 3 | 2.50 (s partially masked, 3 H); 3.39 (s, 3 H); 3.77 (s. 3 H); 3.83 (S, 3 H); 7.05 (d, J - 7.3 Hz. 1 H); 7.79 (d, J - 7.3 Hz, 1 H); 9.92 (s, 1 H) | A 394 0.84 |
11-48 | Methyl 7-{3-methoxypyrldin-2yl)-2-(m ethytsutfinyl)thie no[3,2djpyrim Id lne-6-carboxylate | 5/6.4 | 2.86 (s, 3 H); 3.75 (s. 3 H); 3.78 (s, 3 H); 7.57 (dd, J - 8.0 and 5.0 Hz, 1 H); 7.71 (d, J - 8.0 Hz, 1 H); 8.32 (t, J - 5.0 Hz, 1 H); 9.89 (s, 1 H) | A 364 0.69 |
11-49 | Methyl 7-(8-methylpyridin-3yl)-2-(methytsutfi nyljthle no[3,2djpyrtm ldlne-6-carboxylate | 3 | 2.58 (s, 3 H); 3.4 (s, 3 H); 3.85 (s, 3 H); 7.42 (d. J - 7 Hz, 1 H); 7.93 (dd, J - 7 and 1 Hz, 1 H); 8.65 (d. J - 1 Hz, 1 H); 9.95 (s, 1 H) | D 364 2.33 |
11-50 | Methyl 2-(methylsulfonyl)-7(pyrldin-2-yl)thleno[3,2dlpyrim ldlne-6-carboxylate | 5/6.1 | A 350 0.78 |
III - PREPARATION OF THE COMPOUNDS OF FORMULA (lUa) (example 8)
Method 1: 4-(1 -Methylpiperidîn-4-yl)-2-(propan-2-yloxy)aniline
A mixture of 10.0 g of 4-bromo-2-fluoro-1-nitrobenzene, 44.4 g of caesium carbonate and 100 ml of isopropanol is heated at 85°C (bath) for 1 h 30, and then left to cool to ambient température. The mixture is concentrated under vacuum and the residue is taken up with 400 ml of water and 300 ml of ethyl acetate. The aqueous phase is extracted with 100 ml of ethyl acetate and the combined organic phases are washed twice with 200 ml of water. The organic phases are dried over magnésium sulfate and concentrated under vacuum, so as to obtain 11.59 g of crude 4-bromo-1-nitro-2-(propan-2-yloxy)benzene in the form of a yellow oil which crystallizes. TLC: Rf = 0.52 (dichloromethane/heptane (1/1)).
A mixture of 10.0 g of 4-bromo-1-nitro-2-(propan-2-yloxy)benzene, 5.78 g of 4-pyridylboronic acid, 12.2 g of sodium carbonate and 1.0 g of bÎs(triphenylphosphine)dichloiOpalladium, in 200 ml of dioxane and 35 ml of water, is heated at 110 °C (bath) for 9 h. The mixture is diluted with ethyl acetate and water. The aqueous phase is extracted twice with ethyl acetate and then with dichloromethane. The combined organic phases are dried over magnésium sulfate and concentrated under vacuum. The residue is purified on 330 g of silica, elution being carried out with ethyl acetate/heptane (1/1 to 4/1), so as to obtain 7.35 g of 4-[4-nitro-3-(propan-2y1oxy)phenyl]pyridine in the form of a pale yellow solid.
A mixture of 7.35 g of 4-[4-nitro-3-(propan-2-yloxy)phenyl]pyridine and 16.1 g of methyl iodide in 150 ml of acetonitrile is heated at 50 °C (bath) for 1 h. 2.5 ml of methyl iodide are added and the heating is continued for 1 h 50. The mixture is then concentrated under vacuum, so as to obtain 11.1 g of 1-methyl-4-[4-nitro-3-(propan-2-yloxy)phenyl]pyridinium iodide.
A solution of 10 g of 1’methyl-4-[4-nitro-3-(propan-2-yloxy)phenyl]pyridinium iodide in 280 ml of methanol is hydrogenated in an autoclave on 2.9 g of platinum oxide hydrate, at a hydrogen pressure of 15 bar and at ambient température for 4 h. The catalyst is removed by filtration on Clarcel and the mixture is concentrated under vacuum. The residue is taken up in 200 ml of ethyl acetate and washed with 200 ml of 1M sodium hydroxide and then with a saturated sodium chloride solution. The organic phase is dried over magnésium sulfate and concentrated under vacuum, so as to obtain 6.0 g of 4-(1methylpiperidin-4-yl)-2-(propan-2-yloxy)aniline.
Method 2: 2-Methylpropan-2-yl 4-[4-amino-3-(propan-2-yloxy)phenyl]-2-ethylpiperidine-1carboxylate
0.89 ml of diisopropylamine is introduced Into 5 ml of THF. After cooling to -78°C, 2.45 ml of 2.5 M n-BuLi in hexane are added and the mixture is stirred for 15 minutes at -78 °C. A 5 solution of 1 g of 1-boc-2-ethylpiperidin-4-one in solution in 10 ml of THF is added dropwise. The reaction medium is stirred for 15 minutes at -78°C and then N-phenylbis(trifluoromethanesulfonimide) in solution in 15 ml of THF is added. The reaction medium is brought back to ambient température and stirred for 16 hours at this température. The mixture is poured into 15 ml of a saturated aqueous sodium bicarbonate to solution and then extracted with ethyi acetate, dried over magnésium sulfate, filtered and concentrated under reduced pressure. Purification is carried out by flash chromatography on silica gel (40-63 pm), elution being carried out with a dichloromethane/methanol (98/2) mixture. 870 mg of 2-methylpropan-2-yl 6-ethyl-4-{[(trifluoromethyl)sulfonyl]oxy}-3.6dihydropyridine-1 (2H)-carboxylate are obtained in the form of a pale yellow oil.
A mixture of 5 g of 4-bromo-1-nitro-2-(propan-2-yloxy)benzene, 5.65 g of potassium acetate, 5.85 g of bis(pinacolato)diborane and 704 mg of [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) in 115 ml of dioxane is heated at 90 °C for 4 h 30. The réaction medium is poured into 250 ml of water and then extracted with twice 50 ml of water. The combined organic phases are dried over magnésium 20 sulfate, filtered and evaporated. Purification is carried out by flash chromatography on silica gel (40-63 pm), elution being carried out with a dichloromethane/heptane (80/20) mixture. 2.5 g of 4,4,5,5-tetramethyl-2-[4-nÎtro-3-(propan-2-yloxy)phenylJ-1,3,2dioxaborolane are obtained in the form of a yellow oil.
450 mg of 2-methylpropan-2-yl 6-ethyl-4-{[(trifluoromethyl)sulfonyl]oxy}-3.625 dihydropyrîdine-1 (2H)-carboxylate are introduced into 27 ml of 1,4-dioxane. After sparging for 10 min with argon in the reaction medium, 843 mg of 4,4,5,5-tetramethyl-2-[4-nitro-3(propan-2-yloxy)pheny!]-1,3,2-dioxaborolanel 100 mg of lithium chloride, 1.46 ml of a 2N solution of sodium carbonate and 203 mg of tetrakis(triphenylphosphine)palladium(0) are added. The reaction mixture is heated at 80°C for 2 h. After cooling, the mixture is run into 30 water, extracted with ethyi acetate, washed with a saturated sodium chloride solution, dried over magnésium sulfate, filtered and concentrated under reduced pressure. Purification is carried out by flash chromatography on siiica gel (40-63 pm), elution being carried out with a mixture of heptane and ethyi acetate (90/10), and 470 mg of 2methylpropan-2-yl 6-ethyl-4-[4-nitro-3-(propan-2-yloxy)phenyi]-3,6-dihydropyridine-1(2H)· 35 carboxylate are obtained in the form of a yellow oil.
In a microwave tube, 470 mg of 2-methylpropan-2-yl 6-ethyl-4-[4-nitro-3-(propan-2ytoxy)phenyl]-3,6-dihydropyridine-1(2H)-carboxytate are introduced into 20 ml of methanol. 456 mg of ammonium formate and 385 mg of Pd/C (10%) are added. The reaction medium is microwave-heated at 80*0 for 5 minutes. The mixture Is filtered on Clarcel and the Clarcel is rinsed with methanol. The filtrate is concentrated under reduced pressure. The residue is taken up with 30 ml of ethyl acetate and 3 ml of water. The organic phase is dried over magnésium sulfate, filtered and concentrated under reduced pressure, so as to obtain 370 mg of 2-methylpropan-2-yl 4-[4-amino-3-(propan-2yloxy)phenyl]-2-ethylpiperidine-1-carboxylate in the form of a colourless oil.
Method 3:4-(5-Methoxy-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(prOpan-2-yloxy)aniline A mixture of 2.5 g of 4-bromo-1-nitro-2-(propan-2-yloxy)benzene, 2.58 g of 3-methoxy-4(4,4,5,5-tetramethyl-1,3l2-dioxaborolan-2-yl)pyridine, 9.4 g of caesium carbonate and 703 mg of [1,r-bis(diphenylphosphino)ferrocene]dichloropalladium(ll), in 27 ml of dioxane and 8.8 ml of water, is microwave-heated at 130*C for 20 minutes. The mixture is diluted with ethyl acetate and water. The aqueous phase is extracted with ethyl acetate (2x) and then with dichloromethane (2x10 ml). The combined organic phases are dried over magnésium sulfate and concentrated under vacuum. The residue is purified on 100 g of silica, elution being carried out with heptane/ethyl acetate (50/50 to 0/100), so as to obtain 2.63 g of 3-methoxy-4-[4-nitro-3-(propan-2-yloxy)phenyl]pyridine in the form of a brown solid.
A mixture of 3.41 g of 3-methoxy-4-[4-nitro-3-(propan-2-yloxy)phenyl]pyridine and 1.33 ml of methyl iodide in 55 ml of acetone is heated at 50*C (bath) for 3 h 30.147 μΙ of methyl iodide are added and the heating is continued at 50*C for 50 minutes. The mixture ts then concentrated under vacuum, so as to obtain 5.13 g of 3-methoxy-1-methy!-4-[4-nitro-3(propan-2-yloxy)phenyl]pyridinium iodide in the form of a yellow solid.
672 mg of NaBH4 are added, in portions, to a suspension of 5.09 g of 3-methoxy-1methy!-4-[4-nitro-3-(propan-2-yloxy)phenyl]pyridinium iodide in 90 ml of éthanol brought to 5*C. the reaction medium is stirred for 30 minutes at ambient température. 50 ml of water and 100 ml of ethyl acetate are added. The two phases are separated, and the aqueous phase is washed with twice 50 ml of ethyl acetate. The combined organic phases are dried over magnésium sulfate, filtered and evaporated. Purification is carried out by flash chromatography on silica gel (40-63 pm), elution being carried out with a mixture of dichloromethane and acetone (95/5 to 80/20). 2.78 g of 5-methoxy-1-methyl-4-[4-nitro-3(propan-2-y!oxy)phenyl]-1,2,3,6-tetrahydropyridine are obtained in the form of a brown oil.
w
747 mg of zinc are added to a solution of 500 mg of 5-methoxy-1-methyl-4-[4-nitro-3(propan-2-ytoxy)phenyl]-1,2,3,6-tetrahydropyridine in 8 ml of acetic acid. The reaction medium is stirred for 1 hour at ambient température and then filtered on Clarcel. The Clarcel is rinsed with 8 ml of acetic acid, then 10 ml of éthanol and then of ethyl acetate. The filtrate is evaporated under reduced pressure and then the residue is taken up in 10 ml of ethyl acetate, 5 ml of water and 10 ml of a saturated aqueous sodium bicarbonate solution. 20 ml of ethyl acetate are added and the two phases are separated. The aqueous phase is extracted with ethyl acetate (2x 10 ml). The combined organic phases are washed with a saturated aqueous sodium chloride solution, dried over magnésium sulfate and concentrated under vacuum. The residue is purified on 25 g of silica, elution being carried out with dichloromethane/acetone (100/0 to 95/5), so as to obtain 140 mg of 4-(5-methoxy-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(propan-2yloxy)aniline in the form of a brown oil.
Method 4:4-[4-Amino-3-(propan-2-yloxy)phenyl]-1 -methylpiperidin-3-ol
7.55 g of ammonium formate and 1.5 g of Pd/C (10%) are added to a solution of 5.75 g of
3-methoxy-4-[4-nitro-3-(propan-2-yloxy)phenyl]pyridine în 100 ml of methanol. The reaction medium is microwave-heated at 80*0 for 5 minutes. The mixture is filtered on Clarcel, and the Clarcel is rinsed with methanol. The filtrate is concentrated under reduced pressure. The residue is taken up with 60 ml of ethyl acetate and 20 ml of water. The 2 phases are separated, and the aqueous phase is extracted with twice 20 ml of ethyl acetate. The combined organic phases are dried over magnésium sulfate, filtered and evaporated, so as to give 5.35 g of 4-(3-methoxypyridin-4-yl)-2-(propan-2-yloxy)aniline in the form of a brown gum.
ml of a saturated aqueous sodium bicarbonate solution and then 3.81 ml of benzyl chloroformate are added to a solution of 4.6 g of 4-(3-methoxypyridin-4-yl)-2-(propan-2yloxy)aniline in 115 ml of THF. The reaction medium is stirred ovemight at ambient température and then 3,81 ml of benzyl chloroformate are added and the réaction medium is stirred at ambient température for 2 hours. 2.54 ml of benzyl chloroformate are added and the reaction medium is stirred for a further 2 hours at ambient température. The reaction medium is poured into 100 ml of ethyl acetate and 50 ml of water. The two phases are separated and the aqueous phase is extracted with twice 50 ml of ethyl acetate. The combined organic phases are dried over magnésium sulfate, filtered and evaporated under reduced pressure. The residue is purified on 100 g of silica, elution being carried out with dichloromethane/acetone (100/0 to 95/5), so as to give 3.12 g of
100 benzyl [4-(3-methoxypyridin-4-yl)-2-(propan-2-yloxy)phenyl]carbamate in the form of a colourless oil.
A mixture of 3.58 g of benzyl [4-(3-methoxypyridin-4-yl)-2-(propan-2yloxy)phenyl]carbamate and 1.14 ml of methyl iodide in 107 ml of acetone ïs heated at 5 50°C (bath) for 1 h. 568 pl of methyl iodide are added and the heating is continued at
50°C for 30 minutes. The mixture Is then concentrated under vacuum, so as to give 4.57 g of 4-[4-{[(benzyloxy)carbonyl]amino}-3-(propan-2-yloxy)phenyl]-3-methoxy-1 methyipyridinium Iodide in the form of a yellow solid.
486 mg of NaBH< are added, in portions, to a suspension of 4.57 g of 4-[4îo {[(benzyloxy)carbonyl]amino)-3-(propan-2-yloxy)phenyl]-3-methoxy-1-methylpyridinium iodide ln 100 ml of éthanol brought to 5°C. The reaction medium is stirred for 1 h 30 at ambient température. 50 ml of water, 50 ml of a saturated aqueous sodium bicarbonate solution and 100 ml of ethyi acetate are added. The two phases are separated, and the aqueous phase is washed with twice 50 ml of ethyi acetate. The combined organic phases is are dried over magnésium sulfate, filtered and evaporated. Purification is camed out by flash chromatography on silica gel (40-63 pm), elution being carried out with a mixture of dichloromethane and (MeOH + 10% NH4OH) (99/1 to 90/10). 1.87 g of benzyl [4-(5methoxy-1 -methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(propan-2-yloxy)phenyl]carbamate are obtained in the form of an orangey-coloured oîl.
30 ml of a 6N aqueous hydrochloric acid solution are added to a solution of 1.77 g of benzyl [4-(5-methoxy-1 -methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(propan-2yloxy)phenyl]carbamate in 60 ml of THF. The reaction medium is heated at 50°C for 2 h 30 and then evaporated to dryness. The residue ïs taken up in 15 ml of water, 5 ml of a saturated aqueous sodium carbonate solution and 50 ml of ethyi acetate. The two phases 25 are separated, and the aqueous phase is washed with twice 15 ml of ethyi acetate. The combined organic phases are dried over magnésium sulfate, filtered and evaporated, so as to give 1.7 g of benzyl [4-(1-methyl-3-oxopiperidin-4-yl)-2-(propan-2yloxy)phenyl]carbamate in the form of a brown gum.
486 mg of NaBH4 are added, in portions, to a suspension of 700 mg of benzyl [4-(130 methyl-3-oxopiperidin-4-yl)-2-(propan-2-yloxy)phenyl]carbamate in 35 ml of éthanol brought to 5°C. The reaction medium is stirred at ambient température for 50 minutes.
ml of water, 15 ml of a saturated aqueous sodium chioride solution and 40 ml of ethyi acetate are added. The two phases are separated, and the aqueous phase is washed with twice 20 ml of ethyi acetate. The combined organic phases are dried over magnésium 35 sulfate, filtered and evaporated. Purification is carried out by flash chromatography on silica gel (40-63 pm), elution being carried out with a mixture of dichloromethane and
101 (MeOH + 10% NH4OH) (99/1 to 90/10). 183 mg of benzyl [4-(3-hydroxy-1-methylpiperidin4-yl)-2-(propan-2-yloxy)phenyl]carbamate (trans diastereoisomers) and 183 mg of benzyl [4-(3-hydroxy-1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]carbamate (cis diastereoisomers) are obtained.
178 mg of benzyl [4-(3-hydroxy-1-methylpiperidin-4-yl)-2-(propan-2yioxy)phenyl]carbamate (mixture of the cis diastereoisomers) are dissolved In 45 ml of methanol. The solution is filtered on 0.45 pm Acrodisc and then hydrogenated in an H-cube (Pd/C 10% cartridge and PH2 = 1 atm). The reaction medium Is evaporated to dryness under reduced pressure, so as to give 111 mg of 4-[4-amino-3-(propan-2yloxy)phenyl]-1-methylpiperidin-3-ol in the form of an orangey-coloured solid (mixture of the cis diastereoisomers).
179 mg of benzyl [4-(3-hydroxy-1-methylpiperidin-4-yl)-2-(propan-2yloxy)phenyl]carbamate (mixture of the trans diastereoisomers) are dissolved in 45 ml of methanol. The solution is filtered on 0.45 pm Acrodisc and then hydrogenated in an H-cube (Pd/C 10% cartridge and P H2= 1 atm). The reaction medium is evaporated to dryness under reduced pressure, so as to give 127 mg of 4-[4-amino-3-(propan-2yloxy)phenyi]-1-methylpîperidin-3-ol in the form of a brown gum (mixture of the trans diastereoisomers).
Method 5: 2-Methylpropan-2-yl 4-[4-amino-3-(propan-2-yloxy)phenyl]piperidine-1carboxyiate
A mixture of 3.26 g of 4-bromo-1-nitro-2-(propan-2-yloxy)benzene, 4.65 g of 2methylpropan-2-yl 4-(4,4,5,5-tetramethyl-1l3,2-dioxaborolan-2-yl)-3,6-dihydropyridÎne1 (2H)-carboxytate, 12.5 ml of a 3M solution of sodium carbonate and 350 mg of bis(triphenylphosphine)dichloropalladium(ll) in 41 ml of dioxane is refluxed for 1 h 30. The mixture is diluted with 150 ml of water and 200 ml of ethyl acetate. The aqueous phase Is extracted three times with 200 ml of ethyl acetate. The combined organic phases are washed with 100 ml of a saturated sodium chloride solution, dried over magnésium sulfate and concentrated under vacuum. The residue Is purified on 600 g of silica, elution being carried out with dichloromethane/ethyl acetate (99/1), so as to give 2.95 g of 2-methylpropan-2-yl 4-[4-nitro-3-(propan-2-yloxy)phenyl]-3,6-dihydropyridine-1(2H)carboxylate in the form of a yellow solid.
A solution of 2.76 g of 2-methylpropan-2-yl 4-[4-nitro-3-(propan-2-yloxy)phenyl]-3,6dihydropyridine-1(2H)-carboxylate in 60 mi of methanol Is hydrogenated on 300 mg of pa!ladium-on-carbon (10%) at a pressure of 10 bar and at ambient température for 3 h.
The catalyst Is removed by filtration on Celite and the filtrate is evaporated to dryness so
102 as to obtain 2.44 g of 2-methylpropan-2-yl 4-[4-amino-3-(propan-2yloxy)phenyl]piperidÎne-1-carboxylate in the form of a pink powder.
Method 6:4-(4-Methylpiperazin-1-yl)-2-(propan-2-yloxy)aniline
A mixture of 18.0 g of 5-fluoro-2-nitrophenol, 29.0 g of caesium carbonate and 13.7 ml of 2-iodopropane in 119 ml of DMF is stirred at ambient température ovemight. The mixture is concentrated under vacuum and the residue is taken up with 250 ml of water and extracted twice with 250 ml of ethyl acetate. The organic phases are washed twice with 200 ml of a saturated sodium chloride solution, dried over magnésium sulfate and concentrated under vacuum, so as to obtain 17 g of crude product. The crude product is purified on 400 g of silica, elution being carried out with cyclohexane/ethyl acetate (95/5), so as to obtain 13.0 g of 4-fluoro-1-nitro-2-(propan-2-yloxy)benzene in the form of a light yellow oil.
A mixture of 10.0 g of 4-fluoro-1-nitro-2-(propan-2-yloxy)benzene, 10.0 g of 1-methylpiperazine and 10.4 g of potassium carbonate in 93 ml of DMSO is stirred at ambient température ovemight. The mixture is diluted with 160 ml of water and extracted three times with 150 ml of ethyl acetate. The organic phases are dried over magnésium sulfate and concentrated under vacuum. The residue Is purified on 200 g of silica, elution being carried out with dichloromethane/methanol (98/2 then 95/5), so as to obtain 13.6 g of 1-methyl-4-[4-nitro-3-(propan-2-y!oxy)phenyl]piperazÎne In the form of a yellow oil.
A mixture of 9.0 g of 1-methy!-4-[4-nitro-3-(propan-2-y!oxy)phenyl]piperazine, 19.3 g of hydrazine hydrate and 1.7 g of 10% palladium-on-carbon in 205 ml of éthanol is heated at 80°C (bath) for 45 min. The mixture is filtered and the filtrate is concentrated under vacuum, so as to obtain 13 g of an orangey-coloured oil. The residue is purified on 300 g of silica, elution being carried out with dichloromethane/methanol (95/5), so as to obtain 7.1 g of 4-(4-methylpiperazin-1-y!)-2-(propan-2-yloxy)aniline In the form of a brown oil.
Method 7:1-[4-Amino-3-(propan-2-yloxy)phenyl]piperidin’4-yl acetate
4.75 g of di-tert-butyl dicarbonate are added to a mixture of 2 g of 4-hydroxypiperidine in 4 ml of water and 13.8 ml of a 2N aqueous sodium hydroxide solution. The reaction medium is stirred at ambient température for 2 hours and then 50 ml of chloroform are added. The two phases are separated and the organic phase is washed with an aqueous 25% NH4OH solution and then with a saturated aqueous sodium chloride solution. The
103 organic phase is dried over magnésium sulfate, filtered and evaporated, so as to give 4 g of 2-methylpropan-2-yl 4-hydroxypiperidine-1-carboxylate in the form of a colourless oil.
2.84 g of acetic anhydride are added to a solution of 4.0 g of 2-methylpropan-2-yl
4-hydroxypiperidine>1-carboxylate in 6 ml of pyridine. The reaction medium is stirred for 5 5 hours at ambrent température and then concentrated to dryness. The residue is taken up in dichloromethane and an aqueous 25% NH4OH solution. The two phases are separated and the organic phase is washed with a saturated aqueous sodium chloride solution, dried over magnésium sulfate, filtered and evaporated. Purification is carried out by flash chromatography on silica gel (40-63 pm), elution being carried out with a mixture ίο of dichloromethane and MeOH (95/5), so as to obtain 3 g of 2-methylpropan-2-yl 4-(acetyloxy)piperidïne-1-carboxylate in the form of a colourless oil.
ml of trifluoroacetic acid are added to a solution of 3.18 g of 2-methylpropan-2-yl 4-(acetyloxy)piperidine-1-carboxylate in 40 ml of dichloromethane, cooled to 0Ό. The reaction medium is stirred for 1 hour at 0°C and then 1 hour at ambient température. 5 ml 15 of trifluoroacetic acid are added and the reaction medium is stirred for 30 minutes at ambient température. The reaction medium is evaporated to dryness under reduced pressure, and the resulting product is taken up with dichloromethane and an aqueous 1% NH4OH solution. The organic phase is washed with a saturated aqueous sodium chloride solution, dried over magnésium sulfate, filtered and evaporated, so as to give 175 mg of 20 piperidin-4-yl acetate in the form of a yellow oil.
A mixture of 1 g of 4-bromo-1-nitro-2-(propan-2-yloxy)benzene, 1.19 g of piperidin-4-yl acetate, 5.01 g of caesium carbonate, 86 mg of palladium acetate and 334 mg of 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene, in 50 ml of dioxane, is refluxed for 3 hours. The mixture is diluted with ethyl acetate and water. The aqueous phase is 25 extracted with ethyl acetate (2x). The combined organic phases are dried over magnésium sulfate and concentrated under vacuum. The residue is purified on silica, elution being carried out with cyclohexane/ethyl acetate (80/80 to 50/50), so as to give 530 mg 1-[4-nitro-3-(propan-2-yloxy)phenyl]piperidin-4-yl acetate in the form of a brown solid.
622 mg of ammonium formate and 525 mg of Pd/C (10%) are added to a solution of
530 mg of 1-[4-nitro-3-(propan-2-yloxy)phenyl]piperidin-4-yl acetate in 13 ml of methanoi.
The reaction medium is microwave-heated at 80®C for 5 minutes. The mixture is filtered on Clarcel, and the Clarcel ls rinsed with methanoi. The filtrate is concentrated under reduced pressure. The residue is taken up with 20 ml of ethyl acetate, 2 ml of water and 35 8 ml of a saturated aqueous sodium chloride solution. The two phases are separated and the aqueous phase is washed with 3 times 10 ml of ethyl acetate. The combined organic
106 washed with 100 ml of a saturated sodium chloride solution, dried over magnésium sulfate and concentrated under vacuum. The crude product is purified on 340 g of silica, elution being carried out with 0-100% of acetone in dichloromethane, so as to obtain 5.60 g of 1-methyl-4-[2-methyl-4-nitro-5-(propan-2-yloxy)phenyl]piperazine in the form of a black 5 solid.
Two 20 ml tubes each containing a mixture of 614 mg of 1-methyl-4-[2-methyl-4-nitro-5· (propan-2-yloxy)phenyl]piperazine, 185 mg of 10% Pd on carbon and 793 mg of ammonium formate in 10 ml of methanol are microwave-heated at 80 °C (P 6-7 bar) for 5 min. The content of the tubes is combined and filtered on Clarcel. The Clarcel is washed îo with methanol and the filtrate is concentrated under vacuum. The residue is taken up with ml of ethyl acetate, 2 ml of water and 8 ml of a saturated sodium chloride solution. The aqueous phase is extracted three times with 10 ml of ethyl acetate. The combined organic phases are washed with 10 ml of a saturated aqueous sodium chloride solution, dried over magnésium sulfate and concentrated under vacuum, so as to obtain 1.053 g of 15 5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)aniline in the form of a light brown solid.
Method 11:6-(1-Methy1piperidin-4-yl)-4-(propan-2-yloxy)pyridin-3-amine
3.38 g of sodium isopropoxide are added to a solution of 2.6 g of 2.4-dichloro-520 nitropyridine in 39 ml of DMF. The reaction medium Is stirred at ambient température for h 15 and 3.18 g of sodium isopropoxide are added. The reaction medium is stirred for a further 15 minutes and then the mixture is poured into 200 ml of water and extracted with ethyl acetate. The organic phase is dried over magnésium sulfate, filtered and concentrated under reduced pressure. Purification is carried out by flash chromatography 25 on silica gel (40-63 microns), elution being carried out with a heptane/ethyl acetate mixture (90/10 to 80/20). 1.78 g of 2-chloro-5-nitro-4-(propan-2-yloxy)pyridine are obtained in the form of a pale yellow solid.
800 mg of 2-chloro-5-nitro-4-(propan-2-yloxy)pyridine are introduced into 62 ml of 1,4-dioxane. After sparging for 10 min with argon in the reaction mixture, 1.25 g of 30 1-methyl-4-(4,4,5l5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine hydrochloride, 6.02 g of caesium carbonate, 6.2 ml of water and 467 mg of bis(triphenylphosphine)palladium(ll) dichloride are added. The reaction mixture is heated at 100°C for 16 h. After cooling, the mixture is run into water and extracted with ethyl acetate. The organic phase is washed with a saturated sodium chloride solution, dried over magnésium sulfate, filtered and concentrated under reduced pressure. Purification is carried out by flash chromatography on silica gel (40-63 microns), elution being carried
107 out with a mixture of dichloromethane and methanol (90/10 to 80/20). 401 mg of Γ-methyl-
5- nitro-4-(propan-2-yloxy)-1,,2',3, (6'-tetrahydro-2,4,-bipyridine are obtained in the form of a yellow gum.
In a microwave tube, 400 mg of r-methyl-5-nitro-4-(propan-2-yloxy)-r,2,,3',6,-tetrahydro5 2,4'-bipyridine are introduced into 30 ml of methanol. 546 mg of ammonium formate and 333 mg of Pd/C (10%) are added. The reaction medium is microwave-heated at 80Ό for 5 minutes. The mixture is filtered on Clarcel and the Clarcel is rinsed with methanol. The filtrate is concentrated under reduced pressure, so as to give 380 mg of
6- (1-methylpiperidin-4-yl)-4-(propan-2-yloxy)pyridin-3-amine in the form of a brown oil.
to
Method 12:6-(4-Methylpiperazin-1 -yl)-4-(propan-2-yloxy)pyridin-3-anriine ’ 383 mg of potassium carbonate and 185 mg of 1-methylpiperazine are added to a solution of 400 mg of 2-chloro-5-nitro-4-(propan-2-yloxy)pyridine in 3.7 ml of DMSO. The réaction medium is heated for 1 hour at 105Ό. After cooling, the mixture is run into water, is extracted with ethyl acetate, washed with a saturated sodium chloride solution, dried over magnésium sulfate, filtered and concentrated under reduced pressure. The residue is taken up in diisopropyl ether, and the insoluble material Is filtered off and dried under vacuum, so as to give 481 mg of 1-methyl-4-[5-nitro-4-(propan-2-yloxy)pyridin-2yljpperazine In the form of an orangey-coloured solid.
In a microwave tube, 390 mg of 1-methyl-4-[5-nitro-4-(propan-2-yloxy)pyrîdin-2yljpiperazine are introduced into 12 ml of methanol. 525 mg of ammonium formate and 210 mg of Pd/C (10%) are added. The reaction medium is microwave-heated at 80’C for 5 minutes. The mixture is filtered on Clarcel and the Clarcel is rinsed with methanol. The filtrate Is concentrated under reduced pressure, so as to give 340 mg of 25 6-(4-methylpiperazin-1-yl)-4-(propan-2-yloxy)pyridin-3-amine in the form of a brown oil.
Method 13:6-(1 -Methylpiperidin-4-yl)-2-(propan-2-yloxy)pyridin-3-amine
1.63 g of 6-chloro-3-nîtropyridin-2-ol, 66 ml of heptane, 3.175 g of 2-iodopropane and 3.09 g of silver carbonate are introduced. The reaction medium is microwave-heated at 30 130Ό for 10 minutes and is then evaporated to dryness, bound to silica and purified by flash chromatography on silica gel (40-63 pm), elution being carried out with a mixture of heptane and ethyl acetate (90/10). 1.79 g of 6-chloro-3-nitro-2-(propan-2-yloxy)pyridine are obtained in the form of a beige solid.
g of 6-chloro-3-nitro-2-(propan-2-yloxy)pyridine Is introduced into 78 ml of 1,4-dioxane.
After sparging for 10 min with argon in the reaction medium, 2.16 g of 1-methyl-4-(4,4,5,5tetramethyl-1,3l2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine hydrochloride, 7.5 g of
108 caesium carbonate, 7.75 ml of water and 584 mg of bis(triphenylphosphine)palladium(ll) dichloride are added. The reaction mixture is heated at 100°C for 2 h. The mixture is concentrated under reduced pressure and bound to silica. Purification is carried out by flash chromatography on silica gel (40-63 pm), elution being carried out with a mixture of dichioromethane and methanol (90/10 to 80/20). 500 mg of r-methyl-S-nitro-S-tpropan^yloxy)-1’,2,,3,,6'-tetrahydro-2,4,-bipyridine are obtained in the form of an orangey-coloured gum.
ln a microwave tube, 300 mg of r-methyl-5-nitro-6-(propan-2-yloxy)-1, (2’l3't6'-tetrahydro2,4‘-bipyridine are introduced into 22 ml of methanol. 410 mg of ammonium formate and 345 mg of Pd/C (10%) are added. The reaction medium is microwave-heated at 80 °C for 5 minutes. The mixture is filtered on Clarcel and the Clarcel is rinsed with methanol. The filtrate is concentrated under reduced pressure, so as to give 288 mg of 6-(1methylpiperidin-4-yl)-2-(propan-2-yloxy)pyridin-3-amine in the form of a brown gum.
Method 14:6-(4-Methylpiperazin-1-yl)-2-(propan-2-yloxy)pyridin-3-amine
463 mg of potassium carbonate and 224 mg of 1-methylpiperazine are added to a solution of 484 mg of 6-chloro-3-nitro-2-(propan-2-yloxy)pyridine in 4.45 ml of DMSO. The reaction medium is heated for 1 hour at 105°C. After cooling, the mixture is run into water and extracted with ethyl acetate. The organic phase is washed with a saturated sodium chloride solution, dried over magnésium sulfate, filtered and concentrated under reduced pressure. The residue is taken up ln diisopropyl ether and the insoluble material Is filtered off and dried under vacuum, so as to give 460 mg of 1-methyl-4-[5-nitro-6-(propan-2yioxy)pyridin-2-yl]pperazîne in the form of a yellow solid.
In a microwave tube, 500 mg of 1-methyl-4-[5-nitro-6-(propan-2-yloxy)pyridin-2yljpîperazine are introduced into 15 ml of methanol. 675 mg of ammonium formate and 270 mg of Pd/C (10%) are added. The reaction medium is microwave-heated at 80*0 for 5 minutes. The mixture is filtered on Clarcel and the Clarcel is rinsed with methanol. The filtrate Is concentrated under reduced pressure, so as to give 512mg of 6-(4methylpiperazin-1-yl)-2-(propan-2-yloxy)pyridin-3-amine in the form of a purple gum.
Method 15:7-AmÎno-1-methyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one g of 1,3,4,5-tetrahydro-2H-1-benzazepin-2-one are added to a solution of 25 ml of nitric acid at 70% in water and of 35 ml of sulfuric acid cooled to 0*C. The reaction medium is stirred for 15 minutes at 0°C and then poured into water (250 ml) and extracted with ethyl acetate. The organic phase is washed with a saturated aqueous sodium bicarbonate solution and with water, dried over magnésium sulfate, filtered and concentrated under
109 reduced pressure. The residue is taken up with diisopropyl ether and the insoluble material is filtered off and dried under vacuum, so as to give 1.04 g of 7-nitro-1,3,4,5tetrahydro-2H-1-benzazepin-2-one in the form of a beige solid.
202 mg of NaH (50%) are added to a solution of 771 mg of 7-nitro-1,3,4,5-tetrahydro-2H1-benzazepin-2-one in 20 ml of DMF. The reaction medium is stirred for 15 minutes and then 583 mg of iodomethane are added. The mixture is stirred for 4 hours at ambient température and then run into ice-cold water and extracted with ethyl acetate. The organic phase is washed with a saturated sodium chloride solution, dried over magnésium sulfate, filtered and concentrated under reduced pressure. Purification is carried out by flash chromatography on silica gel (40-63 pm), elution being carried out with a heptane/ethyl acetate (80/20 to 50/50) mixture. 275 mg of 1-methyl-7-nitro-1,3,4,5-tetrahydro-2H-1benzazepin-2-one are obtained in the form of a yellow solid.
In a microwave tube, 275 mg of 1-methyl-7-nitro-1l3l4,5-tetrahydro-2H-1-benzazepin-2one are introduced Into 26 ml of methanol. 473 mg of ammonium formate and 398 mg of Pd/C (10%) are added. The reaction medium is microwave-heated at 80°C for 5 minutes. The mixture is filtered on Clarcel and the Clarcel is rinsed with methanol. The fiitrate is concentrated under reduced pressure, so as to give 250 mg of 7-amino-1-methyl-1,3,4,5tetrahydro-2H-1 -benzazepin-2-one in the form of a purple gum.
Method 16: 7-Amino-1 -methyl-6-(propan-2-yloxy)-1,3,4,5-tetrahydro-2H-1-benzazepin-2one
A mixture of 2.5 g of 5-hydroxy-1-tetralone, 30 ml of acetonitrile, 5 g of caesium carbonate and 3.87 ml of 2-iodopropane is heated for one hour at 80 °C and then evaporated to dryness. The residue is taken up in ethyl acetate and water. The organic phase is washed with a saturated sodium chloride solution, dried over magnésium sulfate, filtered and concentrated under reduced pressure, so as to give 4.87 g of 5-(propan-2-yloxy)-3,4dihydronaphthalen-1(2H)-one in the form of an orangey-coloured oil.
A mixture of 4.39 g of 5-(propan-2-yloxy)-3,4-dihydronaphthalen-1(2H)-one and 1.74 g of sodium azide in 70 ml of TFA is refluxed for 2 hours. The reaction medium is poured into 250 ml of water, brought to pH 7 by adding potassium carbonate and extracted with ethyl acetate. The organic phase is dried over magnésium sulfate, filtered and evaporated under reduced pressure. Purification is carried out by flash chromatography on silica gel (40-63 pm), elution being carried out with a mixture of dichloromethane and MeOH (100/0 to 90/10). 2.87 g of 6-(propan-2-yloxy)-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one are obtained in the form of a beige solid.
110
750 mg of potassium nitrate are added, in portions, to a solution of 1.3 g of 6-(propan-2yloxy)-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one in 13 ml of trifluoroacetic anhydride brought back to ·5°Ο. The reaction medium is stirred for 5 minutes at -5°C and then brought back to pH 5 by adding a saturated aqueous sodium bicarbonate solution. The s mixture is extracted with ethyl acetate and the organic phase is dried over magnésium sulfate, filtered and concentrated under reduced pressure. Purification is carried out by flash chromatography on silica gel (40-63 pm), elution being carried out with a mixture of heptane and of ethyl acetate (80/20 to 50/50). 450 mg of 7-nitro-6-(propan-2-yloxy)1,3,4,5-tetrahydro-2H-1-benzazepin-2-one are obtained in the form of a beige solid.
to 91 mg of sodium hydride at 50% are added to a solution of 445 mg of 7-nitro-6-(propan-2yloxy)-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one in 10 ml of DMF. The reaction medium is stirred for 10 minutes at ambient température and then 263 mg of iodomethane are added. The reaction medium is stirred for 1 hour at ambient température, poured into icecold water and extracted with ethyl acetate. The organic phase is dried over magnésium 15 sulfate, filtered and evaporated under reduced pressure, so as to give 417 mg of 1-methyl-7-nitro-6-(propan-2-yloxy)-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one in the form of a yellow gum.
567 mg of ammonium formate and 478 mg of Pd/C (10%) are added to a solution of 416 mg of 1-methyl-7-nitro-6-(propan-2-yloxy)-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one 20 in 30 ml of methanol. The reaction medium is microwave-heated at 80°C for 5 minutes.
The mixture is filtered on Clarcel, and the Clarcel is rinsed with methanol. The filtrate is concentrated under reduced pressure, so as to give 380 mg of 7-amîno-1-methyl-6(propan-2-y!oxy)-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one in the form of a colourless gum.
Method 17:8-Amino-1-methyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one g of alpha-tetralone are added to 18.2 ml of sulfuric acid cooled to 0°C, while maintaining the température < 10°C. A mixture of 1.87 ml of nitric acid at 70% In water and of 3.65 ml of sulfuric acid is added while maintaining the température < 10*C. The 30 reaction medium is stirred for 30 minutes at a température < 10°C and then stirred for one hour at ambient température. The reaction medium is poured into ice-cold water (250 ml).
The insoluble material is filtered off under vacuum and dried, so as to give 5.2 g of 7-nitro3,4-dihydronaphthalen-1(2H)-one in the form of a beige solid.
A mixture of 5 g of 7-nitro-3,4-dihydronaphtha!en-1(2H)-one, 2.18 g of hydroxylamine 35 hydrochloride, 4.29 g of sodium acetate in 90 ml of éthanol and 90 ml of water is refluxed for one hour. The reaction medium is brought back to ambient température and an
111 aqueous 10% sodium bicarbonate solution is added until a pH of 7 is reached. The mixture is extracted with ethyl acetate and the organic phase is dried over magnésium sulfate, filtered and concentrated under reduced pressure. Purification is carried out by flash chromatography on silica gel (40-63 pm), elution being carried out with a mixture of heptane and of ethyl acetate (80/20 to 50/50). 1.14 g of (1E)-N-hydroxy-7-nitro-3,4dihydronaphthalen-1(2H)-Îmine are obtained in the form of a yellow solid.
A mixture of 1.11 g of (1E)-N-hydroxy-7-nitro-3,4-dihydronaphthalen-1(2H)-imine and 13 g of polyphosphoric acid is heated at 125’C for 16 hours. The reaction medium is poured into ice-cold water and extracted with ethyl acetate. The organic phase is washed with a saturated sodium chloride solution, dried over magnésium sulfate, filtered and concentrated under reduced pressure. 549 mg of 8-nitro-1,3,4,5-tetrahydro-2H-1benzazepin-2-one are obtained in the form of a beige solid.
144 mg of NaH (50%) are added to a solution of 549 mg of 8-nitro-1,3,4,5-tetrahydro-2H1-benzazepin-2-one in 15 ml of DMF. The reaction medium is stirred for 15 minutes and then 187 μΙ of iodomethane are added. The mixture is stirred for 16 hours at ambient température and then run into ice-cold water and extracted with ethyl acetate. The organic phase is washed with a saturated sodium chloride solution, dried over magnésium sulfate, filtered and concentrated under reduced pressure. The residue is taken up in diisopropyl ether and the insoluble material is filtered off and dried under vacuum, so as to give 405 mg of 1-methyl-8-nitro-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one in the form of a beige solid.
696 mg of ammonium formate and 581 mg of Pd/C (10%) are added to a solution of 405 mg of 1-methyl-8-nitro-1,3,4,5-tetrahydro-2H-1-benzazepïn-2-one in 39 ml of methanol. The reaction medium is microwave-heated at 80°C for 5 minutes. The mixture is filtered on Clarcel, and the Clarcel is rinsed with methanol. The filtrate is concentrated under reduced pressure, so as to give 422 mg of 8-amino-1-methyl-1,3,415-tetrahydro-2H1-benzazepin-2-one in the form of a colourless gum.
Method 18: 2-lsopropoxy-4-(4-methylpiperazin-1-ylmethyl)phenylamine
3.0 g of 3-hydroxy-4-nitrobenzaldehyde, 30 ml of acetonitrile, 5.9 g of caesium carbonate and 4.1 ml of 2-iodopropane are successively introduced into a three-necked roundbottomed flask under argon. The reaction mixture is heated at 70Ό for 17 h. After cooling to ambient température, the mixture is filtered through a sintered glass filter and the filtrate is concentrated to dryness under reduced pressure. The residue is taken up in a mixture of 50 ml of ethyl acetate and 15 ml of water, and then separated by settling out. The aqueous phase is separated and the organic phase is washed with 10 ml of water. The
112 organic phase is then dried over magnésium sulfate and then concentrated to dryness under reduced pressure, so as to obtain 3.6 g of 3-isopropoxy-4-nitrobenzaldehyde in the form of a dark brown liquid.
3.25 ml of 1-methylpiperazine are added to a solution of 3.06 g of 3-isopropoxy-45 nitrobenzaldehyde in 15 ml of toluene and 0.34 ml of acetic acid in a three-necked round· bottomed flask under argon. The reaction mixture is stirred at ambient température for 1.5 h and then 5 ml of toluene are added, followed by 4.9 g of sodium triacetoxyborohydride by spatula. The reaction mixture is stirred at ambient température for 16 h, and then treated with 4.5 ml of methanol and 75 ml of a saturated sodium ίο hydrogen carbonate solution. After stirring at ambient température for 30 min, the mixture îs extracted with 30 ml and then 2 x 50 ml of ethyl acetate. The organic extracts are combined, washed with water, dried over magnésium sulfate, and then concentrated to dryness under reduced pressure, so as to give 4.24 g of 1-(3-isopropoxy-4-nitrobenzyl)-4methylpiperazine in the form of a beige solid.
A mixture of 4.2 g of 1-(3-îsopropoxy-4-nitrobenzyl)-4-methylpiperazine and 420 mg of 10% palladium-on-carbon in 145 ml of éthanol is hydrogenated at 25*C under 1 bar for 3 h. The mixture îs filtered on Clarcel and the Clarcel is rinsed with éthanol. The filtrate Is concentrated to dryness under reduced pressure, so as to give 3.8 g of 2-isopropoxy-4-(4methylpiperazîn-1-ylmethyl)phenylamine in the form of a brown oil.
Method 19:2-lsopropoxy-5-(4-methylpiperazin-1-yl)phenylamine
A mixture of 5.0 g of 5-bromo-2-fluoronitrobenzene, 14.8 g of caesium carbonate and 35.0 ml of 2-iodopropane is charged to two 20 ml microwave tubes, and irradiated at 60°C with stirring for 1.5 h, and then stirred at ambient température ovemight. The mixture is 25 poured into 400 ml of water and then extracted three times with 300 ml of ethyl acetate.
The organic extracts are combined and then concentrated to dryness under reduced pressure. The residue is reintroduced into a single-necked round-bottomed flask, into which 50 ml of 2-iodopropane and 10.0 g of caesium carbonate are added. The reaction mixture is heated at 95*C for 10 min, and then at 60 °C for 3 h, and it is then stirred at 30 ambient température ovemight. The mixture is then poured into 400 ml of water and then extracted three times with 400 ml of ethyl acetate. The organic extracts are combined and then concentrated to dryness under reduced pressure, so as to obtain 5.6 g of 4-bromo-1isopropoxy-2-nitrobenzene in the form of a brown oil.
A solution of 1.0 g of 4-bromo-1-isopropoxy-2-nitrobenzene in 36 ml of 1,4-dioxane is degassed with argon for 10 min, and then 0.69 g of 4,5-bis(diphenylphosphino)-9,9dimethylxanthene (Xantphos), 0.70 g of tris(dibenzylideneacetone)dipalladium(0), 2.52 g
113 of caesium carbonate and 0.86 ml of 1-methylpiperazine are successively added. The round-bottomed flask is rinsed with 2 ml of dîoxane, and the reaction mixture is then heated at 90°C for 43 h. After retuming to ambient température, the mixture is diluted with 90 ml of ethyl acetate and then extracted with 90 ml of water. The organic phase is separated, dried over magnésium suifate and concentrated to dryness under reduced pressure. The residue is purified by chromatography on a 70 g silica cartridge, elution being carried out with a 95/5 v/v then 50/50 v/v cyclohexane/ethyl acetate mixture, and then with a 95/5 v/v dichloromethane/methanol mixture at a flow rate of 50 ml/min, so as to obtain 0.57 g of 1-(4-isopropoxy-3-nitrophenyl)-4-methy!piperazine in the form of a brown oil.
A mixture of 0.57 g of 1-(4-isopropoxy-3-nitrophenyl)-4-methylpiperazine and 65 mg of 10% palladium-on-carbon in 200 ml of éthanol is hydrogenated at 25°C under 1 bar for 22 h. The mixture is filtered on Clarcel and the Clarcel is rinsed with methanol. The filtrate is concentrated to dryness under reduced pressure and the residue is purified by chromatography on a 25 g silica cartridge, elution being carried out with pure dichloromethane and then successively with 98/2 and 95/5 v/v dichloromethane/methanol mixtures at a fiow rate of 30 ml/min, so as to obtain 0.32 g of 2-isopropoxy-5-(4methylpiperazin-1-yl)phenylamine in the form of a brown solid.
Method 20: (3-lsopropoxy-4-nitrophenyl)(tetrahydropyran-4-yl)aniine
A mixture of 0.75 g of 5-fiuoro-1-nitro-2-(propan-2-yloxy)benzene, 0.42 g of 4-aminotetrahydropyran and 0.8 g of potassium carbonate in 6 m! of DMSO is stirred at 50’C ovemight. The mixture is diluted with 100 m! of water and extracted three times with 50 ml of ethyl acetate. The organic phases are combined and then dried over magnésium sulfate and concentrated to dryness under reduced pressure. The residue is purified by chromatography on a 50 g silica column, elution being carried out with a dichloromethane/methanol (95/5 v/v) mixture, so as to obtain 0.69 g of (3-isopropoxy-4nitrophenyi)(tetrahydropyran-4-yl)amine in the form of a yellow foam.
A mixture of 0.69 g of (3-isopropoxy-4-nitrophenyl)(tetrahydropyran-4-yl)amine and 0.1 g of 10% palladium-on-carbon in a mixture of 30 m! of éthanol and 10 ml of dichloromethane is hydrogenated at 22’C under 2 bar for 15 h. The mixture is filtered and the fiitrate is concentrated to dryness under reduced pressure. The residue is purified by chromatography on a 50 g silica column, elution being carried out with a dichloromethane/methanol (95/5 v/v) mixture, so as to obtain 0.4 g of (3-isopropoxy-4nitrophenyl)(tetrahydropyran-4-yl)amine in the form of a purple oil.
114
Method 21:2-1sopropoxy-3-(4-methylpiperazine-l-yl)phenylamine
1.23 g of potassium carbonate, 14.6 g of caesium carbonate, 22 ml of dimethylformamide and 1.0 g of 2-bromo-6-nitrophenol are successively introduced into a three-necked round-bottomed flask under argon. The resulting suspension is stirred at ambient température for 10 min, and then 0.91 ml of 2-iodopropane is added in one go. The roundbottomed flask is rinsed with 10 ml of dimethylformamide and then the reaction mixture is heated at 40 °C for 48 h. After cooling to ambient température, the mixture is treated with 50 ml of water and extracted four times with 30 ml of ethyl acetate. The organic extracts are combined and washed with 30 ml of saturated brine and then 30 ml of water. The organic phase is then dried over magnésium sulfate and then concentrated to dryness under reduced pressure. The residue is purified by chromatography on a 30 g silica cartridge, elution being carried out with a 95/5 v/v cyclohexane/ethyl acetate mixture at a flow rate of 30ml/min, so as to obtain 1.04 g of 1-bromo-2-isopropoxy-3-nitrobenzene in the form of a yellow oil.
A solution of 1.04 g of 1-bromo-2-isopropoxy-3-nitrobenzene in 37 ml of 1,4-dioxane is degassed with argon for 10 min, and then 0.72 g of 4,5-bis(diphenylphosphino)-9,9dimethylxanthene (Xantphos), 0.73 g of tris(dibenzylideneacetone)dipalladium(0). 2.62 g of caesium carbonate and 0.90 ml of 1-methylpiperazine are successively added. The round-bottomed flask is rinsed with 3 ml of dioxane, and then the réaction mixture is heated at 90°C for 19 h. After retuming to ambient température, the mixture is diluted with 90 ml of ethyl acetate and then extracted with 90 ml of water. The organic phase is separated, dried over magnésium sulfate and concentrated to dryness under reduced pressure. The residue is purified by chromatography on a 90 g silica cartridge, elution being carried out with a 98/2 v/v dichforomethane/methanol mixture, at a flow rate of 50 ml/min, so as to obtain 0.31 g of 1-(2-isopropoxy-3-nitrophenyl)-4-methylpiperazine in the form of a brown oil.
A mixture of 0.80 g of 1-(2-isopropoxy-3-nitropheny1)’4-methylpiperazine and 91 mg of 10% palladium-on-carbon in 300 ml of éthanol is hydrogenated at 25°C under 1 bar for 22 h. The mixture is filtered on Clarcel and the Clarcel is rinsed with éthanol. The filtrate is concentrated to dryness under reduced pressure and the residue is purified by chromatography on a 50 g silica cartridge, elution being carried out with pure dichloromethane and then successively with 98/2 and 95/5 v/v dichloromethane/methanol mixtures at a flow rate of 30 ml/min, so as to obtain 0.60 g of 2-isopropoxy-3-(4methylpiperazine-1-yl)phenylamine in the form of a yellow powder.
lis
Method 22:2-lsopropoxy-N4-(1 -methylpiperidin-4-yl)benzene-1,4-diamine
1.7 g of potassium carbonate and 1.0 g of 4-amino-1-methyfpiperidine are successively added to a solution of 1.6 g of 4-fluoro-2-lsopropoxy-1-nitrobenzene ln 13.5 ml of dimethyl sulfoxide. The reaction mixture is heated at 120°C for 3 h and is then cooled to ambient température and poured into a mixture of 150 ml of Ice-cold water and 100 ml of ethyi acetate. After settling out, the organic phase Is separated and the aqueous phase is extracted twice with 70 ml of ethyi acetate. The organic extracts are combined, dried over magnésium sulfate and then concentrated to dryness under reduced pressure. The residue Is purified by chromatography on a 90 g silica cartridge, elution being carried out with a 97.5/2/0.5 v/v/v dichloromethane/methanol/20% aqueous ammonia mixture at a flow rate of 50 ml/min, so as to obtain 1.5 g of (3-isopropoxy-4-nitrophenyl)(1methyipiperidin-4-yi)amine in the form of a bright yellow oil.
A mixture of 1.49 g of (3-isopropoxy-4-nitrophenyl)(1-methylpiperidin-4-yl)amine and 150 mg of 10% palladium-on-carbon in 60 ml of éthanol is hydrogenated at 25°C under 1 bar for 3 h. The mixture is filtered on Clarcel and the Ciarcel is rinsed with éthanol. The filtrate is concentrated to dryness under reduced pressure and the residue is purified by chromatography on a 70 g silica cartridge, elution being carried out with a 96.5/3/0.5 v/v/v dichloromethane/methanol/ 28% aqueous ammonia mixture at a flow rate of 50 ml/min, so as to obtain 0.9 g of 2-isopropoxy-N4-(1-methylpiperidin-4-yl)benzene-1,4-diamine in the form of a brown liquid.
Method 23:2-Methylpropan-2-yl 7-[4-amino-3-(propan-2-yloxy)phenyl]-1,7diazaspiro[4.4]nonane-1 -carboxylate
A mixture of 3.0 g of tert-butyl 1,7-diazaspiro[4.4]nonane-1-carboxylate and 2.64 g of 4-fluoro-1-nitro-2-(propan-2-yloxy)benzene (obtained according to method 6), and 2.75 g of potassium carbonate in DMSO is stirred at ambient température ovemight. The mixture is taken up with ethyi acetate and washed twice with 10 volumes of water. The organic phase ts dried over magnésium sulfate and concentrated under vacuum. The crude product is purified on 120 g of silica, elution being carried out with dichloromethane, so as to obtain 3.40 g of 2-methylpropan-2-yl 7-[4-nitro-3-(propan-2-yloxy)phenyl]-1,7diazaspiro[4.4]nonane-1-carboxylate in the form of adark yellow solid.
A mixture of 400 mg of 2-methylpropan-2-yl 7-[4-nitro-3-(propan-2-yloxy)phenyl]-1,7diazaspiro[4.4]nonane-1-carboxylate, 592 mg of hydrazine hydrate and 52.5 mg of 10% palladium-on-carbon ln 10 ml of éthanol is refluxed for 1 h. The mixture is filtered and the filtrate is concentrated under reduced pressure, so as to obtain 365 mg of 217140
116 methylpropan-2-yl 7-[4-amino-3-(propan-2-yloxy)phenyl]-1,7-diazaspiro[4.4]nonane-1 carboxylate in the form of a mauve gum.
Method 24:4-(1-Methyl-1,7-diazaspiro[4.4]non-7-yl)-2-(propan-2-yloxy)aniline s A mixture of 1.42 g of 4-fluoro-1-nitro-2-(propan-2-yloxy)benzene, 1.0 g of 1-methyl-1,7diazaspiro[4,4]nonane and 1.48 g of potassium carbonate in 10 ml of DMSO is stirred at ambient température ovemight. The mixture is diluted with 160 ml of water and extracted three times with 100 ml of ethyl acetate. The organic phases are dried over magnésium sulfate and concentrated under vacuum. The yellow oily residue is purified on silica, with to an elution gradient with dichloromethane/methanol (100/0 then 90/10), so as to obtain 160 mg of 1-methyl-7-[4-nitro-3-(propan-2-yloxy)phenyl]-1,7-diazaspiro[4.4]nonane in the form of an orangey-coloured oil.
A mixture of 160mg of 1-methyl-7-[4-nitro-3-(propan-2-yloxy)phenyi]-1,7diazaspiro[4.4]nonane, 301 mg of hydrazine hydrate and 27 mg of 10% palladium-on15 carbon in 30 ml of éthanol is heated at 80 *C (bath) for 2 h. The mixture is filtered and the filtrate is concentrated under vacuum, so as to obtain 141 mg of 4-(1-methyl-1,7diazaspiro[4,4]non-7-yl)-2-(propan-2-yloxy)aniline in the form of a brown oil.
Method 25:4-( 1 -Ethyl-1,7-diazaspiro[4.4]non-7-yl)-2-(propan-2-yloxy)aniline
0.33 ml of trifluoroacetic acid is added to a solution of 300 mg of 2-methylpropan-2-yl 7-[4nitro-3-(propan-2-yloxy)phenyl]-1,7-diazaspiro[4.4]nonane-1-carboxylate In 30 ml of dichloromethane. The mixture is stirred at ambient température for 15 hours and then 3 ml of trifluoroacetic acid are again added. After stirring for 15 hours, the reaction mixture is run into 50 ml of a saturated potassium carbonate solution. The aqueous phase is extracted three times with 50 ml of dichloromethane. The organic phases are combined, dried over anhydrous magnésium sulfate, filtered and then concentrated to dryness under reduced pressure, so as to give a yellow oil. The residue is purified by chromatography on silica gel, elution being carried out with dichloromethane/methanol (100/0 to 95/5), so as to obtain 221 mg of 7-[4-nitro-3-(propan-2-yloxy)phenyl]-1,7-diazaspiro[4.4]nonane in the form of a yellow solid.
1.0 ml of acetaldehyde is added to a solution of 500 mg of 7-[4-nitro-3-(propan-2yloxy)phenyl]-1,7-diazaspiro[4.4]nonane in 20 ml of 1,4-dichloroethane, cooled in a bath of ice-cold water. After 30 minutes, 1.12 g of sodium triacetoxyborohydride are added in small portions and the mixture is left to retum to ambient température. The mixture is 35 stirred at ambient température for 15 hours. 1 ml of acetaldehyde is then added and the mixture is stirred for 7 h. The mixture Is concentrated to dryness under reduced pressure
117 and the residue is diluted in 100 ml of dichloromethane. The organic phase Is washed three times with 50 ml of water and the organic phase is dried over anhydrous magnésium sulfate, filtered and then concentrated to dryness under reduced pressure. The residue is purified by chromatography on silica gel, elution being carried out with a dichloromethane/isopropanol gradient: 100/0 to 50/50, and then by further chromatography on silica gel, elution being carried out with a dichloromethane/acetone gradient: 100/0 to 50/50, so as to obtain a yellow oil. This oil is taken up with ether, and the precipitate obtained is filtered off. The filtrate is concentrated to dryness under reduced pressure, so as to give 250 mg of 1-ethyl-7-[4-nitro-3-(propan-2-yloxy)phenyl]1,7-diazaspiro[4.4]nonane in the form of a yellow oil.
A mixture of 250 mg of 1-ethyl-7-[4-nitro-3-(propan-2-yloxy)phenyl]-1,7diazaspiro[4.4]nonane, 450 mg of hydrazine hydrate and 40 mg of 10% palladium-oncarbon in 10 ml of éthanol is heated at 80 °C (bath) for 4 h 30 min. 450 mg of hydrazine hydrate are then added and the reflux is maintained for 1 h. The mixture is filtered and the filtrate is concentrated under vacuum, so as to obtain 230 mg of 4-(1-ethyl-1,7diazaspiro[4.4]non-7-yl)-2-(propan-2-yloxy)aniline in the form of a brown oil.
Method 26:4-[(8aR)-Hexahydropynrolo[1,2-a]pyrazin-2(1 H)-yl]-2-(propan-2-yloxy)aniline A mixture of 1.0 g of 4-fluoro-1-nitro-2-(propan-2-ytoxy)benzene, 634 mg of (R)-1,4dÎazabicyclo[4,3,0]nonane and 1,04 g of potassium carbonate in 7 ml of DMSO is stirred at ambient température for 21 hours. The reaction medium is run Into 15 ml of water and the mixture is then extracted three times with 30 ml of ethyl acetate. The organic phases are dried over magnésium sulfate, filtered and concentrated under vacuum, so as to obtain 1.44 g of (8aR)-2-[4-nitro-3-(propan-2-yloxy}phenyl]octahydropyrrolo[1t2-a]pyrazine in the form of an orangey-coloured oily residue.
A mixture of 1.38 g of (8aR)-2-[4-nitro-3-(propan-2-yloxy)phenyl]octahydropyrrolo[1,2ajpyrazine, 2.72 g of hydrazine hydrate and 240 mg of 10% palladium-on-carbon (240 mg, 5 mol%) in 30 ml of éthanol is heated at 80 °C (bath) for 1 h 30. The mixture is filtered on Clarce! and the filtrate is concentrated under vacuum, so as to obtain 1.23 g of 4-[(8aR}hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(propan-2-yloxy)aniline In the form of a purple oil.
Method 27:2-{4-[4-Amino-3-(propan-2-yloxy)phenyl]piperidin-1 -yljethanol
A mixture of 100 mg of 4-[4-nîtro-3-(propan-2-yloxy)phenyl]pyridine (see method 1 ) and
0.075 ml of 2-lodoethanol in 1.7 ml of acetonitrile is heated at 85°C (bath) for 1 h. 75 μΙ of
2-iodoethanol are then added and the heating is continued for 15 h at 91 °C. The mixture
118 ls then concentrated under vacuum, so as to obtain a solid which is taken up with 10 ml of ethyi ether. The resulting heterogeneous mixture is filtered and the solid is rinsed with ethyi ether and dried under reduced pressure, so as to obtain I47mg of 1-(2hydroxyethyl)-4-[4-nitro-3-(propan-2-yloxy)phenyl]pyridinium iodide in the form of a solid.
44 g of sodium borohydride are added, at a température of about 0*0 (ice/water bath) to a solution of 0.142 g of 1-(2-hydroxyethyl)-4-[4-nitro-3-(propan-2-yloxy)phenyl]pyridinium iodide in 2.6 ml of methanol. After 30 minutes, a few drops of water are added and the mixture is left to return to ambient température. The mixture is concentrated to dryness under reduced pressure and then diluted with 150 ml of ethyi acetate. The organic phase to is washed successively with 120 ml of a saturated sodium hydrogen carbonate solution and then 70 ml of a saturated sodium chloride solution. The organic phase is dried over anhydrous magnésium sulfate, filtered and then concentrated to dryness under reduced pressure, so as to obtain 90 mg of 2-{4-[4-nitro-3-(propan-2-yloxy)phenyl]-3,6dihydropyridin-1 (2H)-yl}ethanol.
A mixture of 150 mg of 10% palladium-on-carbon and 400 mg of 2-{4-[4-nitro-3-(propan-2yloxy)phenyl]-3l6-dihydropyridin-1(2H)-yl}ethanol in 15 ml of éthanol is heated at 80°C with stirring. 1.25 g of ammonium formate are then added in two portions. After stirring at 80’C for 1 h, the mixture is allowed to return to ambient température and is filtered on Clarcel. The Clarcel is rinsed with 200 ml of éthanol and the filtrate is concentrated under 20 vacuum, so as to obtain a residue which is solubilised in 150 ml of dîchloromethane. The organic phase Is washed three times with 70 ml of a saturated potassium carbonate solution, and the aqueous phase is extracted twice with 100 ml of dîchloromethane. The combined organic phases are dried over magnésium sulfate, filtered and concentrated under vacuum, so as to obtain 330 mg of 2-{4-[4-amino-3-(propan-225 y loxy)pheny IJpîperidin-1 -y I} éthanol used without further purification.
Method 28: (3R)-1-[4-Amino-3-(propan-2-yloxy)phenyl]-N-methyl-N-(oxetan-3-yl)piperidin3-amine
A mixture of 3.0 g of 4-fluoro-1-nitro-2-(propan-2-yloxy)benzene, 5.0 g of (R)-3-Boc30 aminopiperidine and 3.12 g of potassium carbonate in 28 ml of DMSO is stirred at ambient température ovemight. The mixture is diluted with 30 ml of water and extracted three times with 60 ml of ethyi acetate. The organic phases are dried over magnésium sulfate and concentrated under vacuum. The residue is purified by flash chromatography on silica gel, using a dichloromethane/ethyl acetate (98/2 to 90/10) elution gradient, so as to obtain
5.71 g of 2-methylpropan-2-y1 {(3R)-1-[4-nitro-3-(propan-2-yloxy)phenyl]piperidin-3yljcarbamate in the form of a yellow solid.
119
6.25 ml of trifluoroacetic acid are added, at a température of about 20Ό, to 5.32 g of 2* methylpropan-2-yl {(3R)-1 -[4-nitro-3-(propan-2-yloxy)phenyl]piperidin-3-yl}carbamate ïn solution in 106 ml of dichloromethane, and the mixture is left to stir for 15 h. A further 2 ml of trifluoroacetic acid are added and the stirring is continued for 1 h. The mixture is 5 concentrated under reduced pressure, so as to obtain an oily residue which is precipitated by adding ethyl ether. The solid obtained is filtered off and then washed with ethyl ether, so as to obtain 5.42 g of (3R)-1-[4-nitro-3-(propan-2-yloxy)phenyl]piperidin-3-amine trifluoroacetate in the form of a yellow solid.
5.11g of (3R)-1-[4-nitro-3-(propan-2-yloxy)phenyl]piperidin-3-amine trifluoroacetate are îo added to 40 ml of a saturated potassium carbonate solution and then the mixture is extracted three times with 50 ml of dichloromethane. The combined organic phases are dried over magnésium sulfate, filtered and concentrated under vacuum so as to give 3.60 g of (3R)-1-[4-nitro-3-(propan-2-yloxy)phenyl]pÎperidin-3-amine in the form of a yellow solid.
is 2 ml of 3-oxetanone are added, at a température of about 20O, to a solution of 1.50 g of (3R)-1-[4-nitro-3-(propan-2-yloxy)phenyl]piperidin-3-amine in 54 ml of 1,4-dichloroethane, under an argon atmosphère. After stirring of the mixture, 3.69 g of sodium triacetoxyborohydride are added in small portions and the reaction mixture is heated at 70 °C for 3 h. After retuming to ambient température, 70 ml of a dilute sodium hydrogen 20 carbonate solution are added. The aqueous phase is extracted twice with 80 ml of dichloromethane. The combined organic phases are dried over magnésium sulfate, filtered and concentrated under vacuum, so as to obtain an orangey-coloured oily residue. The residue is purified by chromatography on silica gel, using a dichloromethane/isopropanol (98/2 to 94/6) elution gradient, so as to obtain 1.2 g of (3R)-1-[4-nitro-3-(propan-2-yloxy)phenyl]-N-(oxetan-3-yl)piperidin-3-amine in the form of an orangey-coloured gum.
μΙ of iodomethane are added, at a température of about 20’C, under an argon atmosphère and with magnetic stirring, to a mixture of 293 mg of (3R)-1-[4-nitro-3(propan-2-yloxy)phenyl]-N-(oxetan-3-yl)piperidin-3-amine and 427 mg of caesium 30 carbonate in 8 ml of anhydrous DMF. After stirring for 3 hours, 100 μΙ of iodomethane are added and the mixture is left to stir for a further 2 h. 10 ml of water are then added and the mixture is then extracted three times with 15 ml of ethyl acetate. The combined organic phases are dried over magnésium sulfate, filtered and concentrated under vacuum so as to give an oily yellow residue. The residue is purified by flash chromatography on silica 35 gel, using a dichloromethane/methanol (98/2) eluent, so as to obtain 47 mg of (3R)-N17140
120 methyl-1-[4-nitro-3-(propan-2-yloxy)phenyl]-N-(oxetan-3-yl)piperidin-3-amine in the form of an orangey-yellow solid.
mg of palladium-on-carbon (10%) and then 0.269 ml of hydrazine hydrate are added to a solution of 161 mg of (3R)-N-methy1-1-[4-nitro-3-(propan-2-yloxy)phenyl]-N-(oxetan-3yl)piperïdin-3-amine in 4 ml of éthanol. This mixture is heated at between 85°C/90“C with magnetic stirring for 1 h 30, then 24 mg of palladium-on-carbon (10%) are added while continuing the refluxing for 2 h. 24 mg of palladium-on-carbon (10%) and 0.269 ml of hydrazine hydrate are again added. The mixture is heated for 1 h at δδΌ/ΘΟΌ, and then allowed to return to ambient température and the mixture is filtered through a Whatman AutoCup sintered glass funnel. The filtrate Is concentrated under vacuum so as to obtain 136 mg of (3R)-1-[4-amino-3-(propan-2-yloxy)phenyl]-N-methyl-N-(oxetan-3-y1)piperidin-3amine in the form of an orangey-yellow solid which Is used for the subséquent step without further purification.
Rf = 0.61 (TLC, silica support), eluent dichloromethane/MeOH (95/5), UV 254 nm.
Method 29: 2-Methylpropan-2-yl 4-I5-amino-1-(propan-2-yl)-1H-pyrazol-3-yl]piperidine-1carboxylate
1.82 ml of triethylamine are added to a solution of 3.18 g of 4-(2-cyanoacetyl)piperidine-1carboxylic acid tert-butyl ester and 1.41 g of Isopropylhydrazine hydrochloride in 70 ml of éthanol under an argon atmosphère. The mixture is refluxed with magnetic stirring for 3 hours, and then concentrated to dryness under reduced pressure. The residue is taken up in a mixture of 100 ml of water and 100 ml of ethyl acetate, and then the organic phase is washed twice with 100 ml of water. The combined aqueous phases are extracted twice with 100 ml of ethyl acetate. The combined organic phases are dried over magnésium sulfate, filtered and concentrated under reduced pressure, so as to obtain 3.9 g of 2methylpropan-2-yl 4-[5-amino-1-(propan-2-yl)-1 H-pyrazol-3-yl]piperidine-1-carboxyiate in the form of a solid.
Method 30:1-(Propan-2-y1)-3-(tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-5-amine
26.8 ml of a 1M solution of LiHMDS in THF are introduced into 25 ml of anhydrous THF under an argon atmosphère. The mixture is maintained at a température of about -78°C, and then 1.47 ml of acetonitrile in solution in 3 ml of anhydrous THF are added. The reaction mixture is kept stirring at -78°C for 40 minutes and then a solution of 3.0 g of methyl tetrahydropyran-4-carboxylate in 3 ml of THF is added. After stirring for 2 hours at -78°C, the mixture is left to return to ambient température for 15 hours and it is then diluted with 200 ml of a water/ice mixture. The pH is adjusted to a value of about 3 by
121 adding 2N HCl, and then the mixture is extracted three times with 150 ml of ethyl acetate. The combined organic phases are dried over anhydrous magnésium sulfate, filtered and then concentrated to dryness under reduced pressure, so as to give 3.18 g of 3-oxo-3(tetrahydro-2H-pyran-4'yl)propanenitrile in the form of a light brown oil.
0.43 ml of triethylamine is added to a solution of 640 mg of 3-oxo-3-(tetrahydro-2H-pyran4-yl)propanenitrile and 347 mg of isopropylhydrazine hydrochloride in 8 ml of éthanol under an argon atmosphère. The mixture is refluxed with magnetic stirring for 1 h and then concentrated to dryness under reduced pressure. The residue is taken up in 100 ml of ethyl acetate and the organic phase is washed twice with 40 ml of a saturated sodium îo hydrogen carbonate solution. The combined aqueous phases are extracted twice with 50 ml of ethyl acetate. The combined organic phases are dried over magnésium sulfate, filtered and concentrated under reduced pressure, so as to obtain 536 mg of 1-(propan-2yl)-3-(tetrahydro-2H-pyran-4-yl)-1 H-pyrazol-5-amine.
Method 31:4-Methoxy-2-(propan-2-yloxy)aniline
A mixture of 5.0 g of 4-fluoro-1-nitro-2-(propan-2-yloxy)benzene, 4.07 g of sodium methoxide and 200 mg of 18C6 in 100 ml of methanol is heated at 65’C for 2 h. The mixture is then concentrated and the residue is taken up with a mixture of water and ethyl acetate. The aqueous phase is extracted three times with ethyl acetate. The combined 20 organic phases are dried over anhydrous magnésium sulfate, filtered and then concentrated to dryness under reduced pressure, so as to obtain 5.0 g of 1-nitro-4methoxy-2-(propan-2-yloxy)benzene.
A solution of 5.0 g of 1-nitro-4-methoxy-2-(propan-2-yloxy)benzene in 300 ml of methanol is hydrogenated on 2.5 g of platinum oxide at a hydrogen pressure of 15 bar, for 2 h at 25 ambient température. The mixture is filtered and the filtrate is concentrated to dryness under reduced pressure, so as to obtain 4.36 g of 4-methoxy-2-(propan-2-yloxy)aniline.
Method 32:4-Chloro-2-(propan-2-yloxy)aniline
A mixture of 1.0 g of 4-chloro-2-fluoronitrobenzene and 9,3 g of caesium carbonate in
10 ml of 2-propanol is heated at 60 C for 24 h. The mixture is then concentrated and the residue is taken up with 100 ml of a mixture of water and ethyl acetate. The aqueous phase is extracted three times with 50 ml of ethyl acetate. The combined organic phases are washed with 50 ml of a saturated sodium chloride solution, dried over anhydrous magnésium sulfate, filtered and then concentrated to dryness under reduced pressure.
The residue is purified on 90 g of silica, elution being carried out with 95/5 heptane/ethyl
122 acetate, so as to obtain 885 mg of 4-chloro-1-nitro-2-(propan-2-yloxy)benzene in the form of a yellow solid.
A mixture of 2.55 g of 4-chloro-1-nitro-2-(propan-2-yloxy)benzene in 40 m! of acetic acid is heated at 50 O, and then 7 ml of water and 2.64 g of iron powder are added. The mixture is stirred for 1 h at 50 O, and then cooled to ambient température and filtered on Celite.
The Celite is rinsed three times with 20 ml of methanol, and the filtrate is concentrated under reduced pressure. The residue is taken up in 50 ml of 1N sodium hydroxide and 50 ml of dichloromethane. The aqueous phase is extracted twice with 50 ml of dichloromethane. The combined organic phases are dried over anhydrous magnésium w sulfate, filtered and then concentrated to dryness under reduced pressure, so as to obtain
2.25 g of 4-chloro-2-(propan-2-yloxy)aniline in the form of a green oil.
Method 33:4-(4-Methyl-1,4-diazepan-1 -yl)-2-(propan-2-yloxy)aniline
A mixture of 250 mg of 4-bromo-1-nitro-2-(propan-2-yloxy)benzene, 1.13 g of caesium 15 carbonate, 197mg of N-methylhomopiperazine, 47.5 mg of tris(dibenzylideneacetone)dipalladium(0) and 50 mg of 9,9-dimethyl-4,5bis(diphenylphosphino)xanthene in 5 ml of 1,4-dioxane is microwave-heated in a sealed tube, at 150°C for 30 min, and then 200°C for 10 min. The mixture is diluted with ethyl acetate and filtered on Clarcel. The Clarcel is washed with ethyl acetate and the organic 20 phase is washed with water. The organic phase is dried over anhydrous magnésium sulfate, filtered and then concentrated to dryness under reduced pressure. The residue is purified on 12 g of silica, elution being carried out with 0-5% methanol in dichloromethane, so as to obtain 110 mg of 4-(4-methyl-1,4-diazepan-1-yl)-2-(propan-2-yloxy)nitrobenzene in the form of an orangey-coloured oil.
A solution of 267 mg of 4-(4-methyl-1,4-diazepan-1-yl)-2-(propan-2-yloxy)nitrobenzene in ml of methanol is hydrogenated using an H-cube, on a cartridge of 10% palladium-oncarbon, at a flow rate of 1 ml/min. The hydrogenated solution is concentrated under reduced pressure, so as to obtain 220 mg of 4-(4-methyl-1,4-diazepan-1-yl)-2-(propan-2yloxyjaniline in the form of a grey oil.
Method 34: 7-Amîno-1 -methyl-8-(propan-2-yloxy)-1,3,4,5-tetrahydro-2H-1 -benzazepin-2one
A suspension of 2.0 g of 7-hydroxy-3,4-dihydronaphthalen-1 (2H)-one, 4.04 g of caesium carbonate and 3.15 ml of 2-iodopropane in 23 ml of acetonitrile is heated for 1 hour at
80 O. The reaction medium is brought back to ambient température and then evaporated to dryness. The residue is taken up with 100 ml of water and 100 ml of ethyl acetate. The 123 organic phase is dried over magnésium sulfate, filtered and evaporated under reduced pressure, so as to obtain 2.24 g of 7-(propan-2-yloxy)-3,4-dihydronaphthalen-1 (2H)-one in the form of an orangey-coloured oil.
900 mg of sodium azide are added at ambient température to a solution of 2.24 g of 5 7-(propan-2-yloxy)-3,4-dihydronaphthalen-1(2H)-one in 35 ml of trifluoroacetic acid. The réaction medium Is refluxed for 3 hours and is then brought back to ambient température.
The reaction medium is poured into 100 ml of water and the pH is adjusted to pH 7 by adding sodium carbonate. The mixture is extracted twice with 100 ml of ethyl acetate. The combined organic phases are dried over magnésium sulfate, filtered and evaporated. The ίο residue is purified by flash chromatography on silica gel, elution being carried out with dichloromethane and then a dichloromethane/methanol (9/1) mixture, so as to obtain 346 mg of 8-(propan-2-yloxy)-1,3,4,5-tetrahydro-2H-1-benzazepîn-2-one in the form of an orangey-coloured oil.
460 mg of potassium nitrate are added to a solution of 797 mg of 8-(propan-2-yloxy)15 1,3,4,5-tetrahydro-2H-1-benzazepîn-2-one in 8 ml of trifluoroacetic anhydride, cooled to
-5°C. The reaction medium Is stirred for 5 minutes at -5°C, brought back to pH 7 by adding a saturated aqueous sodium hydrogen carbonate solution, and then extracted with 100 ml of ethyl acetate. The organic phase is dried over magnésium sulfate, filtered and evaporated. The residue is purified by flash chromatography on silica gel, elution being 20 carried out with a heptane/ethyl acetate (1/1) mixture, so as to obtain 489 mg of 7-nitro-8(propan-2-yloxy)-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one in the form of a yeliow solid.
100 mg of sodium hydride at 60% are added to a solution of 485 mg of 7-nitro-8-(propan2-yloxy)-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one in 8 ml of DMF, cooled to 0°C. The reaction medium is stirred for 5 minutes and then 263 mg of iodomethane are added. The 25 reaction medium îs brought back to ambient température and stirred for 1 hour at this température. The reaction medium is poured into 100 ml of ice-cold water and the mixture is extracted with 100 ml of ethyl acetate. The organic phase is dried over magnésium sulfate, filtered and evaporated. The residue is purified by flash chromatography on silica gel, elution being carried out with a heptane/ethyl acetate (1/1) mixture, so as to obtain 30 318 mg of 1-methyl-7-nitro-8-(propan-2-yloxy)-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one in the form of a yeliow solid.
In a microwave tube, 316 mg of 1-methyl-7-nitro-8-(propan-2-yloxy)-1,3,4,5-tetrahydro-2H1-benzazepîn-2-one are introduced into 20 ml of methanol. 443 mg of ammonium formate and 363 mg of Pd/C (10%) are added. The reaction medium is microwave-heated at 80’C 35 for 5 minutes. The mixture is filtered on Clarcel and the Clarcel is rinsed with methanol.
The filtrate is concentrated under reduced pressure, so as to obtain 280 mg of 7-amino-117140
124 methyl-8-(propan-2-yloxy)-1l3,4,5-tetrahydro-2H-1-benzazepin-2-one in the form of a colourless gum.
Method 35:4-(1,2,2,6,6-Pentamethylpiperidin-4-yl)-2-(propan-2-yloxy)aniline s 180 μΙ of formaldéhyde and 3.4 ml of formic acid are added to a solution of 500 mg of 2,2,6,6-tetramethyl-4-[4-nitro-3-(propan-2-yloxy)phenyl]-1121316-tetrahydropyridine (obtained according to method 2) in 15 ml of DMSO. The tube is microwave-heated at 100*C for 5 minutes. After cooling, the mixture is run into water and extracted with ethyl acetate. The organic phase is washed with a saturated sodium chloride solution, dried îo over magnésium sulfate, filtered and concentrated under reduced pressure. Purification is carried out by flash chromatography on silica gel, elution being carried out with a mixture of dichloromethane and methanol (95/5), so as to obtain 230 mg of 1,2,2,6,6-pentamethyl4-[4-nitro-3-(propan-2-yloxy)phenyl]-1l2,3l6-tetrahydropyridine in the form of a yellow oil.
ln a microwave tube, 230 mg of 1,2,2,6,6-pentamethyl-4-[4-nitro-3-(propan-215 yloxy)phenyl]-1,2,3,6-tetrahydropyridine are introduced into 11.5 ml of methanol. 262 mg of ammonium formate and 221 mg of Pd/C (10%) are added. The réaction medium is microwave-heated at 80*C for 5 minutes. The mixture is filtered on Clarcel and the Clarcel is rinsed with methanol. The filtrate is concentrated under reduced pressure and the residue is purified by flash chromatography on alumina, elution being carried out with a 20 dichloromethane/methanol (98/2) mixture, so as to obtain 120 mg of 4-(1,2,2,6,6pentamethylpîperidin-4-yl)-2-(propan-2-yloxy)aniline in the form of a yellow oil.
Method 36:4-(1-Methy!-1H-pyrazol-3-yl)-2-(propan-2-yloxy)aniline
1.02 g of 3-iodo-1-methyl-1H-pyrazole are introduced into 33 ml of 1-4-dioxane. After 25 sparging with argon for 10 min in the reaction medium, 1.5 g of 4,4,5,5-tetramethyl-2-[4nitro-3-(propan-2-yloxy)phenyl]-1,3,2-dioxaborolane (obtained as in method 2), 4.77 g of caesium carbonate, 6.5 ml of water and 179mg of [1,r-bis(diphenylphosphino)ferrocene]dichloropalladium(ll) are added. The réaction medium is heated for 1 hour at 90°C and is then diluted with ethyl acetate and water. The 30 aqueous phase is extracted twice with ethyl acetate. The combined organic phases are dried over magnésium sulfate and concentrated under vacuum. The residue is purified by flash chromatography on silica gel, elution being carried out with dichloromethane and then a dichloromethane/methanol (98/2) mixture, so as to give 865 mg of 1-methyl-3-[4nitro-3-(propan-2-yloxy)phenyl]-1 H-pyrazole in the form of an orange oil.
ln a microwave tube, 860 mg of 1-methyl-3-[4-nÎtro-3-(propan-2-yloxy)phenyl]-1 H-pyrazole are introduced into 30 ml of methanol. 1.25 g of ammonium formate and 1.05 g of Pd/C
123 (10%) are added. The reaction medium is microwave-heated at 80’C for 3 times minutes. The mixture is filtered on Clarcel and the Clarcel is rinsed with methanol. The filtrate Is concentrated under reduced pressure and the residue is taken up with 30 ml of ethyl acetate and 3 ml of water. The organic phase is dried over magnésium sulfate, 5 filtered and concentrated under reduced pressure. The residue is purified by flash chromatography on silica gel, elution being carried out with a dichloromethane/methanol (95/5) mixture, so as to obtain 110 mg of 4-(1-methyl-1H-pyrazol-3-yl)-2-(propan-2yloxy)aniline in the form of a purple oil.
ίο The compounds (Ilia) obtained according to Example 8 (methods 1 to 36) are described in Table 2.
Table 2:
Compounds 111a | Name | Method |
llla-1 | 2-Methoxy-4-(1-(propan-2-yl)plperidin-4-y!]anitine | WQ2009/020990 p92 |
llla-2 | 2-Methoxy-5-m ethy 1-4-(1 -methyfpiperid i n-4-yl)ani!lne | Analogy with W02008/073687 p48 |
llla-3 | 4-( 1 -Methyfpiperid ln-4-yl )-2-(propan-2-yfoxy)anl tine | Method 1 |
llla-4 | 2-Methy1propan-2-yl 4-[4-amino-3-(propan-2yfoxy)phenyl]plperidine-1 -carboxylate | Method 5 |
llla-5 | 2-(Propan-2-ybxyJ-4i1 -(propan-2-y1)piperidin-4yljanillne | Method 1 |
llla-6 | 4-( 1 -Cyclopropylplperidin-4-y1)-2-(propan-2yioxyjaniline | Method 2 |
llla-7 | 5-Methyl-4-{ 1 -methylplperidin-4-yl)-2-(propan-2ybxyjanlllne | W02008/073687 p48 |
llla-8 | 4-(5-Methoxy-1-methyl-1 ,3,6-tetrahydropyridin-4yl)-2-(propan-2-yfoxy)aniline | Method 3 |
llla-9 | 2-(Propan-2-ybxy )-4-(2,2,6,6-te tramethylpiperidln-4yljanillne | Method 2 |
llla-10 | 4-(1,2,2,6,6-Pentamethylplperidin-4-yl)-2-(propan-2yfoxy) aniline | Method 35 |
llla-11 | 2-Methy1propan-2-yl 4-[4-amlno-3-(propan-2ybxy)phenyf]-2,6-dimethyipfperldine-1 -carboxylate | Method 2 |
llïa-12 | 2-Methylpropan-2-y12-ethy1-4-(4-(formylamlno)-3(propan-2-ybxy)phenyl]plperidine-1 -carboxylate | Method 2 |
llla-13 | 4-[2-Ethyl-1-methyfpiperidin-4-y1}-2-(propan-2· yioxy)anlline | Method 35 |
llla-14 | (cis) -4-(4-Amino-3-(propan-2-yfoxy )phenyl]-1 m ethylplperidln-3-ol | Method 4 |
126
Compounds Ilia | Name | Method |
llla-15 | 2-Methylpropan-2-y14-{4-(formylamlno)-3-(propan’ 2-yloxy)phenyl]-2-(propan-2-yl)piperidine-lcarboxylate | Method 2 |
Ilia-16 | 2-{4-{4-Am ino-3-(propan-2-y1oxy)pheny1]pÎperid i n-1 yt) éthanol | Method 27 |
llla-17 | 5-Fluoro-4-( t-m ethylplperidin-4-y l)-2-(propan-2ytoxy)aniline | Method t |
llla-18 | 2-Methoxy-5-m ethy1-4-( 1 -methy iplperidin-3-y t) an lline | Method 1 |
llla-19 | 4-(1-Ethy1plperidin-3-yl)-2-(propan-2-yloxy)anlline | Method 1 |
llla-20 | 4-(Octahydroindollzl n-8-yl)-2-(propan-2-yioxy)anii 1 ne | Method 2 |
llla-21 | 2-Methoxy-4-{4-(pyrrolldtn-1 -yt)plperidln-1 -yljanillne | US2006/46990 p6 |
Il la-22 | 2-Methyl-4-{4-{pyTTOlidin-1 -y Qplperid in-1 -yf] aniline | Method 6 |
llla-23 | 2-Methoxy-4-{4-{propan-2-yl)plperazin-1-y1]aniline | W02009/020990 p102 |
llla-24 | 2-Methoxy-4-(4-methylpiperaztn-1-yl)anjilne | WO2004/080980 pt38 |
llla-25 | 4-(4-Methylpiperazin-1-yl)-2-(propan-2-yloxy)anitine | Method 6 |
llla-26 | 5-Methy1-4-(4-methy1plperazin-1-yl)-2’(propan-2yloxy)ani11ne | Method 10 |
llla-27 | 4-(3,5-Dtmethy1p fcerazin-1 -yi)-2-(propan-2ytoxy)aniline | Méthode |
llla-26 | 2-(Propan-2-ytoxy )-4-(3,4,5-trimethyipiperazin-1yl)anlline | Method 35 |
llla-29 | 4-{5,6-Dihydroimidazo(1,2-a]pyrazin-7(8H)-y1)-2(propan-2-yk>xy)anillne | Method 6 |
llla-30 | 2-(4-[4-Am ino-3-(propan-2-y1oxy)pheny1]-1 · methylpiperazln-2-yl}ethanol | Method 6 |
llla-31 | 4-{3-{2-Methoxyettiyl)-4-methy1piperazin-1-yl]-2(propan-2-yk>xy)anilIne | Method 9 |
llla-32 | 4-{4-Methyt-1,4-diazepan-1 -yl)-2-(propan-2’ yloxy)anitine | Method 33 |
llla-33 | 4-((1 S,4S)-5-Methyl-2.5-diazabicyclo[2.2.1 ]hept-2yl]-2-{propan-2-yloxy)anillne | Method6 |
llla-34 | 1 -[4-Amino-3-(propan-2-y ioxy )phenyl]-N,NdlmethytpyrTolidin-3-amine | Method 6 |
llla-35 | 1-{4-Amino-2-methyl-5-(propan-2-ytoxy)phenyi]-N,Ndtmethy lpyrrolidin-3 -amine | Method 7 |
ll!a-36 | 1-{4-Amino-3-(propan-2-ytoxy )pheny1]-N,N’ diethylpyrrolidin-3-amlne | Méthode |
llla-37 | 4-(1 H-lmidazoi-1 -yl)-2-(propan-2-yloxy)anjline | Méthode |
llla-38 | 4-(2-Methyl-1 H-imidazol-1 -yi)-2-(propan-2yk>xy)anilÎne | MethodC |
127
Compounds Ilia | Name | Method |
llla-39 | 5-Methyl-4-(2-methyl-1 H-lmidazol-1 -yl)-2-(propan-2yloxy)anillne | Méthode |
llla-40 | 4-(4-MethyH H-lmida20i-1 -yl)-2-(propan-2yloxy)ani1lne | Method 8 |
lila-41 | 4-(2,4-ΟΙπΐβίΙιγΙ-1Η-Ιπιίά3ΖθΙ-1-γΙ)-2-{ρι·ορ3η-2yloxy)anlllne | Method 6 |
lfla-42 | 2-(Propan-2-yloxy)-4-(1 H-1,2,4-trlazol-l -yljanlline | Method 8 |
ltla-43 | N-4—methyl-2-(propan-2-yloxy)-N~4—[2(pynolidln-1 -yl)ethyf|benzene-1,4-diamlne | Method 6 |
llla-44 | 4-[(8aR)-Hexahydropyrrolo[1,2-a]pyrazin-2(1 H)-y IJ- 2-(propan-2-yloxy)anlllne | Method 26 |
llla-45 | 2-Methylpropan-2-y1 7-[4-amtno-3-(propan-2yloxy)phenyf]-1,7-diazaspiro[4.4]nonane-1 carboxylate | Method 23 |
llla-46 | 4-(1-Ethyi-1,7-diazaspiro[4.4]non-7-yl)-2-{propan-2ytoxyjaniline | Method 25 |
llla-47 | (3R)-1-[4-Amino-3-{propan-2-yioxy)phenylI-Nmethy1-N-(oxetan-3-y1)plperidin-3-amine | Method 28 |
llla-48 | 4-(3-Methoxypyrldin-4-yl)-2-(propan-2-yloxy)aniline | Method 3 |
llla-49 | 4-(i-Methyl-1 H-pyrazol-4-yl)-2-(propan-2yïoxy)anlllne | Method 36 |
llla-50 | 4-(1 -MethyM H-pyrazol-3-yl)-2-(propan-2yïoxyjaniline | Method 36 |
llla-51 | 4-Methoxy-2-(propan-2-yloxy)aniiine | Method 31 |
llla-52 | 8-Amino-1-methyl-1,3,4,54etrahydro-2H*1 · benzazepin-2-one | Method 17 |
llla-53 | 7-Amino-1 -methyl-13,4,5-tetrahydro-2H-1 benzazepln-2-one | Method 15 |
llla-54 | 6-(4-Methylpiperazin-1 -yl)-4-(propan-2-yloxy)pyridln- 3-amine | Method 12 |
llla-55 | 6-{1-Methylplperidin-4-yl)-4-(propan-2-yloxy)pyTÎdln- 3-amlne | Method 11 |
llla-56 | 6-(4-Methylplperazin-1 -yl)-2-(propan-2-yloxy)pyrid i n3-amlne | Method 14 |
llla-57 | 6-( 1 -MethylplperidÎn-4-yl )-2-(propan-2-yloxy)pyrid i n3-amlne | Method 13 |
llla-58 | 2-Methylpropan-2-yl 4-[5-amlno-1 -(propan-2-yl)-1H· pyrazol-3-yl]piperidine-1 -carboxylate | Method 29 |
llla-59 | 2-Methylpropan-2-yl 3-[5-(formylamino)-1 -(propan- 2-yl)-1 H-pyrazot-3-yÔplperidine-1 -carboxylate | Method 29 |
llla-60 | 1-Phenyl-1 H-pyrazol-5-amtne | [827-85-7] |
128
Compounds Ilia | Name | Method |
llla-61 | 3-Cyclopropyl-l -phenyi-1 H-pyrazol-5-am ine | [175137-45-8] |
llla-62 | 1 -(Propan-2-yl)-3-(pyridin-3-yi)-1 H-pyrazol-5-am ine | Method 29 |
llla-63 | 3-Cyclopropyt-1 -(propan-2-yi)-1 H-pyrazol-5-amlne | Method 29 |
ltla-64 | 3-Methyl-1 -(propan-2-yl)-1 H-pyrazol-5-amine | [1124-16-9] |
ltla-65 | 7-Amino-t -methyt-6-(propan-2-yloxy)-1,3,4,5tetrahydro-2H-1 -benzazepln-2-one | Method 16 |
llla-66 | 4-[(4-Methyipiperazin-1-yl)methyi]-2-(propan-2· yloxyjanillne | Method 18 |
llla-67 | 4-(3,5-DimethyH H-1,2.4-triazol-1 -y1)-2-(propan-2yloxy)anillne | Method 8 |
llla-63 | 5-(4-Methylpiperazin-1-yl)-2-(propan-2-yloxy)anliine | Method 19 |
llla-69 | 2-(Propan-2-ytoxy)-N~4~-{tetrahydro-2H-pyran-4- yl)benzene-1,4-d iamlne | Method 20 |
llla-70 | 1-[4-Amlno-3-(propan-2-yloxy)phenyi]piperidin-4-yt acetate | Method 7 |
llla-71 | 4-(1-MethylpynolidÎn-3-yl)-2-(propan-2-yloxy)anIÎÎne | Method 2 |
llla-72 | 1 -(Propan-2-yl)-3-(tetrahydro-2H-pyran-4-yt)-1 Hpyrazol-5-amlne | Method 30 |
llla-73 | N~4—(1-Methylpiperidln-4-yi)-2-(propan-2y1oxy)benzene-1,4-diamlne | Method 22 |
ll!a-74 | 2-Methylpropan-2-yl 4-(5-amino-1 -cyciobutyl-1 Hpyrazol-3^yl)plperidlne-1 -carboxylate | Method 29 |
llla-75 | 3-(4-Methytptperazin-t-¥l)-2-(propan-2-ytoxy)aniline | Method 21 |
llla-76 | 5-Methyi-2,3,4,5-tetrahydro-1,5-benzoxazepin-7amine | Analogy with US20100173B23 p36 |
lila-77 | 4-(4-Ethy1piperazin-1-yl)-2-(propan-2-yloxy)aniline | Method 6 |
llla-78 | 7-Amino-1-methyi-8-(propan-2^yloxy)-1,3,4,5tetrahydro-2H-1-benzazepin-2-one | Method 34 |
lila-79 | 4-Chloro-2-(propan-2-yioxy)aniÎine | Method 32 |
llla-80 | 4-( 1 -Methyl-1,7-dlazaspiro[4.4]non-7-yl)-2-(propan2-ytoxy)aniline | Méthode |
IV-FORMATION OF THE COMPOUNDS OFFORMULA (lllb) (Example 9)
Example 9.1 : N-[4-(1 -Methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]formamide
A solution of 12.3 g of acetic anhydride is added slowly to 19 ml of formic acid at amblent température. After one hour of stirring, a solution of 6.0 g of 4-(1-methylpiperidin-4-yl)-2(propan-2-yloxy)aniline in 28 ml of formic acid is added dropwise. The mixture is stirred at ambient température for 2 h and then concentrated under vacuum and taken up with ίο water. The aqueous phase is neutralized with a saturated sodium bicarbonate solution
129 and extracted three times with 100 ml of dichoromethane. The organic phases are dried over magnésium sulfate, filtered and concentrated under vacuum. The crude product is triturated with ethyl ether and the solid is filtered off, so as to obtain 5.0 g of N-[4-(1methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]formamide.
Example 9.2: N-[5-Methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]formamide A mixture of 0.53 g of 5-methyl-4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)aniline in 5.7 ml of formic acid is refluxed for 20 h. The mixture is cooled, diluted with water and neutralized with a saturated sodium hydrogen carbonate solution. The aqueous phase is îo extracted with ethyl acetate. The organic phase is dried over magnésium sulfate and concentrated under vacuum. The crude product is purified on 50 g of silica, elution being carried out with methanol in dichioromethane (97/3 and 1% NH4OH), so as to obtain 0.56 g of N-[5-methyl-4-(4-methylpîperazin-1-yl)-2-(propan-2-yloxy)phenyl]formamide.
The compounds (lllb) obtained according to Example 9 are described in Table 3.
Table 3:
Compounds irib | Name | MS Method | MH* | Tr |
ll!b-1 | N-(2-Methoxy-4-[ t -<propan-2-yl)plpertdln4-yf]phenyl)formamid e | D | 277 | 0.83 |
lllb-2 | N-[2-Methoxy-5-methyl-4-(1 methylplperidin-4-yl)phenyl]fonnam)de | A | 263 | 0.28 |
lllb-3 | N-[4 -( 1 -Methy Ipiperid in-4-yl)-2-(propan-2yfoxy)phenyl]formamide | A | 277 | 0.37 |
1llb-4 | 2- Methytpropan-2-yl4-[4-(formylamino)- 3- (propan-2-y1oxy)phenyl]piperidtne-1 - carboxylate | A | 363 | 1.08 |
1llb-5 | N-[2-<Propan-2-y1oxy)-4-[1 -(propan-2y Ijplperidl n-4-yl]phenyl)fonnani ide | A | 305 | 0.44 |
lltb-6 | N44 -( 1 -Cyclopropylpiperidin-4-y i)-2(p ropan-2-yloxy)phenyî]formamlde | A | 303 | 0.55 |
lllb-7 | N-[5-Methyl-4-(1 -methylpiperidtn-4-yl)-2(propan-2-yloxy)phenyÎ]formam1de | A | 291 | 0.39 |
111b-8 | N-[4-(5-Methoxy-1 -methyl-1,2,3,6tetrahydropyridln-4-yl)-2-(propan-2yloxy)phenyl]formamide | A | 305 | 0.40 |
1!ib-9 | N-[2-(P ropan-2-y loxy)-4-(2,2.6,6tetramettiylptperidin-4yl)phenyf]formamide | A | 319 | 0.52 |
130
Compounds Iltb | Name | MS Method | MH* | Tr |
lllb-10 | N-(4-( 1.2,2 ,6,6-Pentamethylpiperidin-4yl)-2-(propan-2-yloxy Jph enyljfonnam ide | A | 333 | 0.48 |
lllb-11 | 2-Methylpropan-2-yl 4-(4-(formy1amino)3-(propan-2-yloxy)phenyl]-2,6d im ethylplperid i ne-1 -carboxylate | C | 391 | 6.28 |
lllb-12 | 2-Methy1propan-2-yl 2-ethyl-444(formylamlno)-3-(propan-2yloxy)pheny1]piperidine-1 -carboxylate | C | 391 | 6.26 |
lllb-13 | N-(4-(2-Ethyl-1 -methylpiperidln-4-yl)-2(propan-2-yloxy)phenyI]fonnamide | A | 305 | 0.55 |
lllb-14 | (cis)-4-[4-(Fonny1aminoJ-3-(propan-2y loxy Jphenyfj-1 -methylptperidin-3-yl formate | A | 321 | 0.33 and 0.36 |
lltb-15 | 2- Methy1propan-2-yl 4-(4-(formy1amino)* 3- (propan-2-yk>xyJpheny(]-2-(propan-2- yl)piperidlne-1 -carboxylate | A | 405 | 1.19 |
lllb-16 | 2-(4-( 4-(Fo rmylaminoJ-3-(propan-2ytoxy)phenyfjplperidin-1-yl]ethyl formate | A | 335 | 0.39 |
lllb-17 | N-(5-Fluoro-4-( 1 -methylplperidin-4-yl)-2· (propan-2-yloxy)pheny1]formamide | A | 295 | 0.41 |
lllb-18 | N-(2-Methoxy-5-methy1-4-(1 methy lplpertdln-3-yl Jphenyljf ormam Ide | A | 263 | 0.31 |
lllb-19 | N-(4-(1 -Ethylplperid in-3-yl)-2-(propan-2ytoxyjphenyljformamide | A | 291 | 0.41 |
lllb-20 | N-(4-(Octahydroindoiizin-8-yl}-2-(propan- 2-ybxy)phenyi]formamide | A | 303 | 0.41 |
lllb-21 | N -{2-Metho xy-4-(4-(pyrroi ldin-1 · yljpiperid i n-1 -yljpheny I] formamld e | E | 304 | 0.83 |
lllb-22 | N-{2-Methyk4-(4-(pynolÎdin-1 -yijpiperidln- 1 -yljphenyijformamide | E | 288 | 0.78 |
lllb-23 | N-(2-Metho xy-4 -(4-(propan-2yl)plperazfn-1 -yljphenyijformamide | |||
lllb-24 | N-[2-Methoxy-4-(4-methylpiperazin-1 yljphenyljformamide | A | 250 | 0.20 |
lllb-25 | N-(4-(4-Methylpiperaztn-1-yl)-2-(propan- 2-ybxy)phenyi]formamide | A | 278 | 0.32 |
lllb-26 | N-(5-Methyl-4-(4-methylpiperazin-1-y1)-2(propan-2-yloxy Jphenyljform amide | A | 292 | 0.39 |
lllb-27 | N-(4-{3,5-Dimethylp lperazin-1-yi)-2(propan-2-yloxy)phenyI]formamide | A | 292 | 0.39 |
lltb-28 | N -(2-( Propan-2-y toxy )-4-(3.4,5trtmethylpiperazin-1 -yljphenyljformamide | A | 306 | 0.38 |
3S0 | 8*8 | S | 8p|LuGiujoj[|Xudqd(Xxo|X -g-UBdojd)-g-{]X- i-u ipyddid[ou|Uje(iX -e-uBjaxo)|Xma^}-e-(y8)}-*l-N | ZK1III |
SSO | 288 | 9 | epf lue LUJOj[jXueqd(Xxo|X-g-UEdoj d)-z-(jX -Z-uou[ÿÿ}oj|dsEZE|p-z‘ μΧι«34)-*>Ν | 9K1III |
98'1 | 388 | V | epfUjBiujQj[|Xu34d(XxO(X-3-UBdojd)-z-(|X -Z-uou[>tr)âj]dsBZB|p-z· hXulioj-l)->ï-N | SK1III |
68'0 | *08 | V | epf LUEtujoj{tXuaqd(Xxo|X -3-ued<ud)-3-bX-(H 03-u|zejXd[B -g· i}o|OJiXdojpXqBX0H-(HE8)]-ÿ>-N | tWlIII |
ISO | 908 | a | sp) uuBiujoj[|Xuaqd(Xxo|X -g-uedajd)-g-[ou]ure[|Xq]9()X - l-uiPtiojiXdJ-sJXLfla^HJ-N | 8>-qill |
9S0 | Z*3 | V | 8pfLUEUjjoj[|Xu9qd(|X> i -ioZBW-fr·? ι-H l)->-(Xxo|X-3-UBdGid)-g]-N | 3K1III |
6Z'l | *Z3 | a | ep|UjEUUQ)[iXu8qd(Xxo|X-g-uedajd) 3-(|X· L-|orep|ui|-H ΐΐΧΜΐΒω!α-*'3Κ*>Ν | it^qiu |
191 | 093 | a | 8p|UJEUUoj[iXu8qd(Xxo|X>g-UEdajd) -2-(lX-HOZBp|tU|-H ΗΧφθΝ-νΚίΝ | 0K111I |
82'1 | *Z3 | a | epf ujb tujoj[jXu8qd(XxqX-g-UBdojd)-g-(jX -H0ZBp|iu(-H 1-ΐΧΐ|1βιυ-3)-*-|ΧΜ13^-9>Ν | 68-qill |
98'0 | 093 | V | sp, ujEUJJOjQXusq d(Xxo|X-g-UBdaid) -g-(lX-l-|0ZBp|Uit-H ΗΧψί>Η-3)-*ΡΝ | ee-qni |
sri | 9*3 | a | 8pfUjeuuo)[)Xu8i|d(Xxo|X -g-UBdojd)-g-(|X-Mozep|U)|-H l)-d-N | ze-qm |
933 | 028 | a | epjujEuuq(|Xu8qd(XxoiX-g-uBdajd) -3-[|X-1 -uipi|QuXd(ou|tuB ΐΧψΒΐα)-ε}-*ΚΝ | 98-qiu |
89'2 | 908 | a | sp) lue ULioj{)Xii8qd(Xxo|X -g-UBdajd)-g-|Xmauj -9-[|Χ’1-ϋΙΡΙΐαυΧ(1(ου|ωΒΐΧΜΐ8ω]α)-ε>*ΡΝ | se-qin |
Ζ8Ό | 363 | V | ep|UJELUJoj(]Xueqd(Xxo|X-g-UEdojd) -3-[|X- l-uipf|ouuXd(ou]LUB|Xm8tuia}-c]-t}-N | *8-qill |
8*0 | 063 | 9 | 8p| UJBUUOj{|XU8qd(XxO|X -g-UBdojd}-g-[|X-g-ictoq[rg-z]ofoXD|qezB|p ·5'3-ιΧΜ18Μ-9-(5*,51)Ρ*ΚΝ | εε-qiii |
9*0 | 363 | 9 | 8p| ujeujjoj[|Xu8q d(Xxo|X-g-uBdajd) -3-(|X- l-UBdazeip-f ι-ιΧμιβ|Α|-*)-Η-Ν | 38-qiti |
333 | 988 | a | e p| LUBUUOj{|Xu8qd(Xj(O|X -g-UBdojd)-g'[iX- i-U|ZBJod|d|Xqj8LU -fr-(|X4JaXxoq] 9^-2)-81-H-N | te-qiii |
86'0 | 338 | a | 8p|LUBlllJOj{|XU8l4d(XXO|A -g-UBdaid)-g-[|X- i-u|ZBJ8d;diXq}8LU -ΗΑίΙ8ΧχωρΧΗ-3)-€ΗΚΝ | οε-qin |
SSO | 108 | V | 8p|lllEUU0j[|XU8 q d(Xxo|X -g-UBdajd}-z-(|X-(n8)Z -u|ZBiXd[B-g* i]ozBp|LU|OjpXqia-9's)-*)-N | 63-qill |
Jl | ♦HW | powwsn | 8LUEN | qui spunoduioo |
ιει
132
Compounds 111b | Name | MS Method | MH* | Tr |
lllb-48 | N-[4-(3-M ethoxypyrid in-4-yl)-2-(propan-2yloxy)phenyl]formamide | A | 287 | 0.47 |
lllb-49 | N-[4-(1 -Methyl-1 H-pyrazot-4-y1)-2(propan-2-ytoxy)pheny[]formamide | A | 260 | 0.66 |
lllb-50 | N-[4-(1-Methyl-1 H-pyrazol-3-yl)-2(propan-2-yloxy)pheny l]fbrmam Ide | A | 260 | 0.70 |
1l!b-51 | N-[4-Methoxy-2-(propan-2yîoxyjp henyljf ormam U e | D | 210 | 0.38 |
lllb-52 | Ν-(1-Μβ0ιγΙ-2-οχο-2,3,4,5-ΙβΐΓ3ΚγΰΓ0*1 H* 1 -benzazeplrt-8-yl)form amide | D | 219 | 2.63 |
lllb-53 | N-( 1 -Methyl-2-oxo-2,3,415-tetrahydro-1 H- 1 -benzazepin-7-yl) formant ide | A | 219 | 0.60 |
lllb-54 | N-(6-(4-Methy1piperazln-1-yl)-4-(propan2-yloxy)pyridin-3-yf]formamide | D | 279 | 0.32 |
lllb-55 | N-[6-( 1 -Metbytpipendin-4-yl)-4-(propan-2yloxy)pyridln-3-yl]fbrmamide | A | 278 | O.t4 |
1llb-56 | N-[6-(4-Methy1piperazin-t-yl)-2-(prc>pan2-ytoxy)pyridln-3-yl]formamide | D | 279 | 0.98 |
1llb-57 | N -(6-(1 -Methyipiperidln-4-yl)-2-(propan-2yloxy)pyridln-3-yl] formant ide | D | 278 | 1.93 |
1llb-58 | 2-Methylpropan-2-y14-(5-(formy1amino)1 -(propan-2-yl)-1 H-pyrazol-3yIJplpendine-1 -carboxylate | A | 337 | 0.82 |
1llb-59 | 2-Methy1propan-2-yl 3-[5-(formylamlno)14propan-2-yl)-1 H-pyrazol-3yIJplperidine-1-carboxylate | D | 337 | 3.76 |
1llb-60 | N-(1-Phenyl-1 H-pyrazol-5-y1)formamide | A | 188 | 0.39 |
1llb-61 | N-(3-Cyclopropyl-1 -phenyl-1 H-pyrazoi-5yf) formant Ide | D | 228 | 3.20 |
1llb-62 | N-( t -(Propan-2-yl)-3-(pyrid in-3-yl)-1 Hpyrazol-5-ylJforrn amide | A | 231 | 0.29 |
1llb-63 | N-(3-Cyclopropyl-1 -(propan-2-yl)-1 Hpyrazol-5-y|]formamide | A | 194 | 0.49 |
1llb-64 | N-[3-Methyl-1 -(propan-2-yi)-1 H-pyrazol5-yl]formamide | A | 168 | 0.33 |
lllb-65 | N-[ 1 -Methyl-2-oxo-6-(propan-2-yloxy)2.3,4,5-tetrahydro-l H-1-benzazepin-7yl] formant ide | A | 277 | 0.81 |
1llb-66 | N-[4 -( (4-Methy iplperazin-1 -yljmethy IJ-2(propan-2-yloxy)phenyt] form amide | A | 292 | 0.47 |
lllb-67 | N-i4-(3,5-Dimethy1-1 H-1,2,4-triazol-l-yl)2-(propan-2-yloxy)pheny11formamlde | A | 275 | 0.78 |
lllb-68 | N-[5-(4-Methylpiperazin-1 -y1)-2-(propan2-ytoxy)phenyf]fonnamlde | B | 278 | 0.55 |
133
Compounds lllb | Name | MS Method | MH* | Tr |
lflb-69 | N-[4-(Fonnylamlno)-3-(propan-2· ytoxy)phenyt]-N-(tetrahydro-2H-pyran-4yljformamide | B | 307 | 0.82 |
lllb-70 | 1-[4-(Formylamino)-3-(pFopan-2yk>xy)pheny(]plperWin-4-yi acetate | A | 321 | 0.87 |
lllb-71 | N-[4-( 1 -Methy1pyrrolidin-3-yl)-2-(propan2-yloxy)phenyf]formamlde | D | 263 | 0.88 |
lllb-72 | N-[1 -<Propan-2-yl)-3-(tetrahydro-2Hpyran-4-yl)-1 H-pyrazol-5-yt]formamlde | A | 238 | 0.66 |
lllb-73 | N-[4-(Formylamlno)-3-{propan-2ytoxy)phenyl]-N-(1 -methylplperldln-4yljformamlde | A | 320 | 0.52 |
lllb-74 | 2-Methylpropan-2-y14-[1-cydobutyl-5(formylaminoj-1 H-pyrazo!-3-yl]plperidlne1-carboxylate | B | 349 | 1.26 |
lllb-75 | N-[3-(4-Methy1piperazin-1-yl)-2-(prDpan2-ybxy)phenyl]formamlde | B | 278 | 0.55 |
ltlb-76 | N-(5-Methyl-2,3,4,5-tetrahydro-1 ,5benzoxazepln-7-yl)formam ide | D | 207 | 1.49 |
1llb-77 | N-{4-(4-Ethylpiperazin-1 -yl)-2-(propan-2Yioxy)phenyf|formamide | A | 292 | 0.65 |
lllb-78 | N-£ 1 -Methyl-2-oxo-8-(propan-2-ytoxy)2,3,4,5-tetrahydro-1 H-1 -benzazepfn-7yljformamide | D | 277 | 3.16 |
lllb-79 | N-[4-Chloro-2-(propan-2ytoxyjphenyfjfonnam Ide | A | 214 | 1.19 |
lllb-80 | N-{4-( 1 -Methyl-1,7-diazaspiro[4.4]non-7yl)-2-(propan-2-y loxy)pheny 1] form amide | A | 318 | 0.69 |
V- PREPARATION OF THE COMPOUNDS OF FORMULA ffl
Example 10: 7-(2-Methoxyphenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrlmidïne-6-carboxamide (1-16)
A mixture of 527 mg of N-[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]formamide and 953 mg of 1-[N-(2-methylpropan-2-yl)-P,P-di(pyrrolidÎn-1-yl)phosphorimidoyl]pyrrolidine (BTPP) in 10 ml of anhydrous DMF Is stirred at ambient température for to 30 min, and then a solution of 577 mg of methyl 7-(2-methoxyphenyl)-2(methylsulfonyl)thieno[3,2-d]pyrimidine-6-carboxylate in 15 ml of anhydrous DMF is siowly added. The mixture is stirred at ambient température for 48 h, and then diluted with ethyi acetate and washed three times with water. The organic phase is dried over magnésium
134 sulfate, filtered and concentrated under vacuum. The crude product Is purified on 80 g of silica, elution being carried out with 5-10% of methanol in dichloromethane, so as to obtain 615 mg of methyl 7-(2-methoxyphenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxylate in the form of a yellow solid.
The crude product îs diluted with 600 ml of 7N ammoniacal methanol and the solution is stirred at ambient température for 48 h, and then concentrated under vacuum. The residue is solubilized with 100 ml of hot ethyl acetate and the solution is left to cool In order to obtain a suspension. The suspension is cooled in an ice bath and filtered. The solid is washed with ethyl ether and dried under vacuum, so as to obtain 477 mg of 7-(210 methoxyphenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thleno[3,2dJpyrimidine-6-carboxamide in the form of a yellow solid.
Example 11: 2-{[4- (1 -Methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-( 1Hpyrazol-4-yl)thieno[3,2-d]pyrimidine-6-carboxamide (I-76)
123 mg of N,N-diisopropylethylamine, 181 mg of HATU and 14 mg of ammonium chloride are added to a solution of 117mg of 2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2yloxy)phenyl]amino}-7-(1H-pyrazol-4’yl)thieno[3l2-d]pyrimidine-6-carboxylic acid in 6 ml of dimethylformamide. The reaction medium is stirred for 16 hours at ambient température and then concentrated to dryness under reduced pressure. Purification is carried out by 20 flash chromatography on alumina, elution being carried out with a mixture of dichloromethane and methanol (+ 10% NH<OH) (95/5). The product resulting from the column purification is taken up in methanol and is purified by préparative thin layer chromatography (eluent: dichloromethane/methanol (+ 10% NH<OH) (95/5)), so as to give 23 mg of 2-{[4-(1-methylpÎperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1H-pyrazol-425 yl)thieno[3,2-d]pyrimidine-6-carboxamide In the form of a yellow solid.
Example 12:7-(4-Fluorophenyl)-2-{[4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thÎeno[3,2-d]pyrÎmidine-6-carboxamide (1-12)
27 mg of sodium hydride (at 60%) are added to a solution of 126 mg of N-[4-(4methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]formamide in 2 ml of dimethylformamide. The suspension is stirred at ambient température for 30 min, and is then diluted with 1 ml of dimethylformamide, and a solution of 80 mg of 7-(4-fluorophenyl)-2(methylsulfonyl)thieno[3,2-d]pyrimidine-6-carboxamide in 2 ml of dimethylformamide is added. The mixture is stirred at ambient température for 30 min, and then diluted with 50 ml of methanol. The mixture îs stirred at ambient température for 1 h, and then
135 concentrated under vacuum. The residue Is purified on 40 g of silica, elution being carried out with 0-20% of methanol in dichloromethane, and then by high performance liquid chromatography (Macherey-Nagel 250x40 mm reverse phase C18 Nucleodur 10 μ column. Eluent: MeCN containing 0.07% TFA and H2O containing 0.07% TFA. 10% 5 MeCN hold: 3 min, gradient up to 95% MeCN in 37 min and then 95% MeCN hold of min. Flow rate: 70 ml/min). The fractions containing the expected material are loaded on to a 2g Varian Bond Elut SCX cartraige (preconditioned with MeOH). Washing the cartridge four times with methanol, followed by elution of the expected material with 2N ammonia in methanol gives, after drying, 10 mg of 7-(4-fluorophenyl)-2-{[4-(4io methylpiperazin-1-yi)-2-(propan-2-yloxy)phenylïamino}thieno[3,2-d]pyrimidÎne-6carboxamide.
The compounds (Γ) obtained according to Examples 10 to 12 are described in Table 4.
Table 4:
Compound 1' | Compound II | Compound lllb | Name | NMR | MS conditions! MH+/Tr |
1-1 | 11-1 | lllb-21 | 2-(|2-Methoxy-4-{4· (pyrrolldln-1 -y1)piperldin1 -yI]pheny1)amlno)-7phenylthleno[35djpyrimldine-6carboxamlde | 1.85 to 2.25 (m. 8 H): 2.88 (m, 1 H); 3.10 (m, 2 H); 3.23 to 3.858 (partially masked m. 6 H); 3.87 (s. 3 H); 6.55 to 7.00 (broad m. 2 H); 7.48 (LJ - 7.7 Hz, 1 H); 7.53 (t, J - 7,7 Hz, 2 H): 7.58 (broad s. 1 H): 7.68 (d. J - 7.7 Hz, 2 H); 7,87 (broad s, 1 H); 8.02 (broad m, 1 H); 8.11 (broad s. 1 H); 9.21 (s, 1 H); 10.48 (broad m, 1 H) | E 529 0.78 |
1-2 | 11-1 | lllb-22 | 2-({2-MethyM-{4(pyrrolldin · 1 -yljplpe rid i n1 -yl]phenyl}amlno)-7phenytthleno[3,2d]pyrimkllne-6carboxamlde | 1.82 to 2.27 (m, 8 H); 2.20 (s, 3 H); 2.85 (m, 1 H); 3.10 (m, 2 H); 3.25 to 3.85 (partially masked m, 6 H); 6.80 to 7.10 (broad m, 2 H); 7.38 to 7.55 (m, 5 H): 7.60 (d, J - 7.7 Hz. 2 H); 7.84 (m, 1 H); 8.70 (s, 1 H); 9.16 (s, 1 H); 10.68 (broad m, IH) | E 513 0.70 |
1-3 | li-3 | lllb-21 | 7-(3-Chlorophenyl)-2-((2methoxy-4-{4-(pyrrolidin- 1- yl)pipeiidin-1yljphenyljaml no)thieno[3, 2- d]pyrimldine-6carboxamfde | 1.78 to 2.30 (m, 8 H); 2.93 to 3.85 (m, 9 H ); 3.81 (s, 3 H); 6.70 to 7.20 (broad m, 2 H); 7.45 (m, 3 H); 7.70 (s, 1 H); 7.79 (s, 1 H): 7.83 (s, 1 H); 8.09 (m, 1 H); 8.20 (s, 1 H); 9.19 (s, 1 H); 11.08 (broad m, 1 H) | E 563 1.03 |
1-4 | II-4 | lllb-21 | 7-(4-Chloropheny1)-2-fl2methoxy-4-[4-(pyrrolidin1 -yl)plpeiidin-1 - yi]phenyljamlno)thieno[3, 2-d]pyrimidlne-6carboxamide | 1.80 to 2.23 (m, 8 H); 2.65 to 3.90 (partially masked m, 9 H); 3.82 (s, 3 H): 6.45 to 6.90 (broad m, 2 H); 7.58 (d, J - 8.8 Hz, 2 H); 7.67 (d. J - 8.8 Hz. 2 H): 7.77 (s. 1 H): 7.87 (m, 2 H); 8.12 (s, 1 H); 9.19 (s, 1 H); 11.70 (broad m, 1 H) | E 563 1.05 |
136
Compound r | Compound 11 | Compound 111b | Name | NMR | MS conditions/ MH+/Tr |
1*5 | II-27 | llib-21 | 2-((2-Methoxy-4-{4(pyrrolldtn-1 -yl)plperldtn1 -yl)pheny1}amino)-7(th!ophen-3-yl)thleno[3t2d]pyrimld1ne-6carboxamlde | 1.83 to 2.40 (m, 8 H); 3.00 to 3.92 (m, 9 H); 3.85 (s. 3 H); 6.70 to 7.22 (broad m, 2 H); 7.52 (d, J - 4.0 Hz, 1 H); 7.69 (m, 1 H); 7.82 (s, 1 H); 7.98 (s, 1 H); 8.07 (m. 1 H): 8.10 (broad m, 1 H); 8.30 (s, 1 H); 9.21 (s, 1 H); 11.09 (broad m, 1 H) | E 535 0.68 |
1-6 | II-28 | lllb-21 | 2-({2-Methoxy-4-[4(pyirolidin-1 -yljpiperidln1 -yl]pheny1}amino)-7(th tophen -2-yl)th leno[3,2d]pyrimldine-6carboxamide | 1.88 to 2.34 (m, 8 H); 3.00 to 3.94 (m, 9 H); 3.89 (s, 3 H): 6.78 to 7.22 (broad m. 2 H); 7.20 (m, 1 H); 7.63 (m. 1 H); 7.72 (m, 1 H); 8.02 (s, 1 H); 8.10 (s, 1 H): Θ.22 (broad m, 1 H); 8.31 (s. 1 H): 9.21 (s, 1 H); 11.94 (broad m, 1 H) | E 535 0.69 |
1-7 | 11-1 | IIIb-23 | 2-({2-Methoxy-4-[4(propan-2-yl)piperazin-1 yl]pheny1}amlno)-7phenytthieno[3,2dJîyrimldine-6carboxamlde | 1.31 (d. J - 6.0 Hz, 6 H); 3.15 (m, 4 H); 3.50 (m, 3 H); 3.80 (m, 2 H); 3.84 (s, 3 H); 6.48 (broad d. J - 8.5 Hz, 1 H); 6.70 (broad s, 1 H); 7.46 (t, J - 7.6 Hz, 1 H); 7.51 (t, J - 7.6 Hz, 2 H); 7.58 (broad s. 1 H); 7.66 (d, J - 7.6 Hz, 2 H); 7.85 (broad s, 1 H); 7.98 (d, J - 8.5 Hz, 1 H}; 8.10 (broad s, 1 H): 9.20 (s, 1 H): 10.55 (broad m, 1 H) | E 503 0.81 |
1-8 | II-1 | lllb-1 | 2-({2-Methoxy-4-[1(propan-2-y1)plperldin-4y1Jphenyi}am[no}-7phenylthleno[3,2dJpyrimldine-6carboxamide | 1.00 (d, J-6.4 Hz, 6 H); 1.55 to 1.69 (m. 2 H); 1.69 to 1.78 (m, 2 H); 2.13 to 2.25 (m, 2 H); 2.35 to 2.47 (m, 1 HJ: 2.70 (quln. J-6.6 Hz, 1 H); 2.82 to 2.94 (m. 2 H); 3.85 (s, 3 H); 6.71 (dd, J-1.5 and 8.3 Hz, 1 H); 6.89 (d, J-1 .5 Hz, 1 H); 7.40 to 7.59 (m. 4 H); 7.65 (d. J-6.8 Hz, 2 H); 7.84 (broad s, 1 H); 8.05 (s, 1 H}; 8.12 (d. J-8.3 Hz, 1 H); 9.23 (s, 1 H) | A 502 0.65 |
1-9 | 11-5 | lllb-25 | 7-(2-Methoxyphenyl)-2([4-(4-methy1piperazln-1 y1)-2-(propan-2ytoxyjph enytjam inojthlen o[3,2-d]pyrimldlne-6carboxamlde | 1.26 (d, J-6.1 Hz, 6 H); 2.23 (s, 3 H); 2.42 to 2.48 (m, 4 H): 3.01 to 3.10 (m, 4 H); 3.70 (s, 3 H); 4.65 (quln, J-6.1 Hz, 1 H); 6.30 (dd. J-2.4 and 8.8 Hz, 1 H); 6.61 (d, J-2.4 Hz, 1 H); 6.82 to 6.93 (m, 1 H); 7.12 (t, J-7.2 Hz, 1 H): 7.18 (d. J-8.1 Hz, 1 H); 7.42 to 7.53 (m, 2 H); 7.71 (broad s, 1 H); 7.77 (s, 1 H); 7.97 (d, J-9.0 Hz. 1 H); 9.16 (s, 1 H) | A 533 0.65 |
1-10 | 11-12 | ltlb-25 | 7-f4-Fluoro-3methoxypheny1)-2-([4-(4meth ylpiperazl n-1 -y1)-2(propan-2yloxy)pheny1]am inojthlen o[3,2-dj3yrlmldine-6carboxamlde | 1.25 (d, J-6.1 Hz, 6 H); 2.23 (s, 3 H); 2.44 to 2.48 (m, 4 H); 3.02 to 3.12 (m, 4 H); 3.82 (s, 3 H); 4.65 (quin, JL5.9 Hz, 1 H); 6.37 (dd, J-2.3 and 8.9 Hz, 1 H); 6.64 (d, J-22 Hz, 1 H); 7.17 (ddd, J-2.0 and 4.3 and 8.4 Hz, 1 H); 7.35 (dd, J-8.3 and 11.5 Hz, 1 H); 7.46 (dd, J-2.0 and 8.6 Hz, 1 H); 7.59 (broad s, 1 H): 7.86 (broad s, 1 H): 7.91 (s, 1 H); 8.01 (d, J-8.1 Hz, 1 H); 9.19 (s, 1 H) | A 551 0.67 |
1-11 | II-7 | illb-25 | 7 -(4-Methoxyphenyl)-2([4-(4-nnethylpiperazin-1 · yl)-2-(propan-2yloxyjph enytjam inojthlen o[3,2-dJjyrimldine-6carboxamide | 1.27 (d. J-5.9 Hz, 6 H); 2.24 (s. 3 H); 2.44 to 2.48 (m, 4 H); 3.06 to 3.12 (m, 4 H); 3.84 (s, 3 H); 4.66 (spt, J-6.1 Hz, 1 H); 6.43 (dd. J-2.4 and 8.8 Hz, 1 H): 6.64 (d, J-2.2 Hz, 1 H); 7.09 (d, J-8.6 Hz, 2 H); 7.46 (broad s, 1 H); 7.60 (d. J-8.6 Hz, 2 H): 7.81 (broad s, 1 H); 7.84 (s, 1 H); 8.06 (d, J-8.8 Hz, 1 H); 9.16 (s. 1 H) | A 533 0.67 |
1-12 | II-17 | ltlb-25 | 7-(4-Fiuorophenyl)-2-([4(4-methylpiperazin-1-yi)2-{propan-2- | 1.27 (d, J-5.9 Hz, 6 H); 2.23 (s, 3 H); 2.43 to 2.48 (m, 4 H); 3.05 to 3.12 (m, 4 H); 4.66 (spt, J-6.1 Hz, 1 H); 6.44 (dd, | A 521 0.67 |
137
Compound 1’ | Compound II | Compound llib | Name | NMR | MS condition! MH+/Tr |
y1oxy)phenyl]amino]thien o[3,2-d]pyrlmidine-6carboxamlde | J-2.4 and 6.8 Hz, 1 H); 6.64 (d, J-2.4 Hz, 1 H); 7.32 to 7.40 (m. 2 H); 7.62 to 7.73 (m, 3 HJ; 7.83 (broad s, 1 H); 7.87 (S, 1 H); 8.01 (d, J-8.8 Hz, 1 H); 9.19 (s, 1 H) | ||||
1-13 | li-1 | lllb-2 | 2-{[2-Methoxy-5-mettiyl-4(1 -methylplperldln-4yf)phenyi]amlno}-7phenylthleno[3,2dJpyrimldlne-6carboxamlde | 1.49 to 1.80 (m, 4 H); 1.89 to 2.05 (m, 2 H); 2.13 (s, 3 H); 2.20 (s, 3 H); 2.53 to 2.64 (m, 1 H); 2.87 (d, J-11.2 Hz, 2 H); 3.83 (s, 3 H); 6.82 (s, 1 H); 7.38 to 7.57 (m, 4 H); 7.59 to 7.70 (m, J-6.8 Hz, 2 H); 7.85 (broad s, 1 H); 6.00 (d, J-9.3 Hz, 2 H); 9.23 (s, 1 H) | A 488 0.62 |
1-14 | 11-10 | lllb-24 | 7-{4-Fluoro-2methoxyphenyl)-2-{[2mettioxy-444methylplperazin-1yf)phenyl]amino}thieno[3, 2-d]pyrimidlne-6carboxamlde | 2.23 (S, 3 H); 2.42 to 2.49 (m, 4 H); 3.04 to 3.14 (m, 4 H); 3.70 (s, 3 H); 3.80 (s, 3 H); 6.37 (dd. J-2.4 and 9.0 Hz, 1 H); 6.61 (d, J-2.4 Hz, 1 H); 6.94 (td, J-2.4 and 8.4 Hz, 1 H): 7.01 to 7.16 (m, 2 H); 7.46 (dd. JL7.1 and 8.6 Hz, 1 H); 7.72 (broad s, 1 H); 7.80 (d, J-8.6 Hz. 1 H}; 7.96(s, 1 H); 9.14 (s, 1 H) | A 523 0.57 |
1-15 | ll-6 | lllb-24 | 2-{[2-Methoxy-4-{4methylplperazin-1yf)phenyl]amino}-7-{3methoxyphenyl)thfeno[3,2 -d}pyrlmidine-6carboxamlde | 2.23 (s. 3 H); 2.45 to 2.49 (m, 4 H); 3.08 to 3.13 (m, 4 H); 3.79 (s, 3 H); 3.81 (s, 3 H): 6.37 (dd, J-2.3 and 6.7 Hz, 1 H); 6.63 (d, J-2.4 Hz, 1 H); 7.02 (dd, JL2.2 and 8.1 Hz, 1 H); 7.18 (d, JL7.8 Hz, 1 H): 7.24 (s. 1 H): 7.41 (t. J-7.8 Hz. 1 H); 7.59 (broad s, 1 H): 7.83 to 7.94 (m, 2 H); 8.04 (S, 1 H); 9.17 (s, 1 H) | A 505 0.58 |
1-16 | II-5 | llib-3 | 7-{2-Methoxyphenyl)-2- {[4 -( 1 -methylpiperidin-4yl)-2-{propan-2ytoxy)phenyt]amlno}thien o(3,2-d]pyilmldine-6carboxamide | 129 (d, JL6.1 Hz, 6 H); 1.56 to 1.74 (m, 4 H): 1.88 to 1.98 (m, 2 H): 2.19 (s, 3 H); 2.30 to 2.43 (m, 1 H): 2.80 to 2.90 (m, 2 H): 3.70 (s. 3 H); 4.67 (spt, JL6.0 Hz, IH);6.60 (d. J^8.3 Hz, 1 H);6,87 (d. J-1.2 Hz. 1 H); 6.90 (broad s, 1 H); 7.13 (t. J-7.3 Hz. 1 H); 7.20 (d, JL8.1 Hz, 1 H); 7.36 to 7.58 (m, 2 H); 7.73 (broad s, 1 H); 7.86 (s, 1 H): 8.13 (d. JL8.3 Hz, 1 H); 9.21 (s, 1 H) | A 532 0.69 |
1-17 | II-1 | lllb-7 | 24[5-Methy1-4-(1methylpiperidin-4-yl)-2(propan-2yloxy)phenyt]amino}-7phenylthieno[3,2dJpyrlmldlne-6carboxamide | 1.29 (d, JU5.9 Hz, 6 H); 1.53 to 1.75 (m, 4 H); 1.96 (td, J-2.9 and 11.1 Hz, 2 H); 2.12 (s, 3 H); 2.19 (s, 3 H); 2.53 to 2.60 (m, 1 H); 2.82 to 2.91 (m, 2 H); 4.63 (quin, <A*6.1 Hz, 1 H); 6.82 (s, 1 H); 7.38 to 7.58 (m, 4 H); 7.67 (d. J-7.3 Hz, 2 H); 7.80 to 7.95 (m, 2 H); 8.12 (s, 1 H); 9.25 (s, 1 H) | A 516 0.67 |
1-18 | 11-1 | lllb-18 | 2-fl2-Methoxy-5-methyl-4(1 -mettiylplperldin-3yl)phenyf]amino}-7phenylthieno[3,2d]pyrimidlne-6carboxamlde | 1.35 to 1.48 (m, 1 H); 1.54 to 1.74 (m, 3 H); 1.90 (t, J-11.0 Hz, 2 H); 2.14 (s, 3 H); 2.18 (s, 3 H); 2.64 to 2.92 (m, 3 H); 3.83 (s, 3 H); 6.83 (s, 1 H): 7.42 to 7.56 (m, 4 H); 7.65 (d, J-7.8 Hz, 2 H); 7.87 (broad s, 1 H); 8.00 (s, 1 H); 8.03 (s, 1 H); 9.24 (s, 1 H) | A 488 0.64 |
138
Compound 1' | Compound II | Compound lllb | Name | NMR | MS conditions) MHWTr |
1-19 | 11-29 | lllb-3 | 2-((4-( 1 -Mettiylplperldin-4yl)-2-(propan-2ytoxy)phenyf]am fno}-7-{ 1 methyt-1 H-pyrazol-5y1)thieno[3,2-d]pyrimldine6-carboxamlde | 1.28 (d. JL5.9 Hz, 6 H); 1.57 to 1.76 (m, 4 H); 1.86 to 2.00 (m, 2 H): 2.19 (s. 3 H); 2.35 to 2.45 (m, 1 H); 2.80 to 2.90 (m, 2 H); 3.69 (s, 3 H); 4.66 (quln, J-6.1 Hz. 1 H); 6.47 (d. J-2.0 Hz, 1 H); 6.67 (dd, JM .7 and 8.3 Hz, 1 H); 6.89 (d, JL1.5 Hz. 1 H); 7.44 (broad s. 1 H); 7.58 (d, JL2.0 Hz, 1 H); 7.93 (broad s, 1 H); 8.00 (d. JL8.3 Hz, 1 H): 8.05 (s, 1 H); 9.26 (s. 1 H) | A 506 0.61 |
I-20 | 11-15 | lllb-3 | 7-[2-Ettioxyphenyt)-2-{[4· (1 -methytpiperidin-4-y1}-2(propan-2y1oxy)ph enyfjam lno}thlen o(3,2-d]pyrimldine-6carboxamlde | 1.13 (t, JL7.0 HZ, 3 H): 1.29 (d. J-6.1 Hz, 6 H); 1.56 to 1.74 (m. 4 H): 1.88 to 1.98 (m, 2 H); 2.19 (s, 3 H); 2.29 to 2.43 (m, 1 H); 2.80 to 2.88 (m. 2 H); 4.00 (q. JL7.1 HZ, 2 H): 4.67 (quln, Λ6.1 Hz, 1 H); 6.60 (dd, JM .5 and 8.3 Hz, 1 H); 6.87 (d, JL1.5 HZ, 1 H); 6.91 (broad s, 1 H); 7.06 to 7.21 (m, 2 H); 7.40 to 7.52 (m, 2 H): 7.73 (broad s, 1 H); 7.86 (s, 1 H); 8.15 (d, J^8.3 Hz, 1 H); 9.21 (s, 1 H) | A 546 0.72 |
1-21 | 11-6 | lilb-3 | 7-[3-Mettioxyphenyl)-2([4-{ 1 -methyfplperidin-4y!)-2-(propan-2yk>xy)phenyt]am Inojthlen o[3,2-d]py rl mid ine-6carboxamide | 1.30 (d, JL5.9 Hz. 6 H): 1.55 to 1.82 (m. 4 H); 1.93 to 2.08 (m, 2 H); 222 (broad s, 3 H); 2.35 to 2.47 (m, 1 H); 2.81 to 2.98 (m, 2 H); 3.81 (s, 3 H); 4.68 (quln, J-5.4 Hz, 1 H); 6.66 (d, J-8.1 Hz. 1 H); 6.90 (s. 1 H): 7.06 (dd. J-2.0 and 8.3 Hz. 1 H); 7.21 (d, MA Hz. 1 H); 7.28 (d. JM.7 Hz. 1 H); 7.44 (ζ J-7.6 Hz. 1 H); 7.56 (broad s. 1 H); 7.87 (broad s. 1 H); 7.95 (s. 1 H); 8.27 (d. J-8.3 Hz. 1 H); 9.24 (s, 1 H) | A 532 0.70 |
I-22 | 11-50 | lllb-7 | 2-([5-Methyt-4-(1mettiylpfperldin-4-yf)-2(propan-2ytoxy)phenyt]am ino)-7(pyridln-2-yf)thleno[3,2d]pyrimidine-6carboxamlde | 1.30 (d. J-5.9 Hz. 6 H); 1.55 to 1.82 (m. 4 H); 1.93 to 2.08 (m, 2 H); 222 (broad s, 3 H); 2.35 to 2.47 (m. 1 H); 2.81 to 2.98 (m, 2 H); 3.81 (s, 3 H); 4.68 (quln, JM>.4 HZ. 1 H); 6.66 (d. JL8.1 Hz. 1 H); 6.90 (s, 1 H); 7.06 (dd. JL2.0 and 8.3 HZ. 1 H); 721 (d. JL7.8 Hz. 1 H); 7.28 (d. JM .7 Hz. 1 H): 7.44 (ζ JL7.8 Hz. 1 H); 7.56 (broad s. 1 H); 7.87 (broad s, 1 H); 7.95 (s, 1 H); 8.27 (d, J-8.3 Hz. 1 H): 9.24 (s, 1 H) | B 517 0.78 |
1-23 | 11-1 | lllb-32 | 2-([4-(4-Methyl-1,4diazepan-1 -yf)-2-{propan2-ytoxy)phenÿt]amino J-7phenytthieno[3,2dJ)yrlmldine-6carboxamlde | 1.25 (d, J-6.1 Hz. 6 H); 1.89 (dq. J-5.7 and 5.9 Hz, 2 H); 2.27 (s. 3 H); 2.45 (m. 2 H); 2.62 (m, 2 H); 3.31 to 3.51 (masked m, 4 H): 4.60 (qd, J-5.9 and 6.0 Hz, 1 H); 6.17 (dd, J-2.4 and 9.3 Hz. 1 H); 6.34 (d, Ji-2.7 Hz, 1 H); 7.43 (m. 1 H); 7.51 (m. 3 H); 7.66 (d, Λ£.8 Hz, 2 H); 7.76 to 7.89 (m, 3 H): 9.14 (s, 1H) | A 517 0.68 |
1-24 | 11-13 | lllb-3 | 7-{2-Fluoro-5methoxyphenyf)-2-{[4-(1 methy Iplpe ridln-4-yi)-2(propan-2ytoxy)phenyi]amlno)thien o[3,2-d]pyrlmidine-6carboxamlde | 129 (d, J-5.9 Hz. 6 H): 1.65 (m. 4 H); 1.95 (m. 2 H); 2.19 (s. 3 H); 2.37 (m. 1 H); 2.85 (m. 2 H): 3.79 (s. 3 H); 4.67 (quin, J-6.1 Hz, 1 H); 6.62 (dd. JL2.0 and 8.3 Hz, 1 H); 6.69 (s. 1 H); 7.08 (dt, J-3.5 and 9.0 Hz. 1 H); 7.20 (dd. J-32 and 5.9 Hz. 1 H); 727 (ζ J^-9.3 Hz. 1 H); 7.56 (broad s. 1 H); 7.77 (broad s, 1 H); 7.96 (s, 1 H); 8.19 (d. J-8.3 Hz. 1 H); 9.26 (s, 1 H) | A 550 0.70 |
139
Compound 1' | Compound 11 | Compound irib | Name | NMR | MS conditions/ MH+/Tr |
1-25 | 11-23 | lltb-3 | 7- (3-Cyanopheny l)-2-{[4(1 -methylptperidin-4-yf)-2(propan-2yloxy) phenyljam inojthf en o[3,2-d]pyrimidtne-6carboxamlde | 1 JO (d. J-5.9 Hz, 6 H); 1.59 to 1.76 (m, 4 H); 1.95 (td, J-2.9 and 11.6 Hz, 2 H); 2.19 (S. 3 H); 2.39 (m. 1 H); 2.85 (d, J-112 Hz, 2 H); 4.68 (spt, J-6.2 Hz, 1 H); 6.81 (dd, J-2.0 and 8.3 Hz, 1 H); 6.92 (d, J-2.2 Hz, 1 H): 7.72 (t, J-7.8 Hz, 1 H): 7.91 (m. 4 H); 8.03 (s. 1 H): 8.17 (m, 2 H); 9.27 (S, 1 H) | A 527 0.68 |
1-26 | 11-19 | lllb-3 | 2-{[4-( 1 -Methylpiperidin-4yt)-2-{propan-2yloxy)phenyl]amino|-7-(2(trlfluoromethoxyjphenytjt hieno[3,2-d]pyrimidine-6carboxamlde | 1.28 (d, J-5.9 Hz, 6 H); 1.59 to 1.78 (m, 4 H); 2.11 (m, 2 H); 2.28 (broad s, 3 H); 2.42 (m, 1 H); 2.95 (m, 2 H); 4.66 (spt, J-6.0 Hz, 1 H); 6.61 (dd, J-1.7 and 8.1 Hz, 1 H); 6.68 (d, J-2.0 Hz, 1 H); 7.46 (broad s, 1 H); 7.50 (dt, J-1.6 and 8.1 Hz, 1 H); 7.56 (td, J-1.2 and 7.3 Hz, 1 H); 7.62 (td, J-2.0 and 7.6 Hz, 1 H); 7.69 (dd, J-2.0 and 7.3 Hz, 1 H); 7.75 (broad s, 1 H); 7.93 (s, 1 H); 8.07 (d. J-8.3 Hz, 1 H); 9.26 (s, 1 H) | A 586 0.76 |
1-27 | 11-1 | lltb-3 | 2-{[4-{1 -Methylplperidin-4yl)-2-(propan-2yloxy)phenyl]am lno|-7phenylthleno[3,2d]pyrimldine-6carboxamlde | I. 30 (d, J-6.1 Hz. 6 H); 1.57 to 1.75 (m, 4 H); 1.94 (td, J-2.4 and 11.4 Hz, 2 H); 2.19 (s, 3 H): 2.39 (m, 1 H); 2.86 (m. 2 H); 4.68 (spt, J-6.1 Hz, 1 H); 6.68 (dd, J. 1.6 and 8.4 Hz, 1 H); 6.90 (d, J-2.0 Hz, 1 H); 7.47 (t, J-7.3 Hz, 1 H); 7.55 (m, 3 H); 7.67 (d, J-7.1 Hz, 2 H); 7.85 (broad s, 1 H); 7.94 (s. 1 H); 8.24 (d, J-8.3 Hz, 1 H); 9.24 (s, 1 H) | A 502 0.69 |
1-28 | II-1 | lllb-33 | 2-{(4-[(1S,4S)-5-methyl2,5diazablcyclo[2.2.l]hept-2yl]-2-{propan-2yloxy)phenyl]amino)-7phenytthleno[3.2d]pyrimldine-6carboxamlde | 1.25 (d, J-5.9 Hz, 6 H); 1.74 to 1.98 (m, 2 H); 2.33 (broad s. 3 H); 2.61 (broad s, 1 H); 2.62 (m, 1 H); 3.13 (m, 1 H); 3.32 (masked m, 1 H): 3.51 (broad s, 1 H); 4.30 (broad 8,1 H); 4.61 (m, 1 H); 6.07 (d, J-9.1 Hz, 1 H); 6.26 (broad s, 1 H): 7,32 to 7.60 (m. 4 H); 7.66 (d, J-7.4 Hz, 2 H): 7.76 to 7.97 (m, 3 H); 9.14 (s. 1 H) | A 515 0.66 |
1-29 | IM | lllb-34 | 2-((4-(3(Dimethylamlno)pyrrolidin -1-yl]-2-(propan-2yloxy) phenyljam fno)-7phenylthieno[3,2d]pyrimidlne-6carboxamide | 1.26 (d, J-5.9 Hz, 6 H); 1.79 (m, 1 H); 2.12 (m, 1 H); 2.21 (s. 6 H); 2.79 (m, 1 H); 3.02 (t, J-8.4 Hz. 1 H); 3.25 (masked m, 2 H); 3.41 (m, 1 H); 4.63 (m, 1 H); 6.03 (dd, J-2.7 and 8.8 Hz, 1 H); 6.23 (d, J-22 Hz, 1 H); 7.39 to 7.57 (m, 4 H); 7.66 (d, J-7.1 Hz, 2 H); 7.79 (s, 1 H); 7.81 (broad s, 1 H); 7.92 (d, J-8.3 Hz, 1 H); 9,14 (s, 1 H) | A 517 0.68 |
1-30 | 11-5 | illb-7 | 7-(2-Methoxyphenyl)-2([5-methyl-4-(1 · methy1piperidin-4-yl)-2(propan-2y loxy) ph enyljam Ino Jthien o[3,2-d]pyrlmidine-6carboxamtde | 1.2B (d. J-5.9 Hz, 6 H); 1.54 to 1.71 (m. 4 H); 1.95 {m, 2 H); 2.04 (s, 3 H); 2.19 (s, 3 H); 2.54 {masked m, 1 H); 2.85 (d, J-11.0 Hz, 2 H); 3.69 {s, 3 H); 4.62 (m, 1 H); 6.79 (s. 1 H); 6.82 (broad S, 1 H); 7.13 (t, J-7.3 Hz, 1 H); 7.20 (d, J-8.1 Hz, 1 H); 7.48 (m. 2 H): 7.74 (broad s, 1 H); 7.81 (s, 1 H); 8.02 {s, 1 H); 9.21 {s, 1H) | A 546 0.67 |
140
Compound r | Compound II | Compound lllb | Name | NMR | MS conditions? MH+/Tr |
1-31 | 11-1 | lllb-51 | 2-{[4-Methoxy-2-(propan- 2-yloxy)phenyl]am 1 no}-7phenytthleno[3,2d]pyrlmidlne-6carboxamlde | 138 (d, J-6.1 Hz, 6 H); 3.73 (s, 3 H); 4.64 (spt, J-6.0 HZ, 1 H); 6.40 (dd, J-2.3 and 8.9 Hz, 1 H); 6.63 (d, J-2.2 Hz, 1 H); 7.46 (t, J-7.1 Hz, 1 H): 7.53 (m, 3 H); 7.66 (d, J-7.3 Hz. 2 H); 7.83 (broad s, 1 H); 7.90 (a. 1 H); 8.09 (d, J-8.8 Hz, 1 H); 9.20 (s, 1 H) | A 435 1.06 |
I-32 | II-25 | lllb-3 | 2-((4-(1 -Methytpiperidin^ylJ-Z-fpropan^yloxy)phenyf]amIno}-7-{3(methy!sulfinyl)phenyl]thle no[3,2-d]pyrimldine-6- . carboxamlde | 129 (d, J-5.9 Hz, 6 H); 1.55 to 1.78 (m, 4 H); 1.91 to 2.02 (m, 2 H); 2.20 (s, 3 H); 2.34 to 2.45 (m, 1 H); 2.79 (s, 3 H); 2.82 to 2.93 (m, 2 H); 4.68 (spt, J-5.9 Hz, 1 H); 6.72 (dd. J-1.5 and 8.3 Hz, 1 H); 6.89 (d. J.13 Hz, 1 H); 7.67 to 7.81 (m, 4 H); 7.88 (broad s, 1 H); 7.92 to 8.01 (m, 2 H); 8.16 (d, J-8.3 Hz, 1 H); 9.27 (s. 1 H) | A 564 0.62 |
I-33 | II-31 | lllb-3 | 7-(2-Methoxypyridln-3-yf)- 2-((4-(1 -methylplperidln-4yl)-2-(propan-2ytoxy)phenyl]am Inojthlen o[3,2-d]pyrlmldlne-6carboxamide | 1.29 (d. J-6.1 Hz, 6 H); 1.53 to 1.77 (m. 4 H); 1.91 to 2.05 (m. 2 H); 2.21 (s. 3 H); 2.34 to 2.46 (m, 1 H); 2.78 to 2.95 (m, 2 H); 3.80 (s, 3 H); 4.67 (spt, J-6.1 Hz, 1 H); 6.64 (d. j-8.3 Hz, 1 H): 6.88 (s, 1 H): 7.18 (dd, J-5.0 and 12. Hz, 1 H); 7.47 (broad s, 1 H); 7.70 (broad s, 1 H); 7.86 to 7.95 (m. 2 H); 8.11 (d. J-8.1 Hz, t H); 8.28 (dd, J-1.7 and 4.9 Hz, 1 H); 9.23 (s, 1 H) | A 533 0.64 |
I-34 | 11-22 | lllb-3 | 7-(2-Cyanopheny1)-2-{[4(t-methyfplperidin-4-yf}-2(propan-2yfoxy)phenyt]am Inojthl en o[3,2-d]pyrlmldine-6carboxamlde | 131 (d, J-6.1 HZ, 6 H); 1.62 to t .80 (m, 4 H); 2.03 (m. 2 H); 2.24 (s. 3 H); 2.44 (partially masked m, 1 H); 2.91 (m, 2 H); 4.70 (m, 1 H); 6.81 (dd, J-1.3 and 8.6 Hz, 1 H); 6.95 (d, J-13 Hz, 1 H); 7.64 (t, J-7.8 Hz, 1 H); 7.78 (t, J-7.8 Hz, 1 H); 7.88 (d, J-7.8 Hz, 1 H); 8.13 (s, 1 H); 8.26 (d, J-8.6 Hz, t H); 8.46 (s, 1 H); 8.52 (s, 1 H); 8.80 (d, J-7.8 Hz, 1 H): 9.28 (s, IH) | A 525 0.64 |
I-35 | 11-1 | lllb-37 | 2-((4-( 1H-lmldazol-1 -y1)-2(propan-2ytoxy)phenyl]am lno}-7phenytthleno[3,2dJpyrlmidlne-6carboxamide | 1.35 (d. J-5.9 Hz, 6 H); 4.87 (spt, J-6.1 Hz. 1 H); 7.07 (m. 2 H); 731 (d, J-2.4 Hz, 1 H); 7.48 (t, J-7.3 Hz. 1 H); 7.58 (m, 3 H); 7.69 (d. J-6.0 Hz, 2 H); 7.71 (s, 1 H); 7.87 (broad s, 1 H); 8.10 (s, 1 H); 8.21 (S. 1 H); 8.46 (d, J-8.8 Hz, 1 H); 9.30 (s, 1 H) | A 471 0.68 |
I-36 | 11-1 | lllb-43 | 2-([4-(Methyt[2-(pyrro1id1n- 1 -yl)ethyl]amlno}-2(propan-2ytoxy)phenyt]am lno}-7phenylthieno[3,2d]pyrlmldlne-6carboxamide | (70-30 conformer mixture): 121 (d, J-6.4 Hz, 6 H); 1.74 (m, 4 H); 2.66 (m. 6 H); 2.87 (s, 3 H); 3.40 (t, J-7.1 Hz, 2 H); 4.56 (m, 1 H); 6.21 (dd, J-2.9 and 8.8 Hz, 0.7 H); 636 (m, 0.3 H); 6.37 (d, J-2.4 Hz, 0.3 H); 6.40 (d. J-2.9 Hz, 0.7 H); 7.34 to 7.55 (m, 5 H); 7.65 (m, 3 H); 7.92 (d, J-8.8 Hz, 1 H); 9.11 (s, 1 H) | A 531 0.71 |
141
Compound ’’ | Compound II | Compound lilb | Name | NMR | MS conditions/ MH+/Tr |
1-37 | II-5 | lllb-54 | 7-(2-Methoxyphenyl)-2([6Ï4-metfiylplperazin-1 yl)-4-(propan-2yloxy)pyiidin-3yljamino) thieno[3,2dÿjyrimldine-6carboxamide | 1.19 (d, J-5.9 Hz. 6 H): 2.25 (s, 3 H); 2.43 (broad s, 4 H): 3.42 (broad s. 4 H); 3.69 (s. 3 H): 4.75 (spt, J-5.9 Hz. 1 H): 6.38 (5.1 H); 6.74 (broad s, 1 H); 7.05 (t, J-7.5 Hz, 1 H); 7.13 (d, J-8.1 Hz. 1 H); 7.38 (dd, J-1.7 and 7.6 Hz, 1 H); 7.40 to 7.47 (m. 1 H); 7.69 (broad s. 1 H); 7.97 (s. 1 H); 827 (s. 1 H); 9.09 (s, 1 H) | A 534 0.46 |
1-38 | II-5 | llib-55 | 7-(2-Methoxyphenyl)-2((6-( 1 -mettiylplperidin-4y()-4-(propan-2yloxy)pyridin-3yf]amlno]thieno[3,2dJpyrimldine-6carboxamide | 1.25 (d, J-5.9 HZ. 6 H); 1.70 to 1.78 (m, 4 H); 1.88 to 2.00 (m, 2 H); 2.19 (s. 3 H); 2.52 to 2.56 (m. 1 H): 2.79 to 2.92 (m. 2 H); 3.70 (s. 3 H): 4.78 (quin, J-6.4 Hz, 1 H): 6.80 (broad s. 1 H): 8.89 (s. 1 H): 7.07 (t, J-7.3 HZ, 1 H): 7.15 (d, J-8.1 Hz, 1 H); 7.40 (dd, J-1.2 and 7.6 Hz, 1 H): 7.43 to 7.49 (m. 1 H): 7.72 (broad s, 1 H): 8.07 (s, 1 H): 8.82 (s, 1 H); 9.19 (s, 1 H) | A 533 0.44 |
1-39 | 11-11 | llib-3 | 7-(5-Fluoro-2methoxyphenyl)-2-([4-(1 methylpiperidin-4-yl)-2(propan-2ytoxy)phenyf]amlno}thlen o[3,2-d]pyrimldine-6carboxamide | 1.29 (d, J-6.1 HZ, 6 H); 1.57 to 1.75 (m, 4 H); 1.95 (m, 2 H): 2.20 (s, 3 H); 2.38 (m. 1 H); 2.86 (m, 2 H); 3.68 (s, 3 H); 4.67 (spt, J-6.2 HZ, 1 H); 6.62 (dd. J-1.5 and 8.3 Hz, 1 H): 6.88 (d, J-1.5 Hz, 1 H); 7.15 (dd, J-4.6 and 9.3 Hz, 1 H); 725 (broad s, 1 H): 7.30 (td, J-3.2 and 8.8 Hz, 1 H); 7.37 (dd, J-3.2 and 9.3 Hz, 1 H); 7.70 (broad a. 1 H); 7.92 (s, 1 H); 8.16 (d, J-83 Hz, 1 H): 922 (s, 1 H) . | A 550 0.70 |
1-40 | II-9 | llib-3 | 7-(3-Fluoro-2methoxyphenyl)-2-([4-(1 methyipiperidin-4-yl)-2(propan-2yloxy)phenyl]amino}thien o[3,2-d]pyrimldlne-6carboxamide | 1.27 (d, J-6.1 HZ, 6 H): 1.56 to 1.73 (m, 4 H): 1.94 (m, 2 H); 2.19 (s, 3 H); 2.37 (m. 1 H); 2.85 (m, 2 H); 3.65 (m. 3 H); 4.65 (spt, J-6.0 Hz, 1 H); 6.60 (dd, J-1.5 and 8.8 Hz, 1 H); 6.87 (d. J-1.0 Hz, 1 H); 726 (m, 3 H); 729 (ddd, J-2.3 and 7.7 and 12.0 Hz, 1 H); 7.76 (broad s. 1 H); 7.92 (s, 1 H); 8.06 (d, J-8.3 Hz, 1 H); 923 (s, 1 H) | A 550 0.69 |
1-41 | li-24 | llib-3 | 2-04-(1 -MethylpIperidln^ytJ-Z-Îpropan^yloxy)phenyl}amino}-7-[2(methylsulfinyl)phenyl]thie nof3,2-d]pyrimldine45carboxamide | (70/30 ratamer mixture): 125 (m, 6 H); 1.56 to 1.71 (m, 4 H); 1.93 (m, 2 H); 2.18 (s, 3 H); 2.35 (m. 1.9 H); 2.54 (s, 2.1 H): 2.84 (d, J-11.0 Hz, 2 H); 4.62 (m, 1 H); 6.47 (d, J-9.3 Hz, 0.7 H); 6.55 (d, J-8.6 HZ, 0.3 H); 6.84 (s, 1 H); 724 (broad s, 1 H); 7.37 (d, J-7.1 Hz, 0.7 H): 7.46 (d. J-7.1 Hz, 0.3 H): 7.64 (t. J-7.5 Hz, 0.7 H); 7.70 (d, J-7.8 Hz, 0.3H); 7.75 to 7.94 (m. 3.7 H): 8.06 (m, 1.3 H); 9.92 (m, 1 H) | A 564 0.60 |
I-42 | II-5 | lltb-34 | 2-((4-(3(Dimethylamino)pyrrotld In -1-yl]-2-(propan-2yloxy)phenyl}amino)-7-(2methoxyphenyl)thleno[3,2 -d]pyrimldlne-6carboxamlde | 1.26 (d, J-6.1 HZ, 6 H): 1.79 (m, 1 H): 2.11 (m. 1 H); 221 (s. 6 H); 2.47 (masked m. 1 H); 2.78 (quln, J-7.8 Hz, 1 H): 3.00 (t, J-8.3 Hz, 1 H): 3.19 (m, 1 H): 3.38 (t, J-8.1 Hz, 1 H): 3.70 (s. 3 H); 4.62 (spt, J-6.0 Hz, 1 H); 5.94 (dd, J-1.8 and 8.4 Hz, 1 H): 621 (d, J-2.4 Hz. 1 H); 6.82 (broad s, 1 H); 7.11 (t, J-7.1 Hz. 1 H); 7.17 (d, J-8.3 Hz, 1 H); 7.47 (m. 2 H); 7.68 (m, 2 H); 7.83 (d, J-8.6 Hz. 1 H); 9.11 (s, 1 H) | A 547 0.67 |
142
Compound 1' | Compound II | Compound lllb | Name | NMR | MS conditions MH+/Tr |
1-43 | 11-5 | lllb-43 | 7-(2-Methoxyphenyl)-2([4-{m ethyl[2-(pyrrolidin-1 yl)ethyl]amino}-2-(propan2ytoxy)phenyl}amlno}thlen o[3,2-d]pyrimidine-6carboxamlde | 1.26 (d, J-6.1 Hz, 6 H); 1.68 (m. 4 H); 2.48 (masked m, 4 H); 2.54 (m, 2 H): 2.86 (s, 3 H); 3.38 (t, J-7.5 Hz, 2 H); 3.70 (s, 3 H); 4.58 (spt, J-6.1 Hz, 1 H); 6.10 (dd, J-2.4 and 8.6 Hz, 1 H); 6.35 (d, J-22 Hz, 1 H); 6.84 (broad s, 1 H); 7.10 (t, J-7.5 Hz, 1 H): 7.16 (d, Λ8.3 Hz, 1 H); 7.44 (m, 2 H): 7.70 (m, 2 H); 7.83 (d, <A>8.6 Hz, 1 H); 9.12 (s, 1 H) | A 561 0.70 |
1-44 | 11-14 | lllb-3 | 7-(2-nuoro-3methoxyphenyl)-2-{[4-(l methylplperidin-4-yl)-2(propan-2ytoxy)phenyl}amlno}thlen o[3,2-d]pyrimldine-6carboxamlde | 1.29 (d, J-6.1 Hz, 6 H); 1.66 (m, 4 H); 1.95 (m, 2 H); 2.20 (s, 3 H); 2.37 (m, 1 H); 2.86 (m, 2 H); 3.93 (s, 3 H); 4.67 (spt, J-6.0 Hz, 1 H); 6.61 (dd, «Λ-1.6 and 7.9 Hz, 1 H}; 6.88 (d, J-2.0 Hz, 1 H); 7.13 (m, 1 H); 7.28 (m, 2 H): 7.53 (broad s, 1 H): 7.77 (broad s, 1 H); 7.93 (s. 1 H); 6.15 (d, J.8.3 Hz, 1 H); 9.25 (s, 1 H) | A 550 0.69 |
1-45 | II-5 | lilb-19 | 24(4-(1 -Ethylpiperid In-Syt^-iptopan-Zytoxy)phenyl]amino)-7-(2methoxyphenyljth 1 eno[3,2 -d]pyrlmldine-6carboxamlde | 1.00 (t, J-7.1 Hz, 3 H); 1.29 (d, J.6.1 Hz. 6 H): 1.40 (m. 1 H); 1.51 (m, 1 H); 1.73 (m, 2 H); 1.89 (m, 2 H): 2.34 (q, «A*7.1 Hz, 2 H); 2.65 (m, 1 H): 2.85 (t, JM 1.1 Hz. 2 H): 3.70 (s. 3 H): 4.67 (spt, J-6.0 Hz, 1 H); 6.61 (d, J-9.0 Hz, 1 H); 6.85 to 6.94 (m. 2 H); 7.13 (t, J-7.5 Hz, 1 H); 720 (d, J-8.1 Hz, 1 H); 7.48 (m, 2 H); 7.73 (broad s, 1 H); 7.87 (s, 1 H); 8.12 (d, «A*8.1 Hz, 1 H); 9.21 (s, 1 H) | A 546 0.72 |
1-46 | 11-16 | lllb-3 | 7-(2-Fluorophenyl)-2-{[4(1 -methylplperidln-4-yl^2(propan-2yloxy)phenyl]amlno}thlen o[3,2-d]pyrimldine-6carboxamlde | 1.29 (d, J^5.9 Hz, 6 H); 1.65 (m, 4 H); 1.93 (m. 2 H); 2.19 (s. 3 H); 2.38 (m. 1 H); 2.85 (d, JM 1.2 Hz, 2 H); 4.67 (spt, J^5.9 Hz, 1 H); 8.64 (d, J-8.8 Hz, 1 H): 6.88 (s. 1 H); 7.36 (m, 2 H): 7.58 (m, 3 H); 7.78 (broad s, 1 H); 7.94 (s, 1 H); 8.15 (d, <Α·8.3 Hz, 1 H): 9.26 (s, 1 H) | A 520 0.69 |
1-47 | II-32 | lllb-3 | 2-{[4-(1-Methylpiperidln-4yl)-2-(propan-2yloxy)phenyljamino}-7(1H-pyrTOl-2-yl)ttileno[3,2· dJpyrlmidine-6carboxamlde | 1.27 (d, J^5.9 Hz, 6 H); 1.71 (m, 4 H); 1.96 (m, 2 H); 2.20 (s, 3 H); 2.43 (m, 1 H); 2.87 (m, 2 H); 4.66 (spt, J-6.0 Hz, 1 H); 6.20 (q. J-2.9 Hz, 1 H): 6.83 (dd, JM .7 and 8.1 Hz, 1 H); 6.94 (m, 3 H): 7.95 to 8.04 (m, 3 H); 8.33 (s, 1 H); 9.19 (s, 1 H); 11.74 (broad s, 1 H) | A 491 0.56 |
1-48 | II-26 | lllb-3 | 7-(2-Fluoro-5(hyd roxymethyljphe nylJ-2 ([4 -( 1 -m ethylp^eridln-4yl)-2-(propan-2ytoxy)phenyf]amino}thlen o[3.2-d]py rim idine-6carboxamide | 1.30 (d, J-5.9 Hz. 6 H); 1.56 to 1.74 (m, 4 H); 1.95 (m, 2 H); 2.19 (s, 3 H); 2.36 (m. 1 H); 2.85 (d, J-11.5 Hz, 2 H); 4.59 (d, J^5.6 Hz, 2 H); 4.68 (spt, J-6.1 Hz, 1 H); 5.30 (t, J-5.9 Hz, 1 H); 6.68 (dd, JM .0 and 7.6 Hz, 1 H); 6.88 (d, JM .5 Hz, 1 H); 7.30 (dd, JL8.6 and 10.0 Hz, 1 H); 7.43 to 7.53 (m, 1 H): 7.53 to 7.61 (m, 2 H); 7.75 (broad s, 1 H); 7.93 (s, 1 H): 8.17 (d, J-8.3 Hz, 1 H); 9.26 (s, 1 H) | A 550 0.64 |
1-49 | II-5 | lllb-8 | 2-[[4-(5-Methoxy-1methyl-1,2,3,6tetrahydropyridin-4-yl)-2(propan-2yloxy)phenyf]amlno]-7-(2methoxyphenyl)thleno[3,2 -d]pyrimidlne-6carboxamlde | 1.31 (d. JU6.4 Hz, 6 H): 2.30 (broad s, 3 H): 239 (m, 2 H); 2.47 (masked m, 2 H); 3.02 (broad s, 2 H); 3.43 (broad s, 3 H); 3.71 (broad s, 3 H); 4.62 (s, 1 H); 6.76 (d, J-9.3 Hz, 1 H); 6.91 (broad s, 1 H); 7.10 (m, 2 H); 7.19 (dd, J-0.6 and 7.9 Hz, 1 H); 7.46 (m, 2 H); 7.74 (broad s, 1 H); 7.91 (d, J-0.7 Hz. 1 H): 8.18 (d, «A*7.8 Hz, 1 H); 9.23 (broad s, 1 H) | C 560 3.58 |
143
Compound r | Compound It | Compound lilb | Name | NMR | MS conditions MH+/Tr |
1-50 | lt-10 | lllb-25 | 7-(4-Huoro-2methoxyphenyl)-2-{[4-(4methylplperazln-1 -yl)-2(propan-2yloxy)ptienyf]amino}thien o[3,2-d]py ri mtdine-6carboxamide | 1.26 (d, X5.9 Hz, 6 H); 2.22 (s, 3 H); 2.45 (t. X4.9 Hz. 4 H); 3.06 (t, X4.6 Hz. 4 H); 3.71 (s, 3 H); 4.65 (spt, X6.0 Hz, 1 H); 6.36 (dd, X2.6 and 8.9 Hz, 1 H): 6.62 (d. X2.4 Hz. 1 H); 6.95 (td. X2.6 and 8.5 Hz. 1 H); 7.04 (broad s. 1 H}; 7.08 (dd. X2.4 and 11.5 Hz. 1 H); 7.48 (dd, X7.0 and 8.4 Hz, 1 H); 7.69 (broad s. 1 H); 7.78 (s. 1 H); 7.95 (d. X9.0 Hz, 1 H); 9.15 (s, 1 H) | C 551 3.39 |
1-51 | 11-5 | lllb-37 | 2-((4-( 1 H-lmldazol-1 -yl)-2(propan-2yloxy)phenyl]amlno}-7-(2methoxyphenyl)thleno[3,2 -d]pyrimldlne-6carboxamide | 1.34 (d, X6.0 Hz. 6 H); 3.72 (s. 3 H); 4.87 (m, 1 H); 6.94 (broad s, 1 H); 6.98 (dd, X2.5 and 8.7 Hz, 1 H); 7.08 (t, X13 Hz, 1 H); 7.16 (m, 1 H); 731 (d. X7.8 Hz, 1 H); 739 (d, X2.5 Hz, 1 H); 7.48 (m, 2 H); 7.69 (t, X1.4 Hz, 1 H): 7.76 (broad s, 1 H); 8.03 (s, 1 H); 8.18 (t, X1 2 Hz, 1 H); 8.35 (d, X8.7 Hz. 1 H); 9.27 (s, 1 H) | C 501 3.46 |
1-52 | 11-5 | ltlb-58 | 2-Methylpropan-2-yl 4-(5{[6-carbamoyl-7-(2methoxyphenyl)thieno[33 -d]pyrimldin-2-yl]aminoJt-(propan-2-yl)-1Hpyrazol-3-yf]pÎperidlne-1 carboxyiate | 133 (d. X6.4 Hz, 6 H); 1.32 (m, 2 H): 1.45 (s, 9 H); 1.70 (m, 2 H); 2.62 (m, 1 H); 2.74 to 2.89 (m, 2 H); 3.66 (s. 3 H); 3.99 (m, 2 H); 4.54 (m. 1 H); 6.03 (s. 1 H); 6.72 (broad s. 1 H); 7.05 (t, X7.0 Hz. 1 H); 7.13 (d, X7.6 Hz, 1 H); 7.37 (dd, X1.7 and 7.6 Hz. 1 H); 7.45 (ddd. X1.7 and 7.2 and 8.5 Hz, 1 H); 7.75 (broad s. 1 H); 932 (s, 1 H); 9.44 (broad s, 1 H) | A 592 0.99 |
1-53 | 11-5 | lllb-9 | 7-(2-Methoxyphenyl)-2{[2-(propan-2-yloxy)-4(2,2,6,6tetramethylpiperidin-4yl)phenyl]amino}tti leno[3. 2-d]pyrimidlne-6carboxamlde | 1.10 (m, 6 H); 133 (m, 6 H); 139 (m, 2 H); 1.30 (d, X6.1 Hz, 6 H); 139 (m, 2 H): 2.96 (m, 1 H); 3.71 (s, 3 H); 4.68 (spt. X6.1 Hz. 1 H); 6.60 (dd, XI.2 and 8.3 Hz. 1 H); 6.89 (m. 2 H); 7.14 (td, XI .0 and 7.5 Hz. 1 H); 730 (d. X7.8 Hz. 1 H}: 7.45 (m, 2 H); 7.73 (broad s. 1 H); 7.88 (s, 1 H); 8.14 (d. X8.3 Hz. 1 H); 932 (s, 1 H] | A 574 0.79 |
1-54 | 11-5 | litb-11 | 2-((4-(2.6- Dimettiy1piperidin-4-yl)-2(propan-2yloxy)phenyl]amino|-7-(2methoxypheny 1) tti leno[3,2 -d]pyrimidine-6carboxamtde | (60/40 diastereoisomer mixture) 0.90 to 1.12 (m. 8.6 H); 139 (dd, X2.6 and 6.0 Hz, 6 H); 1.41 (m. 0.4 H): 1.63 (m, 0.6 H); 1.99 (d, X13.9 Hz, 0.4 H); 2.56 (S, 1 H); 2.64 to 2.82 (m, 2 H}; 3.68 to 3.73 (m, 3 H); 4.53 to4.72 (m, 1 H): 6.57 (dd. XI.2 and 7.6 Hz, 0.6 H): 6.70 (d. X8.6 Hz. 0.4 H); 6.82 to 6.96 (m, 2 H); 7.08 to 732 (m, 2 H); 7.42 to 7.56 (m, 2 H); 7.73 (broad s, 1 H); 7.87 (d, X10.5 Hz. 1 H); 8.03 to 8.16 (m. 1 H); 931 (s. 1H) | A 546 0.75 |
1-55 | 11-5 | lllb-12 | 24[4-(2-Ethylplperidin+yl)-2-(propan-2ytoxy)phenyi]amlno)-7-(2methoxyphenyl)thteno[33 -d]pyrimidlne-6carboxamlde | (50/50 diastereoisomer mixture) 0.88 (t, X7.4 Hz. 3 H}; 1.06 to 1.83 (m, 12 H); 2.35 to 2.43 (m. 0.5 H); 2.52 to 2.86 (m, 5 H); 3.04 (m, 0.5 H); 3.70 (s. 3 H); 4.66 (spt. X6.0 Hz. 1 H): 6.57 (m, 1 H); 6.86 (d. X8.8 Hz, 1 H); 6.91 (broad s. 1 H); 7.13 (t. X7.4 Hz. 1 H); 730 (d, X83 Hz, 1 H); 7.48 (m. 2 H); 7.74 (broad s. 1 H); 7.87 (s, 1 H); 8.13 (d, X8.5 Hz. 1 H); 931 (s, 1 H) | C 546 3.72 and 3.75 |
144
Compound 1’ | Compound II | Compound tilb | Name | NMR | MS conditions: MH+/Tr |
1-56 | 11-5 | lllb-4 | 7-(2-Mettioxypheny1)-2([4-(piperidin-4-yt)-2(propan-2yloxy)phenyl]amino}triien o(3,2-d]pyrimidine-6carboxamlde | 1.30 (d, J-6.1 Hz, 6 H); 1.49 (qd, JL3.9 and 12.3 Hz, 2 H); 1.65 (m, 2 H); 2.48 (masked m. 1 H); 2.59 (m, 2 H); 3.03 (m. 2 H); 3.70 (s. 3 H); 4.66 (spt, J-6.1 Hz, 2 H); 6.58 (dd, J-1.7 and 8.6 Hz, 1 H); 6.85 (d, J-1.2 Hz, 1 H); 6.90 (broad s, 1 H); 7.13 (td. ^1.1 and 7.4 Hz, 1 H); 7.20 (d, J-7.6 Hz. 1 H); 7.48 (m. 2 H); 7.74 (broad s, 1 H): 7.87 (s. 1 H); 8.14 (d. J-8.3 Hz. 1 H); 9.21 (s, 1 H) | A 518 0.68 |
1-57 | 11-10 | lllb-3 | 7-(4-Fluoro-2methoxyphenyl)-2-([4-(1 methylpiperidtn-4-yl)-2{propan-2ytoxy)phenyf]amino}thien o[3,2-d]pyrimidlne-6catboxamide | 1.29 (d, J-6.0 Hz, 6 H); 1.54 to 1.77 (m, 4 H); 1.97 (td, J-3.4 and 11.2 Hz, 2 H); 2.20 (s. 3 H): 2.39 (m. 1 H); 2.87 (d. J-11.8 Hz, 2 H); 3.71 (S, 3 H); 4,67 (spt. J-6.1 Hz, 1 H); 6.66 (dd, J-1.7 and 8.4 Hz, 1 H); 6.88 (d, J-1.7 Hz, 1 H); 6.96 (td, J-2.5 and 8.5 Hz, 1 H); 7.10 (. 1 H); 7.10 (dd, J-2.6 and 11.6 Hz, t H); 7.49 (dd. J-7.1 and 8.3 Hz, 1 H); 7.72 (broad s, 1 H); 7.88 (s, 1 H); 8.13 (d, J-8.4 Hz, 1 H); 9.21 (s, 1 H) | A 550 0.68 |
1-58 | 11-5 | lllb-27 | 24(4-(3,5Dimethylplperazln-1 -yl)-2(propan-2yloxy)phenyl]amino}-742methoxyphenyl)thleno[3,2 -d]pyrimidine-6carboxamide | 1.13 (m, 6 H); 1.27 (d. J-6.1 Hz, 6 H); 2.19 (m. 2 H); 2.89 to 3.13 (m, 2 H); 3.52 (broad s, 2 H): 3.70 (s, 3 H); 4.66 (spt, J-6.1 Hz, 1 H); 6.32 (d, J-9.0 Hz, 1 H); 6.64 (broad s, 1 H); 6.86 (broad s, t H); 7.13 (t, J-73 Hz, 1 H); 7.18 (d, J-8.3 Hz, 1 H); 7.47 (m. 2 H); 7.71 (broad s, 1 H); 7.78 (s. 1 H): 7.96 (d, J-8.6 HZ, 1 H); 9.16 (S, 1 H) | A 547 0.69 |
1-59 | 11-5 | tllb-28 | 7-(2-Methoxyphenyl)-2([2-(propan-2-ytoxy)-4(3,4,5-trlmettiytpiperazln1yl)phenyl]amino}thleno[3, 2-d]pyrimidlne-6carboxamide | 1.06 (s, 3 H); 1.08 (s, 3 H); 1.26 (d. J-5.9 Hz, 6 H); 2.19 (s, 3 H); 2.29 (m, 4 H); 3.43 (d, J-10.8 Hz, 2 H); 3.70 (s, 3 H); 4.66 (spt, J-6.0 Hz, 1 H); 6.29 (dd, J-2.3 and 8.7 Hz, 1 H); 6.61 (dd, J-0.5 and 2/2 Hz. 1 H); 6.85 (broad s, 1 H); 7,13 (t, J-7.5 Hz, 1 H); 7.18 (d. J-7.8 Hz, 1 H); 7.47(m, 2 H); 7.71 (broad s, 1 H); 7.77 (s. 1 H); 7.93 (d, J-8.8 Hz, 1 H); 9.15 (s, 1 H) | A 561 0.70 |
1-60 | 11-5 | lilb-44 | 24{44(8aR)Hexahydropyrrolo[1 ,2a]pyrazin-2(1 H)-ylJ-2(propan-2ytoxy)phenyt Jam Irro )-7-(2methoxyphenyl)thleno[3,2 -d]pyrimidine-6carboxamide | 1.26 (d, J-6.1 Hz, 6 H); 1.37 (m, 1 H): 1.71 (m, 2 H); 1.83 (m. t H); 2.06 (m. 2 H); 2.23 (td, J-3.2 and 11.1 Hz, 1 H); 2.34 (m, 1 H); 2.67 (td, JL3.2 and 11.5 Hz, 1 H); 3.00 (m, 2 H); 3.51 (d. J-1 1.2 Hz, 1 H); 3.66 (d, J-10.5 Hz, 1 H); 3.70 (s, 3 H); 4.65 (spt, J-6.1 Hz, 1 H): 6.31 (dd, J-2.4 and 9.0 Hz, 1 H); 6.63 (d, J-2.7 Hz, 1 H); 6.86 (broad s, 1 H); 7.13 (t, J-7.5 Hz, t H); 7.19 (d, J-7.6 Hz, 1 H); 7.46 (m, 2 H); 7.71 (broad s, 1 H); 7.76 (s. 1 H); 7.96 (d, J-9.0 Hz. 1 H); 9.15 (s. 1 H) | A 559 0.69 |
145
Compound ι· | Compound II | Compound lllb | Name | NMR | MS conditions MH+/Tr |
1-61 | 11-5 | lllb-58 | 7-{2-Methoxyphenyl)-2{[3-{plperidtn-4-yl)-1 · (propan-2-yl)-1 H-pyrazol5-yf]amlno}thteno[3,2d]pyrlmidlne-6carboxamide | 153 (d, J-6.4 Hz, 6 H); 1.68 (m, 2 H); 1.97 (m, 2 H); 2.79 (m, 1 H); 2.98 (m, 2 H): 3.30 (m, 2 H): 3.67 (s, 3 H); 4.52 (spt, J-6.0 Hz, 1 H); 6.01 (S, 1 H): 6.73 (broad s, 1 H); 7.09 (t, J-7.3 Hz, 1 H); 7.17 (d, J-8.3 Hz, 1 H); 755 (dd, J-15 and 7.6 Hz, 1 H); 7.47 (t, J-7.3 Hz, 1 H); 7.78 (broad s, 1 H); 8.49 (m, 1 H); 8.83 (m, 1 H); 9.22 (s, 1 H); 9.44 (s, 1 H) | A 492 0.52 |
1-62 | 11-5 | lllb-19 | 2-((4-( (3R)-1Ethylpiperidin-3-yl]-2(propan-2ytoxy)phenyt}amlno)-7-{2methoxyphenyl)thieno[35 -d]pyrlmidine-6carboxamide | 1.00 (t, J-7.2 Hz, 3 H): 159 (d, J-5.9 Hz, 6 H); 1.40 (m, 1 H); 1.55 (ddd. J-3.0 and 3.9 and 12.3 Hz, 1 H); 1.72 (m, 2 H); 1.89 (m, 2 H): 2.34 (q, J-7.1 Hz, 2 H); 2.64 (m, 1 H): 2.84 (m, 2 H): 3.70 (s, 3 H); 4.67 (spt, J-6.1 Hz, 1 H); 6.61 (dd, J-1.7 and 8.6 Hz, 1 H); 6.90 (broad s, 1 H); 6.90 (d, J-2.0 Hz, 1 H); 7.13 (td, J-1.0 and 7.5 Hz, 1 H); 750 (d, J-7.6 Hz, 1 H); 7.47 (m, 2 H); 7.73 (broad s, 1 H); 7.87 (s, 1 H); 8.12 (d, J-8.3 Hz, 1 H); 9.21 (s, 1 H) | A 546 0.73 |
1-63 | 11-5 | lllb-19 | 2-({4-((3S)-1Ethy!piperidin-3-yl]-2(propan-2ytoxy)phenyt}am lno)-7-{2mettroxyphenyljth leno[35 •d]pyrimidine-6carboxamlde | 1.00 (t, J-7.1 Hz, 3 H); 1.29 (d, J-5.9 Hz, 6 H); 1.40 (qd, J-3.7 and 12.1 Hz, 1 H): 1.53 (m, 1 H); 1.72 (m,2 H); 1.90 (m, 2 H); 254 (q, J-7.3 Hz, 2 H); 2.64 (m, 1 H); 2.84 (m, 2 H); 3.70 (s, 3 H); 4.67 (spt, J-6.0 Hz, 1 H); 6.61 (dd, J-15 and 8.1 Hz, 1 H); 6.90 (broad s, 1 H); 6.90 (d, J-15 Hz, 1 H); 7.13 (td, Λ1.1 and 7.4 Hz, 1 H): 750 (d, J-7.6 Hz, 1 H); 7.49 (m, 2 H); 7.73 (broad s, 1 H); 7.87 (s, 1 H); 8.12 (d, J-8.3 Hz, 1 H); 951 (s, 1 H) | A 546 0.73 |
1-64 | 11-27 | llib-3 | 2-Q4-{1 -Methylplperidln-4y!)-2-(propan-2yfoxy)phenyljam1no}-7(thiophen-3-yl)thieno[35dfcjyrimidine-6carboxamide | 159 (d, J-5.9 Hz, 6 H): 1.68 (m, 4 H); 1.96 (m. 2 H); 2.19 (s, 3 H); 2.41 (m, 1 H); 2.86 (m, 2 H); 4.68 (spt, J-6.1 Hz. 1 H); 6.76 (dt, J.1.0 and 85 Hz, 1 H); 6.92 (d, J-2.0 Hz, 1 H); 753 (dd, J-15 and 5.0 Hz, 1 H); 7.70 (dd, J-2.9 and 5.1 Hz, 1 H); 7.78 (broad s, 1 H); 7.92 (broad s, 1 H); 8.02 (m, 2 H): 850 (d, J-B.3 Hz, 1 H); 9.22 (s, 1 H) | A 508 0.68 |
1-65 | 11-33 | IUb-3 | 7-{5-Fluoro-2mettroxypyridin-4-yl)-2([4-( 1 -methylpiperid i n-4yl)-2-(propan-2ytoxy)phenyl]amino}thien o[3,2-d]pyrimidine-6carboxamide | 157 (m. 6 H); 155 to 1.83 (m, 4 H); 1.92 to 255 (m, 6 H); 2.83 to 3.02 (m, 2 H); 3.94 (broad s. 3 H); 4.66 (m, 1 H); 6.67 (d, J-8.6 Hz, 1 H): 6.90 (broad s, 1 H); 7.11 (m, 1 H): 7.80 (m. 2 H); 8.04 (broad s, 1 H); 8.12 (d, J-S.3 Hz, 1 H); 8.26 (broad s, 1 H); 958 (broad s, 1 H) | A 551 0.67 |
1-66 | 11-5 | lllb-15 | 7-(2-Methoxyphenyf)-2((2-(propan-2-yloxy)-4· [(2R,4S)-2-(propan-2yl)p1perldÎn-4yl]phenyt}amlno)thieno[3, 2-dfcjyrlm1dine-6carboxamlde | 0.89 (t, J-75 Hz, 6 H); 1.15 (m, 1 H); 1.29 (d, J-5.9 Hz, 6 H); 1.39 to 1.72 (m, 4 H); 255 (m, 1 H)*. 2.53 (d, J-6.6 Hz. 1 H); 2.65 (m, 1 H); 3.09 (m, 1 H); 3.70 (s, 3 H); 4.66 (spt, J-6.0 Hz, 1 H); 6.59 (dd, J-1.6 and 8.2 Hz, 1 H); 6.85 (d, J. 1.5 Hz, 1 H); 6.90 (broad s, 1 H); 7.13 (t, J-7.5 Hz. 1 H); 7.19 (d, J-7.8 Hz, 1 H); 7.49 (m, 2 H); 7.73 (broad s, 1 H): 7.87 (s, 1 H): 8.12 (d, J-8.1 Hz, 1 H); 951 (s, 1 H) | A 560 0.77 |
146
Compound 1' | Compound II | Compound lllb | Name | NMR | MS conditions MH+/Tr |
1-67 | 11-5 | Il (b-15 | 7-(2- Methoxyph enyl)-2({2-(propan-2-ytoxy)-4[(2R,4R)-2-(propan-2yl)piperldin-4yf]phenyl)amlno)thieno[3, 2-dJpyrimidine-6carboxamlde | 0.86 (d, J-6.6 Hz. 3 H); 0.92 (d, J-6.6 Hz. 3 H); 120 (d, J-6.1 Hz, 6 H); 1.55 to 1.82 (m, 4 H); 1.94 (m, 1 H); 2.38 (m, 1 H): 2-61 to 2.91 (m. 3 H): 3.70 (s. 3 H); 4.64 (spt, J-6.0 Hz, 1 H); 6.62 (d, J-3.3 Hz, 1 H); 6.87 (s, 1 H); 6.90 (broad s, 1 H); 7.13 (t, J-7.5 Hz, 1 H); 7.19 (d, J-82 Hz. 1 H); 7.49 (m. 2 H); 7.73 (broad s. 1 H): 7.87 (s, 1 H); 8.13 (d, J-82 Hz. 1 H); 921 (s. 1 H) | A 560 0.77 |
1-68 | 11-2 | lllb-3 | 7-(2-Chtorophenyl)-2-([4(1 -methy!piperidin-4-yl)-2· (propan-2ylo xy)phenyf]amlno}thien o[3,2-d]pyri mldlne-6carboxamide | 128 (d, J-6.1 Hz. 6 H): 1.63 (m, 4 H); 1.93 (m, 2 H): 2.19 (s, 3 H); 2.36 (m, 1 H); 2.84 (m, 2 H): 4.66 (spt, J-6.1 Hz. 1 H); 6.54 (dd, J-2.0 and 8.3 Hz. 1 H); 6.86 (d, J-2.0 Hz. 1 H); 7.19 (broad s, 1 H); 7.52 (m. 3 H): 7.63 (m, 1 H); 7.79 (broad s. 1 H); 7.91 (s, 1 H}; 8.01 (d, J-8.3 Hz, 1 H); 9.25 (s, 1 H) | A 536 0.71 |
1-69 | 11-31 | lllb-44 | 2-([4-((8aR)Hexahydropynolof 1 2-a]pyrazin-2(1 H)-yl]-2(propan-2yloxy)phenyl]amino )-7-(2methoxypyridin-3yl)thleno[3,2-d]pyr1mld1ne6-carboxamkte | 1 -26 (d. J-5.9 Hz, 6 H); 1.32 to 1.58 (m, 1 H); 1.65 to 1.76 (m. 1 H); 1.83 (m. 1 H): 2.06 (m, 2 H); 223 (m. 1 H); 2.34 (m. 2 H); 2.67 (m. 1 H); 3.02 (m, 2 H); 3.53 (d. J-11.7 Hz, 1 H); 3.68 (d, J-11.7 Hz, 1 H); 3.80 (s, 3 H); 4.66 (spt, J-6.0 Hz, 1 H); 6.35 (d, J-82 Hz. 1 H); 6.64 (d, J-1.5 Hz, 1 H); 7.17 (dd, Λ5.1 and 7.6 Hz. 1 H): 7.46 (broad s, 1 H); 7.68 (broad s, 1 H); 7.82 (s, 1 H); 7.92 (m. 2 H); 826 (d, J-2.9 Hz. 1 H); 9.18 (s, 1 H) | A 560 0.64 |
1-70 | 11-5 | lllb-58 | 2-([3-(1-Ettiylpfperidin-4yt)-1 -(propan-2-yl)-1 Hpyrazol-5-yt]amino)-7-(2methoxyphenyl)thieno[32 -d]pyrimldine-6carboxamide | 1.04 (t J-7.1 Hz, 3 H): 1.22 (d, J-6.8 Hz, 6 H); 1.48 (m. 2 H): 1.73 (m, 2 H): 1.91 (m, 2 H); 2.37 (m, 3 H); 2.91 (d, J-11.7 Hz, 2 H); 3.66 (s. 3 H): 4.48 (spt, J-6.0 Hz, 1 H): 6.00 (S, 1 H); 6.71 (broad s, 1 H); 7.08 (t. J-7.6 Hz, 1 H); 7.14 (d, JUB.3 Hz, 1 H): 7.36 (d, J-7.3 Hz, 1 H); 7.43 (t, J-7.8 Hz, 1 H); 7.75 (broad s, 1 H): 921 (s. 1 H); 9.34 (s, 1 H) | A 520 0.53 |
1-71 | 11-3 | lllb-3 | 7-(3-Chlorophenyl)-2-([4( 1 -methylpiperidin-4-yl)-2(propan-2yloxy)phenyl]amlno]thien o[3,2-d]pyrimldine-6carboxamlde | 120 (d. J-5.9 Hz, 6 H); 1.67 (m, 4 H); 1.95 (td, J-2.3 and 11.8 Hz. 2 H); 2.19 (s. 3 H): 2.40 (m. 1 H); 2.86 (m, 2 H); 4.69 (spt, J-6.1 Hz, 1 H); 6.76 (dd, J-2.0 and 82 Hz, 1 H); 6.91 (d, J-1.5 Hz, 1 H); 7.55 (m, 3 H); 7.81 (d, JU1.5 Hz, 1 H); 7.84 (broad s. 1 H); 7.88 (broad s, 1 H); 8.00 (s, 1 H): 824 (d, J-8.3 Hz. 1 H); 926 (s, 1 H) | A 536 0.73 |
1-72 | 11-21 | lllb-3 | 7-(2-Methylphenyl)-2-([4(1 -methylplperidin-4-yty-2(propan-2yloxy)phenyf]am inojthlen o[3.2-d]pyrimldine-6carboxamide | 127 (d, J-6.1 Hz, 6 H); 1.55 to 1.71 (m, 4 H)’, 1.93 (m, 2 H); 2.11 (s, 3 H): 2.19 (s, 3 H); 226 (m, 1 H); 2.85 (d, J-11.7 Hz, 2 H); 4.64 (spt, J-6.0 Hz, 1 H): 6.52 (dd, J-1.5 and 82 Hz, 1 H); 6.63 (broad s. 1 H); 6.86 (d, J-1.0 Hz, 1 H); 7.33 (m. 2 H): 7.44 (m, 2 H); 7.84 (broad s, 1 H); 7.90 (s, 1 H); 7.95 (d, J-8.3 Hz, 1 H); 9.24 (s, 1 H) | A 516 0.73 |
147
Compound Γ | Compound It | Compound irib | Name | NMR | MS conditions MH+/ Tr |
1-73 | 11-34 | lllb-3 | 2-([4-(1-Methylpiperidin-4yl)-2-(propan-2yioxy)phenyl]amlno}-7-(1 · methyl-1 H-pyrazol-4y1)thieno(3,2-d] pyrlmidlne6-carboxamide | 1.29 (d. J.5.9 Hz, 6 H): 1.72 (m. 4 H); 1.96 (t, </*10.5 Hz, 2 H); 2.20 (s, 3 H); 2.45 (m, 1 H); 2.87 (d, J-11.5 Hz, 2 H); 3.92 (s, 3 H); 4.69 (m, 1 H); 6.84 (d, «/7.8 Hz, 1 H); 6.95 (S. 1 H): 7.90 (broad s, 1 H); 7.97 (m. 2 H); 8.08 (s, 1 H); 8.14 (d, JL>8.3 Hz, 1 H); 8.32 (s, 1 H); 9.18 (S, 1 H) | A 506 0.60 |
1-74 | 11-8 | llib-3 | 7-(2,5-Dlmethoxyphenyl)- 2-([4-(1-methytpiperidln-4yl)-2-(propan-2yloxy) phenyljam inojthien o[3,2-d]pyiimidine-6carboxamlde | 1.29 (d, J-5.Q Hz, 6 H); 1.53 to 1.75 (m, 4 H); 1.94 (m. 2 H); 2.19 (s. 3 H); 2.37 (m. 1 H); 2.85 (d. */*112 Hz, 2 H): 3.65 (s, 3 H); 3.77 (s, 3 H); 4.67 (spt, «/-5.9 Hz, 1 H): 6.59 (d. */*8.3 Hz, 1 H); 6.88 (s, 1 H); 6.97 (broad s, 1 H); 7.07 (m, 3 H); 7.72 (broad s, 1 H); 7.88 (s, 1 H); 8.18 (d, */*8.3 Hz, 1 H); 9.21 (s. 1 H) | A 562 0.69 |
1-75 | 11-16 | lllb-3 | 7-[2(Difluoromethoxy)phenylJ2-([4-( 1 -methylpiperidln-4yl)-2-(propan-2yloxy) phenyljam inojthien o[3,2-d]pyrlmidlne-6carboxamide | 1.27 (d, J-6.1 Hz, 6 H); 1.66 to 1.90 (m, 4 H); 2.38 to 2.57 (partially masked m, 6 H); 3.20 (m, 2 H): 4.62 (m. 1 H): 6.61 (dd, J-1.3 and 8.5 Hz, 1 H); 6.86 (d, J-1.3 Hz, 1 H); 6.92 (t, J-74.1 Hz, 1 H); 7.32 (d, J-7.8 Hz, 1 H); 7.35 (broad s, 1 H); 7.40 (t, *1-7.8 Hz, 1 H); 7.52 to 7.59 (m, 2 H): 7.77 (broad s. 1 H); 8.01 (m, 2 H); 9.24 (s. 1 H) | A 568 0.70 |
1-78 | li-35 | lilb-3 | 2-{[4-(1-Methylplperidln-4yl)-2-(propan-2yloxy)phenyl]amlnoJ-7(1 H-pyrazol-4yl)thleno[3,2-d]pyrlmidlne6-carboxamide | 1.30 (d. </*5.9 Hz, 6 H); 1.74 (m, 4 H); 2.03 (t, </*10.5 Hz, 2 H); 2.24 (s, 3 H); 2.44 (m, 1 H); 2,92 (m, 2 H); 4.68 (spt, */*6.1 Hz. 1 H); 6.81 (dd. J-1.5 and 8.3 Hz. 1 H): 6.94 (d. «A 1.5 Hz, 1 H); 7.91 (m, 2 H); 8.05 (s, 1 H); 8.19 (m, 3 H); 9.19 (s, 1 H); 12.96 (broad s, 1 H) | A 492 0.59 |
1-77 | Il -5 | llib-30 | 2-((4-{3-(2-Hydroxyethy1)- 4-methylplperazln-1 -yt]-2(propan-2yloxy)phenylJamlno)-7-(2methoxyphenyl)thieno[3t2 -d]pyrlmldine-6carboxamlde | 1.26 (d, JL6.1 Hz, 6 H); 1.52 (dq, */*7.0 and 14.0 Hz, 1 H); 1.77 (m, 1 H): 2.26 (m, 5 H); 2.48 (masked m. 1 H): 2.74 (m, 2 H); 3.38 (m, 2 H): 3.53 (t, */-6.7 Hz, 2 H); 3.70 (s. 3 H); 4.44 (broad s. 1 H); 4.64 (spt, «/-6.0 Hz, 1 H); 6.30 (dd. */2.3 and 6.9 Hz, 1 H); 6.60 (d. «/-2.4 Hz, 1 H); 6.86 (broad s, 1 H); 7.12 (t, */7.5 Hz, 1 H); 7.18 (d, </-8.3 Hz, 1 H); 7.47 (m. 2 H); 7.71 (broad s, 1 H); 7.77 (s, 1 H); 7.94 (d. J-9.0 Hz, 1 H); 9.15 (s, 1 H) | A 577 0.64 |
1-78 | II-31 | lilb-7 | 7-(2-methoxypyridin-3-ylJ2-{[5-methyl-4-(1methylplperldln-4-yt)-2(propan-2yloxyjphenyljam Inojthien o[3,2-d] py ri mid lne-6carboxamlde | 1.28 (d, */*5.9 Hz, 6 H): 1.64 (m. 4 H); 1.96 (t, J-10.3 Hz, 2 H); 2.09 (S, 3 H); 2.19 (s. 3 H): 2.55 (m. 1 H); 2.86 (d, </10.8 Hz, 2 H); 3.79 (s, 3 H); 4.62 (spt, «/6.0 Hz, 1 H); 6.81 (s, 1 H); 7.16 (dd, J-5.4 and 11.7 Hz, 1 H); 7.46 (broad s, 1 H); 7.71 (broad s, 1 H); 7.86 (s. 1 H): 7.91 (d, «Λ-6.8 Hz, 1 H); 8.00 (s, 1 H); 8.27 (d, J-3.9 Hz, 1 H); 9.24 (s, 1 H) | A 547 0.63 |
148
Compound r | Compound II | Compound lllb | Name | NMR | MS conditions MH+/Tr |
1-79 | 11-31 | lllb-25 | 7-(2-Methoxypyridin-3-yl)- 2-{[4-(4-methylplperazln1-yi)-2-(propan-2ytoxy)phenyl]amlno}thien o[3,2-d Jjyrimid lne-6carboxamlde | 126 (d, JL5.9 Hz, 6 H): 2.22 (s, 3 H); 2.44 (m, 4 H); 3.05 (m, 4 H); 3.80 (s, 3 H); 4.65 (spt, J-6.0 Hz, 1 H); 6.34 (dd. J-2.3 and 8.9 Hz, 1 H); 6.62 (d, J-2.4 Hz, 1 H); 7.17 (dd, JL4.9 and 7.3 Hz, 1 H); 7.45 (broad s, 1 H); 7.67 (broad s, 1 H): 7.83 (s, 1 H); 7.90 (dd, J-2.0 and 7.3 Hz, 1 H); 7.94 (d. JL8.8 Hz, 1 H); 826 (dd, JL2.0 and 5.1 Hz, 1 H); 9.18 (s. 1 H) | A 534 0.60 |
1-80 | II-5 | lllb-16 | Hydroxyethyt )plperidl n-4yl]-2-(propan-2ytoxy)phenyt[amino)-7-(2methoxyphenyl)thleno{32 -d]pyrimldine-6carboxamlde | 129 (d, JL5.9 HZ, 6 H); 1.64 (m, 4 H); 2.07 (m. 2 H): 2.41 (m. 3 H): 2.98 (d, JL 10.8 Hz, 2 H); 3.52 (broad s, 2 H); 3.70 (s, 3 H); 4.37 (broad s. 1 H); 4.67 (spt, J-6.0 Hz, 1 H); 6.60 (d. J-7.8 Hz, 1 H); 6.87 (s. 1 H); 6.92 (broad s. 1 H); 7.13 (t. JL7.1 Hz, 1 H); 720 (d, JL8.3 Hz, 1 H); 7.49 (m, 2 H); 7.75 (broad s, 1 H); 7.87 (s, 1 H); 8.14 (d, JL8.3 Hz, 1 H); 921 (s, 1 H) | A 562 0.67 |
1-81 | II-5 | llib-48 | 7-(2-Methoxyphenyl)-2{[4-(3-methoxypyridin -4yl)-2-(propan-2ybxy)phenyt]amino)thlen o[3,2-d]pyrimldine-6carboxamlde | 1.35 (d, JL5.9 Hz, 6 H); 3.72 (s, 3 H); 3.91 (S, 3 H); 4.72 {spt. JL6.0 Hz, 1 H); 6.96 (broad s, 1 H); 6.98 (dd. J-1.7 and 8.6 Hz. 1 H); 7.15 (t, JL7.5 Hz. 1 H); 7.21 (d, JL8.3 Hz. 1 H); 7.26 (d, JL 1.7 Hz, 1 H); 7.37 (d, JL4.6 Hz, 1 H); 7.51 (m, 2 H); 7.76 (broad s, 1 H); 8.04 (s, 1 H); 826 (d. JL4.6 Hz, 1 H); 8.37 {d, JL8.3 HZ, 1 H); 8.43 (s, 1 H); 929 (s, 1 H) | A 542 0.78 |
1-82 | II-5 | lllb-56 | 7-(2-Methoxyphenyl)-2[[6-(4-mettiylplperazin-1 yl)-2-(propan-2ytoxy)pyridin-3yl]am 1 no} thieno[3,2· d[pyrimidine-6carboxamide | 127 (d, JL6.1 Hz, 6 H); 2.22 (s. 3 H); 2.40 (t, JL4.7 Hz, 4 H); 3.37 (m, 4 H); 3.70 (S. 3 H); 5.19 (spt, JL6.1 Hz, 1 H); 6.16 (d. JL8.5 Hz. 1 H); 6.85 (broad s. 1 H); 7.11 (t, JL7.4 Hz, 1 H): 7.17 (d. JL82 Hz, 1 H); 7.42 (d, JL7.4 HZ, 1 H); 7.47 (t, JL72 Hz, 1 H): 7.73 (broad s. 1 H); 7.83 (s, 1 H); 8.02 (d, JL7.7 Hz, 1 H); 9.15 (s, 1 H) | A 534 0.68 |
1-83 | II-5 | lllb-10 | 7-(2-Methoxyphenyl)-2{[4-(1,22.6.6pentamethylpiperldin-4yl)-2-(propan-2yloxy)phenyl]amlno)thien o[3,2-d]py rimldin e-6carboxamlde | 1.11 (m. 12 H): 120 (d, JL5.9 Hz. 6 H); 1.56 {m, «M 2.7 Hz, 4 H); 2.14 to 229 (m, 3 H); 2.88 {broad s, 1 H); 3.71 (s, 3 H); 4.69 (spt, JL5.9 Hz, 1 H); 6.61 {d. JL8.8 HZ, 1 H); 6.91 (m, 2 H); 7.14 (t, JL7.3 Hz, 1 H); 720 (d, JL8.3 Hz, 1 H); 7.49 (m, 2 H); 7.74 (broad s. 1 H); 7.88 (s. 1 H); 8.15 (d. JL8.3 Hz, 1 H); 9.22 (s. 1 H) | A 588 0.78 |
1-84 | II-5 | lllb-13 | 2-({4-K2S.4S)-2-Ethyl-1methylplperidin-4-yt]-2(propan-2ytoxy)phenyl}amlno )-7-(2methoxyphenyl)thleno[32 -d]pyrimidine-6carboxamlde | 0.84 (t, JL7.3 Hz. 3 H); 1.30 (d, JL5.9 Hz, 6 H): 1.33 to 1.70 (m, 6 H); 1.86 (m, 1 H); 2.12 (m. 1 H): 2.18 (s, 3 H); 2.44 (m, 1 H): 2.89 (dt, JL2.9 and 11.2 Hz, 1 H); 3.71 (s, 3 H): 4.68 (spt, J-6.1 Hz, 1 H); 6.60 (dd, JL1.6 and 8.4 Hz, 1 H); 6.87 (d. JL1.5 Hz. 1 H); 6.90 {broad s. 1 H); 7.14 (t. JL7.5 Hz. 1 H); 720 (d, JL7.8 Hz, 1 H): 7.49 (m. 2 H): 7.74 {broad s. 1 H); 7.87 (s, 1 H); 8.13 (d. JL82 Hz. 1 H): 922 (s. 1 H) | A 560 0.74 |
149
Compound 1' | Compound II | Compound lllb | Name | NMR | MS conditions? MH+/Tr |
Ι-β5 | II-5 | ltlb-13 | 2-({4-[(2S,4R)-2-Ethyl-1methylplperidin-4-ylÎ-2· (propan-2ytoxy)phenylJamino)-7-(2methoxyphenyl)thleno[3J -d]pyrimidine-6carboxamkle | 0.86 (t, J-7.5 Hz. 3 H); 1 JO (dd, J-1 J and 6.1 Hz, 6 H); 1.43 to 1.84 (m, 6 H); 2.30 (s, 3 H); 2.45(m, 1 H); 2.55 to 2.74 (m, 3 H); 3.71 (s, 3 H); 4.68 (spt, J-5.9 Hz. 1 H); 6.62 (dd, J-1.7 and 8.6 Hz, 1 H); 6.89 (d, J-1.7 Hz. 1 H); 6.92 (broad s. 1 H); 7.14 (t, J-7.5 Hz, 1 H); 7.20 (d, J-3.1 Hz, 1 H); 7.49 (m. 2 H); 7.74 (broad s, 1 H); 7.87 (s, 1 H); 8.13 (d, J-8.1 Hz. 1 H); 9.22 (s, 1 H) | A 560 0.76 |
1-66 | 11-31 | lllb-5 | 7-(2-Methoxypyridin-3-yl)- 2-({2-(propan-2-yloxy)-4[ 1 -(propan-2-yl)plperidln4yf]phenyl}amlno)ttiie no[3, 2-d]pyTimidine-6carboxamlde | 1.00 (d, J-6.4 Hz, 6 H); 1.30 (d, J-5.9 Hz, 6 H); 1.58 (m, 2 H): 1.72 (m, 2 H); 2 J0 (t, J-10.6 Hz, 2 H); 2.40 (m, J-12.0 Hz, 1 H); 2.72 (m, 1 H); 2.88 (d. J-9.3 Hz, 2 H); 3.80 (s, 3 H); 4.68 (m. 1 H); 6.64 (d, J-8.1 Hz, 1 H); 6.88 (s, 1 H); 7.19 (t, J-5.9 Hz, 1 H); 7.48 (broad s, 1 H); 7.70 (broad s, 1 H): 7.92 (m, 2 H); 8.11 (d. J-8.1 Hz. 1 H); 8.28 (d, J-3.7 Hz, 1 H); 9.24 (s, 1 H) | A 561 0.69 |
Ι-β7 | II-36 | lllb-3 | 7-(5-Fluoro-2methoxypyridln-3-yl)-2([4-( 1 -methylplperidin-4yl)-2-(propan-2ytoxy)phenyl]am Inojthten o[3,2-d]pyrimidlne-8carboxamlde | 1.29 (d, J-5.9 Hz, 6 H); 1.56 to 1.75 (m, 4 H): 1.98 (t, J-11.0 Hz, 2 H): 2.21 (s, 3 H); 2.40 (m, 1 H); 2.87 (d, J-11.2 Hz, 2 H); 3.78 (s, 3 H): 4.67 (spt, J-6.1 Hz, 1 H); 6.64 (dd. J-1.5 and 8.3 Hz, 1 H): 6.89 (d, J-1.7 Hz, 1 H); 7.66 (m, 2 H); 7.93 (dd, J-2.9 and 8.8 Hz, 1 H); 7.99 (s, 1 H); 8.09 (d, J-8.3 Hz. 1 H): 8.26 (d. J-3.2 HZ, 1 H): 9.25 (s. 1 H) | A 551 0.67 |
1-68 | II-36 | ltlb-5 | 7-(5-Fluoro-2methoxypyridin-3-yl)-2((2-(propan-2-yloxy)-4-[1 (propan-2-yl)piperidln-4yf]phenyl}am I no)thieno[3, 2-djpyrimidlne-6carboxamlde | 1.01 (d, J-6.1 Hz, 6 H); 1.29 (d, J-6.1 Hz. 6 H); 1.48 to 1.66 (m, 2 H); 1.75 (S, 2 H); 2.14 to 2 J9 (m, 2 H); 2.41 (broad s, 1 H); 2.73 (broad s, 1 H): 2.84 to 2.95 (m. 2 H); 3.78 (s, 3 H); 4.67 (spt. J-6 J Hz, 1 H); 6.63 (dd, J-t.6 and 8.4 Hz, 1 H); 6.89 (d, J-1 J Hz, 1 H): 7.61 to 7.74 (m, 2 H); 7.93 (dd, J-3.1 and 8.9 Hz, 1 H); 7.99 (s, 1 H); 8.09 (d. J-8.3 Hz, 1 H); 8.26 (d, J-2.9 Hz, 1 H); 9.25 (s, 1 H) | A 579 0.72 |
1-89 | II-36 | lllb-7 | 7-(5-Fluoro-2methoxypyridln-3-yl)-2([5-methyl-4-(1methylp^eridln-4-yl)-2(propan-2ytoxy)phenyf]amino]thlen o[3,2-d]pyrim)dine-6carboxamide | 1.28 (d. J-6.1 Hz. 6 H); 1.63 (m. 4 H); 1.99 (t, J-10.5 HZ. 2 H); 2.09 (s, 3 H); 2.20 (s. 3 H); 2.57 (m, 1 H); 2.87 (d. J-11.0 Hz, 2 H); 3.78 (s, 3 H); 4.62 (spt. J-6.1 Hz, 1 H); 6.81 (s, 1 H); 7.61 (broad s, 1 H); 7.71 (broad s. 1 H): 7.91 (m, 2 H); 7.98 (s, 1 H); 8.25 (d, J-2.9 Hz, 1 H); 9.25 (s, 1 H) | A 565 0.68 |
1-90 | II-37 | lllb-3 | 7-(6-Methoxypyridln-2-yl)- 2-j [4-( 1 -methylpl perid ln-4 · yl)-2-(propan-2ytoxyjphenyfjaminojthien o[3,2-d]pyTim)dine-6carboxamide | 1.31 (d, J-5.9 HZ, 6 H); 1.76 to2.03 (m, 4 H); 2.55 to 2.63 (masked m, 2 H); 2.68 to 2.79 (m. 4 H); 3.89 (s, 3 H): 4.67 (m. 1 H); 6.79 (d, J-8.3 Hz, 1 H); 6.88 (dd, J-3.5 and 5.3 Hz. 1 H); 6.93 (broad s, 1 H); 7.86 to 7.93 (m. 4 H); 8.09 (s, 1 H); 8.25 (s. 3 H): 9.26 (s, 1 H) | A 533 0.70 |
1-91 | II-2 | lllb-16 | 7-(2-Chlorophenyl)-2-((4[1-(2hyd roxyethyljpiperid ln-4yl]-2-(propan-2yioxy)pheny1)am Inojthlen of3,2-d]pyrimldine-6- | 1.28 (d, J-5.9 Hz. 6 H); 1.53 to 1.72 (m, 4 H); 1.96 to 2.07 (m. 2 H): 2.34 (m. 1 H); 2.40 (t. J-6.4 Hz. 2 H); 2.95 (d, J-11.5 HZ, 2 H); 3.51 (q, JL5.9 Hz, 2 H); 4.31 (t, J-5.4 Hz, 1 H); 4.66 (spt, J-8.0 Hz, 1 H); 6.54 (d, J-8.3 Hz, 1 H); | A 566 0.69 |
150
Compound Γ | Compound 11 | Compound lllb | Name | NMR | MS conditions) MH+/Tr |
carboxamlde | 6.86 (s, 1 H); 7.18 (broad s. 1 H); 7.46 to 7.57 (m. 3 H): 7.63 (m. 1 H); 7.79 (broad s, 1 H); 7.91 (s. t H); 8.01 (d, J-8.3 Hz. 1 H); 9.25 (s. 1 H) | ||||
1-92 | 11-5 | lllb-57 | 7-(2-Methoxyphenyl)-2((6-(1 -methylplperidin-4yl)-2-(propan-2yloxy)pyridin-3yf]amlno)thieno[3,2d]pyrimidlne-6carboxamlde | 1.34 (d. J-6.1 Hz, 6 H): 1-98 (m. 4 H); 2.76 (S. 4 H); 3.02 (s, 2 H); 3.45 (m, J-5.4 Hz, 2 H): 3.70 (s, 3 H); 5.30 (spt, J-6.2 HZ, 1 H); 6.66 (d, J-7.6 Hz, 1 H); 6.92 (broad s, 1 H); 7.12 (td, J-0.9 and 7.4 Hz, 1 H); 7.19 (d, J-8.1 Hz, 1 H); 7.45 (dd. J-1.6 and 7.5 Hz, 1 H); 7.49 (td, J-1.7 and 8.3 Hz, 1 H); 7.76 (broad s, 1 H); 7.98 (s. 1 H): 8.36 (d. J-8.1 Hz. 1 H); 9.27 (s, 1 H); 9.74 (broad s, 1 H) | A 533 0.71 |
1-93 | 11-5 | lllb-45 | 2-((4-(1,7Dlazaspiro[4A]non-7-yf)2-(propan-2ytoxy)pheny1]amino}-7-(2methoxyphenyl)thleno[3,2 -d]pyrimidine-6carboxamlde | 1.27 (d. J-6.1 Hz, 6 H); 1.54 (m, 1 H); 1.89 (m, 4 H); 2.15 (m, 2 H); 2.35 (m, 1 H); 3.15 (t, J-7.1 Hz, 1 H): 3.23 (masked m, 2 H); 3.41 (s, 1 H); 3.70 (s, 3 H); 4.63 (spt, J-6.0 Hz, t H); 5.96 (dd, J-2.6 and 8.9 Hz, 1 H); 622 (d, J-2.2 Hz, 1 H); 6.83 (broad s, 1 H); 7.11 (td, J-1.1 and 7.5 Hz. 1 H); 7.17 (d, J-8.1 Hz. 1 H); 7.47 (m, 2 H); 7.71 (broad s, 1 H ); 7.73 (s, 1 H); 7.88 (d, J-8.8 Hz, 1 H); 9.12 (s, 1 H) | A 559 0.71 |
1-94 | 11-31 | lllb-36 | 2-((4-(3(Dlethy!amino)pyrrolidfn1 -yl]-2-(propan-2yloxy)ph eny1}amino)-7-(2methoxypyridin-3yl)thleno(32-d]pyrimidine6-carboxamlde | 0.98 (t, J-7.1 HZ, 6 H); 1.25 (d, J-5.9 Hz. 6 H); 1.80 (m, 1 H); 2.12 (m, 1 H); 2.59 (m, 4 H); 2.98 (t, J-7.8 Hz, 1 H); 3.18 (m. t H); 3.38 to 3.42 (partially masked m, 3 H); 3.79 (s, 3 H); 4.63 (spt, J-5.9 Hz, 1 H); 5.97 (dd, J-2.4 and 8.8 Hz, 1 H): 621 (d, J-2.4 Hz, 1 H); 7.15 (dd. J-5.1 and 7.3 Hz. 1 H); 7.43 (broad s, 1 H); 7.66 (broad s. 1 H): 7.77 (s, 1 H); 7.80 (d, J-8.8 Hz. 1 H); 7.89 (dd, J-1.7 and 7.3 Hz, 1 H); 825 (dd, J-1.7 and 5.1 Hz, 1 H); 9.13 (s, 1 H) | A 576 0.67 |
1-95 | II-38 | lllb-34 | 2-((4-(3(Dimethylamlno)pyrrotldin -1-yl]-2-(propan-2ytoxy)phenyl}amino)-7-(1 methyl-1H-pyrrol-2yl)thieno[32-d]pyrimidlne6-carboxamide | 124 (d, J-6.1 Hz, 6 H); 1.79 (m, 1 H); 2.13 (m. 1 H); 221 (s. 6 H); 2.78 (m, 1 H); 3.01 (t, J-7.8 Hz, t H); 321 (m, 1 H); 328 to 3.44 (partially masked m, 2 H); 3.48 (s, 3 H); 4.61 (spt. J-6.1 Hz, 1 H); 6.02 (dd, J-2.4 and 8.8 Hz, 1 H); 6.17 to 628 (m, 3 H); 6.80 (broad s, 1 H); 7.04 (t. J-22 Hz, 1 H); 7.74 (d, J-8.8 Hz, 1 H): 7.86 (s. 1 H); 7.91 (broad s, 1 H); 9.12 (s, 1 H) | A 520 0.67 |
1-96 | II-38 | lllb-3 | 2-((4-(1-Methy Iplperidln^ylJ^-lpropan^yloxy)phenyl]amino}-7-(1 m ethyi-1 H-pyrrol-2yl)toieno[3,2-d]pyrlmldlne6-carboxamide | 129 (d, J-5.9 Hz, 6 H); 1.63 to 1.88 (m, 4 H); 224 to 2.58 (partially masked m, 6 H); 3.08 (m, 2 H); 3.48 (s, 3 H); 4.66 (m, t H): 6.22 (t, J-32 Hz, 1 H); 6.30 (dd, J-1.3 and 3.8 Hz, 1 H); 6.69 (broad d, J-8.1 Hz, 1 H): 6.85 (broad s. 1 H); 6.89 (broad s, 1 H); 7.08 (broad s, 1 H); 7.96 (broad s, 1 H); 8.00 (s, 1 H); 8.10 (d, J-8.1 Hz, 1 H); 923 (s, 1 H) | A 505 0.68 |
1-97 | ΙΙ-39 | lltb-3 | 2-((4-( 1 -Methy lpiperidln-4yl)-2-{propan-2yloxy )ph enyl]amlno}-7-(2methyipyridin-3- yl) thi enof3,2-dlpyrim Id ine- | 127 (d, J-6.1 Hz. 6 H); 1.54 to 1.74 (m, 4 H); 1.97 (m, 2 H); 220 (s, 3 H); 2.29 (s, 3 H}; 2.38 (m, 1 H); 2.86 (m, 2 H); 4.65 (m, 1 H); 6.55 (dd. J-2.1 and 8.3 Hz, 1 H); 6.87 (d, J-2.1 Hz, 1 H); 7.36 | A 517 0.49 |
151
Compound ι· | Compound II | Compound lilb | Name | NMR | MS conditions/ MH+/Tr |
6-carboxamlde | (dd. J-4.9 and 7.6 Hz, 1 H): 7.39 (broad s, 1 H); 7.70 (dd, J-2.0 and 7.6 Hz, 1 H); 7.79 (broad s, 1 H); 7.92 (d, J-6.3 Hz. 1 H); 7.95 (S, 1 H); 8.56 (dd, J-2.0 and 4.9 Hz, 1 H); 9.26 (s, 1 H) | ||||
1-98 | I1-40 | lilb-3 | 7-{Furan-2-yl)-2-{[4-(1 methy1plperidin-4-yl)-2(propan-2yloxy)phenyf]am Inojthien o[3.2-d]pyrimidine-6carboxamlde | 1.29 (d. J-6.1 Hz, 6 H); 1.62 to 1.80 (m, 4 H); 1.97 (m. 2 H): 2.20 (s, 3 H): 2.45 (m, 1 H); 2.88 (m. 2 H); 4.68 (m. 1 H); 6.68 (dd, J-1.8 and 3.3 Hz, 1 H); 6.86 (dd, J-2.1 and B.4 Hz, 1 H); 6.95 (d, J-2.1 Hz, 1 H); 7.33 (broad d, J-3.3 Hz, 1 H); 7.84 (broad d, J-1.8 Hz, 1 H); 7.90 (broad s. 1 H); 8.09 (broad s, 1 H); 6.12 (s. 1 H); 8.20 (d. J-8.1 Hz, 1 H); 9.20 (s, 1 H) | A 492 0.65 |
1-99 | 11-41 | lllb-3 | 7-[5-(Am Inomethy l)furan2-yi?24[4-(imettiy1p1peridin-4-yl)-2(propan-2ytoxy)phenyl]amino)tfiien o[3,2-d)pyrimldine-6carboxamlde | 1..0 (d, J-6.1 Hz, 6 H); 1.59 to 1.80 (m, 4 H); 1.98 (m. 2 H); 2.21 (s. 3 H); 2.43 (partially masked m, 1 H); 2.88 (m. 2 H); 3.77 (s, 2 H); 4.69 (m, 1 H); 6.42 (broad d, J-2.9 Hz, 1 H); 6.84 (broad d, J-8.3 Hz, 1 H); 6.95 (broad s, 1 H); 7.20 (broad d, J-2.9 Hz, 1 H); 7.94 (broad s, 1 H); 8.04 (broad s, 1 H); 8.10 (s, 1 H); 8.22 (d, J-8 3 Hz, 1 H); 9.19 (s, 1 H) | A 521 0.48 |
1-100 | 11-31 | lilb-26 | 7-(2-Methoxypyrld[n-3-yl)24I5-methy1-4-(4methyipiperazln-1 -yl}-2(propan-2ytoxy)phenyf]aminojthlen o[3,2-d]pyrimldine-6carboxamide | 1.28 (d, J-6.1 Hz, 6 H); 2.05 (s, 3 H); 2.23 (s, 3 H); 2.46 (m, 4 H); 2.78 (m, 4 H); 3.79 (s, 3 H); 4,60 (spt, J-6.1 Hz, 1 H): 6.69 (s, 1 H); 7.16 (dd, J-5.1 and 7.3 Hz, 1 H): 7.43 (broad s, 1 H); 7.69 (broad s. 1 H); 7.82 (s, 1 H); 7.91 (dd, J-2.0 and 7.3 Hz. 1 H); 8.01 (s, 1 H); 8.27 (dd, J-2.0 and 5.1 Hz. 1 H); 9.22 (s, 1 H) | A 548 0.63 |
1-101 | 11-43 | lllb-3 | 2-((4-( 1 -Methylplperidin-4yl)-2-(propan-2ytoxy)phenyl]amino)-7(1 H-pyrrol-3-yl)thleno[3,2d]pyrfmldÎne-6carboxamide | 1.32 (d, J-8.1 Hz, 6 H); 1.61 to 1.79 (m, 4 H); 1.97 (m, 2 H); 2.20 (s, 3 H); 2.42 (m, 1 H); 2.B8 (m. 2 H); 4.70 (m. 1 H); 6.56 (m, 1 H); 6.81 (dd. J-2.0 and 8.5 Hz, 1 H); 6.92 (m. 2 H); 7.51 (m. 1 H); 7.60 (broad s, 1 H): 7.68 (broad s, 1 H); 7.92 (s, 1 H); 8.37 (d. J-8.5 Hz. 1 H): 9.16(3, 1 H): 11.18(broads, 1 H) | A 491 0.64 |
1-102 | 11-31 | lllb-34 | 24(4-(3(Dimethylamino)pyrrolÎdln -1 -yl]-2-(propan-2ytoxy)phen^Jamino)-742methoxypyridIn-3yl)tti ieno[3.2-d]pyrimidine6-carboxamlde | 1.25 (d, J-6.1 Hz, 6 H): 1.79 (m, 1 H); 2.13 (m, 1 H); 2.21 (s, 6 H); 2.78 (m. 1 H); 3.00 (m, 1 H); 3.21 (m. 1 H); 3.25 to 3.42 (partially masked m, 2 H); 3.79 (s, 3 H); 4.63 (m. 1 H): 5.98 (dd. J-2.5 and 9.0 Hz, 1 H); 6.21 (d. J-2.5 Hz, 1 H): 7.15 (dd, J-5.1 and 7.3 Hz, 1 H); 7.42 (broad s, 1 H); 7.66 (broad s. 1 H); 7.77 (s, 1 H); 7.60 (broad d, J-9.0 Hz, 1 H): 7.89 (dd, J-2.1 and 7.3 Hz. 1 H); 8.25 (dd, J-2.1 and 5.1 Hz, 1 H); 9.13 (s, 1 H) | A 548 0.62 |
Μ 03 | II-44 | llib-5 | 7-{2-Ethoxypyridin-3-yl)- 2-((2-(propan-2-yloxy)-4[1 -(propan-2-y!)plperidin4yf]phenyl)amlno)ttileno[3, 2-d]pyrfmldine-6carboxamide | 0.99 (d, J-6.6 Hz, 6 H); 1.19 (t, J-7.1 Hz, 3 H); 1.29 (d, J-6.1 Hz, 6 H); 1.59 (m, 2 H); 1.72 (m, 2 H); 2.18 (m. 2 H); 2.39 (m, 1 H); 2.70 (m, 1 H); 2.87 (m, 2 H); 4.28 (q, J-7.1 Hz, 2 H); 4.68 (m, 1 H); 6.64 (dd, J-2.3 and 8.5 Hz, 1 H); 6.68 (d, J-2.3 Hz, 1 H); 7.17 (dd, J-5.1 and 7.3 Hz, 1 H); 7.48 (broad s, 1 H); 7.69 (broad s, 1 H); 7.91 (s, 1 H); 7.93 | A 575 0.72 |
152
Compound Γ | Compound II | Compound lllb | Name | NMR | MS conditions/ MH+/Tr |
(dd. J-2.1 and 7.3 Hz. 1 H): 8.13 (d, J-8.5 Hz, 1 H); 8.25 (dd, J-2.1 and 5.1 Hz, 1 H); 9.23 (s, 1 H) | |||||
1-104 | 11-44 | lllb-7 | 7-(2-Ethoxypyrldin-3-yl)2-([5-methyl-4-(1methylpiperidin-4-y!)-2(propan-2ytoxyjphenyljam Inojthlen o[3,2-d]pyrtmidIne-6· carboxamlde | 1.17 (t, J-7.1 HZ, 3 H); 1.28 (d, J-6.1 Hz, 6 H); 1.50 to 1.71 (m, 4 H); 1.97 (m, 2 H): 2.09 (s. 3 H); 2.19 (s. 3 H); 2.54 (partially masked m, 1 H); 2.86 (m, 2 H): 4.28 (q, J-7.1 Hz, 2 H); 4.62 (m, 1 H); 6.81 (s. 1 H); 7.14 (dd, J-5.1 and 7.3 Hz, 1 H); 7.46 (broad s, 1 H); 7.69 (broad s, 1 H); 7.85 (s, 1 H); 7.93 (dd. J-2.1 and 7.3 Hz, 1 H); 8.02 (s, 1 H); 8.24 (dd, J-2.1 and 5.1 Hz, 1 H): 9.24 (s. 1 H) | A 561 0.67 |
1-105 | 11-5 | llib-26 | 7-(2-Methoxyphenyl)-2{(5-methyi-4-(4methylplperazin-1 -y!)-2(propan-2yloxyjphenyfjam Inojthlen o[3.2-djpyri midine-6carboxamide | 128 (d, J-5.9 Hz, 6 H); 2.00 (s, 3 H); 2.22 (s. 3 H); 2.43 (m. 4 H); 2.77 (t. J-4.4 Hz, 4 H); 3.69 (s, 3 H); 4.59 (spt, J-6.1 Hz. 1 H): 6.68 (s. 1 H); 6.82 (broad s. 1 H); 7.13 (t, J-7.3 Hz, 1 H); 7.19 (d, J-8.3 Hz, 1 H): 7.48 (m. 2 H); 7.73 (broad s, 1 H); 7.77 (s, 1 H); 8.03 (s, 1 H); 9.19 (s, 1 H) | A 547 0.68 |
1-106 | 11-44 | lilb-3 | 7-(2-Ethoxypyridin-3-yl)- 2-{[4-(1 -methylpiperidin-4yl)-2-(propan-2yloxyjphenyljam Inojthlen o[3,2-d]pyrimidlne-6carboxamlde | 1.19 (t, J-7.1 Hz. 3 H); 1.29 (d, J-6.1 Hz, 6 H): 1.58 to 1.75 (m. 4 H): 1.93 (m. 2 H); 2.19 (s, 3 H); 2.39 (m. 1 H): 2.85 (d. J-11.0 Hz, 2 H); 4.28 (q. J-7.1 Hz, 2 H); 4.67 (quln, J-6.1 Hz, 1 H); 6.64 (dd. J-1.7 and 8.3 Hz, 1 H); 6.88 (d, J-1.5 Hz, 1 H); 7.16 (dd. J-5.1 and 7.3 Hz, 1 H); 7.48 (broad s, 1 H): 7.69 (broad s, 1 H): 7.93 (m, 2 H); 8.13 (d, J-8.3 Hz, 1 H); 8.24 (dd, J-2.0 and 5.1 Hz, 1 H); 9.23 (s, 1 H) | A 547 0.67 |
1-107 | 11-44 | lllb-25 | 7-(2-Ethoxypyridin-3-yl)- 2-([4-(4-methylpiperazin1-yl)-2-(propan-2ytoxyjphenyljam Inojthlen o[3,2-djpyrimidine-6carboxamlde | 1.20 (t, J-7.1 Hz. 3 H); 1.26 (d, J-5.9 Hz, 6 H): 222 (s, 3 H); 2.44 (m. 4 H); 3.05 (m, 4 H); 4.28 (q. J-7.1 Hz, 2 H): 4.65 (m, 1 H); 6.34 (dd. J-2.5 and 8.8 Hz, 1 H): 6.62 (d, J-2.5 Hz, 1 H); 7.15 (dd, J-5.1 and 7.3 Hz, 1 H); 7.46 (broad s, 1 H); 7.67 (broad s, 1 H); 7.82 (s. 1 H); 7.91 (dd, J-2.2 and 7.3 Hz, 1 H); 7.96 (d. J-8.8 Hz. 1 H); 8-23 (dd, J-2.2 and 5.1 Hz, 1 H); 9.18 (s, 1 H) | A 548 0.85 |
1-108 | 11-45 | lllb-25 | 7-(2-Methoxy-5methy!pyridin-3-yî)-2-([4(4-methytplperazln-1 -yl)2-(propart-2yloxy)phenyl]amlno}thlen o[3,2-djpyrimidine-6carboxamlde | 126 (d. J-5.9 Hz. 6 H); 2.22 (s, 3 H); 2.32 (s, 3 H); 2.45 (m, 4 H); 3.06 (m, 4 H); 3.76 (s, 3 H); 4.65 (spt, J-6.0 Hz, 1 H); 6.33 (dd, J-2.4 and 8.8 Hz, 1 H); 6.64 (d, J-2.4 Hz. 1 H); 7.42 (broad s. 1 H); 7.65 (broad s, 1 H): 7,77 (d, J-2.2 Hz, 1 HJ; 7.85 (s, 1 H): 7.94 (d, J-8.8 Hz, 1 H): 8.07 (d, J-2.4 Hz, 1 H): 9.17 (s, 1 H) | A 548 0.63 |
1-109 | 11-45 | lllb-3 | 7-(2-Methoxy-5methylpyridin-3-yl)-24[4(1 -methylptperidin-4-yl)-2(propart-2yk)xy)phenyl]aminojthien o[3,2-d]pyrimid ine-6carboxamlde | 1.30 (d, J-6.1 Hz, 6 H); 1.54 to 1.77 (m, 4 H); 1.94 (td, J-2.3 and 11.6 Hz, 2 H); 2.19 (s, 3 H); 2.34 (s, 3 H); 2.40 (m, 1 H); 2.85 (d, J-112 Hz, 2 H); 3.77 (s. 3 H); 4.68 (spt, J-6.1 Hz, 1 H); 6.64 (dd, J-1.5 and 8.3 Hz, 1 H): 6.90 (d, J-1,7 Hz, 1 H); 7.45 (broad s, 1 H); 7.67 (broad s, 1 H); 7.80 (d, J-2.2 Hz, 1 H); 7.94 (s, 1 H); 8.09 (dd, J-0.7 and 2.4 | A 547 0.67 |
153
Compound 1’ | Compound II | Compound lllb | Name | NMR | MS conditions MH+/Tr |
Hz, 1 H): 0.14 (d. J-8.3 Hz, 1 H); 9.23 (s, 1 H) | |||||
1-110 | II-36 | llib-25 | 7-(5-Fluoro-2methoxypyridin-3-yl)-2{[4-(4-methylpiperazin-1 yl)-2-(propan-2yloxy)phenyf]amlno}thien o[3,2-djpy ri midlne-6carboxamide | 125 (d. J-6.1 Hz. 6 H): 2.22 (s. 3 H); 2.43 (m. 4 H); 3.06 (m, 4 H); 3.78 (s, 3 H); 4.64 (spt, J-6.0 Hz, 1 H); 6.33 (dd, J-2.4 and 8.8 Hz, 1 H); 6.63 (d, J-2.4 Hz, 1 H); 7.62 (broad s. 1 H); 7.68 (broad s, 1 H); 7.87 to 7.93 (m, 3 H): 824 (d, J-2.9 Hz, 1 H); 9.19 (s, 1 H) | A 552 0.63 |
1-111 | Il-4 5 | llib-7 | 7-(2-Methoxy-5m ethylpyridin-3 -y 1)-2-( [5methy1-4-(1methy1piperidin-4-yl)-2(propan-2yloxy)phenyi]amlno}thien o{3,2-d]py ri mldine-6carboxamide | 128 (d, JL6.1 Hz, 6 H); 1.65 (m, 4 H); 2.05 (s, 3 H); 2.25 (m, 8 H); 2.55 (d, J-8.3 Hz, 1 H); 2.90 (d, J-8.6 Hz, 2 H); 3.76 (s, 3 H); 4.61 (spt, J-6.1 Hz, 1 H): 6.80 (s, 1 H); 7.35 (broad s, 1 H); 7.68 (d, J-2.4 Hz, 1 H); 7.71 (broad s, 1 H); 7.88 (s, 1 H); 7.96 (s, 1 H); 8.09 (d, JL1.5 Hz, 1 H); 923 (s, 1 H) | A 561 0.67 |
1-112 | Il-4 6 | lllb-3 | 2-((4-(1 -Methylplperidin-4yl)-2-(propan-2yloxy)pheny1]amlno}-7-(1methyl-1 H-pyrazol-3yl)thleno{3,2-d]pyrimid Ine6-carboxamlde | 1.30 (d, J-6.1 Hz, 6 H); 1.68 (m, 4 H); 1.97 (m, 2 H); 220 (s, 3 H); 2.41 (m, 1 H); 2.87 (d, J-112 Hz, 2 H); 3.99 (S, 3 H): 4.68 (spt, J-6.1 Hz, 1 H); 6.79 (dd, J-1.6 and 8.4 Hz, 1 H); 6.93 (d, J-1.7 Hz, 1 H): 7.17 (d. J-22 Hz, 1 H); 7.98 (d, J-2.2 Hz, 1 H); 8.02 (s, 1 H); 8.04 (broad s, 1 H); 826 (d, J-8.3 Hz, 1 H); 9.23 (s, 1 H); 9.85 (broad s, 1 H) | A 506 0.66 |
1-113 | II-5 | llib-31 | 2-({4-[3-(2-Methoxyethyl)- 4-methy!piperazin-1 -ylJ-2(propan-2ytoxy)phenyl)am ino)-7-(2methoxyphenyf)thieno[3,2 -d]pyrimidine-6carboxamide | 126 (d, J-5.8 Hz, 6 H); 1.62 (m, 1 H); 1.86 (m, 1 H); 2.13 to 2.31 (m, 5 H); 2.71 (t, J-9.6 HZ, 1 H); 2.79 (d, J-11.5 Hz, 1 H); 3.26 (s, 3 H); 3.35 to 3.49 (m, 5 H); 3.70 (s, 3 H); 4.59 to 4.72 (m, 1 H); 6.30 (d, J-8.5 Hz, 1 H): 6.60 (s, 1 H); 6.91 (broad s. 1 H): 7.12 (t, J-7.4 Hz, 1 H); 7.18 (d. J-82 Hz, 1 H); 7.48 (m. 2 H): 7.74 (broad s. 1 H); 7.79 (s, 1 H); 7.95 (d. J-9.6 Hz, 1 H); 9.16 (s, 1 H) | A 591 0.71 |
1-114 | II-5 | llib-47 | 7-(2-Methoxyphenyl)-2{I44(3R)-3[methyl(oxetan-3yl)am lno]plperidin-1 -yl}-2(propan-2ytoxy)phenyl]amino}thien o{3,2-d]pyri mldine-6carboxamide | 1.26 (d. J-6.1 Hz, 7 H); 1.51 (m, 1 H); 1.71 (d, J-8.8 Hz. 2 H): 2.21 (s, 3 H); 2.46 (broad s, 3 H): 3.48 (m, 2 H): 3.70 (s, 3 H); 4.00 (quin, J-6.8 Hz, 1 H); 4.50 (m, 4 H); 4.65 (spt, J-5.9 Hz, 1 H); 628 (d, J-7.1 Hz, 1 H); 6.58 (d, J-2.0 Hz, 1 H): 6.86 (broad s, 1 H); 7.12 (t. J-7.6 Hz, 1 H); 7.18 (d, J-8.3 Hz, 1 H); 7,38 to 7.53 (m, 2 H); 7.71 (broad s. 1 H): 7.76 (s, 1 H); 7.94 (d, JL8.8 Hz, 1 H); 9.15(5.1 H) | A 603 0.70 |
1-115 | Il-42 | ltib-3 | 7-{2-Methytfuran-3-yi)-2{14-(1 -methylp Iperid I n-4yl)-2-(propan-2ytoxy)phenyf]amlno}thien o(3,2-d]pyrim idine-6 · carboxamide | 1.30 (d, J-6.1 Hz, 6 H); 1.57 to 1.77 (m, 4 H): 1.95 (m, 2 H); 2.19 (s, 3 H); 2.21 (s, 3 H); 2.40 (m, 1 H); 2.86 (m. 2 H): 4.68 (m, 1 H); 6.68 (d, J-2.0 Hz, 1 H); 6.73 (dd, J-2.3 and 8.3 Hz. 1 H); 6.90 (d, J-2.3 Hz, 1 H); 7.30 (broad s, 1 H); 7.71 (d, J-2.0 Hz, 1 H); 7.90 (broad s, 1 H): 7.95 (s. 1 H): 8.24 (d, J-8.3 Hz, 1 H); 9.22 (s, 1 H) | A 506 0.68 |
1-116 | II-37 | ltib-7 | 7-(6-Methoxypyridin-2-yl)2-{[5-methyl-4-(1 methylplperidtn-4-yl)-2(propan-2yloxy)phenyf]amlno)thien o(3,2-d]pYrlm idine-6- | 1.29 (d, J-6.1 Hz, 6 H): 1.62 (m, 4 H); 1.95 to 2.06 (m, 2 H); 2.20 (s, 3 H): 221 (s, 3 H): 2.60 (m, 1 H); 2.88 (d, J-11.0 Hz. 2 H); 3.88 (s, 3 H); 4.64 (dt. J-6.1 and 11.9 Hz, 1 H): 6.85 (s, 1 H); 6.89 (d, J-7.8 Hz, 1 H); 7.88 (m, 3 H); 7.97 | A 547 0.70 |
154
Compound C | Compound II | Compound lllb | Name | NMR | MS conditions? MH+/Tr |
carboxamide | (s, 1 H); 8.14 (s, 1 H); 830 (broad s. 1 H); 935 (s, 1 H) | ||||
1-117 | II-31 | lltb-35 | 2-((4-(3(Dimettiylamino)pyr roildin -1 -yl]-5-mettiyl-2-{propan2-ytoxy)phenyl}amino)-7(2-methoxypyrid(n-3yl)thieno(33^1]pyrimldine6-carboxamide | 138 (dd. J-1.0 and 5.9 Hz, 6 H); 1.58 (m. 1 H); 1.86 (m. 1 H); 2.06 (s. 3 H); 2.18 (s, 3 H): 233 (dd. J-6.0 and 93 Hz, 1 H); 2.41 (m, 5 H): 2.59 (m, 1 H): 3.61 (m, 1 H); 3.79 (m. 3 H); 4.60 (dt. JU6.3 and 123 Hz, 1 H): 6.77 (s, 1 H): 7.16 (dd. J-5.0 and 7.2 Hz. 1 H): 7.44 (broad s, 1 H); 7.70 (broad s, 1 H): 7.84 (s, 1 H); 7.91 (dd. J-2.0 and 7.3 Hz, 1 H); 8.01 (s, 1 H); 837 (dd, J-1.8 and 5.0 Hz, 1 H): 9.22 (s, 1 H) | A 562 0.70 |
ΙΊ18 | 11-5 | lllb-35 | 2-((4-(3(Dimethylamlno)pyrroiidin -1 -yf]-5-mettiyl-2-{propan2-yloxy)pheny1}amino)-7(2methoxyphenyi)ttileno[3,2 -d]pyrimidlne-6carboxamide | 138 (dd, ^1.0 and 5.9 Hz, 6 H); 1.57 (m, 1 H); 1.85 (m, 1 H); 2.02 (s, 3 H); 2.18 (s. 3 H); 231 (dd, J-6.0 and 9.2 Hz, 1 H): 2.38 (m, 1 H); 2.46 (S, 4 H); 2.58 (dd. J-7.2 and 8.9 Hz, 1 H); 3.60 (m, 1 H): 3.70 (s, 3 H); 4.60 (spt, J-6.1 Hz, 1 H); 6.76 (s, 1 H); 6.82 (broad s, 1 H); 7.13 (t, JU7.5 Hz, 1 H); 730 (d. JU8.1 Hz, 1 H); 7.49 (m, 2 H); 7.73 (broad s, 1 H); 7.79 (s, 1 H); 8.03 (s, 1 H); 930 (s, 1 H) | A 561 0.75 |
1-119 | 11-19 | lllb-56 | 2-((3-(1 -(Oxetan-3yl)plperidin-4-y f]-1 (propan-2-yl)-1 H-pyrazol5-ylJamino)-7-(2(trifluoromethoxy)phenyl]t hieno[33-d]pyrimidine-6carboxamide | I. 22 (d, J-6.4 Hz, 6 H); 1,50 (qd, J-3.4 and 123 Hz, 2 H): 1.74 (d, J-11.5 Hz, 2 H); 1.83 (m, 2 H); 2.42 (tt, J-3.8 and II. 6 Hz, 1 H); 2.73 (d. J-11.2 Hz, 2 H); 3.39 (s, 1 H); 4.43 to 4.51 (m, 3 H); 4.57 (m, 2 H); 6.01 (s, 1 H); 7.36 (broad s, 1 H); 7.47 (m, 2 H); 7.60 (m, 2 H); 7.74 (broad s. 1 H); 936 (s, 1 H): 9.40 (broad s, 1 H) | A 602 0.59 |
1-120 | li-47 | lllb-7 | 7-(2-Methoxy-6methylpyridin-3-yl)-2-((5methyl-4-(1methylpiperidln-4-yl)-2(propan-2yfoxy)phenyQamino}thien o[3,2-d]py rim idine-6carboxamide | 1.29 (d, J-6.1 Hz, 6 H); 1.56 Id 1.73 (m, 4 H); 2.03 (m, 2 H); 2.10 (s. 3 H); 2.23 (s, 3 H): 2.49 (S, 3 H); 2.58 (m, 1 H); 2.90 (d, J-10.5 Hz. 2 H); 3.77 (s. 3 H); 4.62 (spt, J-6.0 Hz, 1 H): 6.80 (s. 1 H): 7.01 (d, J-7.3 Hz, 1 H); 7.31 (broad s, 1 H); 7.71 (broad s, 1 H); 7.77 (d. J-7.6 Hz. 1 H); 7.84 (s. 1 H): 8.03 (s, 1 H); 9.22 (s, 1 H) | A 561 0.68 |
1-121 | II-47 | lllb-25 | 7-{2-Methoxy-6mettiyipyrldin-3-yl)-2-([4(4-methylpiperazin-1 -yl)2-{propan-2yloxy)phenyl]amino]thien o[3,2-d]pyri midine-6carboxamide | 1.26 (d, J-6.1 Hz, 6 H); 235 (s, 3 H); 2.46 (masked m, 7 H); 3.07 (m, 4 H); 3.77 (s, 3 H); 4.64 (spt, J-6.0 Hz, 1 H); 6.35 (dd, J-2.6 and 8.9 Hz. 1 H); 6.62 (d. J-2.4 Hz, 1 H); 7.01 (d, J-7.6 Hz, 1 H): 7.33 (broad s, 1 H); 7.66 (broad s, 1 H): 7.78 (d, J-7.3 Hz, 1 H); 7.82 (s, 1 H); 7.92 (d. J-8.8 Hz. 1 H); 9.16 (s, 1 H) | A 548 0.64 |
1-122 | II-47 | lllb-3 | 7-(2-Methoxy-6methylpyridin-3-yl)-2-([4(1 -methylplperidin-4-yty-2(propan-2yloxy)phenyl]amino}thien o[3,2-d]pyrim idine-6carboxamide | 1.29 (d, J-6.1 Hz, 6 H); 1.55 to 1.78 (m, 4 H); 2.00 (t, J-10.8 Hz. 2 H): 2.22 (s. 3 H); 2.41 (m. 1 H); 2.50 (masked s, 3 H): 2.89 (d, J-113 Hz, 2 H); 3.78 (s. 3 H); 4.67 (spt, J-6.0 Hz, 1 H); 6.65 (dd, J-1.6 and 8.4 Hz, 1 H); 6.89 (d. J-1.5 Hz, 1 H); 7.03 (d, J-7.3 Hz, 1 H); 7.36 (broad s, 1 H); 7.69 (broad s. 1 H); 7.80 (d, J-7.3 Hz, 1 H); 7.91 (s, 1 H); 8.11 (d, J-8.3 Hz, 1 H); 932 (s, 1 H) | A 547 0.68 |
1-123 | 11-19 | lllb-58 | 2-((3-(1-Ethylplperidin-4yl)-1 -(propan-2-yl)-1 H- | 1.04 (t, J-7.3 Hz, 3 H); 132 (d, J-6.8 Hz, 6 H); 1.48 (qd, J-3.4 and 12.7 Hz, 2 | A 572 |
155
Compound Γ | Compound II | Compound lllb | Name | NMR | MS conditions MH+/Tr |
pyrazol-5-y1]ami no}-7-{2(trifluorometboxy)pheny!]t hieno[3,2-<Î]pyrifnidlne-6carboxamlde | H); 1.73 (d, J-11.7 Hz, 2 H); 1.93 (m, 2 H); 2.37 (m, 3 H); 2.90 (d, J.11.7 Hz. 2 H); 4.47 (dt, J-6.8 and 13 J Hz, 1 H); 5.98 (s, 1 H); 7.33 (broad s, 1 H); 7.46 (m, 2 H); 7.57 (m, 2 H); 7.72 (broad s, 1 H); 9.25 (s, 1 H); 9.35 (s, 1 H) | 0.61 | |||
1-124 | 11-5 | ll!b-8 | 2-({4-{(3R,4S)-3-Hydroxy- 1 -methy1piperldJn-4-y1]-2(propan-2y!oxy)pheny1}am ino)-7-(2methoxyphenyl)thleno[3,2 -dJpyrimldine-6carboxamide | Ή NMR spectrum (500 MHz, d in ppm, CHLOROFORM-d): 1.37 (d. J-5.5 Hz, 6 H); 1.65 (d. J-11.0 Hz, 1 H): 2.06 (m, 1 H); 2.21 (m. 2 H): 2.32 (s. 3 H): 2.36 (broad s, 1 H); 2.55 (d, J-12.6 Hz. 1 H); 2.95 (d, J-11.0 HZ, 1 H); 3.01 (d, J-11.0 Hz, 1 H): 3.76 (s. 3 H); 3.87 (broad s, 1 H); 4.61 (dt, J-6.0 and 12.1 Hz, 1 H); 5.49 (broad s, 1 H); 6.03 (broad s. 1 H); 6.64 (d, J-8.5 Hz, 1 H): 6.88 (s, 1 H); 7.11 (d, J-8.2 Hz, 1 H); 7.18 (t, J-7.4 Hz, 1 H); 7.47 (d, J-7.7 Hz, 1 H); 7.54 (t, J-7.8 Hz. 1 H): 7.86 (s, 1 H); 8.31 (d, J-8.2 Hz, 1 H); 8.97 (s, 1 H) | A 548 0.64 |
1-125 | 11-31 | lllb-20 | 7-(2-Methoxypyridi n-3-yl)2-({4-{(8S.8aS)octatiydrolndollzln-8-yl]-2(propan-2y Ioxy)pheny1)am inojthlen o[3,2-d]pyrimldlne-6carboxamide | 124 (m, Jt6.1 Hz. 7 H); 1.35 to 1.80 (m. 7 H); 1.91 (td, J-6.1 and 9.8 Hz, 1 H): 2.07 (m, 2 H); 2.31 (m, 1 H); 3.01 (m, 2 H); 3.80 (S, 3 H); 4.67 (spt, J^.O Hz, 1 H); 6.62 (dd. J-1.5 and 8.3 Hz, 1 H); 6.87 (d, J-1.5 Hz, 1 H); 7.18 (dd, J-5.1 and 7.3 Hz. 1 H); 7.47 (broad s, 1 H); 7.69 (broad s, 1 H); 7.91 (dd, J-2.0 and 7.3 Hz. 1 H): 7.93 (s, 1 H); 8.08 (d, J-8.3 Hz, 1 H); 8.28 (dd. J^2.0 and 5.1 Hz, 1 H); 9.24 (s, 1 H) | A 559 0.67 |
1-126 | II-31 | lllb-20 | 7-(2-Methoxypyrldin-3-y1)2-({4-Î(8R,8aS)octatiydroindollzin-8-yl}-2(propan-2yloxy)pheny1}amlno)thlen o[3,2-d]pyrim ldine-6carboxamide | I. 25 to 1.34 (m, 6 H); 1.39 to 1.74 (m, 8 H); 1.96 (m, 2 H): 2.21 (broad s, 1 H); 3.00 (d, J-16.9 Hz, 2 H); 3.12 (d, J. 10.0 Hz, 1 H); 3.79 (s. 3 H); 4.52 (spt, J-6.0 Hz, 1 H); 6.84 (d, J-8.1 Hz. 1 H); 7.14 (dd. J-5.0 and 7.2 Hz. 1 H); 7.47 (broad s. 1 H); 7.53 (broad s. 1 H); 7.69 (broad s. 1 H): 7.90 (m, 2 H); 8.03 (d, J-8.3 Hz. 1 H); 8.26 (dd. J-2.0 and 4.9 Hz. 1 H); 9.23 (s, 1 H) | A 559 0.68 |
1-127 | 11-5 | lllb-49 | 7-(2-Methoxyphenyl)-2{[4-(1 -rnethyH H-pyrazol4-yl)-2-(propan-2yloxy)pheny1]amlno}thlen o[3.2-d)pyrimldïne-6carboxamide | 1.33 (d, J-5.9 Hz, 6 H); 3.72 (s, 3 H); 3.85 (s, 3 H); 4,78 (spt, J-6.0 Hz. 1 H): 6.92 (d, JU6.8.HZ, 2 H); 7.19 (m, 3 H); 7.51 (m. 2 H): 7.74 (broad s, 1 H): 7.81 (s, 1 H): 7.92 (s, 1 H); 8.08 (S, 1 H): 8.23 (d, J-8.6 Hz, 1 H); 9.24 (s, 1 H) | A 484 0.97 |
1-128 | 11-31 | llib-52 | 7 - (2 -Methoxypyrid in-3-yl)2-[( 1 -mettiyl-2-oxo2,3,4,5-tetrahydro-1H-1 benzazepln-8y1)amlno)thleno[3,2d]pyrimidine-6carboxamide | 1.99 (m, 2 H); 2.13 (m, 2 H); 2.55 (t, J-6.8 Hz, 2 H); 2.97 (s, 3 H); 3.77 (s, 3 H); 7.06 (m. 2 H); 7.38 (m, 2 H); 7.67 (broad s. 1 H); 7.75 (s. 1 H); 7.86 (m. 1 H); 8.22 (d, J-4.9 Hz. 1 H): 92Ί (s, 1 H); 9.75 (s. 1 H) | A 475 0.70 |
157
Compound 1' | Compound II | Compound lllb | Name | NMR | MS conditions/ MH+/Tr |
1-136 | 11-31 | lllb-64 | 7-(2-Methoxypyrld in-3-yl)- 2-{[3-methy1-1 -(propan-2y1)-1H-pyrazol-5yl]amino}th leno[3,2d]pyr1midlne-6carboxamide | 1.22 (d. J - 6.0 Hz. 6 H); 2.09 (s. 3 H): 3.78 (s, 3 H): 4.45 (m. 1 H): 5.93 (s. 1 H): 7.10 (dd. J - 5.0 and 73 Hz, 1 H): 7.39 (broad m, 1 H); 7.69 (broad m, 1 H); 7.80 (dd, J - 2.2 and Ί2. Hz, 1 H): 8.22 (dd, J - 2.2 and 5.0 Hz. 1 H): 931 (s. 1 H); 9.32 (s, 1 H) | A 424 0.58 |
1-137 | 11-16 | lllb-7 | 7-{2-Fluorophenyl)-2-{[5methyt-4-(1methylplperidin-4-yf)-2(propan-2ytoxy)pheny1]amlno)thlen o[3,2-d]pyr1midlne-6carboxamlde | 139 (d, J - 6.0 Hz. 6 H); 1.53 to 1.70 (m. 4 H); 1.97 (m, 2 H); 2.08 (s. 3 H); 2.20 (s, 3 H): 2.52 (partially masked m, 1 H); 2.85 (m, 2 H): 4.62 (m, 1 H); 6.80 (S. 1 H); 7.35 (m, 2 H): 7.48 to 7.67 (m, 3 H); 7.78 (broad m. 1 H); 7.88 (s. 1 H); 8.02 (s, 1 H); 9.28 (s, 1 H) | B 534 0.83 |
1-138 | II-5 | lllb-52 | 7-{2-Methoxyphenyl)-2[(1 -methy1-2-oxo-2,3,4,5tetrahydro-lH-1benzazepin-8yl)am1 no]thleno{3,2d]pyr1midine-6carboxamide | 1.99 (m, 2 H); 2.11 (t, J - 6.9 Hz, 2 H); 2.52 (t, J - 6.9 Hz. 2 H); 2.72 (s. 3 H); 3.68 (s, 3 H); 6.72 (broad m, 1 H): 7.05 (m, 2 H); 7.15 (d, J - 8.5 Hz, 1 H); 7.38 (dd. J - 2.5 and 8.5 Hz. 1 H): 7.40 to 7.49 (m. 2 H); 7.73 (broad m, 1 H); 7.79 (d. J - 2.5 Hz, 1 H); 933 (s, 1 H); 9.73 (s, 1 H) | B 474 1.01 |
1-139 | 11-10 | lllb-59 | 7-(4-Fluoro-2methoxyphenyl)-2-{[3(piperidin-3-yl)-1 -{propan2-yl)-1 H-pyrazol-5yl]amino]thleno[3,2d]pyrimidine-6carboxamlde | 1.21 (broad d. J - 6.0 Hz. 6 H); 1,30 to 1.53 (m, 2 H); 1.63 (m, 1 H); 1.88 (m, 1 H); 2.40 to 2.60 (partially masked m, 3 H); 2.90 to 3.08 (m, 2 H): 3.58 (broad m, 1 H); 3.68 (s, 3 H); 4.52 (m, 1 H); 6.00 (s, 1 H); 6.89 (dt, J - 2.5 and 8.5 Hz. 1 H): 6.93 (broad m. 1 H): 7.04 (dd, J - 2.5 and 11,4 Hz, 1 H); 7.39 (dd, J - 7.1 and 8.5 Hz, 1 H): 7.72 (broad m, 1 H); 9.21 (s, 1 H); 9.39 (broad s, 1 H) | B 510 0.74 |
1-140 | 11-31 | lllb-63 | 2-{[3-Cyclopropyl-1 (propan-2-yf )-1 H-pyrazol- 5- y1]amino)-7-{2methoxypyridin-3- y1)thieno[3,2-d]pyrlmidlne- 6- carboxamide | 0.49 (m. 2 H); 0.80 (m, 2 H); 122 (d, J - 6.0 Hz, 6 H); 1.78 (m, 1 H); 3.78 (s, 3 H); 4.49 (m, 1 H); 5.79 (s. 1 H ): 7.10 (dd, J - 5.0 and 73 Hz. 1 H): 738 (broad m, 1 H); 7.70 (broad m, 1 H); 7.79 (dd, J - 2.0 and 7.3 Hz. 1 H); 833 (dd, J - 2.0 and 5.0 Hz, 1 H); 9.21 (s, 1 H); 9.31 (broad s, 1 H) | B 450 0.92 |
1-141 | II-10 | llib-62 | 7-(4-Fluoro-2methoxyphenyl)-2-{[1 (propan-2-y1)-3-(pyrid in-3y1)-1 H-pyrazol-5yljamino} thleno[3,2d]pyrimldine-6carboxamide | 1.33 (d. J - 6.0 Hz. 6 H); 3.68 (s. 3 H): 4.69 (m. 1 H); 6.71 (s, 1 H); 6.89 (dt, J 2.9 and 8.8 Hz. 1 H); 6.97 (broad m, 1 H); 7.05 (dd, J - 2.9 and 11.9 Hz, 1 H); 739 to 7.49 (m, 2 H); 7.73 (broad m, 1 H): 7.99 (td, J - 1.7 and 7.5 Hz, 1 H); 8.50 (dd, J - 1.7 and 5.0 Hz, 1 H); 8.90 (d. J - 1.7 Hz, 1 H); 937 (s, 1 H); 9.65 (broad s, 1 H) | B 504 0.86 |
1-142 | 11-31 | 111b-53 | 7-(2-Methoxypyridin-3-yi)2-((1-methy1-2-oxo2,3.4,5-tetrahydro-l H-1 benzazepin-7yt)amino]thleno[3,2dJpyrimldlne-6carboxamide | 2.00 (m, 2 H): 2.11 (m, 2 H); 2.48 (partially masked m, 2 H); 3.28 (s, 3 H); 3.80 (s. 3 H); 7.12 (d. J - 8.8 Hz, 1 H); 7.18 (dd, J - 5.0 and 73 Hz. 1 H); 6.91 (broad m. 1 H); 7.48 (dd, J - 2.6 and 8.8 Hz, 1 H): 7.71 (broad m, 1 H); 7.82 (d. J - 2.6 Hz, 1 H); 7.90 (dd, J - 1.8 and 73 Hz, 1 H); 8.28 (dd, J -1.8 and 5.0 Hz, 1 H); 938 (s. 1 H); 9.80 (broad 8,1 H) | B 475 0.88 |
1-143 | II-10 | lllb-42 | 7-(4-Fluoro-2methoxyphenyl)-2-{[2(propan-2-yloxy )-4-( 1 H- | 135 (d. J - 6.0 Hz, 6 H); 3.72 (s, 3 H); 4.73 (m, 1 H); 6.99 (m, 1 H); 7.08 to 7.19 (m, 2 H); 7.28 (d, J - 8.5 Hz, 1 H); | B 520 1.19 |
158
Compound Γ | Compound Η | Compound 111b | Name | NMR | MS conditions/ MH+/Tr |
1,2,4-triazol-lyl)phenyl]amlno}thleno[3, 2-d]pyr1midine-6carboxamide | 7.51 (m. 2 H); 7.73 (s. 1 H): 8.09 (s, 1 H); 8.20 (s, 1 H); 8.42 (d, J - 8.5 Hz, 1 H); 9.22 (s, 1 H): 9.29 (s, 1 H) | ||||
1-144 | li-31 | illb-41 | 2-((4-(2,4-DlmethyHHimidazoi-1 -y!)-2-(propan2-yloxy)pheny1]amino}-7(2-methoxypyridi n-3yf)thieno(35-d]pyrimidlne· 6-carboxamide | 1.30 (d, J - 6.0 Hz, 6 H): 2.09 (s, 3 H): 2.21 (s, 3 H): 3.80 (S, 3 H): 4.75 (m. 1 H); 6.76 (d, J - 8.5 Hz, 1 H); 6.90 (s, 1 H): 7.05 (s, 1 H); 7.20 (m, 1 H); 7.49 (broad m, 1 H); 7.70 (broad m, 1 H); 7.92 (m, 1 H); 8.10 (s. 1 H); 8.25 (m, 1 H); 8.30 (d, J - 8.5 Hz, 1 H); 9.30 (s, 1 H) . | B 530 0.89 |
1-145 | 11-31 | illb-51 | 2-{[4-Methoxy-2-(propan- 2-yioxy)pheny1]amino}-7(2-methoxypyridin-3yf)tti ienof3,2-djpyrimldlne6-carboxamide | 1.28 (d, J - 6.0 Hz, 6 H): 3.71 (s. 3 H); 3.80 (s. 3 H); 4.63 (m, t H); 6.35 (broad d, J - 8.5 Hz, 1 H); 6.61 (broad s, 1 H): 7.17 (m, t H); 7.43 (broad m, 1 H); 7.68 (broad m. 1 H): 7.88 (m. 2 H); 7.97 (d, J - 8.5 Hz, 1 H): 8.25 (d, J - 5.0 Hz, 1 H); 9.19 (s, 1 H) | B 466 1.26 |
1-146 | ii-5 | lilb-61 | 2-[(3-Cyclopropyl-1 phenyM H-pyrazol-5y!)amlno]-7-(2metfioxyphenyl)thieno[3,2 -d]pyrimidine-6carboxamlde | 0.61 (m, 2 H); 0.89 (m, 2 H); 1.36 (m, 1 H): 3.68 (s, 3 H); 6.04 (s. 1 H); 6.75 (broad m. 1 H); 7.08 (t, J - 7.8 Hz, 1 H): 7.24 (d, J - 8.0 Hz, 1 H); 727 (tt, J 1.7 and 7.5 Hz, 1 H); 729 (dd, J - 2.0 and 8.0 Hz, 1 H); 7.37 (t, J - 7.8 Hz, 2 H); 7.45 (m, 3 H); 7.71 (broad m, t H); 9.11 (s, 1 H); 9.22 (broad s, 1 H) | B 483 1.17 |
1-147 | il-31 | llib-29 | 2-((4-(5,6- DihydroÎmidazofl ,2a]pyrazln-7(8H)-yl)-2(propan-2ytoxy)phenyi]amlno}-7-(2methoxypyridin-3yf)thieno(3,2-d]pyr1mldine6-carboxamWe | 1.29 (d. J - 6.0 Hz, 6 H); 3.61 (m. 2 H); 3.80 (s, 3 H); 4.08 (m, 2 H); 4.31 (s, 2 H); 4.72 (m, 1 H); 6.48 (dd, J - 3.0 and 8.9 HZ, 1 H); 6.79 (d, J - 3.0 Hz, 1 H); 6.90 (d, J - 10 Hz, 1 H); 7.10 (d, J - 1,0 Hz, 1 H): 7.19 (dd, J - 5.0 and 7.3 Hz, 1 H); 7.46 (broad m, 1 H): 7.69 (broad m, 1 H); 7.88 (s. 1 H); 7.90 (dd, J - 2.0 and 7.3 Hz, 1 H): 8.00 (d, J - 8.9 Hz, t H): B2B (dd, J - 2.0 and 5.0 Hz, 1 H); 9.20 (s. 1 H) | B 557 0.84 |
1-148 | il-5 | illb-6 | 2-04-(1- Cydopropylpiperidin-4yl)-2-(propan-2ytoxy)phenyl]amlno}-7-(2methoxyphenyl)thieno[3,2 -d]pyrimidine-6carboxamlde | 0.30 (m, 2 H); 0.42 (m, 2 H); 1.29 (d, J - 6.0 Hz, 6 H); 1.48 to 1.72 (m. 5 H); 2.21 (m. 2 H); 2.41 (m, 1 H): 3.00 (m, 2 H); 3.70 (s, 3 H): 4.68 (m, 1 H); 6.59 (dd, J - 1.7 and 8.6 Hz, 1 H); 6.86 (d, J - 1.7 Hz, 1 H); 6.90 (broad m, 1 H); 7.13 (t, J - 7.8 Hz, 1 H); 7.20 (d. J - 8,0 Hz, 1 H); 7.42 to 7.52 (m. 2 H): 7.74 (broad m. 1 H): 7.86 (s. 1 H): 8.12 (d, J - 8.6 Hz, 1 H); 9.20 (s, 1 H) | B 558 0.95 |
1-149 | ii-11 | lllb-6 | 2-((4-(1- Cyclopropylpiperidin-4y()-2-(propan-2ytoxy)pheny1]amino}-7-(5nuoro-2methoxyphenyOthienopÆ -dJpyrlmidine-6carboxamlde | 0.30 (m. 2 H); 0.42 (m, 2 H); 1.29 (d, J - 6.0 Hz, 6 H); 1.48 to 1.72 (m, 5 H); 2.21 (m, 2 H); 2.42 (m, 1 H); 3.00 (m, 2 H); 3.69 (s, 3 H); 4.68 (m, 1 H); 6.60 (dd, J - 1.7 and 8.6 Hz, 1 H); 6.89 (d, J - 1.7 Hz, 1 H); 7.15 (dd, J - 4.5 and 9.2 Hz, 1 H); 7.24 (broad m, 1 H); 7.30 (dt, J - 3.0 and 9.02 Hz, 1 H); 7.38 (dd, J. 3.0 and 9.4 Hz, 1 H); 7.70 (broad m, 1 H): 7.90 (s, 1 H); 8.15 (d, J - 8.6 Hz, 1 H);9.21 (s, IH) | B 576 0.96 |
Μ 50 | li-31 | llib-6 | 2-04-(1- Cyclopropylpiperidin-4ylj-2-(propan-2- | 0.30 (m, 2 H); 0.42 (m, 2 H); 1.29 (d, J - 6.0 Hz, 6 H); 1.48 to 1.72 (m, 5 HJ; 222 (m, 2 H): 2.42 (m, 1 H); 3.01 (m. 2 | B 559 0.89 |
139
Compound Γ | Compound II | Compound llib | Name | NMR | MS conditions) ΜΗ+/ΊΪ |
yloxy)phenyl]am ino}-7-{2methoxypyrldln-3yl)thieno(3,2-d]pyrimidine6-carboxamide | H); 3.80 (s, 3 H); 4.68 (m, 1 H); 6.61 (dd. J - 1.7 and 8.4 Hz, 1 H); 6.89 (d, J - 1.7 Hz, 1 H): 7.19 (dd, J - 4.9 and 7.4 Hz, 1 H); 7.48 (broad m, 1 H); 7.70 (broad m, 1 H); 7.81 (m, 2 H): 8.10 (d, J - 8.4 Hz, 1 H); 8.29 (dd, J - 1.9 and 4.9 Hz, 1 H); 9.22 (s, 1 H) | ||||
1-151 | 11-31 | itlb-40 | 7-(2-Methoxypyridin-3-ylF 2-{[4-{4-mettiyl-1Himidazol-1 -yl}-2-(propan2yloxy)phenyf]amlno}thlen o[3,2-d]pyrimldlne-6carboxamlde | 1.32 (d, J - 6.0 Hz, 6 H); 225 (s, 3 H); 3.80 (s, 3 H); 3.83 (m, 1 H); 6.98 (dd, J - 2.1 and 8.7 Hz, 1 H); 7.21 (dd, J - 5.0 and 7.5 Hz, 1 H); 824 (d, J - 2.1 Hz, 1 H); 7.40 (s, 1 H); 7.50 (broad m, 1 H); 7.71 (broad m, 1 H); 7.92 (dd. J - 1,9 and 7.5 Hz, 1 H); 8.08 (s, 2 H); 8.28 (m, 2 H); 9.29 (s, 1 H) | B 516 0.87 |
1-152 | 11-10 | itlb-53 | 7-(4-Fluoro-2methoxypheny 1)-2-((1 methyl-2-oxo-2,3,4.5tetrahydro-1 H-1 benzazepin-7yl)am Inojth leno(3,2d]pyrimidlne-6carboxamlde | 2.00 (m, 2 H); 2.10 (m, 2 H): 2.48 (m, 2 H): 3.18 (s, 3 H); 3.70 (s, 3 H): 6.90 to 7.16 (m. 4 H); 7.48 (m, 2 H); 7.72 (broad m, 1 H); 7.82 (d, J - 2.1 Hz, 1 H); 9.22 (s, 1 H); 9.78 (s, 1 H) | B 492 0.99 |
1-153 | II-30 | lllb-25 | 2-((4-(4 Methylplperazin1-yf)-2-(propan-2yloxy) phenyljam lno}-7-{ 1 oxidopyridln-2y1)thieno(32-d]pyrim1d1ne6-carboxamide | 125 (d, J - 6.0 Hz, 6 H); 221 (s, 3 H): 2.43 (m. 4 H); 3.05 (m, 4 H): 4.65 (m, 1 H); 6.40 (dd, J - 2.2 and 9.0 Hz, 1 H); 6.60 (d, J - 2.1 Hz. 1 H): 7.62 (m. 2 H); 7.76 (m, 2 H): 7.80 (d, J - 9.0 Hz, 1 H): 7.89 (s, 1 H); 8.50 (m, 1 H); 9.00 (broad m, 1 H): 929 (s, 1 H) | B 520 0.68 |
1-154 | II-5 | lllb-46 | 2-((4-(1 -EttiyH, 7diazasplro[4.4]non-7-ylF 2-(propan-2yloxy)phenyl]am1no}-7-{2methoxyphenyl)triieno[32 -d]pyrimidine-6carboxamlde | 1.02 (t, J - 7.0 Hz, 3 H); 123 (d, J - 6.0 Hz, 6 H); 1.64 (m, 1 H); 1.76 (m, 4 H); 2.08 (m, 1 H); 2.40 to 2.65 (partially masked m, 3 H); 2.82 (m, 1 H); 2.92 (d, J - 9.3 Hz, 1 H); 3.10 to 3.38 (partially masked m, 3 H); 3.70 (s, 3 H); 4.61 (m, 1 H); 5.92 (dd, J - 2.1 and 9.0 Hz, 1 H); 6.19 (d, J - 2.1 Hz, 1 H): 6.82 (broad m, 1 H); 7.11 (t, J - 7.8 Hz, 1 H); 7.19 (d, J - 8.0 Hz, 1 H); 7.41 to 7.51 (m, 2 H); 7.70 (m, 2 H); 7.82 (d, J - 9.0 Hz, 1 H); 9.10 (s, 1 H) | B 587 0.96 |
1-155 | II-44 | lllb-26 | 7-{2-Etboxypyrldin-3-yl)2-{(5-methyl-4-{4methylpiperazln-1 -yl}-2(propan-2ytoxy)phenyf]amino]thien o[3,2-d]pyr1midine-6carboxamkfe | 1.08 (t. J - 7.0 Hz, 3 H): 129 (d, J - 6.0 Hz, 6 H); 2.03 (s, 3 H): 222 (s, 3 H); 2.45 (m, 4 H); 2.79 (m, 4 H): 429 (q, J - 7.0 Hz, 2 H); 4.60 (m, 1 H); 6.70 (s, 1 H); 7.13 (dd, J - 5.1 and 7.4 Hz, 1 H); 7.47 (broad m, 1 H): 7.70 (broad m, 1 H); 7.81 (s. 1 H); 7.92 (dd. J - 2.1 and 7.4 Hz, 1 H); 8.03 (s, 1 H); 823 (dd, J 2.1 and 5.1 Hz, 1 H); 921 (s, 1 H) | B 562 0.88 |
1-156 | ll-5 | llib-67 | 2-{[4-{3,5-DimethyHH1,2,4-triazol-1-yl}-2(propan-2yloxy)phenyl]am lno)-7-(2metboxypheny1)tbleno(3.2 -d]pyrlmidlne-6carboxamlde | 1.31 (d, J - 6.0 Hz, 6 H); 225 (s, 3 H); 2.39 (s, 3 H); 3.70 (s, 3 H); 4.76 (m, 1 H); 6.85 (dd, J - 2.1 and 8.8 Hz, 1 H): 6.95 (broad m, 1 H): 7.13 (t. J - 7.8 Hz, 1 H); 7.19 (d, J - 2.1 Hz, 1 H); 720 (d, J - 8.0 Hz, 1 H); 7.49 (m, 2 H); 7.78 (broad m, 1 H); 8.09 (s, 1 H); 8.40 (d, J - 8.8 Hz, 1 H); 9.29 (s, 1 H) | B 530 1.13 |
1-157 | 11-36 | lllb-26 | 7-(5-Fluoro-2mettioxypyrldin-3-yl}-2n5-mettiyl-4-(4- | 128 (d, J-6.1 Hz, 6 H); 2.05 (s, 3 H); 223 (s. 3 H); 2.46 (m, 4 H): 2.78 (m, 4 H); 3.78 (s, 3 H); 4.60 (m. 1 H); 6.70 (s. | B 566 0.88 |
160
Compound ι· | Compound II | Compound lllb | Name | NMR | MS conditions/ MH+JTr |
methylpiperazin-1 -yl)-2(propan-2ytoxy)phenyl]amino}thien o[3,2-d]pyrimidlne-6cartraxamide | 1 H); 7.55 to 7.74 (broad m. 2 H); 7.86 to 7.94 (m, 2 H): 7.98 (s. 1 H); 8.25 (d. J-3.1 Hz, 1 H): 9.23 (s. 1 H) | ||||
1-156 | li-47 | illb-38 | 7-(2-Methoxy-6methylpyridin-3-yl)-2-([4(2-methyH H-imidazol-l yl)-2-(propan-2ytoxy) ph enyl]amlno}thle n o[3,2-d]pyr1 mid ine-6carboxamide | 1.31 (d. J - 6.0 Hz. 6 H); 2.29 (s, 3 H); 2.47 (s, 3 H); 3.79 (s. 3 H); 4.79 (m. 1 H); 6.81 (dd, J - 2.2 and 8.6 Hz, 1 H): 6.90 (d, J - 1.0 Hz, 1 H); 7.04 (d, J - 7.6 Hz, 1 H); 7.11 (d. J - 2.1 Hz. 1 H): 7.22 (d, J - 1.0 Hz, 1 H); 7.40 (broad m, 1 H); 7.70 (broad m. 1 H); 7.81 (d, J - 7.6 Hz. 1 H); 8.11 (s. 1 H): 8.36 (d, J - 8.6 Hz, 1 H); 9.29 (s, 1 H) | B 530 0.89 |
1-159 | Il-5 | lllb-66 | 7-(2-Methoxyphenyl)-2((44(4-methytpiperazin-1 y1)methyl]-2-{propan-2yfoxy)p henyl)amino)thlen o[3,2-d]pyr1 mldin e-6carboxamide | 1.30 (d, J - 6.0 Hz, 6 H); 2.13 (s, 3 H); 2.30 (broad m, 8 H); 3.38 (s, 2 H); 3.70 (s. 3 H); 4.61 (m, 1 H): 6.82 (dd, J - 1.9 and 8.8 Hz, 1 H); 6.89 (broad m, 1 H); 6.91 (d, J - 1.9 Hz, 1 H); 7.11 (t, J - 7.8 Hz, 1 H); 7.19 (d, J - 8.0 Hz, 1 H); 7.42 to 7.52 (m, 2 H); 7.71 (broad m. 1 H): 7.90 (s. 1 H); 8.17 (d, J - 8.8 Hz, 1 H); 9.21 (s. 1 H) | B 547 0.82 |
1-160 | 11-47 | illb-26 | 7-(2-Methoxy-6m ethylpyr idi n-3-y 1)-2-( [5 · methyt-4-(4· methytpiperazin-1 -yt)-2(propan-2yfoxy)phenyl]amino)thlen o[3,2-d]pyrimldine-6carboxamide | 1.30 (d, J - 6.0 HZ, 6 H): 2.03 (s, 3 H); 2.22 (s. 3 H): 2.40 to 2.53 (partially masked m, 7 H); 2.79 (m, 4 H); 3.78 (s, 3 H); 4.60 (m. 1 H); 6.70 (s. 1 H); 7.01 (d, J - 7.7 Hz. 1 H); 7.30 (broad m, 1 H): 7.70 (broad m. 1 H); 7.78 (d. J - 7.7 Hz, 1 H); 7.80 (s, 1 H); 8.03 (s, 1 H); 9.20 (s, 1 H) | B 562 0.89 |
1-161 | 11-5 | lllb-65 | 7-(2-Methoxyphenyl)-2{(1-methyl-2-oxo-6(propan-2-yloxy)-2,3,4,5tetrahydro-lH-1benzazepin-7yl]am 1 no)thieno(3,2d]pyrimldlne-6carboxamide | 1.22 (d. J - 6.0 Hz. 6 H); 2.04 (m, 2 H); 2.16 (m. 2 H): 2.69 (m, 2 H); 3.20 (s, 3 H); 3.70 (s, 3 H); 4.18 (m. 1 H); 6.90 (m, 2 H); 7.11 (t, J-8.0 Hz, 1 H); 7.19 (d, J - 8 0 Hz, 1 H); 7.48 (m, 2 H); 7.72 (broad m, 1 H); 8.03 (d, J - 8.0 Hz, 1 H): 8.13 (3,1 H); 9.22 (s. 1 H) | B 532 1.18 |
1-162 | 11-31 | lllb-65 | 7-(2-Methoxypyridin-3-yt)2-{[ 1 -methyk2-oxo-6(propan-2-y loxy)-2,3,4,5tetrahydro-lH-1benzazepin-7yl]amino]thieno[3,2dJpyrimidine-6carboxamide | 1.21 (d, J - 6.0 Hz, 6 H); 2.04 (m, 2 H); 2.17 (m. 2 H): 2.69 (m. 2 H): 3.20 (s, 3 H): 3.70 (s, 3 H); 4.16 (m, 1 H); 6.95 (d, J - 8.8 Hz, 1 H); 7.18 (dd. J - 5.0 and 7.3 Hz, 1 H); 7.48 (broad m, 1 H); 7.70 (broad m, 1 H); 7.91 (dd. J - 2.0 and 7.3 Hz, 1 H); 8.00 (d, J - 8.8 Hz, 1 H); 8.23 (m, 2 H); 9.26 (s. 1 H) | B 533 1.09 |
1-163 | 11-5 | lllb-68 | 7-(2-Methoxypheny1)-2{[5-(4-methytplperazln-1 yl)-2-(propan-2yk>xy)p henyl]amino|thie n o(3,2-d]pyrimidine-6cafboxamide | 1.28 (d. J-6.1 Hz, 6 H); 2.24 (s, 3 H); 2.34 (m, 4 H); 2.68 (m, 4 H); 3.68 (s, 3 H); 4.49 (m, 1 H); 6.43 (dd, J-2.9 and 9.0 Hz, 1 H); 6.64 (broad s, 1 H); 6.89 (d, J-9.0 Hz, 1 H); 7.09 (broad t, J-7.8 Hz, 1 H); 7.19 (broad d, J-7.8 Hz, 1 H); 7.38 (dd, J-1.8 and 7.8 Hz, 1 H): 7.48 (m. 1 H); 7.74 (d, J-2.9 Hz, 1 H); 7.78 (broad s, 1 H); 7.92 (s. 1 H); 9.26 (s, 1 H) | B 533 0.93 |
1-164 | 11-5 | lllb-69 | 7-(2-Methoxyphenyl)-2([2-(propan-2-yloxy}-4(tetrahydro-2H-pyran-4ytamlno)phenyl]amino}thl enof3,2-dlPYr1mldine-6- | 1.24 (d, J-6.1 Hz, 6 H): 1-33 (m. 2 H); 1.85 (m, 2 H); 3.41 (m, 3 H); 3.70 (s, 3 H); 3.86 (m, 2 H); 4.49 (m, 1 H): 5.17 (broad d, J-8.3 Hz, 1 H); 6.03 (dd, J-2.5 and 8.5 Hz, 1 H); 6.31 (d, J-2.5 | B 534 0.98 |
161
Compound ι· | Compound II | Compound lut* | Name | NMR | MS conditions/ MH+/Tr |
carboxamide | Hz, 1 H); 6.82 (broad s, 1 H); 7.09 (t, J-7.8 Hz, 1 H); 7.15 (d, J-7.8 Hz, 1 H); 7.40 to 7.50 (m, 2 H); 7.65 to 7.75 (m, 3 H); 9.10 (s. 1 H) | ||||
1-165 | 11-48 | lllb-26 | 7-(3-Methoxypyrld i n-2-yl)2J[5-methyl-4J4methyipiperazin-1 -yl)-2(propan-2ytoxy)phenyl]amlnojthien o[3,2-d]pyrimldine-6carboxamlde | 1.28 (m, 6 H); 2.00 (s, 3 H); 2.23 (s, 3 H); 2.50 (masked m, 4 H); 2.77 (m, 4 H): 3.70 (s, 3 H): 4.59 (m, 1 H); 6.68 (s, 1 H); 7.49 to 7.97 (m, 6 H); 8.35 (m, 1 H); 9.23 (s, 1 H) | B 548 0.82 |
1-166 | 11-31 | lllb-70 | 2-([4-(4-Hydroxypiperldin1-yl)-2-(propan-2ytoxy)phenyl]amino}-7-(2methoxypyridin-3yf)thieno{33-d]pyrlmldlne6-carboxamWe | 136 (d, J-6.1 Hz, 6 H); 1.49 (m. 2 H); l. 82 (m. 2 H); 2.75 (m, 2 H): 3.42 (m, 2 H); 3.60 (m, 1 H); 3.80 (s, 3 H); 4.57 to 4.68 (m, 2 H); 6.34 (dd, J-2.1 and 8.4 Hz, 1 H); 6.61 (d, J-2.1 Hz, 1 H); 7.17 (dd, J-5.1 and 8.3 Hz, 1 H); 7.45 (broad m. 1 H); 7.67 (broad m, 1 H): 7.81 (s, 1 H); 7.87 to 7.93 (m, 2 H): 836 (dd. J-2.0 and 5.1 Hz, 1 H): 9.17 (s, 1 H) | B 535 0.83 |
1-167 | II-5 | llib-73 | 7-(2-Methoxyphenyl)-2((4-((1 -methylpiperldln-4yl)amlno]-2-(propan-2yloxy)phenyl}amlno)thien o[3,2-d]pyr1mld irte-6carboxamide | 134 (d. J-6.1 Hz, 6 H); 1.35 (m. 2 H); 1.85 (m, 2 H); 2.02 (m, 2 H); 2.17 (s, 3 H); 2.71 (m, 2 H); 3.13 (m, 1 H); 3.69 (s, 3 H); 4.48 (m, 1 H): 5.09 (broad d, J-8.6 Hz, 1 H); 6.00 (dd, J-2.5 and 8.5 Hz. 1 H); 838 (d, J-2.5 Hz, 1 H); 6.82 (broad s, 1 H): 7.08 (t, J-7.8 Hz. 1 H); 7.15 (d, J-7.8 Hz. 1 H); 7.39 to 7.48 (m. 2 H); 7.62 to 7.76 (m, 3 H); 9.09 (s, 1 H) | B 547 0.86 |
1-168 | 11-10 | 1llb-74 | 2J[1-Cyclobuty1-3-(1ethylpiperidin-4-yl)-1 Hpyrazol-5-yl]amlnoj-7-(4fluoro-2methoxyphenyl)thleno[33 -d]pyrimldlne-6carboxamlde | 1.03 (t, J-7.3 Hz, 3 H); 1.44 to 1.82 (m, 6 H): 1.94 (m, 2 H); 2.16 (m, 2 H); 2.34 (q, J-7.3 Hz, 2 H); 2.42 (m, 3 H); 2.91 (m. 2 H); 3.67 (s, 3 H); 4.78 (m, 1 H); 6.02 (s, 1 H); 6.88 (td, J-2,4 and 8.6 Hz. 1 H); 6.94 (broad m, 1 H); 7.03 (dd, J-2.4 and 11.5 Hz, 1 H); 7.39 (dd. J-6.8 and 8.6 Hz, 1 H); 7.72 (broad m, 1 H); 931 (s, 1 H); 9.42 (broad s, 1 H) | B 550 0.84 |
1-169 | II-31 | lllb-66 | 7-(2-Methoxypyridin-3-yl)- 2-({4-[(4-m ethy Ipiperazin- 1 -yl)methyl]-2-(propan-2yk>xy)phenyl}amlno)thien o[3,2-d]pyrimidlne-6caiboxamide | 1.30 (d, J-6.1 Hz, 6 H); 2.15 (s, 3 H); 2.55 to 2.45 (broad m, 8 H); 3.38 (s, 2 H); 3.60 (s, 3 H); 4.63 (m, 1 H); 6.68 (dd. J-1.7 and 8.3 Hz, 1 H); 6.94 (d, J-1.7 Hz. 1 H); 7.17 (dd, J-5.0 and 7.3 Hz, 1 H); 7.48 (broad s, 1 H): 7.71 (broad s. 1 H); 7.91 (dd, J-2.0 and 7.3 Hz. 1 H); 7.96 (s. 1 H); 8.14 (d, J-8.3 Hz, 1 H); 838 (dd, J-2.0 and 5.0 Hz, 1 H); 9.25 (s, 1 H) | B 548 0.83 |
1-170 | 11-31 | lllb-71 | 7-(2-Methoxypyrldin-3-yl)- 2^(4-(1-methyipyrrolldin3-yl)-2-(propan-2yloxy)phenyl]amino}thlen o[3.2-d]pyrimldlne-6carboxamide | 1.29 (d, J-6.1 Hz, 6 H); 1.73 (m, 1 H): 230 (m, 1 H); 2.30 (s, 3 H): 2.39 (dd. J-5.7 and 8.5 Hz, 1 H); 2.61 (m, 2 H): 2.83 (t, J-8.5 Hz, 1 H): 337 (partially masked m. 1 H): 3.80 (s, 3 H): 4.64 (m, 1 H); 6.66 (dd, J-2.1 and 8.3 Hz, 1 H); 6.92 (d, J-2,1 Hz, 1 H); 7,17 (dd. J-5.1 and 7.3 Hz, 1 H); 7.47 (broad m, 1 H): 7.70 (broad m, 1 H); 7.91 (dd, J-2.0 and 7.3 Hz, 1 H); 7.93 (s, 1 H); 8.08 (d, J-8.3 Hz, 1 H): 838 (dd, J-2.0 and 5.1 Hz. 1 H); 934 (s, 1 H) | B 519 0.89 |
162
Compound r | Compound il | Compound itib | Name | NMR | MS conditions/ MH+/Tr |
1-171 | 11-5 | lllb-75 | 7-(2-Methoxyphenyl)-2{[3-(4-methylpiperazin-1 yl)-2-(propan-2yloxy)phenyf]am Inojthien o[3,2-d]pyrimidine-6carboxamide | 120 (d, J-6.1 Hz, 6 H); 2.22 (s, 3 H); 2.47 (partially masked broad m, 4 H); 2.99 (broad m, 4 H); 3.70 (s, 3 H); 4.85 (m, 1 H): 6.59 (dd, J-1.5 and 8.3 Hz, 1 H); 6.81 (t, J-8.3 Hz, 1 H); 7.00 (broad s. 1 H); 7.12 (t, J-7.8 Hz, 1 H); 7.19 (d. J-7.8 Hz. 1 H); 7.45 to 7.52 (m, 2 H); 7.79 (broad s, 1 H); 7.99 (dd, J-1.5 and 8.3 Hz, 1 H); 8.03 (s, 1 H); 9.25 (s, 1 H) | B 533 0.83 |
1-172 | 11-36 | lllb-72 | 7-(5-Fluoro-2methoxypyrldln-3-yt)-2 ((1-(propan-2-yl)-3(tetrahydro-2H-pyran-4yî)-1 H-pyrazol-5yf]amino}thieno[3,2d]pyrimldine-6carboxamide | 1.23 (d, J-6.6 Hz, 6 H); 1.54 (m, 2 H); l. 71 (m, 2 H); 2.70 (m. 1 H): 3.41 (m. 2 H); 3.75 (s, 3 H); 3.89 (m, 2 H); 4.50 (m, 1 H): 6.02 (s. 1 H); 7.48 to 7.72 (broad m, 2 H); 7.78 (dd, J-2.9 and 8.6 Hz, 1 H); 8.19 (d, J-2.9 Hz, 1 H); 9.25 (s, 1 H); 9.43 (broad s, 1 H) | B 512 1.01 |
1-173 | 11-36 | lllb-64 | 7-(5-Fluoro-2methoxypyridin-3-yl)-2{[3-methyi-1 -(propan-2yf)-1 H-pyrazol-5yl]amino}thieno[3.2d]pyrimldine-6carboxamlde | 123 (d. J-8.6 HZ. 6 H); 2.10 (s. 3 H); 3.76 (s, 3 H): 4.46 (m, 1 H); 5.98 (s. 1 H); 7.53 to 7.72 (broad m, 2 H); 7.82 (dd, J-3.1 and 8.7 Hz, 1 H); 8.21 (d, J-3.1 HZ, 1 H); 9.23 (S. 1 H); 9.39 (broad s, 1 H) | B 442 0.95 |
1-174 | 11-31 | lllb-76 | 7-(2-Methoxypyridln-3-yf)2-{(5-methyl-2,3.4.5tetrahydro-1,5benzoxazepln-7yf)amino]thieno[3,2d]pyr1mldine-6carboxamlde | 1.88 (m, 2 H); 2.52 (s, 3 H): 3.00 (m, 2 H); 3.78 (s, 3 H); 3.87 (m, 2 H); 6.66 (d, J-8.6 Hz, 1 H); 7.07 to 7.16 (m, 2 H); 723 (d. J-2.1 Hz, 1 H): 7.33 (broad s, 1 H); 7.67 (broad s, 1 H): 7.82 (dd, J-2.0 and 7.3 Hz, 1 H); 8.25 (dd, J-2.0 and 5.1 Hz. 1 H); 9.21 (s. 1 H); 9.45 (broad s. 1 H) | B 463 0.90 |
1-175 | 11-19 | ltib-72 | 2-[[1-(Propan-2-yl)-3(tetrahydro-2H-pyran-4yf)-1 H-pyrazol-5yl]amino}-7-[2(trtfluoromethoxy)phenyf]t hieno(3,2-d)pyrimidine-6carboxamide | 1 /23 (d. J-6.5 HZ. 6 H): 1.50 (m, 2 H); 1.68 (m, 2 H); 2.68 (m, 1 H); 3.40 (m. 2 H); 3.89 (m, 2 H); 4.49 (m. 1 H); 5.99 (s, 1 H); 7.36 (broad m. 1 H); 7.41 to 7.50 (m, 2 H); 7.57 (m, 2 H); 7.74 (broad m, 1 H); 926 (s, 1 H); 9.41 (broad s, 1 H) | B 547 1.14 |
1-176 | 11-31 | lllb-75 | 7-(2-Methoxypyridin-3-yl)- 2-j[3-(4-methylpiperazin1-yl)-2-(propan-2ytoxy)phenyt]amino}thien o[3,2-d]pyrimldirte-6carboxamide | For this batch, ail the signais are broad with: 1.20 (d, J-6.0 Hz, 6 H); 2.22 (s, 3 H); 2.48 (partially masked m, 4 H); 2.99 (m. 4 H); 3.80 (s, 3 H); 4.83 (m. 1 H); 6.60 (d. J-8.0 Hz, 1 H); 6.84 (t, J-8.2 Hz. 1 H); 7.19 (m. 1 H); 7.53 (s, 1 H); 7.75 (s. 1 H): 7.90 to 8.00 (m, 2 H): 8.08 (s, 1 H); 828 (d, J-5.0 Hz. 1 H); 928 (3,1 H) | B 534 0.74 |
1-177 | li-31 | illb-68 | 7-(2-Methoxypyridin-3-yl)- 2-[[5- (4-methylplperazln1-yI]-2-(propart-2yloxy)phenyf]am1no}thien o[3,2-d]pyri mldine-6carboxamlde | For this batch, ali the signais are broad with: 1.19 (d, J-6.0 Hz, 6 H); 225 (s. 3 H); 2.39 (m, 4 H); 2.71 (m, 4 H); 3.78 (s, 3 H); 4.50 (m, 1 H); 6.45 (dd. J-2.1 and 8.5 Hz, 1 H); 6.90 (d, J-8.5 Hz, 1 H); 7.11 (m, 1 H): 7.41 (s. 1 H): 7.72 (s, 1 H); 7.76 (d, J-2.1 Hz, 1 H); 7.81 (d, J-7.4 HZ, 1 H); 7.96 (s, 1 H); 8.27 (d. J-5.0 Hz, 1 H); 9.29 (s, 1 H) | B 534 0.82 |
1-178 | li-31 | iilb-73 | 7-(2-Methoxypyridin-3-yl)- 2-((4-( { 1 -methytpl peridin4-yi)amino]-2-(propan-2ytoxy) ph enyfjam lno)thien ol3,2-dlpvrim ktine-6- | 124 (d, J-6.1 Hz, 6 H); 126 (m, 2 H); 1.85 (m, 2 H); 2.01 (m, 2 H); 2.17 (s. 3 H); 2.70 (m, 2 H); 3.13 (m, 1 H); 3.79 (s, 3 H); 4.48 (m, 1 H); 5.11 (d, J-8.3 Hz, 1 H); 6 03 (dd, J-2.4 and 8.8 Hz, 1 H): | B 548 0.73 |
163
Compound I’ | Compound II | Compound lllb | Name | NMR | MS conditions/ MH+/Tr |
carboxamide | 6.29 (d, J-2.4 Hz. 1 H): 7.11 (dd. J-5.1 and 7.3 Hz, 1 H); 7.42 (broad s, 1 H); 7.65 (partialfy masked broad s. 1 H); 7.68 (d, J-8.8 Hz, 1 H); 7.72 (s. 1 H); 7.87 (dd. J-2.0 and 7.3 Hz, 1 H); 8.23 (dd, J-2.0 and 5.1 Hz, 1 H); 9.12 (s, 1 H) | ||||
1-179 | 11-31 | lllb-77 | 2-{[4-(4-Ethy1pfperazin-1 · yl)-2-(propan-2ytoxy)phenyt]am lno}-7-(2methoxypyridin-3yljth ieno[3,2-d]pyrlmfdine6-carboxamlde | 1.03 (t, J-7.2 Hz, 3 H); 1.26 (d, J-6.1 Hz, 6 H); 2.37 (q. J-7.2 Hz, 2 H); 2.50 (masked m, 4 H)*, 3.06 (m, 4 H); 3.80 (s, 3 H); 4.64 (m, 1 H); 6.34 (dd. J-2.5 and 8.8 Hz, 1 H); 6.62 (d. J-2.5 Hz, 1 H); 7.17 (dd, J-4.9 and 7.3 Hz, 1 H); 7.44 (broad s. 1 H); 7.67 (broad s, 1 H); 7.83 (s, 1 H); 7.90 (dd, J-2.0 and 7.3 Hz, 1 H); 7.93 (d. J-8.8 Hz, 1 H); 8.26 (dd, J-2.0 and 4.9 Hz, 1 H); 9.18 (s. 1 H) | CD CA “Sri |
1-180 | 11-5 | lllb-78 | 7-(2-Methoxyphenyl)-2{[1 · methy I-2-oxo-8(p ropan-2-yloxy)-2.3.4.5tetrahydro-1 H-1 benzazepln-7y!]amlno}thieno[3,2d]pyrimldine-6carboxamide | 1.32 (d, J-6.0 Hz, 6 H); 1.96 (m, 2 H): 2.10 (t, J-6.5 Hz, 2 H); 2.35 (broad X, J-6.5 Hz, 2 H); 3.19 (s, 3 H); 3.69 (s. 3 H); 4.71 (m. 1 H); 6.82 (broad m, 1 H); 7.00 (s, 1 H); 7.13 (t, J-7.8 Hz, 1 H); 7.20 (d, J-7.8 Hz, 1 H); 7.41 to 7.55 (m, 2 H); 7.76 (broad m, 1 H); 7.91 (s, 1 H): 8.14 (s, 1 H); 9.25 (s. 1 H) | B 532 1.3 |
1-181 | 11-5 | lllb-72 | 7-(2-Methoxyphenyl}-2{[1-(propan-2-yl)-3(tetrahydro-2H-py ran-4 · yt)-1 H-pyrazol-5yf]amino]thieno[3,2d]pyrimldine-6carboxamide | 1.23 (d, J-6.5 Hz. 6 H); 1.52 (m, 2 H); 1.68 (m, 2 H); 2.68 (m, 1 H): 3.40 (m, 2 H); 3.67 (s. 3 H); 3.90 (m, 2 H); 4.50 (m, 1 H); 6.01 (s, 1 H); 6.70 (broad m, 1 H); 7.07 (t, J-7.6 Hz, 1 H): 7.15 (d, J-7.8 Hz, 1 H); 7.36 (dd, J-1.8 and 7.8 Hz, 1 H); 7.45 (tri, J-1.8 and 7.8 Hz, 1 H); 7.75 (broad m, 1 H); 9.21 (s, 1 H); 9.37 (broad s, 1 H) | B 493 1.03 |
1-182 | 11-31 | lllb-78 | 7-(2-Methoxypyrid i n-3-yt)2-((1 -methyl-2-oxo-8(propan-2-ytoxy)-2,3,4,5tetrahydro-1H-1benzazepin-7y(]amino}thleno[3,2dJpyrimldlne-6carboxamlde | l. 32 (d, J-6.0 Hz, 6 H); 1.99 (m, 2 H); 2.11 (t, J-6.5 Hz, 2 H); 2.41 (broad t, J-6.5 Hz, 2 H); 3.19 (s, 3 H); 3.79 (s, 3 H); 4.71 (m, 1 H); 7.01 (s, 1 H); 7.15 (dd, J-5.0 and 7.3 Hz, 1 H); 7.45 (broad m, 1 H); 7.73 (broad m, 1 H); 7.89 (dd, J-2.0 and 7.3 Hz, 1 H): 7.95 (s, 1 H); 8.12 (s. 1 H); 8.27 (dd, J-2.0 and 5.0 Hz, 1 H); 9.27(8,1 H) | B 533 1.31 |
i-183 | il-31 | lilb-49 | 7-(2- Methoxypyridin-3-yl)2-((4-(1 -methyl- 1Hpyrazol-4-yl)-2-(propan-2ytoxy)pheny1]amino}thien o[3,2-d]pyrimldine-6carboxamide | l. 33 (d, J-6.1 Hz. 6 H); 3.81 (s, 3 H); 3.85 (s, 3 H); 4.78 (m, 1 H); 6.96 (dd. J-2.1 and 8.6 Hz, 1 H); 7.17 to 7.23 (m, 2 H); 7.49 (broad m. 1 H); 7.71 (broad m. 1 H); 7.62 (s. 1 H); 7.94 (dd, J-2.1 and 7.3 Hz, 1 H); 7.98 (s, 1 H); 8.09 (s, 1 H); 8.20 (d, J-6.6 Hz, 1 H); 8.29 (dd, J-2.1 and 5.0 Hz, 1 H): 9.26 (s, 1 H) | B 516 1.19 |
Note 1 :
Examples 1-1 to I-8 were prepared in hydrochloride form.
164
Note 2:
Examples 1-54, 1-55, 1-56, 1-66, 1-67, 1-99 and 1-139 of Table 4 are obtained after deprotection of the piperidinyl ring, protected on the nitrogen atom with a tert5 butyloxycarbonyl group, by treatment with an acid as described in the example below: 7-(2-Methoxyphenyl)-2-{[4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino)thieno[3,2d]pyrimidine-6-carboxamide
A 1M solution of hydrochloric acid in ethyl acetate (90 ml) is added slowly to a mixture of 536 mg of 2-methylpropan-2-yl 4-[4-{[6-carbamoyl-7-(2-methoxyphenyl)thieno[3,2io d]pyrimidin-2-yl]amino}-3-(propan-2-yloxy)phenyl]piperidine-1-carboxylate in 5 ml of cold ethyl acetate in an ice bath. After the addition, the mixture is stirred at ambient température for 18 h, and then the precipitate is filtered off and rinsed with ether. The solid is suspended In 60 ml of water and 40 ml of a 1M sodium hydroxide solution are added and the mixture is left to stir for 5 min. The mixture is extracted three times with 100 ml of 15 ethyl acetate. The organic phases are washed with 50 ml of water and then with 50 ml of a saturated sodium chioride solution. The organic phases are dried over magnésium sulfate, filtered and concentrated under vacuum. The residue is taken up with ether and the solid is filtered off and dried under vacuum, so as to obtain 321 mg of 7-(2-methoxyphenyl)-2-{[4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino)thieno[3,220 d]pyrimidine-6-carboxamlde in the form of a yellow solid.
Note 3: Example 1-61 was prepared from Example I-52 according to the following method:
140 mg of 2-methylpropan-2-yl 4-[5-{[6-carbamoyl-7-(2-methoxyphenyl)thieno[3,2d]pyrimidin-2-yl]amino}-1-(propan-2-yl)-1 H-pyrazol-3-yl]piperidîne-1-carboxylate are added 25 to a solution of 4 ml of 4N hydrochloric acid in dioxane at a température of about 20 °C and the mixture is left to stir for 30 minutes. After concentration of the mixture under reduced pressure, a solid is obtained which is washed successîvely with ethyl ether, with dichloromethane, with dioxane and to finish with dichloromethane. The solid is dried under reduced pressure, so as to obtain 112 mg of 7-(2-methoxyphenyl)-2-{[3-(piperidin-4-yi)-130 (propan-2-yl)-1 H-pyrazol-5-yl]amino}thieno[3,2-d]pyrimidÎne-6-carboxamide hydrochloride.
Note 4: Example i-70 was prepared from Example 1-61 according to the following method:
microlitres of triethylamine and 14 microlitres of iodoethane are added, at a température of about 20°C, to a solution of 69 mg of 7-(2-methoxyphenyl)-2-{[3-(piperidin35 4-yl)-1 -(propan-2-yl)-1 H-pyrazol-5-yl]amino}thîeno[3,2-d]pyrimidine-6-carboxamide hydrochloride in 1.7 ml of DMF, under an argon atmosphère, and the mixture is left to stir
165 for 15 h at ambient température. 30 microlitres of triethylamine and 6 microlitres of iodoethane are then added and then, after stirring for 15 h, a further addition of 30 microlitres of triethylamine and of 16 microlitres of iodoethane is carried out, while leaving the mixture to stir for a further 48 hours. The reaction medium is diluted with 30 ml of ethyl acetate and then the organic phase is washed three times with 15 ml of water. The aqueous phase is extracted twice with 25 ml of ethyl acetate. The combined organic phases are dried over magnésium sulfate, fiitered and concentrated under vacuum, so as to obtain a yellow solid. The residue is purified by flash chromatography on silica gel, using a dichloromethane/methanol/NH4OH (95/5/0.05% to 90/10/0.1%) elution gradient, so as to obtain 40 mg of 2-{[3-(1-ethylpiperidin-4-yl)-1-(propan-2-yl)-1H-pyrazol-5yl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide In the form of a yellow solid.
Note 5: Example 1-119 was prepared from 2-methylpropan-2-yl 4-[5-({6-carbamoyl-7-[2(trifluoromethoxy)phenyl]thieno[3l2-d]pyrimidin-2-yl}amino)-1-(propan-2-yl)-1H-pyrazol-3yl]piperidine-1-carboxylate, obtained according to Example 10, according to the following steps:
220 mg of 2-methylpropan-2-yl 4-[5-({6-carbamoyi-7-[2(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidin-2-yl}amino)-1-(propan-2-yl)-1 H-pyrazol-3yl]piperidine-1-carboxylate are added to 5 ml of a 1N solution of hydrochloric acid tn ethyl acetate at a température of about 20°C and the mixture is left to stir for 30 minutes. A further addition of 3 ml of the 1N acid solution is carried out and the mixture is left to stir for 15 h. After concentration of the mixture under reduced pressure, a solid is obtained which is washed successively with dichloromethane and then with ether. The solid is dried under reduced pressure, so as to obtain 139 mg of 2-{[3-(piperidin-4-yl)-1-(propan-2-yl)1H-pyrazol-5-yl]amino}-7-[2-(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimîdine-6carboxamide hydrochloride.
ml of 1N sodium hydroxide are added to a solution of 50 mg of 2-{[3-(pîperidin-4-yl)-1 (ρΓορ3η-2^Ι)-1Η^Γ3Ζθ!-5-νΙ]3Γηίηο}-7-[2-(ΐΓίίΙυοΓθΓηθΙΐΊθχγ)ρΐΊθη^]ΐΝθηο[3,2d]pyrimidine-6-carboxamide hydrochloride in 10 ml of ethyl acetate. The mixture is stirred, and then the aqueous phase is extracted twice with 30 ml of ethyl acetate. The combined organic phases are dried over magnésium sulfate, fiitered and concentrated under vacuum, so as to obtain 42 mg of 2-{[3-(ρiρeridin-4-yl)-1-(ρroρan-2-yl)-1H-ρyrazol·5yl]amino}-7-[2-(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide.
ml of acetic acid, 6 microlitres of 3-oxetanone and 190 mg of amberlite resin IRA400 cyanoborohydride (Aldrich, loading 2 χ 10'3 mol/g) are added, at ambient température, to
166 a solution of 50 mg of 2-{[3-(piperidin-4-yl)-1-(propan-2-yl)-1H-pyrazol-5-yl]amino]-7-[2(trifluoromethoxy)phenyl]thienoI3,2-d]pyrimidine-6-carboxamide in 3 mi of anhydrous THF, under an argon atmosphère. After stirring for 4 h at ambient température, 10 microlitres of 3-oxetanone and 186 mg of the same amberlite resin IRA400 cyanoborohydride are 5 added and the mixture is left to stir for a further 15 h. A further 6 microlitres of 3oxetanone and 100 mg of amberlite resin IRA400 cyanoborohydride are added and the mixture is then left to stir for 2 h. The mixture Is filtered and the resin is washed with 50 ml of ethyl acetate then 20 ml of ethanoi. The filtrate is concentrated under vacuum and the crude product is purified by flash chromatography on silica gel, elution being carried out to with a dichloromethane/methanol/NH4OH (96/4/0.1%) mixture, so as to obtain 30 mg of 2([3-[ 1 -(oxetan-3-yl)piperidin-4-yl]-1 -(propan-2-yl)-1 H-pyrazol-5-yl)amino)-7-[2(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidÎne-6-carboxamide in the form of a yellow solid.
Note 6: Example 1-123 was prepared from 2-{[3-(prperidin-4-yl)-1-(propan-2-yl)-1Hpyrazol-5-yl]amino}-7-[2-(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide hydrochloride (see note 5), according to the following steps:
microlitres of triethylamine and 17 microlitres of iodoethane are added, at a température of about 20 Ό, to a solution of 100 mg of 2-{[3-(piperidin-4-yl)-1-(propan-2-yl)20 1H-pyrazol-5-yl]amino}-7-[2-(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidine-6carboxamide hydrochloride in 2.5 ml of DMF under an argon atmosphère, and the mixture is left to stir for 4 h. 70 microlitres of triethylamine and 10 microlitres of Iodoethane are then added and then, after stirring for 15 h, a further addition of 70 microlitres of triethylamine and 10 microlitres of iodoethane is carried out and the mixture is left to stir 25 for a further 24 hours. The reaction medium is diluted with 40 ml of ethyl acetate and then the organic phase is washed three times with 15 ml of water. The aqueous phase is extracted twice with 20 ml of ethyl acetate. The combined organic phases are dried over magnésium sulfate, filtered and concentrated under vacuum, so as to obtain a yellow solid. The crude product is purified by flash chromatography on silica gel, elution being 30 carried out with a dichloromethane/methanol/NH4OH (96/4/0.1 %) mixture, so as to obtain mg of 2-f[3-(1-ethylpiperidin-4-y1)-1-(propan-2-yl)-1H-pyrazol-5-yl]amino}-7-[2(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidine-6-carboxamide in the form of a yellow solid.
167
Note 7:
Examples 1-62 and 1-63 are Isolated by séparation of the enantiomers of Example 1-45 by chiral chromatography according to the following conditions: Chiralpak IC, 5pm, 20x250 mm column, détection at λ = 254 nm, elution with 60 MTBE/15 heptane/5 methanol/0.1 TEA at a flow rate of 20 ml/min. This séparation produces 1-62 (TR 14.2 min, OR (589 nm) 20.1 (c=1.635 mg/0.5 ml DMSO)) and I-63 (TR 19.3 min, OR (589 nm) 20.1 (c=1.793 mg/0.5 ml DMSO)).
Note8:2-[2-lsopropy-4-(tetrahydropyran-4-ylamino)phenylamino]-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide
Example 1-164 was obtained from 2-{4-[formyl-(tetrahydropyran-4-yl)amino]-2isopropoxyphenylamino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide, obtained according to Example 10, according to the following steps:
A mixture of 0.3 g of 2-{4-[formyl·(tetrahydropyran-4-yl)amino]-2-isopropoxyphenylamino}7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide and 30 ml of a 1.25 M hydrochloric acid solution in methanol is stined in an autoclave at 60Ό for 15 h. The mixture is concentrated to dryness under reduced pressure. The residue is taken up in water and alkalinized with an ammonical solution, and then extracted three times with 30 ml of ethyl acetate. The organic phases are combined, dried over magnésium sulfate and concentrated to dryness under reduced pressure. The residue is purified by chromatography on a 50 g silica column, elution being carried out with a dichloromethane/methanol/acetonitrile (95/5/5 v/v/v) mixture, so as to obtain an impure batch of 0.23 g which is subjected to a second purification on 50 g of silica, with the same eluent, so as to obtain 0.20 g of 2-[2-isopropy-4-(tetrahydropyran-4-ylamino)phenylamino]7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide. The latter is taken up with stirring in a mixture of 5 ml of diethyl ether and 5 ml of petroleum ether and then filtered. The yellow solid obtained is dried under vacuum (20mbar/1h) at 40*C, so as to obtain 0.19 g of 2-[2-isopropy-4-(tetrahydropyran-4-ylamino)phenylamino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide, in the form of an orangey-coloured solid (melting point: 192*C).
Rétention time Tr (min) = 0.98; [M+H]+: m/z 534 (method B).
Note 9:2-[2-lsopropoxy-4-(1 -methylpiperidin-4-ylamino)phenylamino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide
168
Example 1-167 was obtained from 2-{4-[formyl-(1-methylpiperidin-4-yl)amino]-2isopropoxyphenylamino}-7-(2-methoxyphenyl)thienoI3,2-d]pyrimidine-6-carboxamide, obtained according to Example 10, according to the following steps:
A 5N hydrochloric acid solution (6.25 ml) is added to a single-necked round-bottomed flask containing 0.25 g of 2-{4-[formyl-(1-methylpiperidin-4-yl)amino]-2isopropoxyphenylamino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide. The reaction mixture is stirred at ambient température for 40 h, and then a further 2.0 ml of 5N hydrochloric acid solution are added and the stirring is continued for 20 h. The mixture is then poured into 25 ml of water and alkalinized by adding a solution of aqueous ammonia at 28% (8 ml). After extraction with ethyl acetate (3x30 ml), the organic extracts are combined, washed with water (3x20 ml) to neutral pH, dried over magnésium sulfate, and then concentrated to dryness under reduced pressure. The residue is purified by chromatography on a 25 g cartridge of 15-40 pm silica, elution being carried out successively with 94/3/3 v/v/v then 90/5/5 v/v/v dichloromethane/methanol/acetonitrile mixtures, and then a dichloromethane/methanol/acetonitrile/28% aqueous ammonia mixture (93/3/3/1 v/v/v/v) at a flow rate of 20 ml/ min. The pasty orange solid obtained is triturated from diisopropyl ether and reconcentrated to dryness under reduced pressure, and then triturated from petroleum ether and filtered. The solid obtained is stove-dried under reduced pressure (40®C, 10-3 mbar), so as to obtain 0.13 g of 2-(2-isopropoxy-4-(1methylpiperidin-4-ylamÎno)phenylamino]-7-(2-methoxyphenyl)thÎeno[3,2-d]pyrimidine-6carboxamide in the form of a dark orange solid.
Rétention time Tr (min) = 0.86; [M+H]+: m/z 547 (method B).
Note 10: Example I-93 was obtained from 2-((4-( 1-formyl-1,7-diazaspiro[4.4]non-7-yl)-2(propan-2-yloxy)phenyl]amino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6carboxamide, obtained according to Example 10, according to the following steps:
A mixture of 76 mg of 2-((4-(1-formyl-1,7-diazaspiro[4.4]non-7-yl)-2-(propan-2yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide and 2 ml of 5N sodium hydroxide in 15 ml of methanol is stirred at ambient température for 3 hours, and then maintained at reflux for 1 h 30. The mixture is stirred at AT for 15 h and then again maintained at reflux for 5 h 30. The reaction medium is then run into 20 ml of water and then the methanol is eliminated by concentration under reduced pressure. The resuiting aqueous phase is washed several times with dichloromethane (3 times 20 ml) and then acidified so as to obtain a pH with a value of about 7/8, and then the aqueous phase ts extracted a further three times with 20 ml of dichloromethane. The combined organic phases are dried over magnésium sulfate, filtered and concentrated under
169 vacuum, so as to obtain 72 mg of 2-{[4-(1,7-diazaspiro[4.4]non-7-yl)-2-(propan-2yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxy!ic acid in the form of a brown solid.
A mixture of 40 mg of 2-((4-( 1,7-diazaspiro[4.4]non-7-yl)-2-(propan-2-yloxy)phenyl]amino}5 7-(2-methoxypheny!}thieno[3,2-d]pyrimidine-6-carboxy!ic acid, 63 mg of BOP and 68 mg of HOBt in 20 m! of DMF is stirred at ambient température for 20 minutes. 23 mg of ammonium chioride and 74 mg of Ν,Ν-diisopropylethylamine are then added. The mixture is stirred at AT for 48 h. The residue is purified by flash chromatography on silica gel, using a dichloromethane/methanol (100/0 to 90/10) elution gradient. After concentration of io the fractions to dryness, a brown solid is obtained which Is repurified by reverse-phase
HPLC (Macherey-Nagel 250x40 mm, reverse phase C18 Nucleodur 10 pm column; eluent: MeCN containing 0.07% TFA, H2O containing 0.07% TFA; elution gradient from 10 to 95% of MeCN; flow rate 70 ml/min and collection by LIV détection at 254 nm).
The fractions containing the expected product are loaded on to a Varian Bond Elut SCX 15 cartridge (2 g) conditioned with methanol. The phase is washed with methanol and then methanol/NH3 7N. After concentration of the solvent to dryness, 7mg of 2-((4-(1,7diazaspiro[4.4]non-7-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3I2d]pyrimidine-6-carboxamide are obtained in the form of an orangey-coloured solid.
Example 13: [7-(2-Methoxyphenyl)-2-{[4-(4-methylpiperazîn-1 -yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol (1-185)
A mixture of 1.80 g of methyl 7-(2-methoxyphenyl)-2-(methylsulfonyl)thieno[3,2dJpyrimidine-6-carboxylate, 1.37 g of N-[4-(4-methylpiperazin-1-yl)-2-(propan-225 yloxy)phenyl]formamide and 4.44 g of 1-[N-(2-methylpropan-2-yl)-P,P-dÎ(pyrrolidin-1yOphosphorimidoylJpyrrolidine (BTPP) in 50 ml of anhydrous DMF is stirred at ambient température for 16 h. The mixture is then evaporated under vacuum at a température of 55°C, and the residue is diluted with ethyi acetate and water. The aqueous phase is extracted three times with ethyi acetate. The organic phases are washed with a saturated 30 sodium chioride solution, dried over magnésium sulfate, filtered and concentrated under vacuum. The crude product is purified on 100 g of silica, elution being carried out with 0-2.5% of methanol containing 10% by volume of 28% aqueous ammonia solution in dichloromethane, so as to obtain 2.264 g of methyl 2-{formyl[4-(4-methylpiperazin-1-yl)-2(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxylate 35 in the form of a brown solid.
170
A 1M solution of hydrido[bis(2-methylpropyl)]aluminium in toluene is added dropwise to a solution of 2.26 g of methyl 2-{formyl[4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxylate In 30 ml of toluene and 30 ml of THF, cooled to -70°C under argon. After 5 min, the bath is replaced with a bath of ice-cold water and the mixture is stirred for 2 h. The mixture Is then cooled to -40 °C and treated with 10 ml of a saturated ammonium chloride solution, 10 ml of water and 30 ml of ethyl acetate. The resulting suspension is filtered on Clarcel and the Clarcel is rinsed with ethyl acetate. The aqueous phase is saturated with sodium chloride and extracted three times with ethyl acetate. The organic phases are washed with a saturated sodium chloride solution, dried over magnésium sulfate, filtered and concentrated under vacuum, so as to obtain 1.47 g of a mixture containing mainiy {[6-(hydroxymethyl)-7-(2methoxyphenyl)thieno[3,2-d]pyrimidin-2-yl][4-(4-methylpipera2in-1-yl)-2-(propan-2yloxy)phenyl]amino}methanol in the form of an orangey-coloured solid.
A solution of 1.47 g of {[6-(hydroxymethyl)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidin-2yl][4-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy}phenyl]amino}methanol mixture in 30 ml of THF and 13.4 ml of 1M sodium hydroxide is stirred at ambient température for 1 h 40. The mixture is diluted with 80 ml of ethyl acetate and 10 ml of an aqueous 10% citric acid solution. The aqueous phase is extracted three times with ethyl acetate. The aqueous phase is saturated with sodium chloride and again extracted twice with ethyl acetate. The organic phases are washed with a saturated sodium chloride solution, dried over magnésium sulfate, filtered and concentrated under vacuum. The crude product Is purified on 50 g of silica, elution being carried out with 50-100% of acetone in dichloromethane, and then with 2-4% of methanol containing 10% by volume of 28% aqueous ammonia solution In dichloromethane, so as to obtain a brown solid. Trituration from ethyl ether gives 457 mg of [7-(2-methoxyphenyl)-2-{[4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy}phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol in the form of a yellow solid.
Example 14:2-[2-{[2-Methoxy-4-(4-methylpiperazin-1 -yl)phenyl]amino}-7-(2methoxyphenyl)thieno[3,2-d]pyrimidin-6-yl]propan-2-ol ( I-210)
A 3M solution of méthylmagnésium bromide (11.2 ml) Is added slowly to a solution of 2.60 g of methyl 7-(2-methoxyphenyl)-2-(methylsulfanyl)thieno[312-d]pyrimÎdine-6carboxylate in 30 ml of THF, cooled to -70°C. The mixture is stirred while allowing the température to corne back up to ambient température. After 1 h at ambient température, the mixture is treated with a saturated ammonium chloride solution and the aqueous phase Is extracted with ethyl acetate. The organic phases are dried over sodium sulfate,
171 filtered and concentrated under vacuum, so as to obtain 2.58 g of 2-[7-(2-methoxyphenyl)2-(methylsulfanyl)thieno[3,2-dJpyrimidin-6-yl]prcpan-2-ol in the form of a yellow powder.
A mixture of 2.58 g of 2-[7-(2-methoxyphenyl)-2-(methylsulfanyl)thîeno[3,2-d]pyrimidin-6yl]propan-2-ol and 4.08 g of sodium perborate hydrate in 15 ml of acetic acid is heated at 95°C for 1 h, and then concentrated under reduced pressure. The residue is diluted with 1M sodium hydroxide and extracted with ethyl acetate. The organic phases are washed with water, dried over sodium sulfate, filtered and concentrated under vacuum. The residue is purified on 80 g of silica, elution being carried out with dichloromethane, so as to obtain 1.57 g of 2-[7-(2-methoxyphenyl)-2-(methylsulfonyl)thieno[3,2-d]pyrimidin-6yl]propan-2-ol in the form of a yellow powder.
170 mg of sodium hydride at 60% are added to a solution of 424 mg of N-[2-methoxy-4-(4methylpiperazin-1-yl)phenyl]formamide in 7 ml of DMSO. The mixture is stirred at ambient température for 30 min, and then 643 mg of 2-[7-(2-methoxyphenyl)-2(methylsulfonyl)thieno[3,2-d]pyrimldin-6-yl]propan-2-ol are added. The mixture Is stirred at ambient température for 4 h. The mixture is purified on 40 g of silica (solid déposition), elution being carried out with 2% methanol in dichloromethane. The fractions containing the expected product are combined and concentrated under reduced pressure. The residue Is purified by reverse-phase HPLC, elution being carried out with acetonîtrile/0.001 M hydrochloric acid, so as to obtain 180 mg of 2-[2-{[2-methoxy-4-(4methylpiperazin-1-yl)phenyl]amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidin-6yl]propan-2-ol hydrochloride in the form of a yellow powder.
Exemple 15: 2-[7-(4-Fluoro-2-methoxyphenyl)-2-{[2-methoxy-4-(4-methylpiperazin-1 yl)phenyl]amino)thïeno[3,2’d]pyrimidin-6-yl]propan-2-ol (1-211)
170 mg of sodium hydride at 60% are added to a solution of 424 mg of N-[2-methoxy-4-(4methylpiperazin-1-yl)phenyl]formamide in 7 ml of DMSO. The mixture is stirred at ambient température for 30 min, and then 674 mg of methyl 7-(4-fluoro-2-methoxyphenyl)-2(methylsulfonyl)thieno[3,2-d]pyrimidine-6-carboxylate are added. The mixture is stirred at ambient température for 4 h. The mixture is purified on silica (solid déposition), elution being canied out with dichloromethane/cyclohexane (1/1), and then with dichloromethane/methanol/NH4OH (96/4/0.4). The compound Is again purified on 80 g of silica, elution being carried out with dichloromethane/methanol/NHiOH (98/2/0.2), so as to obtain 217 mg of methyl 7-(4-fluoro-2-methoxyphenyl)-2-{[4-(4-methylpiperazin-1-yl)-2(propan-2-yloxy)phenyl]amino)thieno[3,2-d]pyrimidine-6-carboxylate in the form of a beige powder.
172
A 3M solution of méthylmagnésium bromide (0.44 ml) is added slowly to a solution of 158mg of methyl 7-(4-fluoro-2-methoxyphenyl)-2-{[4-(4-methylpiperazin-1-yl)-2-(propan2-yloxy)phenyl]amino)thieno[3,2-d]pyrimtdine-6-carboxylate in 1.2 ml of THF, cooled to ΟΌ. The mixture is stirred while allowing the température to corne back up to ambient température. After 1 h at ambient température, the mixture is treated with a saturated ammonium chioride solution and the aqueous phase is extracted with ethyl acetate. The organic phases are dried over sodium sulfate, filtered and concentrated under vacuum. The crude product is purified by chromatography on 40 g of silica, elution being carried out with dichloromethane/methanol (98/2), so as to obtain 150mg of 2-[7-(4-fluoro-2methoxyphenyl)-2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenylîamino}thieno[3,2d]pyrimidin-6-yl]propan-2-ol. The solid is treated with one équivalent of a 1M solution of hydrochloric acid in dioxane and the mixture is concentrated under vacuum, so as to obtain 130 mg of 2-[7-(4-fluoro-2-methoxyphenyl)-2-([2-methoxy-4-(4-methylpiperazin-1y!)pheny!]amino)thieno[3,2-d]pyrimidin-6-yl]propan-2-ol hydrochloride in the form of an orange powder.
Example 16: p-(2-Methoxy-6-methylpyridin-3-yl)-2-{(5-methyl-4-(4-methylpipera2in-1 -yl)2-(propan-2-yloxy)phenyl]amino)thieno[312-d]pyrimidin-6-yl]methanol (1-191 )
0.7 ml of 1-[N-(2-methylpropan-2-yl)-PlP-di(pyrrolidin-1-yl)phosphorimidoyl]pyrrolidîne (BTPP) is added to a mixture of 300 mg of methyl 7-(2-methoxy-6-methylpyridin-3-yl)-2(methylsulfonyl)thieno[3,2-d]pyrimidine-6-carboxylate and 231 mg of N-[5-methyl-4-(4methylpiperazin-1-yi)-2-(propan-2-yloxy)phenyl]formamide in 8 ml of anhydrous DMF. The mixture is stirred at ambient température for 16 h, and then evaporated under vacuum at a température of 55*0, and the residue is diluted with ethyl acetate and water. The aqueous phase is extracted three times with ethyl acetate. The organic phases are washed with a saturated sodium chioride solution, dried over magnésium sulfate, filtered and concentrated under vacuum. The crude product is purified on 25 g of silica, elution being carried out with 50-100% of acetone in dichloromethane so as to obtain 422 mg of methyl 2-{formyl[5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxy-6-methylpyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxylate in the form of an orangey-coloured solid.
4.85 ml of a 1M solution of hydrido[bis(2-methylpropyl)]aluminium in toluene are added dropwise to a solution of 419 mg of methyl 2-{formyl[5-methyl-4-(4-methylpÎperazin-1-yl)2-(propan-2-yloxy)phenyl]amîno)-7-(2-methoxy-6-methylpyridin-3-yl)thieno[3,2d]pyrimidine-G-carboxylate in 15 ml of toluene and 15 ml of THF, cooled to -70Ό under argon. After 5 min, the bath is replaced with a bath of ice-cold water and the mixture is
173 stirred for 2 h. The mixture ts then cooled to -40’C and treated with 30 ml of a saturated ammonium chloride solution and 30 ml of ethyl acetate. The aqueous phase is extracted three times with 15 ml of ethyl acetate. The organic phases are combined with the organic phases of another reaction carried out under the same conditions, but starting from 5 145 mg of methyl 2-{[5-ιηβ^Ι-4-(4-ΓηβΗιγΙρΐρβΓ3ζίη-ΐ7ΐ)-2-(ρΓ0ρ3η-2yloxy)phenyl]amino}-7-(2-methoxy-6-methylpyridin-3-yl)thieno[3,2-d]pyrimidine-6carboxylate. The combined organic phases are washed with a saturated sodium chloride solution, dried over magnésium sulfate, filtered and concentrated under vacuum, so as to obtain 457 mg of a mixture containing mainly {[6-(hydroxymethyl)-7-(2-methoxy-6îo methylpyridin-3-yl)thieno[3,2-d]pyrimidin-2-yl][5-methyl-4-(4-methylpiperazin-1-yl)-2(propan-2-yloxy)phenyl]amino)methanol in the form of a beige solid.
A solution of 457 mg of the {[6-(hydroxymethyl)-7-(2-methoxy-6-methylpyridin-3yl)thieno[3,2-d]pyrimidin-2-yl][5-methyl-4-(4-methylpipera2in-1-yl)-2-(propan-2yloxy)phenyl]amino}methanol mixture in 30 ml of THF and 4.75 ml of 1 M sodium 15 hydroxide is stirred at ambient température for 2 h 15. The mixture is diluted with 80 ml of ethyl acetate, 40 ml of water and 5 ml of an aqueous 10% cïtric acid solution. The aqueous phase is extracted three times with 40 ml of ethyl acetate. The organic phases are washed with 50 ml of a saturated sodium chloride solution, dried over magnésium sulfate, filtered and concentrated under vacuum. The crude product is purified on 25 g of 20 silica, elution being carried out with 1-5% of methanol (containing 10% by volume of 28% ammonium hydroxide) in dichloromethane, so as to obtain a brown oil. Placing the oil in solution in 1 ml of acetonitrile and adding diisopropyl ether and pentane gives a suspension which is concentrated under vacuum. After trituration with pentane, the resulting solid is filtered off and dried under vacuum, so as to obtain 177 mg of [7-(225 methoxy-6-methylpyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino)thieno[3,2-d]pyrimidin-6-yl]methanol in the form of a beige solid.
Example 17: [7-(5-Fluoro-2-methoxyphenyl)-2-([4-(4-methylpiperazin-1-yl)-2-(propan-2yloxyjphenyljaminojthienop^-dlpyrimidin-e-yljmethanol (I-202)
0.7 ml of 1-[N-(2-methylpropan-2-yl)-P,P-di(pyrrolidin-1-yl)phosphorimidoyl]pyrrolidine (BTPP) is added to a solution of 245 mg of N-[4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]formamide in 5 ml of anhydrous DMF. After 10 min, a solution of 350 mg of methyl 7-(5-fluoro-2-methoxyphenyl)-2-(methylsulfonyl)thieno[3,2-d]pyrimidine-6carboxylate in 6.5 ml of anhydrous DMF is added and the mixture is stirred at ambient 35 température for 42 h. The mixture is then evaporated under vacuum at a température of
60’C, and the residue is purified on 120 g of silica, elution being carried out with 5% of
174 methanol in dichloromethane, so as to obtain 503 mg of methyl 2-{formyl[4-(4methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(5-fluoro-2methoxyphenyl)thîeno[3,2-d]pyrimidine-6-carboxylate in the form of an orangey-coloured solid.
5.47 ml of a 1M solution of hydrido[bis(2-methylpropyl)]aluminium in toluene are added dropwise to a solution of 500 mg of methyl 2-{formyl[4-(4-methylpiperazin-1-yl)-2-(propan2-yloxy)phenyl]amino}-7-(5-fluoro-2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxylate in 13 ml of anhydrous toluene, cooled to -70°C under argon. After 3 h at -70Ό, 10 ml of a 5N sodium hydroxide solution are added. After returning to ambient température, the îo mixture îs extracted three times with 10 ml of ethyl acetate. The organic phases are washed with a mixture of 10 ml of water and 6 ml of 5N sodium hydroxide. The aqueous phase is extracted twice with 10 ml of ethyl acetate and the combined organic phases are dried over magnésium sulfate, filtered and concentrated under vacuum, so as to obtain 517 mg of a mixture containing mainly {[6-(hydroxymethyl)-7-(5-fluoro-215 methoxyphenyl)thieno[3,2-d]pyrimidin-2-yl][4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}methanol in the form of an orangey-coloured solid.
A solution of 517 mg of the {[6-(hydroxymethyl)-7-(5-fluoro-2-methoxyphenyl)thieno[3,2d]pyrimidin-2-yl][4-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)phenylIamino}methanol mixture in 24 ml of THF and 10 ml of 1M sodium hydroxide is stirred at ambient 20 température for 4 h. The mixture is extracted three times with 10 ml of ethyl acetate. The organic phases are washed with 10 ml of water and the organic phases are concentrated under vacuum. The crude product is purified on 80 g of silica, elution being carried out with 5-8% of methanol in dichloromethane, so as to obtain a yellow foam. After trituration with ether, the resulting solid is filtered off and dried under vacuum, so as to obtain 25 247 mg of [7-(5-fluoro-2-methoxyphenyl)-2-([4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol in the form of a yellow solid.
175
The compounds (I) obtained according to Examples 13 to 17 are described in Table 5.
Table 5:
Compound 1” | Compound II | Compound lllb | Name | NMR | MS conditions/ MH+/Tr |
1-184 | 11-5 | lllb-3 | [7-(2-Mettioxyphenyl)-2{{4-{l -mettiylplperidin-4yt)-2-(propan-2yloxy)phenyf]amlno}th1e no[33-d]pyrlmldin-6yfjmethanol | 1.30 (d. J-6.1 Hz. 6 H); 133 to 1.74 (m, m. 4 H); 1.93 (m, 2 H); 2.18 (s, 3 H); 2.37 (m, 1 H); 2.84 (m. 2 H); 3.74 (S, 3 H): 4.66 (m. 3 H); 5.86 (t, J-5.6 Hz. t H); 6.60 (dd, J-1.7 and 8.3 Hz, 1 H); 6.86 (d. J-1.7 Hz, t H); 7.10 (t, J-7.8 Hz, 1 H): 7.19 (d. J-7.8 Hz, 1 H); 7.38 (dd, J-1.8 and 7.8 Hz, 1 H); 7.47 (dt, J-1.8 and 7.8 Hz, t H); 7.72 (s, 1 H); 8.21 (d. J-8.3 Hz, 1 H): 9.06 (s. 1 H) | A 519 0.73 |
1-185 | 11-5 | lllb-25 | [7 -(2-Methoxyphenyl)-2{[4 -(4-mettiytpiperaz Int-yl)-2-(propan-2yloxyjphenyfjaminojthle no{3,2-d]pyTlmldln-6yfjmethanol | 1.27 (d, J-6.1 Hz, 6 H); 2.22 (s, 3 H); 2.44 (m. 4 H); 3.04 (m. 4 H); 3.74 (s, 3 H); 4.53 to 4.71 (m, 3 H); 5.84 (broad t, J-5.7 Hz. 1 H); 6.31 (dd. J-1.9 and 8.8 Hz. 1 H); 6.61 (d, J-1.9 Hz, t H); 7.09 (t, J-8.0 Hz, t H); 7.18 (d, J-8.0 Hz, 1 H); 737 (dd. J-1.7 and 8.0 Hz, t H); 7.45 (td. J-1.7 and 8.0 Hz, 1 H); 7.61 {s. t H): 8.05 (d, J-8.8 Hz, 1 H); 9 01 (s, t H) | B 520 0.79 |
1-186 | 11-47 | lllb-25 | [7-{2-Methoxy-6methylpyridtn-3-yl>-2{[4-{4-methytplperazin1-yl)-2-(propan-2ytoxy)phenyf]amlno)thle no[33-d]pyrimidin-6yljmettianol | 136 (d. J-6.1 Hz. 6 H); 2.22 (s, 3 H); 2.45 (m, 4 H); 2.50 (masked s. 3 H); 3.05 (m. 4 H); 3.83 (s. 3 H); 4.64 {m, 3 H); 5.88 (broad s. 1 H); 6.34 (dd, J-1.9 and 8.8 Hz. t H): 6.61 (d, J-1.9 Hz, 1 H); 7.01 (d, J-7.6 Hz, t H); 7.65 (s, 1 H); 7.69 (d. J-7.6 Hz, 1 H); 7.97 (d, J-8.8 Hz, t H); 9.02 (S, 1 H) | B 535 0.79 |
1-187 | 11-36 | lllb-25 | [7-(5-Fluoro-2methoxypyridln-3-yl)-2{[4-(4-mettiytpiperazlnt-yl}-2-(propan-2ytoxy)phenyl]am inojttile no[3,2-d]p^imldln-6yfjmethanol | 136 (d, J-6.1 Hz, 6 H); 2.22 (s, 3 H); 2.45 (m. 4 H); 3.04 (m, 4 H); 3.84 (s, 3 H); 4.64 (spt, J-6.1 Hz, 1 H); 4.69 (d. J-5.8 Hz, t H); 5.94 (t, J-5.8 Hz, t H); 6.31 (dd, J-2.5 and 9.0 Hz, t H); 6.62 (d, J-2.5 Hz, 1 H): 7.72 (s, 1 H); 7.87 (dd. J-2.9 and 8.8 Hz, t H); 7.95 (d, J-9.0 HZ. 1 H); 8.28 (d, J-2.9 Hz, 1 H); 9.04 (s, 1 H) | B 539 0.91 |
1-188 | 11-44 | lllb-25 | [7-(2-Ethoxypyridtn-3yl>-2-{[4-(4mettiylplperazln-1 -y l)-2(propan-2ytoxy)phenyf]amlno}thle no[3,2-d]pyrimidin-6yfjmethanol | 131 (t, J-7.2 Hz, 3 H); 137 (d, J-6.1 Hz. 6 H); 2.22 (s. 3 H); 2.44 (m. 4 H); 3.04 (m, 4 H): 4.34 {q. J-73 Hz, 2 H); 4.65 (spt, J-6.1 Hz, t H); 4.69 (broad s, 2 H); 5.92 (broad s, 1 H): 632 (dd, J-2.6 and 8.9 Hz. 1 H); 6.62 (d. J-2.6 Hz, t H); 7.15 (dd, J-5.0 and 7.3 Hz, 1 H); 7.66 (s, 1 H): 7.83 (dd, J-2.0 and 7.3 Hz, 1 H); 8.00 (d. J-8.9 Hz, 1 H); 836 {dd, J-2.0 and 5.0 Hz, 1 H); 9.03 (s, 1 H) | B 535 0.91 |
1-189 | 11-31 | lllb-2 6 | {7-(2-Methoxypyrid ln-3yl)-2-{[5-methyl-4-(4mettiytplperazfn-1 -yl)-2(propan-2yloxy)phenyl]amino}thie noT33-dlpyrimldin-6- | 138 (d, J-6.1 Hz, 6 H); 2.03 (s, 3 H); 2.22 {s. 3 H); 2.45 (broad m. 4 H); 2.77 {m, 4 H); 3.85 {s, 3 H): 4.59 (m, 1 H); 4.67 (d, J-5.7 Hz, 2 H); 5.92 (t. J-5.7 Hz, t H); 6.68 {s, t H); 7.17 (dd, J-4.9 and 73 Hz, 1 H); 7.68 (s, | B 535 0.89 |
176
Compound Γ | Compound II | Compound Itib | Name | NMR | MS conditions/ MH+/Tr |
yljmetfianol | 1 H); 7.85 (dd, J-2.1 and 7.3 Hz, 1 H): 8.07 (s, 1 H): 8.29 (dd. J-2.1 and 4.9 HZ, 1 H); 9.07 (s, 1 H) | ||||
1-190 | II-36 | lllb-26 | [7-(5-Ftuoro-2methoxypyrldin-3-yl)-2{[5-methyl-4-(4methylpiperazln-1 -yl)-2(propan-2yloxy)ptienyl]amlno}ttile no[3,2-d]pyTimidi n-6yljmethanot | 128 (d. J-6.1 Hz, 6 H): 2.04 (s. 3 H): 223 (s, 3 H); 2.45 (broad m, 4 H); 2.77 (m, 4 H); 3.84 (s. 3 H); 4.59 (m. 1 H); 4.70 (d, J-5.7 Hz. 2 H): 5.95 (t, J-5.7 Hz, 1 H); 6.69 (s, 1 H); 7.73 (s. 1 H); 7.89 (dd, J-2.9 and 8.7 Hz, 1 H); 8.04 (s, 1 H); 829 (d, J-2.9 Hz, 1 H); 9.08 (s, 1 H) | B 553 0.95 |
1-191 | II-47 | lllb-26 | [7-(2-Methoxy-6mettiylpyridin-3-yt)-2([5-methyl-4-(4mettiylpiperazin-1-yl)-2(propan-2ytoxy)phenyt]am i no] tfiie no(3,2-d]pyrimldin-6yljmethanol | 128 (d, J-6.1 Hz, 6 H); 2.04 (s. 3 H); 223 (s, 3 H)', 2.45 (m, 4 H); 2.50 (masked s, 3 H): 2.78 (m. 4 H): 3.82 (s, 3 H); 4.59 (m, 1 H); 4.67 (d. J-5.7 Hz, 2 H); 5.90 (t, J-5.7 Hz. 1 H); 6.69 (s, 1 H); 7.01 (d. J-7.6 Hz, 1 H): 7.67 (8,1 H); 7.71 (d. J-7.6 Hz. 1 H): 8.09 (s, 1 H); 9.05 (s. 1 H) | B 549 0.84 |
1-192 | II-47 | lllb-72 | [7-(2-Methoxy-6methylpyridin-3-yl)-2([1 -(propan-2-yl)-3(tetrahydro-2H-pyran-4yl)-1H-pyrazol-5yf]amino]ttileno[3,2d]pyrimldin-6yijmethanol | 125 (d, J-6.1 Hz. 6 H); 1.53 (m, 2 H): 1.69 (m. 2 H); 2.47 (s. 3 H); 2.69 (m, 1 H); 3.41 (m, 2 H): 3.80 (s. 3 H): 3.90 (m, 2 H); 4.55 (m, 1 H); 4.64 (d, J-5.6 Hz, 2 H); 5.89 (t, J-5.6 Hz, 1 H); 6.06 (s, 1 H); 6.96 (d. J-7.6 Hz, 1 H): 7.63 (d. J-7.6 Hz, 1 H); 9.07 (s, 1 H); 9.27 (s, 1 H) | B 495 1.11 |
(-193 | II-44 | lllb-26 | ]7-(2-Ethoxypyridin-3yt)-2-([5-methyt-4-(4mettiyipiperazin-1 -y1)-2(propan-2ytoxy)phenyf]am inojthle no[3,2-d]pyîimldin-6yt]methanol | 1.18 (t, J-7.2 HZ, 2 H); 128 (d. J-6.1 Hz, 4 H); 2.03 (s, 3 H); 223 (s, 3 H): 2.45 (broad m. 4 H): 2.77 (m, 4 H): 4.34 (q, J-7.2 Hz, 2 H); 4.59 (m. 1 H): 4.69 (broad m, 1 H); 5.93 (broad t, J-5.6 Hz, 1 H): 6.69 (s. 1 H); 7.15 (dd. J-5.0 and 7.5 Hz, 1 H); 7.68 (3. 1 H); 7.85 (dd. J-2.1 and 7.5 Hz, 1 H); 8.07 (s, 1 H); 827 (dd, J-2.1 and 5.0 Hz. 1 H): 9.07 (s. 1 H) | B 549 0.96 |
1-194 | II-5 | lllb-26 | [7-(2-Methoxyptienyl)-2([5-mettiyl-4-(4m ettiytptperazin-1-yl)-2(propan-2ytoxy)pheny1]amino]tNe no[32-d]pyrlmldin-eyi]methanol | 128 (d. J-6.1 Hz, 6 H): 2.01 (s, 3 H); 2.22 (s. 3 H); 2.44 (m, 4 H); 2.76 (m, 4 H); 3.73 (S. 3 H); 4.54 to 4.69 (m, 3 H); 5.85 (t, J-5.7 Hz, 1 H); 6.68 (s, 1 H): 7.10 (t, J-7.8 Hz. 1 H): 7.18 (d, J-7.8 Hz, 1 H); 729 (dd. J-1.7 and 7.8 Hz. 1 H); 7.45 (dt. J-1.7 and 7.8 Hz. 1 H); 7.64 (s, 1 H); 8.12 (s. 1 H): 9.04 (s, 1 H) | B 534 0.65 |
1-195 | 11-47 | lllb-80 | [7-(2-Methoxy-6mettiylpyridîn-3-yt)-2{[441-methyl-1,7dlazasplro[4.4]non-7yl)-2-(propan-2ytoxy)phenyi]amino]thle no(32-d]pyrim ldin-6yljmethanot | 125 (d. J-6.1 Hz. 6 H); 1.65 (m, 1 H); 1.69 to 1.81 (m, 4 H): 2.08 (m. 1 H); 224 (s, 3 H); 2.50 (masked s, 3 H): 2.64 (m, 1 H): 2.74 (m, 1 H): 2.91 (d, J-9.5 Hz, 1 H): 3.19 (m. 1 H); 326 (partialiy masked d, J-9.5 Hz, 1 H); 3.33 (m. 1 H): 3.83 (s, 3 H); 4.57 to 4.65 (m, 3 H); 5.86 (t, J-5.8 Hz. 1 H); 5.97 (dd, J-22 and 8.6 Hz. 1 H); 6.19 (d. J-2.2 Hz. 1 H): 7.00 (d, J-7.5 Hz, 1 H); 7.58 (s. 1 H): 7.68 (d, J-7.5 Hz, 1 H): 7.83 (d. J-8.6 Hz, 1 H); 8.97 (s, 1 H) | B 575 1.01 |
177
Compound I” | Compound II | Compound lllb | Name | NMR | MS conditions/ MH+/Tr |
1-196 | lî-31 | lllb-79 | [2-[[4-Ch loro-2-(p ropan2-yioxy)pheny1]amino}742-01 et hoxypyridin-3yl)thlenop2d]pyrimidin-6yfjmethanol | 1.30 (d. J-6.1 Hz. 6 H); 3.85 (s. 3 H): 4.66 to 4.77 (m. 3 H); 5.95 (broad s, 1 H); 6.78 (dd, J-22 and 8.8 Hz, 1 H); 7.09 (d, J-2.2 Hz, 1 H): 7.19 (dd. J-5.1 and 7.4 Hz, 1 H); 7.85 (dd. J-1.7and 7.4 Hz, 1 H): 7.88 (s, 1 H); 827 (d. J-8.8 Hz, 1 H); 8.30 (dd, J-1.7and5.1 Hz, 1 H); 9.14 (s, 1 H) | B 457 1.59 |
1-197 | 11-19 | lllb-64 | (2-[[3-Methyl-1 -{propan2-yl)-1H-pyrazol-5yl]amlno}-7-{2(trifluoromethoxy)phenyl ]thfeno[3,2-d]pyrimldin6-yl)methanol | 122 (d. J-6.6 Hz. 6 H); 2.07 (s, 3 H); 4.41 (spt, J-6.6 Hz, 1 H); 4.63 (broad m, 2 H); 5.69 (s, 1 H); 5.98 (broad t, J-5.6 HZ, 1 H); 7.46 to 7.62 (m, 4 H); 9.06 (s, 1 H); 9.12 (broad s, 1 H) | B 464 1.22 |
1-198 | II-36 | lllb-64 | [7-(5-Fluoro-2methoxypyridin-3-yl)-2([3-methyl-1 -(propan-2yl)-1H-pyrazol-5yf]amlno]thieno[32d]pyrlmldln-6yljmethanol | 123 (d. J-6.6 HZ, 6 H); 2.08 (s. 3 H); 3.81 (s, 3 H); 4.44 (spt, J-6.6 Hz, 1 H); 4.66 (d, J-5.4 Hz, 2 H); 5.94 (m, 2 H); 7.80 (dd. J-2.9 and 8.6 Hz, 1 H): 824 (d, J-2.9 Hz, 1 H); 9.07 (s. 1 H): 9.19 (broad s. 1 H) | B 429 1.05 |
1-199 | 11-19 | lllb-72 | (2-{[1 (Propan-2-yl)-3(tetrahydro-2H-pyran-4yl)-1 H-pyrazol-5yl]amino}-7-[2(trtfluoromethoxy)phenyl ]thleno(32-d]pyrimidln6-yl)methanol | 123 (broad m, 6 H); 1.50 (m, 2 H); 1.69 (m. 2 H); 2.68 (m, 1 H); 3.39 (m, 2 H): 3.88 (m, 2 H): 4.48 (spt, J-6.6 Hz, 1 H); 4.64 (broad m, 2 H); 5.98 (broad s, î H); 6.01 (s, 1 H): 7.45 to 7.63 (m, 4 H); 9.09 (s, 1 H); 922 (broad s, 1 H) | B 534 127 |
Ι-200 | II-5 | lllb-72 | [7-{2-Mettioxyphenyl)-2{[1-(propan-2-yl)-3(tetrahyd ro-2H-pyran-4yl)-1 H-pyrazol-5yl]amino)thleno[32d]pyrimldin-6yQmethanol | 123 (d, J-6.6 Hz. 6 H): 1.52 (m, 2 H); 1.69 (m, 2 H); 2.69 (m, 1 H); 3.40 (m, 2 H); 3.69 (s, 3 H): 3.89 (d, J-14.0 Hz, 2 H); 4.49 (dt, J-6.6 and 13.0 Hz, 1 H); 4.60 (broad m, 2 H); 5.65 (broad t, J-5.7 Hz, 1 H); 6.03 (s, 1 H); 7.04 (t, J-7.8 Hz, 1 H); 7.12 (d, J-7.8 Hz, 1 H); 729 (dd. J-1.8 and 7.5 Hz, 1 H); 7.40 (m, 1 H); 9.05 (s. 1 H); 9.17 (s, 1 H) | B 480 12 |
1-201 | 11-11 | lltb-64 | [7-(5-Fluoro-2methoxyphenyl)-2-{[3methyl-1 -(propan-2-yl )1H-pyrazol-5yljam lno)thleno[3,2dJpyrimidin-6yf] methanol | 123 (d, J-6.5 Hz, 6 H); 2.08 (s, 3 H); 3,69 (s, 3 H); 4.45 (spt, J-6.5 Hz, 1 H); 4.61 (broad s, 2 H); 5.88 (broad S, 1 H); 5.95 (s, 1 H); 7.12 (dd. J-4.6 and 9.0 Hz, 1 H); 7.17 (dd, J-3.2 and 9.0 Hz. 1 H); 724 (dt, J-32 and 9.0 Hz, 1 H); 9.04 (s, 1 H); 9.14 (s, 1 H) | B 428 1.04 |
1-202 | 11-11 | llib-25 | [7-(5-Fluoro-2methoxyphenyl )-2-((4(4-methylplperazin-1 yl)-2-(propan-2y1oxy)phenyl]amlno]thle no[3,2-d]pyrimidin-6yl]methanol | 127 (d, J-6.1 HZ, 6 H); 2.22 (s, 3 H); 2.44 (m, 4 H); 3.04 (m, 4 H): 3.72 (s, 3 H); 4.64 (m, 3 H); 5.87 (t, J-5.7 Hz, 1 H); 6.31 (dd, J-2.6 and 8.9 Hz, 1 H); 6.62 (d, J-2.6 Hz, 1 H); 7.17 (dd, J-4.6 and 9.0 Hz. 1 H); 723 to 7.33 (m, 2 H); 7.66 (broad s. î H); 8.02 (d, J-8.9 Hz, 1 H); 9.02 (s, 1 H) | B 538 0.82 |
1-203 | II-19 | lllb-25 | (2-((4-(4Methylpiperazln-1 -yl)-2(propan-2ytoxy)phenyl]amlno}-7Œ: | 125 (d, J-6.1 Hz. 6 H); 2.22 (s. 3 H); 2.44 (m, 4 H); 3.04 (m. 4 H); 4.56 to 4.76 (m, 3 H); 5.97 (t. J-5.7 Hz. 1 H); 6.30 (dd, J-2.5 and 8.8 Hz, 1 H); 6.60 (d, J-2.5 Hz, 1 H); 7.49 to 7.65 | B 574 0.89 |
178
Compound Γ | Compound II | Compound lllb | Name | NMR | MS conditions/ MH+/Tr |
(trifiuoromethoxy)phenyl ]th ie no[3,2-d]pyiÎmidin6-yi) methanol | (m. 4 H); 7.66 (s. 1 H); 7.94 (d. J-8.8 Hz, 1 H); 9.05 (s, 1 H) | ||||
1-204 | 11-31 | lllb-49 | (7-(2-Methoxypyrldin-3yl)-2-{[4-(1 -methyl-1Hpyrazoi-4-yl)-2-(propan2yfoxy)phenyf]amlno)thle no[3,2-d]pyrimidin-6yfjmethanol | 1.33 (d, J-6.1 Hz, 6 H); 3.85 (s, 3 H); 3.87 (s, 3 H); 4.69 (broad d, J-5.3 Hz, 2 H); 4.78 (spt J-6.1 Hz, 1 H); 5.94 (broad t, J-5.3 Hz, 1 H); 6.94 (dd, J-2.0 and 8.6 Hz, 1 H); 7.18 to 7.23 (m, 2 H); 7.80 (s. 1 H): 7.83 (s, 1 H); 7.87 (dd, J-2.0 and 7.3 Hz, 1 H); 8.08 (s, 1 H); 8.24 (d, J-8.3 Hz, 1 H); 8.32 (dd, J-2.0 and 4.9 Hz, 1 H); 9.11 (s. 1 H) | B 503 138 |
1-205 | 11-5 | lllb-49 | [7-(2-Methoxyphenyl)-2[(4-(1 -methyl-1Hpyrazol-4-yl)-2-(propan2yloxy)phenyl]amlno)thie no(33-d]pyrlmldin-6yljmethanol | 1.33 (d, J-6.1 Hz, 6 H); 3.75 (s. 3 H): 3.85 (s, 3 H); 4.66 (broad m, 2 H); 4.77 (spt, J-6.1 Hz. 1 H); 5.87 (broad t, J-5.7 Hz, 1 H); 6.93 (d, J-7.8 Hz, 1 H); 7.12 (t, J-7.8 Hz, 1 H); 7.17 to 7.24 (m, 2 H): 7.40 (d. J-7.8 Hz, 1 H); 7.48 (t. J-7.8 Hz, 1 H); 7.79 (s, 1 H); 7.80 (s, 1 H); 8.07 (s, 1 H); 8.30 (d, J-8.6 Hz, 1 H); 9.09 (s, 1 H) | B 502 1.34 |
1-206 | Il-4 9 | lllb-26 | [2-([5-Methyl-4-(4methylplperazin-1 -y l)-2(propan-2yloxy)phenyl]amino]-7(6-methylpyrldin-3y!)thieno[3,2d]pyrlmldin-6yljmethanol | 139 (d, J-6.1 Hz, 6 H); 2.11 (s, 3 H); 235 to 2.93 (partially masked broad m. 8 H); 2.56 (s. 3 H); 4.61 (spt, J-6.1 Hz, 1 H); 4.87 (d, J-5.6 Hz. 2 H); 6.00 (t, J-5.6 Hz, 1 H); 6.71 (s, 1 H); 7.42 (d, J-8.1 Hz. 1 H); 7.75 (s, 1 H); 7.94 (dd, J-2.4 and 8.1 Hz, 1 H); 8.17 (s, 1 H); 8,70 (d, J-2.4 Hz, 1 H); 9.11 (s, 1 H) | B 519 0.59 |
1-207 | 11-31 | ltlb-25 | [7-(2-Methoxypyridin-3yl)-2-([4-(4methylplperazin-1 -y l)-2(propan-2yloxy)phenyl]amino}thie no[3.2-d] pyrimidln-6yf] methanol | 137 (d, J-6.1 Hz, 6 H): 2.22 (s, 3 H); 2.44 (m. 4 H); 3.05 (m. 4 H); 3.85 (s, 3 H); 4.57 to 4.72 (m, 3 H); 5.89 (t. J-5.7 Hz, 1 H); 6.31 (dd, J-2.6 and 8.8 Hz, 1 H); 6.61 (d, J-2.6 Hz, 1 H); 7.17 (dd, J-5.0 and 7.4 Hz, 1 H); 7.66 (s, 1 H): 7.83 (dd, J-2.0 and 7.4 Hz, 1 H); 7.98 (d, J-8.8 Hz, 1 H); 839 (dd, J-2.0 and 5.0 Hz, 1 H); 9.03 (s, 1 H) | B 521 0.72 |
1-208 | II-5 | lllb-71 | (7-(2-Methoxyphenyi)-2([4 -( 1 -methytpyrrolldln 3-yt)-2-(propan-2yloxy) phenyl]amlno}thîe no[33-d]pyrimidln-6yljmethanol | 1.30 (d. J-6.1 Hz, 6 H); 1.72 (m, 1 H); 2.19 (m, 1 H); 239 (s, 3 H); 2.37 (t. J-8.6 Hz. 1 H); 2.60 (m, 2 H); 2.82 (t. J-8.6 Hz, 1 H); 333 (partially masked m, 1 H); 3.74 (s, 3 H); 4.56 to 4.72 (m, 3 H): 5.85 (broad t, J-5.7 Hz, 1 H); 6.63 (broad d, J-8.3 Hz. 1 H); 6.90 (broad s, 1 H); 7.10 (t, J-7.8 Hz, 1 H); 7.18 (d, J-7.8 Hz, 1 H); 7.38 (d, J-7.8 Hz, 1 H); 7.47 (t, J-7.8 Hz, 1 H); 7.73 (s, 1 H); 8.19 (d, J-8.3 Hz, 1 H); 9.07 (s, 1 H) | B 505 0.81 |
179
Compound Γ | Compound II | Compound lllb | Name | NMR | MS conditions/ MH+/Tr |
1-209 | 11-1 | lllb-24 | 2-(2-([2-Methoxy-4-{4methylplperazin-1yljpheny |]arn ino}-7phenytthieno[32d]pyrimidin-6-yt)propan2-ol | 1.36 (s. 6 H); 2.81 (d, J-4.8 Hz. 3 H); 3.02 (m, 2 H); 3.13 (m, 2 H); 3.45 (partially masked m, 2 H); 3.72 (m, 2 H); 3.81 (s, 3 H); 6.29 (dd, J-2.5 and 8.8 Hz, 1 H); 6.66 (d, J-2.5 Hz, 1 H); 7.31 (m, 2 H); 7.43 to 7.54 (m. 3 H); 7.78 (d, J-8.8 Hz, 1 H); 7.84 (broad m , 1 H): 9.01 (s, 1 H); 10.72 (broad m, 1 H) | E 490 0.75 |
1-210 | II-5 | lllb-24 | 2-[2-{[2-Methoxy-4-{4methylplperazin-1y!)phenylJamlnol-7-{2methoxyphenyl)thieno[3 ,2-d]pyrlmidln-6yf]propan-2-ol | 125 (s, 3 H); 1.37 (s, 3 H); 2.72 (broad s, 3 H); 3.00 to 3.50 (partially masked broad m, 8 H): 3.65 (s, 3 H); 3.80 (s, 3 H); 628 (dd, J-2.5 and 8.8 Hz, 1 H); 6.64 (d, J-2.5 Hz, 1 H); 7.04 (td, J-1.3 and 7.5 Hz, 1 H); 7.10 to 7.16 (m. 2 H); 725 (broad m, 1 H): 7.45 (ddd, J-2.0 and 7.5 and 8.3 Hz, 1 H); 7.78 (d, J-8.8 Hz, 1 H); 8.95 (s, 1 H); 10.64 (broad m, 1 H) | E 520 0.82 |
1-211 | 11-10 | lllb-24 | 2-{7-(4·Πυοπο-2methoxyphenyt)-24[2· methoxy-4-(4methylplpetazin-1yf)phenyf]amino}thleno{ 3,2-d]pyrlmldln-6yl]propan-2ol | Spectrum at 500 MHz: 125 (s, 3 H): 1.37 (s, 3 H); 2.82 (d, J-4.7 Hz. 3 H); 3.00 (m, 2 H); 3.15 (m, 2 H); 3.48 (m, 2 H); 3.67 (s. 3 H): 3.74 (m, 2 H); 3.81 (s, 3 H); 8.34 (dd, J-2.5 and 8.8 Hz, 1 H); 6.67 (d, J-2.5 Hz. 1 H); 6.88 (dt, J-2.5 and 8.5 Hz, 1 H); 7.07 (dd, J-2.5 and 11.5 Hz, 1 H); 7.16 (dd, J-7.0 and 8.5 Hz, 1 H); 7.75 (d, J-8.8 Hz. 1 H); 7.87 (broad m. 1 H); 8.97 (s, 1 H): 10.47 (broad m, 1 H) | E 538 0.85 |
The compounds according to the Invention were the subject of pharmacological tests for determining their ALK kinase-inhibiting effect
Tests consisted in measuring the in vitro activity of the compounds of the invention on ALK.
A first test uses a GST-Alk protein (wild-type form 1058-1620), obtained from Cama Biosciences (reference 08-518).
The reagents used hâve the following composition:
to -Enzyme buffer (EB): 50 mM HEPES (pH: 7.0) (Sigma H7523), 100 mM NaCi (Sigma S7653), NaN3 at 0.01% (Sigma S8032), BSA at 0.005% (Sigma A2153), 0.05 mM sodium orthovanadate (Calbiochem 587540).
- Détection buffer (DB): 50 mM HEPES (pH: 7.0), BSA at 0.1%, 0.8 M KF (Fluka 60239), 20 mM EDTA (Sigma E5134).
The peptide used is the one described in Biochemistry, 2005, 44, 8533-8542; A-21K(biotin)NH2, obtained from NeoMPS (reference SP081233). Ail the HTRF reagents Mab PT66-K (61T66KLB) and streptavidin-XL665 (610SAXLB), and the SEB reagent, are purchased from Cisbio.
180
The test is carried out in a 384-well plate (Greiner 784076). The serial dilutions are carried out in pure DMSO, and then an intermediate one*in*three dilution in water is carried out, with 1 microlitre of each concentration being distributed, ail these operations being performed using the Zéphyr apparatus (Caliper Life Sciences). The substrate/ATP mixture is prepared in the following way: addition of ATP (final concentration 400 microM, Sigma A7699), of the peptide (final concentration 1 microM) and of the SEB reagent (final concentration 1.56 nM) to the EB, which is then distributed as 7 μΐ. The enzymatic reaction is initiated by adding 2 μΙ of enzymatic mixture (final concentration 2 πΜ) ίπ EB supplemented with DTT (final concentration 1 mM, Sigma D5545). These two distributions are carried out with a multichannel pipette (biohit). The plate is incubated at 30°C for 1 hour. In order to stop the enzymatic réaction, 10 microtitres of the détection mixture, prepared by adding the two antibodies, Mab PT66-K and streptavidin-XL665, to the DB, are added. The incubation time before reading is ovemight at 4°C, The HTRF signal is detected on a Rubystar apparatus (BMG Labtech).
A second test uses a commercial GST-Alk protein (mutant L1196M 1058-1620) from Camabio Sciences (08-529). The protocol is the same as the one for the wild-type form, but the final ATP concentration is 200 microM and the final enzyme concentration is 1 nM.
The inhibîtory activity with respect to ALK in these tests ts given by the concentration which inhibits 50% of the ALK activity (or ICso).
The IC50 values for the compounds according to the invention are less than 1 μΜ, preferably less than 10 μΜ, and more particulariy less than 100 nM.
The table hereinafter indicates the activity results for compounds according to the invention.
Ex. No. | Name | ALK (nM) | ALK L1186M (nM) |
1-7 | 2-({2-Methoxy-4-[4-(propan-2yl)plperazin-1 -y1]phenyl}amino)-7phenylthleno[3,2-d]pyrimidine-6carboxamide | 28 | NT |
181
Ex. No. | Name | ALK(nM) | ALK L1196M (nM) |
1-13 | 2-([2-Methoxy-5-methyl-4-(1 methylplperidin-4-yl)phenyl]amino}-7phenylthleno[3,2-d]pyrimldine-6carboxamlde | 14 | NT |
1-16 | 7-(2-Methoxypheny1)-2-([4-(1methylplperidln-4-yl)-2-(propan-2yloxy)phenyf]amlno}thleno(3,2d]pyrimldlne-6-carboxam kJe | 7 | NT |
1-26 | 2-((4-(1 -Methylplperidln-4-yl)-2(propan-2-yk»cy)phenyl]amino}-7-(2(trifluoromethoxy)phenyfjth leno[3,2d]pyri mld 1 ne-6-carboxam Ide | 0.5 | NT |
1-38 | 7-(2-M ethoxyp heny 1)-2-((6-( 1 methylplperidin-4-yt)-4-(propan-2yloxy jpyrid ln-3 -yljam inojtfiieno(3,2d]pyrimldlne-6-carboxamlde | 7 | NT |
1-100 | 7-(2-Methoxypyridin-3-yl)-2-([5methyl-4-(4-fnethylplperazin-1 -yl)-2(propan-2yloxy)phenyl]amlno}thieno[3,2dj3yrimldine-6-carboxamlde | 3 | 3 |
1-115 | 7-(2-Methylfuran-3-yl)-2-{[4-(1 m ethylplperidln -4-yl)-2-(propan-2y loxy)pheny Ijamino) thieno[3,2 d]pyrimldine-6-carboxamlde | 13 | 17 |
1-118 | 2-({4-(3-(Dfmethylamino)pyrroildin-1 yl]-5-methyl-2-(propan-2yloxy)phenyf]amlno)-7-(2methoxyp h enyl)thieno[3,2d]pyrimldine-6-cartx)xamlde | 2 | 2 |
182
Ex. No. | Name | ALK(nM) | ALK L1196M (nM) |
1-123 | 2-((3-(1 -Ethyfplperidin-4-yl)-1 (propan-2-yl)-1 H-pyrazo1-5-yl]anilno}7-[2-(trif1uoromethoxy)phenyl]thieno[3.2-d]pyrimldine-6carboxamide | 0.5 | 4 |
l-t27 | 7-(2-Methoxyphenyl)-2-{[4-( 1-methyl1 H-pyrazol-4-yl)-2-(propan-2yloxy)phenyl]amlno}thieno[3,2djpyrimidine-6-carboxannide | 43 | 54 |
1-131 | 2-((5-Huoro-4-(1 -methylplperldin-4y1)-2-(propan-2-yloxy)phenyl]amino}7-(2-methoxypyridin-3-yl)ttileno[3,2d]pyrimidine-6-carboxamid e | 3 | 1 |
1-132 | 7-(2-Methoxypyrldln-3-yl)-2-{[5methyl-4-(2-niethyt-1 H-imldazol-1 -y I)2-(propan-2yloxy)phenyl]amlno}thieno[3.2d]pyrim)dine-6-carboxam Ide | 17 | 65 |
1-159 | 7-(2-Mettioxyphenyl)-2- ({4-((4methylpiperazin-1 -yl)methyl}-2(propan-2- y loxyjpheny I] am lno)thieno[3,2d]pyrlmldine-6-carboxamlde | 4 | 9 |
1-164 | 7-(2-Mettioxyphenyi)-2-([2-{propan-2yloxy)-4-(tetrahydro-2H-pyran-4ylamino)phenyi]amlno}thieno[3^d]pyrfmldlne-6-carboxamide | 35 | 57 |
1-172 | 7-{5-Fluoro-2-niethoxypyrldin-3-yl)-2{[1 -{propan-2-yl)-3-(tetrahydro-2Hpyran-4-yl)-1 H-pyrazol-5y1]amino)ttiieno[3,2-djpyrlni)dlrie-6carboxamide | B | 13 |
183
Ex. No. | Name | ALK(nM) | ALK L1196M (nM) |
1-176 | 7-(2-Methoxypyrldin-3-yt)-2-{[3-{4methylplperazln-1 -yl)-2-(propan-2ytoxy)phenyl]am ino)thleno[3,2d]pyrlm ldine-6-carboxamlde | 23 | 43 |
1-180 | 7-{2-Methoxyphenyl)-2-{(1 -methyl-2oxo-6-(pfopan-2-yloxy)-2,3,4,5tetrahydro-1 H-1 -benzazepin-7yljamino) thleno[3,2-d]pyrlm ldine-6carboxamide | 310 | 424 |
1-191 | [7-{2-Methoxy-6-niethylpyridln-3-yl)-2([5-methyl-4-(4-methylpiperazln-1 -yl)2-{propan-2yloxy)p h enyi]am ino)thleno(3,2d]pyrimldin-6-yl]methanol | 12 | 14 |
t-202 | [7-(5-Fluoro-2-methoxyphenyl)-2-{[4(4-methylplperazln-1-yl)-2-{propan-2yloxy)pheny1]amino}thieno[3,2djpyrim ldin-6-y1]methanoi | 27 | 29 |
1-210 | 2-{2-{[2-Methoxy-4-{4methytpiperazÎn-1 -yi)phenyl]amlno)-7(2-methoxyphenyl)thieno(3,2djpyrim ldin-6-yl]propan-2-ol | 130 | NT |
NT: not tested
It therefore appears that the compounds according to the invention hâve an ALK-inhibiting 5 activity.
The compounds according to the invention can therefore be used for preparing médicaments, in particular ALK-inhibiting medicînes.
Thus, according to another of its aspects, a subject of the invention is médicaments which îo comprise a compound of formula (I), (Γ) or (I), or an addition sait thereof with a pharmaceutically acceptable acid.
184
The présent invention also relates to a médicament comprising a compound of formula (I), (I') or (I”) as defined above, or a pharmaceutically acceptable sait thereof.
These médicaments are of use in therapy, in particular in the treatment of cancer.
Among these cancers, attention is given to the treatment of solid or liquid tumours, and to the treatment of cancers which are résistant to cytotoxic agents.
According to another of its aspects, the présent invention relates to pharmaceutical compositions comprising, as active ingrédient, a compound according to the invention, îo These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable sait, and also at least one pharmaceutically acceptable excipient.
Said excipients are selected, according to the pharmaceutical form and the mode of administration desired, from the usual excipients which are known to those skilled in the 15 art.
In the pharmaceutical compositions of the présent invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active Ingrédient of formula (I), (Γ) or (I) above, or the sait thereof, can be administered in unit administration form, as a mixture with 20 conventional pharmaceutical excipients, to animais and to human beings for the treatment of the disorders and diseases above.
The suitable unit administration forms inciude oral forms such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for administration by 25 inhalation, topical, transdermal, subcutaneous, intramuscular or Intravenous administration forms, rectal administration forms, and implants. For topical application, the compounds according to the invention can be used in creams, gels, ointments or lotions.
By way of example, a unit administration form of a compound according to the invention in tablet form can comprise the following constituents:
Compound according to the invention 50.0 mg
Mannitol 223.75 mg
Sodium croscaramellose 6.0 mg
Com starch 15.0 mg
Hydroxypropylmethylcellulose 2.25 mg
Magnésium stéarate 3.0 mg
185
According to the usual practice, the dosage suitable for each patient is determined by the physician according to the mode of administration and the weight and response of said patient.
s The présent invention relates to a compound of the formula (I), (Γ) or (I) according to the présent invention, for use in treating cancer.
The présent invention relates to a compound of formula (I), (Γ) or (I) as defîned above, or an addition sait of this compound with a pharmaceutically acceptable acid, for use as a medicine.
lo The présent invention relates to a compound of formula (I), (I*) or (I) as defîned above, or a pharmaceutically acceptable sait of this compound, for use as a drug.
The présent invention, according to another of its aspects, also relates to a method for treating the pathological conditions indicated above, which comprises the administration, to a patient, of an effective dose of a compound according to the invention, or a 15 pharmaceutically acceptable sait thereof.
Claims (21)
1. A compound of formula (I):
wherein:
R6 is -CONH2 or a -C(Ra)(Rp)(OH) group in which Ra and Rp are, independently of one another, a hydrogen atom or a (CrCe) alkyl group or together form, with the carbon atom which bears them, a 3- to 5-membered carbocycle;
R is a phenyl or heteroaryl group substituted with R1, R’1, R2 and R3;
R1 is a hydrogen atom or is selected from the following groups: (Ci-Ce)alkyl, (0,Ce)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted with one or several substituents selected, independently in each instance, from: amino, hydroxyl, thîol, halogen, (Ci-Ce)alkyl, (Ci-Ce)aikoxy, (CrCeJalkylthio, (Cr Ce)alkylamino, aryloxy, aryt(Ci-Ce)alkoxy, cyano, ha!o(Ci-Ce)alky1, carboxyl and carboxy(Ci-Ce)alkyl;
R'1 is a hydrogen atom or a (Cf-Cejalkoxy group;
R2 is selected from:
- a hydrogen atom, a halogen atom, or a (Ci-Ce)alkyl, (C3-C7)cycloalkyl or (Cr Ce)alkoxy group;
- a heterocycloalkyi, heterocycloalkyl-CH2- or heteroaryl group;
wherein each said heterocycloalkyi, heterocycloalky!-CH2- and heteroaryl group is optionally substituted with one or several substituents selected, independently in each instance, from: (Ci-Ce)alkyl, (C3-C7)cycloalky!, (CrCe)alkoxy, heterocycloalkyi, carboxy(CrCe)alkyl, NR4R5 and 0R4;
187 said (CrCe)alkyl group being optionally substituted with a halogen atom or a (CrCe)alkoxy, heterocycloalkyl, NH2 or OH group; and
R4 and R5 being each, independently of one another, a hydrogen atom, a (CrCe)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;
- an NRaRb group, where Ra and Rb are, independently of one another:
. a hydrogen atom;
. a heterocycloalkyl group, said heterocycloalkyl group being optionally substituted with a (Ci-Ce)a!kyl group; or . a (CrCe)alkyl group, said alkyl group being optionally substituted with an NR4R5 group;
R4 and R5 being each, independently of one another, a hydrogen atom, a (CpCe)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;
R3 is a hydrogen atom, a halogen atom or a (Ci-Ce)a!kyl group;
wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyl ring fused with the phenyl bearing them, this heterocycloalkyl being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (Ci-Ce)alkyl group;
R7 is an aryl group or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (CrC^alkyl, OR’4, CH20H, CH2NH2, S(O)nR’4, R8 and OR8;
wherein:
R’4 is a hydrogen atom or a (CrC^alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
n is 1 or 2; and
R8 is a halo(CrCe)alkyl group;
wherein each of the nitrogen atom(s) of the compounds of formula (I) may be, independently of one another, optionally in oxidized form (N-oxide);
188 or a pharmaceutically acceptable sait thereof.
2. A compound according to Claim 1, wherein:
R6 is -CONH2 or a -C(R0)(RP)(OH) group wherein Ra and Rp are, independently of one another, a hydrogen atom or a (Ci-Ce)alkyl group;
or a pharmaceutically acceptable sait thereof.
3. A compound according to Claim 1 or 2, wherein:
R is a phenyl, pyridinyl or pyrazolyl group substituted with R1, R'1, R2 and R3; R1, R’1, R2 and R3 being as defîned in formula (I) according to Claim 1 ;
or a pharmaceutically acceptable sait thereof.
4. A compound according to any one of Claims 1 to 3, wherein R is selected from the following groups:
R1, R'1, R2 and R3 being as defîned in formula (I) according to Claim 1; or a pharmaceutically acceptable sait thereof.
5. A compound according to any one of Claims 1 to 4, wherein R1 is a hydrogen atom or is selected from the following groups: {CrCe)alkyl, (CrCe)alkoxy, (Qj-CïJcycloalkyl and aryl;
or a pharmaceutically acceptable sait thereof.
6. A compound of formula (I) according to any one of Claims 1 to 5, wherein R'1 is a hydrogen atom or an isopropyloxy group;
189 or a pharmaceutically acceptable sait thereof.
7. A compound according to any one of Claims 1 to 6, wherein:
5 R2 is selected from:
- a hydrogen or chlorine atom or a methyl, cyclopropyl or methoxy group;
•a pyrrolidinyl, pïperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl,
1,4-diazepan-1 -yl, diazabicycloheptanyl, (8aR)-hexahydropyrroloI1,2-a]pyrazin2(1H)-yl, 1,7-diazaspiro[4.4]non-7-yl, octahydroindolizinyl, îo dihydroimidazopyrazînyl, piperazinyl-CH21 pyrazolyl, imidazolyl, triazolyl or pyridinyl group; these groups being optionally substituted with one or more substituents selected, independently in each instance, from: (CrC9)alkyl, (Ca-C^Jcycloalkyl, (C,C9)alkoxy, heterocycloalkyl, carboxyiCrCeJalkyl, NR4R5 and 0R4;
said (CpCgJalkyl group being optionally substituted with a halogen atom or a 15 (CpCeïalkoxy, heterocycloalkyl, NH2 or OH group;
wherein:
R4 and R5 each is, independently of one another, a hydrogen atom, a (Cr Ce)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom bearing them, a 4- to 20 7-membered ring; and
- an NRaRb group, where Ra and Rb are, Independently of one another:
. a hydrogen atom;
. a piperidinyl group or tetrahydropyranyl group, wherein each of said piperidinyl and tetrahydropyranyl groups is Independently optionally substituted with a (Cr 25 C9)alkyl group; or . a methyl or ethyl group, said alkyl group being optionally substituted with an
NR4R5 group;
wherein:
R4 and R5 each is, independently of one another, a hydrogen atom, a (C,30 C9)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom bearing them, a 4- to
7-membered ring; and
R3 is a hydrogen atom, a halogen atom or a (CrC9)alkyl group;
190 wherein when R corresponds to formula (A), R2 and R3 can together form an azepinyl or oxazepinyl ring fused with the phenyl bearing them, this azepinyl or oxazepinyl being optionally substituted with one or more substituents selected, independently in each instance, from: an oxo group and a (CrCe)alkyl group;
or a pharmaceutically acceptable sait thereof.
8. A compound according to any one of Claims 1 to 7, wherein:
R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, Independently In each instance, from: cyano, halogen, (Ct-Ce)alkyl, OR’4, CH2OH, CH2NH2, S(O)nR’4, R8 and OR8;
wherein:
- R'4 is a hydrogen atom or a (CrCeJalkyl group or aryl group, said (CrCeJalkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
- n is 1 or 2;
- R8 is a halo(CrCe)alkyl group;
or a pharmaceutically acceptable sait thereof.
9. A compound according to any one of Claims 1 to 8, wherein
R6 is -CONH2 or a -C(Ra)(Rp)(OH) group wherein Re and Rp are, independently of one another, a hydrogen atom or a (CrCe)alkyl group;
R is a phenyl, pyridinyl or pyrazolyl group substituted with R1, R'1, R2 and R3;
R1 is a hydrogen atom or Is selected from the following groups: (CrCeJalkyl, (Ci-Ce)alkoxy, (C3-C7)cycloalkyl and aryl;
R'1 is a hydrogen atom or an isopropyloxy group;
R2 Is selected from:
- a hydrogen or chlorine atom or a methyl, cyclopropyl or methoxy group;
191
- a pyrroîidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, tetrahydropyranyl, 1,4diazepan-1-yl, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1 H)yl, 1,7-diazaspiro[4.4]non-7-yl, octahydroîndolizinyl, dihydrolmidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group; these groups being optionally substituted with one or more substituents independently selected from: (Ci-Ce)alkyl, (C3-C7)cycloalkyl, (CrCe)alkoxy, heterocycloalkyl, carboxy(Cr Ce)alkyl, NR4R5 andOR4;
said (CrCe)alkyl group being optionally substituted with a halogen atom or a (CrCe)alkoxy, heterocycloalkyl, NH2 or OH group;
and wherein:
R4 and R5 each is, independently of one another, a hydrogen atom, a (Cr Ce)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and
- an NRaRb group, where Ra and Rb are, independently of one another:
. a hydrogen atom;
.a piperidinyl or tetrahydropyranyl group, said group being optionally substituted with a (CrCe)alkyl group; or .a methyl or ethyl group, said group being optionally substituted with an NR4R5 group;
wherein:
R4 and R5 each is, independently of one another, a hydrogen atom, a (Cr Cfl)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and
R3 is a hydrogen atom, a halogen atom or a (Ci-Ce)alkyf group;
wherein when R corresponds to formula (A), R2 and R3 may together form an azepinyl or oxazepinyl ring fused with the phenyl bearing them, this azepinyl or oxazepinyl ring being optionally substituted with at least one substituent selected from: an oxo group and a (CrCe)alkyl group;
R7 Is a phenyl, pyridinyl, thîenyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each
192 instance, from: cyano, halogen, (CrCe)alkyl, OR’4, CH2OH, CH2NH2, S(O)nR'4, R8 and OR8;
wherein:
. R'4 is a hydrogen atom or a (CrCeJalkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
. n is 1 or 2; and . R8 is a halo(Ci-Ce)alkyl group;
or a pharmaceutically acceptable sait thereof.
10. A compound according to any one of Claims 1 to 9, wherein:
R6 is -CONH2 or a -C(Ra)(Rp)(OH) group wherein Ra and Rp are, independently of one another, a hydrogen atom or a (C1-Ce)alkyl group;
R is selected from the following groups:
R1 is a hydrogen atom or is selected from the following groups: (CrCe)alkyl, (Cj-CeJalkoxy, (Cs-Czjcycloalkyl and aryl;
R’1 is a hydrogen atom or an isopropyloxy group;
R2 is a pyrrolidinyl, piperidinyl, tetrahydropyridinyl, pîperazinyl, tetrahydropyranyl,
1,4-diazepan-1-yî, diazabicycloheptanyl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin2(1H)-yl, 1,7-dtazaspiro[4.4]non-7-yl, octahydroindolizinyl, dihydroimidazopyrazinyl, piperazinyl-CH2, pyrazolyl, imidazolyl, triazolyl or pyridinyl group; these groups being
193 optionally substituted with one or more substituents selected, independently in each instance, from: (CrCe)alkyl, (C3-C7)cycloalkyl, (CrCe)alkoxy, heterocycloalkyl, carboxy(CrCe)alkyl, NR4R5 and OH;
said (CrCe)alkyl group being optionally substituted with a (CrCe)alkoxy group or 5 OH;
wherein:
R4 and R5 each is, independently of one another, a hydrogen atom, a (Cr CB)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4to to 7-membered ring;
R3 is a hydrogen atom, a halogen atom or a (Ci-Ce)alkyl group;
R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being 15 optionally substituted with one or more substituents selected, independently In each instance, from: cyano, halogen, (Ci-Ce)alkyf, OR’4, CH2OH, CH2NH21 S(O)nR’4, R8 and 0R8;
wherein:
R’4 is a hydrogen atom or a (Ci-C«)alkyl or aryl group, said alkyl and aryl groups
20 being optionally substituted with a halogen atom or an NH2 or OH group;
n is 1 or 2; and
R8 is a halo(CrCe)alkyl group;
or a pharmaceutically acceptable sait thereof.
25
11. A compound according to any one of Claims 1 to 10, wherein:
R6 is -CONH2 or a -C(Ra)(Rp)(OH) group wherein Ra and Rp are, independently of one another, a hydrogen atom or a (CrCe)alkyl group;
194
R1 is an isopropyloxy group;
R’1 is a hydrogen atom;
R2 is a piperidinyl or piperazinyl group, these groups being optionally substituted with one or more substituents selected, independently In each instance, from: a methyl, ethyl, isopropyl, cyclopropyl, OH, oxetanyl, pyrrolidinyl, C(O)O(CH3)3, NR4R5 and OR4 group;
said methyl, ethyl and isopropyl groups being optionally substituted with a (C,· Ce)alkoxy group, such as methoxy, or with an OH;
wherein R4 and R5 each is, independently of one another, a hydrogen atom, a (Ci-Ce)alkyl group or a heterocycloalkyl group;
R3 is a hydrogen or fluorine atom or a methyl;
R7 is a phenyl, pyridinyl, thienyl, furanyl, pyrazolyl or pyrolyl group, this group being optionally substituted with one or more substituents selected, independently in each instance, from: cyano, halogen, (CrCe)alkyl, OR'4, CH2OH, CH2NH2, S(O)nR'4 and OR8;
wherein:
R'4 is a (Ci-Ce)alkyl group;
n is equal to 1 ; and
R8 is a halo(Ci-Ce)alkyl group;
or a pharmaceutically acceptable sait thereof.
12. A compound according to any one of Claims 1 to 11, wherein it is selected from the following compounds: 2-({2-methoxy-4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl)amino)-7-phenylthieno[3,2-d]pyrimÎdine-6-carboxamide;
2-((2-methyl-4-[4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}amino)-7-phenylthîeno[3,2-d]pyrimidÎne-6-carboxamide;
7-(3-chlorophenyl)-2-((2-methoxy-4-I4-(pynOlidin-1-yl)piperidin-1-yl]phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(4-chlorophenyl)-2-({2-methoxy-4-î4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}· amino)thieno[3,2-d]pyrimidine-6-carboxamide;
195
2-((2-methoxy-4-I4-(pyrrolidin-1-yl)piperidin-1-yl]phenyl}amino)-7-(thiophen-3yl)thleno[3,2-d]pyrimidine-6-carboxamide;
2-({2-methoxy-4-[4-(pyrrolÎdin-1-yl)piperidin-1-yl]phenyl}amino)-7-(thiophen-2yl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-({2-methoxy-4-[4-(propan-2-yl)piperazin-1-yl]phenyl}amino)-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide;
2-({2-methoxy-4-[1-(propan-2-yl)piperidin-4-yl]phenyl}aniÎno)-7-phenylthieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-{[4-(4-methylpipera2in-1-yl)-2-(propan-2-yloxy)phenyl]amîno)thïeno[3,2-d]pyrimÎdine-6-carboxaniide;
7-(4-fluoro-3-methoxyphenyl)-2-{[4'(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(4-methoxyphenyl)-2-{[4-(4-methylpïpera2in-1-yl)-2-(propan-2-yloxy)phenyl]amino)thieno[3t2-d]pyrimidine-6-carboxaniide;
7-(4-fluorophenyl)-2-{[4-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]amino)thieno[3,2-d]pyrimidine-6-caitoxaniide;
2-{[2'methoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl]amino)-7-phenylthieno[3,2d]pyrimidine-6-carboxamide;
7-(4-fluoro-2-methoxyphenyl)-2-{[2-methoxy-4-(4-methylpiperazïn-1-yl)phenyl]amino)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[2'methoxy-4-(4-methylpÎperazin-1-yl)phenyl]aminoJ-7-(3-methoxyphenyl)thieno[3,2-d]pyrimïdine-6-carboxamïde;
7-(2-methoxyphenyl)-2-{[4-(1-methylpîperidin-4-yl)-2-(propan-2-yloxy)phenyl]amÎno)thieno[3,2-d]pyrÎmidine-6-carboxamide;
2-{[5-methyl-4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]aminoJ-7phenylthieno[3,2-d]pyrimidine-6-carboxamÎde;
2-{[2-methoxy-5-methyl-4-(1-methylpiperidin-3-yl)phenyl]amino}-7-phenylthieno[3,2d]pyrimidine-6-carboxamide;
2'({2-methoxy-4-[1-(propan-2-yl)piperidin-4-yl]phenyl}amino)'7-phenylthÎeno[3,2-d]pyrimidine-6-carboxamîde;
2-{[4-( 1 -methylpiperidïn-4-yl)-2-(propan-2-yloxy)phenyl]amino)-7-( 1 -methyl-1 Hpyrazol-5-yl)thÎeno[3,2-d]pyrimidine-6-carboxamide;
7-(2-ethoxyphenyl)-2-{[4-(1-methylpiperidin'4-yl)-2-(propan-2-yloxy)phenyl]amïno}thïeno[3,2-d]pyrimidine-6-carboxamide;
7-(3-methoxyphenyl)-2-{[4-(1’methylpiperidin-4-yl)'2-(propan-2'yloxy)phenyl]· amino)thieno[3,2-d]pyrimldine'6-carboxamide;
.·
C
196
2-{[5-methyl-4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(pyridin-2yl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(4-methyl-1,4-diazepan-1-y1)-2-(propan-2-yloxy)phenyl]amino}-7· phenylthieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-fluoro-5-methoxyphenyl)-2-([4-(1-methylpÎperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(3-cyanophenyl)-2-{[4-(1-methylpîperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-[2(trifluoromethoxy)phenyi]thieno[3,2-d]pyrimidine-6-carboxamide;
24(4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-phenylthieno[3,2-d]pyrimidÎne-6-carboxamÎde;
2-({4-[(1Sl4S)-5-methyl-2l5-diazabicyclo[2.2.1]hept-2-yl]-2-(propan-2-yloxy)phenyl}amino)-7-phenylthieno[3,2-d]pyrïmidine-6-carboxamide;
2-((4-( 1 -methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1 -methyl-1,2,3,6tetrahydropyridin-4-yl)thÎeno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-{[5-methyl-4-(1-methylpîperîdin-4-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimÎdine-6-carboxamide;
2-{[4-methoxy-2-(propan-2-yloxy)phenyl]amino}-7-phenylthieno[312-d]pyrimidine-6-carboxamide;
2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-[3(methyisulfinyi)phenyi]thÎeno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypyridin-3-yl)-24(4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenylJaminoJthÎenofS^-dlpyrimidine-e-carboxaniide;
7-(2-cyanophenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-y1oxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1H-imidazol-1-yl}-2-(propan-2-yloxy)phenyl]amino}-7-phenylthieno[3,2djpyrim idin e-6-carboxamide ;
2-{[4-{methyl[2-(pyrrolidin-1-yl)ethyl]amino]-2-(propan-2-yloxy)phenyl]amino}-7phenylthieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-{[6-(4-methylpiperazin-1-yl)-4-(propan-2-yloxy)pyridîn-3yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-{[6-(1-methylpiperidin-4-yl)-4-(propan-2-yloxy)pyridin-3y l]am in o] thien o[3,2-d]pyrimidine-6-carboxamide ;
7-(5-fluoro-2-methoxyphenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino]thieno[3,2-d]pyrimidine-6-carboxamide;
197
7-(3-fluoro-2-methoxyphenyl)-2-{[4-(1’niethylpiperidin-4-yl)-2’(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamIde;
2-{(4-(1-methylpÎperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7*[2(methylsulfinyOphenylJthienofS^’dJpyrimîdine-e-carboxamide;
5 2-({4-[3-(dimethylamino)pyrrolidin-1-yl]-2-(propan-2-yloxy)phenyl}amino)-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-((4-{methyl[2’(pyrrolidin-1-yl)ethyl]aniÎno}-2-(propan-2yloxy)phenyl]amino)thieno(3,2-d]pyriniidine-6-carboxaniide;
7-(2-fluoro-3-methoxyphenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)îo phenyljaminojthienots^-dlpyrimidine-e-carboxamide;
2-{[4-(1-ethylpîperidin-3-yl)-2-(propan-2-yloxy)phenyl]aniino}-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
7'(2-fluorophenyl)-2-{[4'(1-rnethylpiperidin-4-yl)'2-(propan-2’yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
13 2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}*7-(1H-pyrrol-2yl)thieno[3,2-d]pyrimîdine-6-carboxamîde;
7-(2-fluoro-5-(hydroxymethyl)phenyl]-2-{(4-(1-niethylpiperïdin-4-yl)-2-(propan-2yloxy)phenyl]amîno}thieno[3,2-d]pyrimidine-6-carboxamide;
2-Î[4-(5-methoxy-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(propan-2-yloxy)20 phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(4-fluoro-2-methoxyphenyl)-2-[[4-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]amino}thÎeno[3,2-dJpyrimidine-6-carboxamide;
2-((4-(1 H-imidazol-1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
25 2-methylpropan-2-yl 4-[5-{[6-carbarnoyl-7-(2-methoxyphenyl)thienO’ (3,2-d]pyrimidin-2-yl]amino}-1 -(propan-2-yl)-1 H-pyrazol-3-yl]pîperîdine-1 carboxylate;
7-(2-methoxyphenyl)-2-{(2-(propan-2-yloxy)-4-(2,2,6,6-tetramethylpiperidin-4yl)phenyl]amino}thieno(3,2-d]pyriniidÎne-6-carboxarTiide;
30 2-((4-(2,6-dimethylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxyphenyl)thieno(3,2-d]pyrimidine-6-carboxamide;
2-{[4-(2-ethylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]aniino}-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxaniide;
7-(2-methoxyphenyl)-2-{[4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}35 thieno[3,2-d)pyrimidine-G-carboxamide;
198
7-(4-fluoro-2-methoxyphenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyljaminojlhienota^-djpyrimidine-e-carboxamide;
2-i[4-(3,5-dimethylpiperazin-1-y1)-2-(propan-2-y1oxy)pheny!]amino)-7-(2melhoxyphenyl)lhieno[3,2-d]pyrimidine-6-carboxamide;
5 7-(2-methoxyphenyl)-2-{[2-(propan-2-yloxy)-4-(3,4,5-lrimelhylpiperazin-1-yt)phenyl]amino)lhieno[3,2-d]pyrimidine-6-carboxamÎde;
2-({4-[(8aR)-hexahydropyrroto[1,2-a]pyrazin-2( 1 H)-yl]-2-(propan-2-ytoxy)phenyl}amino)-7-(2-methoxyphenyt)lhieno[312-d]pyrimidine-6-carboxamide; 7-(2-methoxyphenyt)-2-{[3-(piperidin-4-yl)-1-(propan-2-yl)-1 H-pyrazol-5io yl]amino}thieno[3l2<qpyrimidine-6-cart)oxamide;
2-({4-[(3R)-1-ethylpiperidin-3-yl]-2-(propan-2-yloxy)phenyt)amino)-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-({4-[(3S)-1-ethytpiperidin-3-yl]-2-(propan-2-yloxy)phenyl}amtno)-7-(2methoxyphenyl)lhieno[3,2-d]pyrimidine-6-carboxamide;
15 2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino)-7-(thiophen-3yl)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(5-fluoro-2-methoxypyridin-4-yl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2yloxy)phenyOamino)thieno[3,2-d]pyrirnidine-6-carboxamide;
7-(2-methoxyphenyl)-2-({2-(propan-2-yloxy)-4-[(2R,4S)-2-(propan-2-yl)20 piperidin-4-yl]phenyl}amino)thieno[3,2-d]pyrÎmidine-6-carboxamide;
7-(2-methoxyphenyl)-2-({2-(propan-2-yloxy)-4-[(2R,4R)-2-(propan-2-yl)piperidin-4-y1]phenyl}amino)thieno[3,2-d]pyrimidine-6-carix)xamide; 7-(2-chlorophenyl)-2-{[4-(1-methylpiperidin-4-yî)-2-(propan-2-yloxy)phenyI]’ amino}thieno[3,2-d]pyrimidine-6-carboxamide;
25 2-({4-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1 H)-yl]-2-(propan-2-yloxy)phenyl]amino)-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide; 7-(3-chlorophenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenylîamino}thîeno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methylphenyl)-2-([4-(1-methylpiperidin-4-yt)-2-(propan-2-yloxy)phenyl]·
30 amino}lhieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]aniino)-7-(1-methyl-1HpyrazoM-ylJthienoES^-dJpyrimidine-e-carboxamide;
7-(2,5-dimethoxyphenyl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenylJamino)thieno[3,2-d]pyrimidine-6-carboxamide;
35 7-[2-(difluoromethoxy)phenyl]-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenylJaminoJthienoISÆ-dJpyrimidine-e-carboxaniide;
199
2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1H-pyrazol-4yl)thieno[3,2-dJpyrimidine-6-carboxamide;
2-({4-[3-(2-hydroxyethyl)-4-methylpiperazin-1-yl]-2-(propan-2-yloxy)phenyl}amino}-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidÎne-6-carboxamide,· 7-(2-methoxypyridin-3-yl)-2-{[5-methyl-4-(1-methylpiperidÎn-4-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide:
7-(2-methoxypyridin-3-yl)-2-{[4-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]amino]thieno[3,2-d]pyrimÎdÎne-6-carboxamide;
2-({4-[1-(2-hydroxyethyl)pÎperidin-4-yl]-2-(propan-2-yloxy)phenylJamino)-7-(2methoxyphenyl)thieno[3,2-d]pyrimÎdine-6-carboxamide;
7-(2-melhoxyphenyl)-2-{[4-(3-melhoxypyridin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-{[6-(4-melhylpîperazin-1-yl)-2-(propan-2-yloxy)pyridin-3ylJamino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-{[4-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2-(propan-2yloxy)phenyl]amino]thieno[3,2-d]pyrimidine-6-carboxamide;
2-({4-[(2S,4S)’2-ethyl-1-methylpiperidin-4-yl]-2-(propan-2-yloxy)phenyi}amino)-7-(2-methoxyphenyl}thÎeno[3,2-d]pyrimidine-6-carboxamide;
2-({4-[(2S,4R)-2-ethyl-1-methylpiperidin-4-yl]-2-(propan-2-yloxy)phenyl}amino)-7-(2-methoxyphenyl}thieno[3,2-d]pyrimidine-6-carboxamÎde;
7-(2-methoxypyridin-3-yl}-2-({2-(propan-2-yloxy}-4-[1-(propan-2-yl}pîperidin-4ynphenyl}amino)thieno[3,2-d]pyrimidine-6-cartx)xamide;
7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[4-(1-methylpÎperidin-4-yl)-2-(propan-2yloxy)phenyl]amino]thieno[3,2-d]pyrimidine-6-carboxamide;
7-(5-fluoro-2-melhoxypyridin-3-yl)-2-({2-(propan-2-yloxy)-4-[1-(propan-2-yl}piperidin-4-yl]phenyl}amino)thieno[312-d]pyrimidine-6-carboxamide;
7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[5-methyl-4-(1-methylpiperidin-4-yl)-2-(propan2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(6-melhoxypyridin-2-yl)-2-{[4-(1-methylpfperidÎn-4-yl)-2’(propan’2-yloxy)phenynamino}thieno[3,2-d]pyrimidine-6-carboxarnide;
7-(2-chlorophenyl)-2-({4-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(propan-2-yloxy)phenylJaminoJthienofS^-dlpyrimidine-e’Carboxamide;
7-(2-methoxyphenyl)-2-{[6-(1-methylpiperid!n-4-yl)-2-(propan-2-yloxy)pyridin-3yl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-{1,7-diazaspiro[4.4]non-7-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxyphenyi)thieno[3,2-d]pyrimidine-6-carboxamide;
200
2-({4-[3-(diethylamino)pyrrolidin-1-yl]-2-(propan-2-yfoxy)phenyl}amino)-7-(2methoxypyridin-3-yl)thieno[3,2-d]pyrimîdine-6-carboxamide;
2-({4-[3-(dimethylamino)pynolidin-1-yl]-2-(propan-2-yloxy)phenyl}amÎno)-7-(1methyl-1H-pyrrol-2-yl)thieno[3)2-d]pyrimidine-6-carboxamide;
5 2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino]-7-(1-methyl‘1Hpyrrol-2-yl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methylpyridin-3yl)thieno[3,2-d]pyriniidÎne-6-cart)oxamide;
7-(furan-2-yl)-2-{[4-(1-methylpiperÎdin-4-yl)-2-(propan-2îo yloxylphenyllaminolthienoIS^-dlpyrimidine-e-carboxarnide,·
7-[5-(amÎnoniethyl)furan-2-yl]-2-{[4-(1-methylpiperidÎn-4-yl)-2-(propan-2yloxy)phenyl]amino]thieno[3,2-d]pyriniidine-6-carboxarnide;
7-(2-σΐθΙΐΊί^ρ^ΐη-3^Ι)-2-{[5-ΓπβΙ1ψΙ-4-(4-Γπβ0^ΙρϊρβΓ3ζΐη-1-^)-2-(ρΓορ3η-2yloxy)phenyl)amino}thieno[3,2-d]pyrimidine-6-carboxamide;
15 2-{I4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1H-pyπol·3ylJthienoISÆ-dJpyrimidine-G-carboxamide;
2-({4-[3-(dimethylamino)pynrolidin-1-yl]-2-(propan-2-yloxy)phenyl]amino)-7-(2methoxypyridin-3-yl)thieno[3,2-d]pyrimÎdine-6-carboxamide,'
7-(2-ethoxypyridin-3-yl)-2-((2-(propan-2-yloxy)-4-[1-(propan-2-yl)piperidin-4-yl]20 phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxaniide;
7-(2-ethoxypyridin-3-yl)-2-([5-methyl-4-(1-methylpiperidin-4-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyriniidine-6-carboxamÎde;
7-(2-methoxyphenyl)‘2-([5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amÎno}thÎeno[3,2-d]pyrimÎdine-6-carboxamide;
25 7-(2-ethoxypyridin-3‘yl)‘2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2· yloxy)phenyl]amÎno}thieno[3,2-d]pyriniidine-6-carboxamide; 7-(2-ethoxypyridin-3-yl)-2-([4-(4-methylpiperazin-1-yl)-2-(propan-2· yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide,· 7-(2-methoxy-5-methylpyridin-3-yl)-2-{[4-(4-methylpiperazin-1-yl)-2-(propan-230 yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamîde;
7-(2-methoxy-5-methylpyridîn-3-yl)-2-{[4-(1-methylpÎperÎdin-4-yl)-2-(propan-2yloxy)phenyl]amino}thÎeno[3,2-d]pyriniÎdine-6-carboxamÎde;
7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[4-(4-methylpÎperazin-1-yl)-2-(propan-2yloxy)phenyl]amino]thieno[3,2-d]pyrimidine-6-carboxamide;
35 7-(2-methoxy-5-methylpyridin-3-yl)-2-{[5-methyl-4-(1-methylpiperidin-4-yl)-2(propan-2-yloxy)phenyl]amino}thieno[3I2-d]pyriniidine-6-cart)Oxamide;
fl «
201
2-j[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1-methyl-1Hpyrazol-S-ynthienop^-dlpyrimidine-G-carboxamide;
2-({4-[3-(2-melhoxyelhy1)-4-methylpiperazin-1-yl]-2-(propan-2-y1oxy)phenyl}amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-{[4-{(3R)-3-[methyl(oxelan-3-yl)amino]piperidin-1-yl}-2(propan^-yloxyJphenylJamÎnoJthienofS^-dJpyrimidine-O-carboxamide;
7-(2-methylfuran-3-yl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)’ phenyl]amino)thÎenoI3,2-d]pyrÎmÎdine-6-carboxamide;
/-(B-methoxypyridin^-ylJ^-flS-methyl^-fl-methylpiperidirM-ylJ^-fpropan^yloxy)pheny(]amino)thÎeno[3,2-d]pyrimidine-6-carboxamide;
2-({4-[3-(dimethylamino)pyrrolidin-1-yl]-5-methy1-2-(propan-2-yloxy)phenyl)amino)-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimÎdine-6-carboxamide;
2-({4-[3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-2-(propan-2-yloxy)phenyl)amÎno)-7-(2-methoxyphenyl)thieno[312-d]pyrimidÎne-6-carboxamide;
2-({3-[1-(oxetan-3-yl)piperidin-4-yl]-1-(propan-2-yl)-1H-pyrazol-5-yl]amino)-7-[2(IrifluoromethoxyJphenylJthienoIS^-dJpyrimidine-e-carboxamide;
7-(2-melhoxy-6-methylpyridin-3-yl)-2-{[5-methyl-4-(1-methylpiperidin-4-yl)-2(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxy-6-methylpyridin-3-yl)-2-{[4-(4-methy1piperazin-1-yl)-2-(propan-2yloxyJphenylJaminoJthienofS^-dJpyrimidine-G-carboxamide;
7-(2-methoxy-6-methylpyridin-3-yl)-2-{[4-(1-methylpiperidin-4-yl)-2-(propan-2yloxyJphenyljaminoJthienoIS^-dlpyrimidine-G-carboxamide;
2-{[3-(1-elhylpiperidin-4-yl)-1-(propan-2-yl)-1 H-pyrazol-5-yl]amino}-7-[2(trifluoromethoxyJphenylJthienofS^-dJpyrimidine-e-carboxamide;
2-({4-[(3R,4S)-3-hydroxy-1-methylpiperidin-4-yl]-2-(propan-2-yloxy)phenyl}amino)-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-({4-[(8S,8aS)-octahydroindolizin-8-ylI-2-(propan-2yloxy)phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-((4-[(8R,8aS)-octahydroindolizin-8-yl]-2-(propan-2yloxyJphenylîaminoJthienolS^-dlpyrimÎdine-e-carboxamide
7-(2-methoxyphenyl)-2-{[4-(1-methyl-1H-pyrazol-4-yl)-2-(propan-2-yloxy)phenyl]amino}lhfeno[3,2-d]pyrimidine-6-carboxamÎde;
7-(2-methoxypyridin-3-yl)-2-[(1-methyl-2-oxo-2,3,4I5-tetrahydro-1H-1-benzazepin-8yl)amino]thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-{[4-(2-methyl’1H-imidazoM-yl)-2-(propan-2-yloxy)phenyl]amtno)thieno[3,2-d]pyrimidine-6-carboxamide;
202
24I5-fluoro-4-(1 -methylpiperidin-4-yl)-2-(propan-2-yIoxy)phenyI]amino}-7-(2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[5-fluoro-4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;
5 7-(2-methoxypyridin-3-yl)-2-{[5-methyl-4-(2-methyl-1 H-imidazol-1 -yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-([2-(propan-2-yloxy)-4-( 1 H-1,2.4-triazol-1 -yljphenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-[(1-phenyl-1H-pyrazol-5-yl)amino]thieno[3,2-d]pyrimidine-6ίο carboxamîde;
7-(2-methoxyphenyl)-2-([4-(1-methyl-1H-pyrazol-3-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypyrïdin-3-yl)-2-{[3-methyl-1-(propan-2-yl)-1 H-pyra2Ol-5-yl]amino}thieno[3,2-d]pyrimidin e-6-carboxamide;
15 7-(2-fIuorophenyl)-2-{[5-methyl-4-(1-methylpiperidin-4-yl)-2-(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-[(1 -methyl-2-oxo-2,3,4,5-tetrahydro-1 H-1 -benzazepin-8yl)amino]thieno[3,2-d]pyrimidine-6-carboxamide,'
7-(4-fluoro-2-methoxyphenyl)-2-{[3-(piperidin-3-yl)-1-(propan-2-yl)-lH-pyTa2ol-520 yl]amlno}thieno[3,2-d]pyrimidine-6-carboxamide;
2-{(3-cyclopropyl-1-(propan-2-yl)-1 H-pyra2ol-5-yl]amino}-7-(2-methoxypyridin-3yl)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(4-ΑυοΓο-2-ωθ{ήοχγρήθηγΙ)-2-{[1-(ρΓορ3η-2^Ι)-3-(ργι^ίη-3-γΙ)-ΐΗ^Γ32θΙ-5yl]amÎno}thieno(3,2-d]pyrimidine-6-carboxamide;
25 7-(2-methoxyp^’idin-3-yl)-2-[(1-methyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-7yl)amino]thieno[3,2-d]pyrimidine-6-carboxamide;
7-(4-fluoro-2-methoxyphenyl)-2-{[2-(propan-2-yloxy)-4-(1 H-1 ,2.4-trîazol-1 -yl )phenyl]amino]thieno[3,2-d]pyrîmidine-6-carboxamide;
2-((4-(2,4-dimethyl-1 H-imidazol-1-yl)-2-(propan-2-yloxy)phenyl]amîno}-7-(23o methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[4-methoxy-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;
2-[(3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl)amino]-7-(2-methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
35 2-((4-(5,6-dihydrolmldazo(1,2-a]pyrazin-7(8H)-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamide;
203
2-{[4-(1-cyclopropylpiperidin-4-yî)-2-(propan-2-yloxy)phenyl]aminoî-7-(2methoxyphenyl)thîeno(3,2-d]pyrimÎdine-6-carboxamide;
2-{[4-(1-cyclopropylpiperidin-4-y1)-2-(propan-2-yloxy)phenyl]amino}-7-(5-fluoro-2methoxyphenyl)thieno[3,2-d]pyrimidine-6-carboxamide;
5 2-{[4-(1-cyclopropylpiperidin-4-y1)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxypyridin-3-yl)thîeno[3,2-d]pyrimidine-6-carboxamide;
7-(2-πΐ60ιοχγρνπάη-3-νΙ)-2-{[4-(4-ΓηθΙΗνΙ-1Η'ίπΉ^3ΖθΙΊ-^)-2-(ρΓθρ3η-2-γΙοχν)phenyl]amlno)thleno[3,2-d]pyrimldine-6-cart)oxamide;
/-^-fluoro^-methoxyphenylJ^'KI-methyl^-oxo^.S^.S-tetrahydro-IH-l· îo benzazepÎn-7-y1)amino]thieno[3,2-d]pyrimidine-6-carboxarnide;
2-{[4-(4-methylpiperazÎn-1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(1-oxidopyridin-2yl)thieno[3,2-d]pyrimÎdîne-6-carboxamide;
2-((4-( 1-ethyl-1,7-dÎazaspiro(4.4]non-7-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxyphenyl)thieno[3,2-d]pyrimÎdine-6-carboxamide;
15 7-(2-ethoxypyridin-3-yl)-2-([5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
24(4-(3, 5-dimethyl-1 H-1,2.4-triazol-1 -yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxyphenyl)thîeno[3,2-d]pyrimidÎne-6-carboxamide;
/-(S-fluoro^-methoxypyrÎdin-S-ylJ^-GS-methyl^-^methyîpiperazin-l-ylJ^-Îpropan20 2-yloxy)phenyl]amino]thieno[312-d]pyrimidine-6-carboxamide;
7-(2-methoxy-6-methylpyridin-3-yl)-2-([4-(2-methyl-1H-lmldazol-1-yl)-2-(propan-2yîoxy)pheny0amino}thieno[3,2-d]pyrimidÎne-6-carboxamide;
7-(2-methoxyphenyl)-2-((4-[(4-methylpiperazin-1-yl)methyl]-2-(propan-2yloxy)phenyl}amino)thieno[3,2-d]pyrimidine-6-carboxamÎde;
25 7-(2-methoxy-6-methylpyridin-3-yl)-2-([5-methyl-4-(4-methylpiperazin-1-yl)-2· (propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide; 7-(2-methoxyphenyl)-2-([1 -methy1-2-oxo-6-(propan-2-yloxy)-2l3>4l5-tetrahydro-1 H-1 benzazepfn-7-yî]amino}thieno[3,2-d]pyrimidine-6-carboxarnide;
7-(2-methoxypyridin-3-yl)-2-([1-methyl-2-oxo-6-(propan-2-yloxy)-2,3,4l5-tetrahydro30 1 H-1 -benzazepin-7-yl]amino}thieno[3,2-d]pyrimidine-6-cart)Oxamide;
7-(2-methoxyphenyl)-2-([5-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]amino]thleno[3,2-d]pyrimidine-6-cart)oxamide;
7-(2-methoxyphenyl)-2-([2-(propan-2-yloxy)-4-(tetrahydro-2H-pyran-4y1amino)phenyl]amino}thieno[3t2-d]pyrimidine-6-carboxamÎde;
35 7-(3-methoxypyridin-2-yl)-2-([5-methyl-4-(4-methylpiperazln-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidine-6-carboxamide;
2<M
2-{[4-(4-hydroxyprperidîn-1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2methoxypyridin-3-yl)thieno[3,2-d]pyrimidine-6-carboxamtde; 7-(2-methoxyphenyl)-2-({4-[(1*methylpperidin-4-yl)amino]-2-(propan-2· yloxy)phenyl}amino)thîeno[3,2-d]pyrimîdine-6-carboxamide;
24I1-cyclobutyl-3-(1-ethylpiperidin-4-yl)-1H-pyrazol-5-yl]amino]-7-(4-fluoro-2methoxyphenyOthienoIS^-dlpyrimidine-e-carboxamide;
7-(2-methoxypyridin-3-yl)-2-({4-[(4-methylpiperazin*1-yl)methyl]-2-(propan-2yloxyjphenyljaminojthrenop^-djpyrimidine-e-carboxamide;
7-(2-methoxypyridin-3-yl)-2-{[4-(1-methylpyrrolidin-3-yl)-2-(propan-2· yloxy)phenyl]amino]thieno[3,2-d]pyrimidîne-6-carboxamide;
7-(2-methoxyphenyl)-2-{[3-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino]thieno[3,2-d]pyrimidine-6-carboxamide;
7'(5-fluoro-2-methoxypyrîdin-3-yl)-2-{[1'(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)1H-pyrazol-5-yl]amino}thleno[3,2-d]pyrimidine-6-carboxamide;
7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[3-methyl-1*(propan-2-yl)-1 H-pyrazol-5yl]amino]thieno[3,2-d]pyrimîdine-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-[(5-methyl-2l3l4l5-tetrahydro-1,5-benzoxazepin-7yl)amino]thieno[3,2-d]pyrimidine-6-carboxamide;
2-{[1-(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-yl]amino}-7-[2(trifluoromethoxy)phenyl]thîeno[3,2-d]pyrimidîne-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-{[3-(4-methylpiperazin-1-yl)-2-(propan-2· yloxy)phenyl]amino]thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-{[5-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amîno}thieno[3,2-d]pyrimidîne-6-carboxamide;
7-(2-methoxypyridin-3-yl)-2-({4'[(1-methylp(peridin-4-yl)amino]-2-(propan-2yloxy)phenyl}amino)thÎeno[3,2-d]pyrimidine*6-carboxamide;
2-{[4-(4-ethylpiperazin-1*yl)-2-(propan-2-yloxy)phenyl]amino}-7-(2-methoxypyridin-3yl)thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2-methoxyphenyl)-2-{I1 -methyl-2-oxo-8-(propan-2'yloxy)-2,3l4,5-tetrahydro-1 H-1 benzazepin-7-yl]amino}thieno[312-d]pyrimidine-6-carboxamîde;
7-(2-methoxyphenyl)-2-{[1-(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5yljaminojthienois^-djpyrimidîne-e-carboxamide;
7-(2-methoxypyridin-3-yl)-2-{[1-methyl-2-oxo-8-(propan-2-yloxy)-2l3.4l5-tetrahydro1 H-1 -benzazepin-7-yl]amino]thieno[3,2-d]pyrimidine-6-carboxamide;
7-(2- met hoxypyridin -3-y I) -2-{[4- {1 -meth yl-1 H-pyrazo l-4-yl)-2- (p ropan-2yloxyJphenylJaminoJthienoISÆ'dJpyrimidine-e-carboxamide;
205 [7-(2-methoxyphenyl)-2-{[4-(1-methylpÎperidin-4-yl)-2-(propan-2· yloxy)phenyl]amino)lhieno[3,2-d]pyrimidin-6-yl]methanol; [7-(2-methoxyphenyl)-2-{[4’(4-methy1piperazin-1-yl)-2-(propan-2yloxy)phenyl]amino)thieno[3,2-d]pyrimîdin-6-yl]methanol; [7-(2-methoxy-6-methylpyridin-3-yl)-2-{[4-(4-melhylpiperazin-1-yl)-2-(propan-2· y1oxy)phenyl]amÎno)thieno[3,2-d]pyrimidin-6-ylJmethanol;
[7-(5-fluoro-2-melhoxypyridin-3-yl)-2-{[4-(4-methylpÎperazin-1-yl)-2-(propan-2yloxyjphenyljaminojlhienop^-djpyrimidin-e-yljmethanol;
[7-(2-ethoxypyridin-3-yl)-2-{[4-(4-methylpiperazin’1-y!)-2-(propan-2yfoxy)phenyl]amino)thienoI3,2-d]pyrimidin-6-yl]methanol;
[7-(2-methoxypyridin-3-yl)-2-{[5-methy1-4-(4-methylpiperazin-1-yl)-2-(propan-2yloxy)phenyl]amino)thieno[3,2-d]pyrimîdin-6-yl]methanol;
[7-(5-fluoro-2-methoxypyridin-3-yl)-2-{[5-methyl-4-(4-methylpiperazin-1-y1)-2(propan-2-yloxy)phenyl]amino)thieno[3,2-d]pyrimidin-6-yl]methanol;
[7-(2-methoxy-6-methylpyridin-3-yl)-2-{[5-melhyl-4-(4-methy1piperazin-1-yl)-2(propan-2-yloxy)phenyl]amino)thieno[3,2-d]pyrimidin-6-yl]methanol;
[7-(2-methoxy-6-methylpyridin-3-yl)-2-{[1-(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)IH-pyrazol-S-ynaminolthienoISÆ-dJpyrîmidin-G-yljrnethanol;
[7-(2-ethoxypyridin-3-yl)-2-{[5-methyl-4-(4’melhylpiperazin-1-y1)-2-(propan-2yloxy)phenyl]amïno}thieno[3,2-d]pyrimidin-6-yl]methanol;
[7-(2-methoxyphenyl)-2-{[5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2y1oxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;
[7-(2-methoxy-6-methylpyiïdîn-3-yl)-2-{[4-(1-methyl-1,7-diazaspiro[4.4]non-7-y1)-2(propan-2-yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-ylJmethanol;
[2-{[4-chloro-2-(propan-2-y1oxy)phenyl]amino}-7-(2-methoxypyridÎn-3-yl)thieno[3,2d]pyrimidin-6-yl]methanol;
(2-{[3-methyl-1 -(propan-2-yl )-1 H-pyrazol-5-yl]arTiino)-7-[2(trifluoromethoxy)phenyl]thieno[3,2-d]pyrimidin-6-yl)methanol; [7-(5-fluoro-2-melhoxypyridin-3-yl)-2-{[3-methyl-1-(propan-2-yl)-1H-pyrazol-5ylJamino}thleno[3,2-d]pyrimidin-6-ylJmethanol;
(2-{[1-(propan-2-yl)-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-yl]amino}-7-[2(trifluoromethoxyJphenylJthienolSÆ-dlpyrimidin-e-ylJmethanol;
[7-(2-ΠΊ6ΐίιοχγρΙιβΓψΙ)-2-{Ι1-(ρΓορ3η-2·7ΐ)-3-Π6ΐΓαΙ^Γθ-2Η-ργΓ3η-4-γΙ)-1Η-ργΓ3ζοΙ-5yl]amino}thieno[3,2-d]pyrimidÎn-6-ylJmethanol;
[7-(5-fluoro-2-methoxyphenyl)-24I3-methyl-1-(propan-2-yl)-1H-pyrazol-5yl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;
206 [7-(5-fluoro-2-methoxyphenyl)-2-{[4-(4-methylpipera2in-1-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimÎdin-6-yl]methanol;
(2-{[4-(4-methyIpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-[2(trifluoromethoxy)phenyl]thÎeno[3,2-d]pyrÎmidin-6-yl)methanol; [7-(2-methoxypyridin-3-yl)-2-([4-(1-methyl-1H-pyrazol-4-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;
[7-(2-methoxyphenyI)-2-{[4-(1-methyl-1 H-pyrazoI-4-yl)’2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;
[2-{[5-methyl-4-(4-methylpiperazin-1-yl)-2-(propan-2-yloxy)phenyl]amino}-7-(6methylpyridin-3-yl)thieno[3,2-d]pyrimidin-6-yl]methanol;
[7-(2-methoxypyridin-3-yl)-2-{[4-(4-methylpiperazÎn-1-yl)-2-(propan-2yloxy)phenyI]amino}thieno[3,2-d]pyrimldin-6-yl]methanol;
[7-(2-methoxyphenyl)-2-([4-(1-methylpyrrolidin-3-yl)-2-(propan-2yloxy)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]methanol;
2-(2-{[2-methoxy-4-(4-methylpiperazÎn-1-yl)phenyl]amino}-7-phenylthieno[3,2d]pyrimidin-6-yl)propan-2-oI;
2-[2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-7-{2methoxyphenyl)thieno[3,2-d]pyrimidin-6-yl]propan-2-ol; and 2-[7-(4-fluoro-2-methoxyphenyl)-2-{[2-methoxy-4-(4-methylpiperazin-1yl)phenyl]amino}thieno[3,2-d]pyrimidin-6-yl]propan-2-ol;
or a pharmaceutically acceptable sait thereof.
13. A process for preparing a compound according to Claim 1, wherein a thienopyrimidine of formula (II):
wherein
R7 is an aryl or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (CrCeJalkyl, OR’4, CH2OH, CH2NH2, S(O)nR’4, R8 and OR8;
V «< *
207 wherein:
R’4 is a hydrogen atom or a (Ci-Ce)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
R8 is a halo(CrCe)alkyl group;
n is 1 or 2;
R16 is a (Ci-Ce)alkoxy group;
îs reacted
a) with a compound of formula (lllb):
.CHO (n*b)
HN
R wherein
R is a phenyl or heteroaryl group substituted with R1, R'1, R2 and R3;
R1 is a hydrogen atom or is selected from the following groups: (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted with one or several substituents selected, independently in each instance, from: amino, hydroxyl, thiol, halogen, (CrCe)alkyl, (Cf-Cejalkoxy, (Cf-Cejalkylthio, (CiCe)alkylamino, aryloxy, aryl(Ci-Ce)alkoxy, cyano, halo(CrCe)alky1, carboxyl and carboxy(Ci-Ce)alky1;
R'1 is a hydrogen atom or a (CrCe)alkoxy group;
R2 is selected from:
- a hydrogen atom, a halogen atom or a (CfCeJalkyi, (C3-C7)cycloalkyl or (Cr Ce)alkoxy group;
- a heterocycloalkyl, heterocycloalkyl-CH2- or heteroaryl group;
these heterocycloalkyl, heterocycloalkyl-CH2- and heteroaryl groups being optionally substituted with one or several substituents selected, independently in each instance, from: (CrCe)alkyl, (C3-C7)cycloalkyl, (Ci-Ce)alkoxy, heterocycloalkyl, carboxyCCrCeJalkyl, NR4R5 and OR4;
«
208 said (Ci-Ce)alkyl group being optionally substituted with a halogen atom or a (Ci-Ce)alkoxy, heterocycloalkyl, NH2 or OH group; and
- an NRaRb group, where Ra and Rb are, Independently of one another:
. a hydrogen atom;
.a heterocycloalkyl group, said heterocycloalkyl group being optionally substituted with a (Ci-Ce)alkyl group; or . a (Ci-Cs)alkyl group, said (Ci-Ce)alkyl group being optionally substituted with an NR4R5 group;
wherein;
R4 and R5 each is, independently of one another, a hydrogen atom, a (Cr Ce)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring;
R3 is a hydrogen atom, a halogen atom or a (CrCe)alkyl group;
wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyl ring fused with the phenyl bearing them, this heterocycloalkyl being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (Ci-Ce)alkyl group;
b) then step a) is followed:
- either by a step of treating the mixture obtained with an aqueous ammonia solution so as to obtain the compounds of formula (I) wherein R6 is -C0NH2;
- or by a step of reducing the mixture obtained with a reducing agent in a solvent, which makes it possible to obtain the compounds of formula (I) in which R6 Is a -C(Ra)(Rp)(OH) group wherein Ra and Rp are hydrogen atoms;
- or by a step of treating the mixture obtained with an excess of an organometallic dérivative (RaMgX or RPLÎ for example) in a solvent, which makes it possible to obtain the compounds of formula (I) wherein R6 is a -C(RD)(Rp)(OH) group where Ra and Rp are identical and are a (CrCeJalkyl group.
209
14. A process for preparing a compound according to Claim 1 and wherein R6is-CONH2, wherein a compound of formula (XII):
(Xll) in which
R7 is an aryl or heteroaryl group, this group being optionally substituted with at least îo one substituent selected from: cyano, halogen, (CrCe)alkyl, OR’4, CH2OH, CH2NH2,
S(O)nR’4, R8 and OR8;
wherein:
R’4 is a hydrogen atom or a (Cf-Cejalkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
15 R8 being a haloiCrCeJalkyl group;
n Is 1 or 2;
is reacted
20 with a compound of formula (IlIb) .CHO HN
R (lllb) wherein
25 R is a phenyl or heteroaryl group substituted with R1, R’1, R2 and R3;
R1 îs a hydrogen atom or is selected from the following groups: (CrCe)alkyl, (Ci-Ce)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted with one or severai substituents selected, independently in each instance, from: 30 amino, hydroxyl, thiol, halogen, (CrCe)alkyl, (Ci-Ce)alkoxy, (CrCe)alkylthio, (Cr .* < <·
210
Ce)alkylamino, aryloxy, aryl(CpCe)alkoxy, cyano, ha!o(CpCe)a!kyl, carboxyl and carboxy(CpCe)alkyl;
R’1 is a hydrogen atom or a (CpCe)alkoxy group;
R2 is selected from:
- a hydrogen atom, a halogen atom or a (CpCe)alkyl, (C3-C7)cycloalkyl or (Cp Ce)alkoxy group;
- a heterocycloalkyl, heterocycloalkyl-CH2- or heteroaryl group;
these heterocycloalkyl, heterocycloalkyl-CHr and heteroaryl groups being optionally substituted with one or several substituents selected, independently in each instance, from: (CpCe)alkyl, (C3-C7)cycloalkyl, (CpCe)alkoxy, heterocycloalkyl, carboxy(CpCe)alkyl, NR4R5 and OR4;
said alkyl group being optionally substituted with a halogen atom or a (C,Ce)alkoxy, heterocycloalkyl, NH2 or OH group;
wherein:
R4 and R5 each Is, Independently of one another, a hydrogen atom, a (Cp Ce)a!kyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and
- an NRaRb group, where Ra and Rb are, independently of one another:
. a hydrogen atom;
. a heterocycloalkyl group, said heterocycloalkyl group being optionally substituted with a (CpCe)alkyl group; or . a (CrCe)alkyl group, said alkyl group being optionally substituted with an NR4R5 group;
wherein:
R4 and R5 each Is, independently of one another, a hydrogen atom, a (Cp Ce)alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and
R3 is a hydrogen atom, a halogen atom or a (CpCe)alkyl group;
wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyl ring fused with the phenyl bearing them, this
211 heterocycloalkyl being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (Ci-Ce)alkyl group;
5 in the presence of an organic or inorganic base in a polar aprotic solvent.
15. A process for preparing a compound according to Claim 1 and in which R6 is a ·0(Πο)(Πρ)(ΟΗ) group, wherein R», and Rp are, independently of one another, a hydrogen atom or a (Ci-C6)alkyl group, or together form, with the carbon atom to which bears them, a 3- to 5-membered carbocycle, wherein a compound of formula (XIV):
(XIV) n= 1,2 wherein
Ra and Rp are, independently of one another, a hydrogen atom or a (CrCe)alkyl group, or together form, with the carbon atom which bears them, a 3- to 5membered carbocycle;
is reacted
20 R7 is an aryl or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (CrCe)alkyl, OR’4, CH2OH, CH2NH2i S(O)nR’4, R8 and OR8;
wherein:
R'4 is a hydrogen atom or a (CrCe)alkyl or aryl group, said alkyl and aryl groups
25 being optionally substituted with at least one halogen atom or an NH2 or OH group;
R8 Is a halo(CrCe)alkyl group;
n is 1 or 2;
212 with a compound of formula <lllb) .CHO
HN
I
R (lllb) wherein
R is a phenyl or heteroaryl group substituted with R1, R’1, R2 and R3;
R1 is a hydrogen atom or is selected from the following groups: (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (C3-C7)cycloalkyl and aryl, these groups being optionally substituted îo with one or several substituents selected, independently in each instance, from:
amino, hydroxyl, thiol, halogen, (Ci-Ce)alkyl, (CrCe)alkoxy, (CrCe)alkylthio, (Cr Ce)alkylamino, aryloxy, aryl(Ci-Ce)alkoxy, cyano, halo(Ci-Ce)alkyl, carboxyl and carboxy(CrCe)alkyl;
15 R'1 is a hydrogen atom or a (Ct-Ce)alkoxy group;
R2 is selected from:
- a hydrogen atom, a halogen atom or a (Ci-Ce)alkyl, (C3-C7)cycloalkyl or (Cr Ce)alkoxy group;
20 - a heterocycloalkyl, heterocycloalkyl-CH2- or heteroaryl group;
these heterocycloalkyl, heterocycloalkyl-CH2- and heteroaryl groups being optionally substituted with one or several substituents selected, independently in each instance, from: (Ct-Cejalkyl, (C3-C7)cycloalkyl, (Ci-Ce)alkoxy, heterocycloalkyl, carboxy(CrCe)alkyl, NR4R5 and OR4;
25 said alkyl group being optionally substituted with a halogen atom or a (Cr
Ce)alkoxy, heterocycloalkyl, NH2 or OH group; and wherein:
R4 and R5 each is, independently of one another, a hydrogen atom, a (Ci· Cc)a1kyl group or a heterocycloalkyl group;
30 or else R4 and R5 together form, with the nitrogen atom which bears them, a 4to 7-membered ring; and
- an NRaRb group, where Ra and Rb are, independently of one another:
. a hydrogen atom;
213 . a heterocycloalkyl group, said heterocycloalkyl group being optionally substituted with a (CrCe)alkyl group; or . a (Ci-Ce)alkyl group, said alkyl group being optionally substituted with an
NR4R5 group;
wherein:
R4 and R5 each is, independently of one another, a hydrogen atom, a (Cr C9) alkyl group or a heterocycloalkyl group;
or else R4 and R5 together form, with the nitrogen atom which bears them, a 4- to 7-membered ring; and
R3 is a hydrogen atom, a halogen atom or a (Ci-C9)alkyl group;
wherein when R is a phenyl group, two adjacent substituents on the phenyl group may together form a heterocycloalkyl ring fused with the phenyl bearing them, this heterocycloalkyl being optionally substituted with one or several substituents selected, independently in each instance, from: an oxo group and a (Ci-C9)alkyl group;
in the presence of an organic or inorganic base in a polar aprotic solvent.
16. A compound of formula (II):
wherein:
R7 is an aryl group or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (CrCfl)alkyl, OR'4, CHsOH, CH2NH2, SfOJnR^, R8 and 0R8;
wherein:
R'4 Is a hydrogen atom or a (CrCeJalkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
R8 is a halo(CrCfl)alkyl group;
n is 1 or 2;
«
214
R16 is a (CrCe)alkoxy group;
or a pharmaceutically acceptable sait thereof.
17. A compound of formula (XII):
O
R7
NH2 (XII) wherein:
R7 is an aryl or heteroaryl group, this group being optionally substituted with one or severai substituents selected, independently in each instance, from: cyano, halogen, (CrCe)alkyl, OR'4, CH2OH, CH2NH2, S(O)nR'4, R8 and 0R8;
wherein:
R'4 is a hydrogen atom or a (Ci-Ce)alkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
R8 is a halo(Ci-Cs)alkyl group;
n is equal to 1 or to 2;
or a pharmaceutically acceptable sait thereof.
18. A compound of formula (XIV) :
(XIV) n= 1,2 wherein:
«, 17140
Ra and Rp are, independently of one another, a hydrogen atom or a (Ci-Ce)aJKyl group or together form, with the carbon atom which bears them, a 3- to 5-membered carbocycle:
R7 is an aryl or heteroaryl group, this group being optionally substituted with one or several substituents selected, independently in each instance, from: cyano, halogen, (CrCe)alkyl, OR’4, CH2OH, CH2NHj, S(O)nR'4, R8 and OR8;
wherein:
R’4 is a hydrogen atom or a (CrCeJalkyl or aryl group, said alkyl and aryl groups being optionally substituted with a halogen atom or an NH2 or OH group;
R8 is a halo(Ci-Ce)alkyl group; .
n is 1 or2;
or a pharmaceutically acceptable sait thereof.
19. A médicament comprising a compound according to any one of Claims 1 to 12, or a pharmaceutically acceptable sait thereof.
20. A pharmaceutical composition, comprising a compound according to any one of Claims 1 to 12, or a pharmaceutically acceptable sait thereof, and also at least one pharmaceutically acceptable excipient.
21. A compound according to any one of Claims 1 to 12, for use in treating cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1253044 | 2012-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA17140A true OA17140A (en) | 2016-03-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2868685C (en) | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | |
AU2018372211B2 (en) | Heterocyclic compounds as PRMT5 inhibitors | |
TW202246255A (en) | Cdk inhibitors and methods of use thereof | |
TW202128685A (en) | Bicyclic heterocycles as fgfr inhibitors | |
FR3052452A1 (en) | ||
EP2922844A1 (en) | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors | |
KR20200100760A (en) | Diazaindole compound | |
US20230242533A9 (en) | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | |
CN115996929A (en) | Antagonists of adenosine A2a receptors | |
US11584737B2 (en) | Heterocyclic compound | |
OA17140A (en) | Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | |
RU2815003C2 (en) | Heterocyclic compound | |
US20240034731A1 (en) | Aza-quinazoline compounds and methods of use |